<SEC-DOCUMENT>0001104659-25-032262.txt : 20250404
<SEC-HEADER>0001104659-25-032262.hdr.sgml : 20250404
<ACCEPTANCE-DATETIME>20250404170042
ACCESSION NUMBER:		0001104659-25-032262
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		22
CONFORMED PERIOD OF REPORT:	20250522
FILED AS OF DATE:		20250404
DATE AS OF CHANGE:		20250404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-TESTING LABORATORIES [8734]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36745
		FILM NUMBER:		25815639

	BUSINESS ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631-240-8800

	MAIL ADDRESS:	
		STREET 1:		50 HEALTH SCIENCES DRIVE
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>tm252562-4_pre14a.htm
<DESCRIPTION>FORM- PRE 14A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Apr 04 20:42:13 UTC 2025 -->
<html xmlns:apdn="http://adnas.com/20240930" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://xbrl.us/us-types/2009-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>tm252562-3_nonfiling - none - 7.3070468s</title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
  <body><div style="margin-left:auto;margin-right:auto;width:595.31pt;"><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">UNITED STATES
          <br/>
          SECURITIES AND EXCHANGE COMMISSION</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Washington, D.C. 20549</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:16pt; text-align:center; width:456pt; line-height:18pt;font-weight:bold;font-size:16pt;"> <span style="letter-spacing:-0.32pt;"><span style="-sec-ix-hidden: hidden-fact-0">SCHEDULE 14A</span></span><span style="font-weight:normal;letter-spacing:0.32pt;"> </span> </div>
        <div style="margin-top:19.167pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Proxy Statement Pursuant to Section&#160;14(a)
          <br/>
          of the Securities Exchange Act of 1934
          <br/>
          (Amendment No.&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;)</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:18.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Filed by the Registrant &#9746; </span>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Filed by a Party other than the Registrant &#9744; </span>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Check the appropriate box: </span>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#9746;</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Preliminary Proxy Statement </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#9744;</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Confidential, for Use of the Commission Only (as permitted by Rule&#160;14a-6(e)(2))</span><span style="letter-spacing:0.2pt;"> </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#9744;</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Definitive Proxy Statement </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#9744;</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Definitive Additional Materials </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#9744;</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Soliciting Material Pursuant to &#167;240.14a-12 </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:18pt;font-weight:bold;font-size:16pt;"> <span style="letter-spacing:-0.32pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-7946">Applied DNA Sciences, Inc</ix:nonNumeric>. </span> </div>
        <div style="margin-top:2.167pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:10pt;font-size:8pt;">
          <span style="letter-spacing:0.16pt;">(Name of Registrant as Specified In Its Charter) </span>
        </div>
        <div style="margin-top:10pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#8199;</span>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:10pt;font-size:8pt;">
          <span style="letter-spacing:0.16pt;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </span>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Payment of Filing Fee (Check all boxes that apply): </span>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#9746;</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">No fee required. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#9744;</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Fee paid previously with preliminary materials. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#9744;</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Fee computed on table in exhibit required by Item&#160;25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:3pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;text-align:center; width:456pt;">
          <img alt="[MISSING IMAGE: lg_applieddna-4c.jpg]" src="lg_applieddna-4c.jpg" style="height: 44px; width: 289px;"/>
        </div>
        <div style="margin-top:16.6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">APPLIED DNA SCIENCES, INC.
          <br/>
          50 HEALTH SCIENCES DRIVE
          <br/>
          STONY BROOK, NEW YORK 11790
          <br/>
          (631) 240-8800
          <br/>
          April&#160;15, 2025</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Dear Fellow Stockholder: </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Annual Meeting</span><span style="letter-spacing:0.2pt;">&#8221;) of Applied DNA Sciences, Inc. (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Applied DNA Sciences</span><span style="letter-spacing:0.2pt;">,&#8221; the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Company</span><span style="letter-spacing:0.2pt;">,&#8221; &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">we</span><span style="letter-spacing:0.2pt;">&#8221; or &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">us</span><span style="letter-spacing:0.2pt;">&#8221;) to be held at </span><span style="font-weight:bold;letter-spacing:-0.2pt;">11:00&#160;a.m., Eastern Time</span><span style="letter-spacing:0.2pt;">, on </span><span style="font-weight:bold;letter-spacing:-0.2pt;">Thursday, May&#160;22, 2025</span><span style="letter-spacing:0.2pt;">. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">We are very pleased that this year&#8217;s Annual Meeting will be a completely virtual meeting of stockholders, which will be conducted via live webcast. The Annual Meeting will be held in a virtual format only, via the Internet, with no physical in-person meeting. You will be able to attend the Annual Meeting online and submit your questions during the meeting by visiting www.virtualshareholdermeeting.com/APDN2025. You will also be able to vote your shares electronically at the annual meeting. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">We are pleased to use the latest technology to increase access, to improve communication and to obtain cost savings for our stockholders and the Company. Use of a virtual meeting will enable increased stockholder attendance and participation as stockholders can participate from any location. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">At the Annual Meeting, you will be asked to (i)&#160;elect six directors; (ii)&#160;ratify our appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending September&#160;30, 2025; (iii)&#160;grant the Board of Directors the discretionary authority for 12&#160;months to amend the Company&#8217;s certificate of incorporation, as amended, to authorize a reverse stock split of common stock, at a ratio in the range from one-for-five to one-for-fifty, with such specific ratio to be determined by the Company&#8217;s Board of Directors following the Annual Meeting; (iv)&#160;approve, in accordance with Nasdaq Listing Rule&#160;5635(d), the exercisability of certain common stock purchase warrants, and the issuance of the common stock underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on October&#160;30, 2024; (v)&#160;approve an amendment to the Company&#8217;s 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by 3&#160;million shares; (vi)&#160;approve, on a non-binding advisory basis, the compensation of the Company&#8217;s named executive officers; and (vii)&#160;approve, on a non-binding advisory basis, the frequency of the stockholder vote on the compensation of the Company&#8217;s named executive officers. In addition, we will be pleased to report on our affairs and a discussion period will be provided for questions and comments of general interest to stockholders. Detailed information with respect to these matters is set forth in the accompanying Proxy Statement, which we encourage you to carefully read in its entirety. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">We look forward to greeting personally those stockholders who are able to attend the meeting online. However, whether or not you plan to join us at the meeting, it is important that your shares be represented. Stockholders of record at the close of business on April&#160;3, 2025 are entitled to notice of and to vote at the meeting. Such stockholders are urged to promptly submit the enclosed proxy card, even if their shares were sold after the record date. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">You may vote over the Internet, as well as by telephone pursuant to instructions provided on the proxy card. Please review the instructions for each of your voting options described in the Proxy Statement. </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Thank you for your ongoing support of Applied DNA Sciences. </span>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Very truly yours, </span>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">/s/ James A. Hayward</span>
        </div>
        <div style="margin-left:240pt; margin-top:2.4pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:1.9pt; width:216pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">James A. Hayward
          <br/>
          Chairman and Chief Executive Officer</span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">APPLIED DNA SCIENCES, INC.</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Notice is hereby given that the 2025 Annual Meeting of Stockholders (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Annual Meeting</span><span style="letter-spacing:0.2pt;">&#8221;) of Applied DNA Sciences, Inc. (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Applied DNA Sciences</span><span style="letter-spacing:0.2pt;">&#8221; or the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Company</span><span style="letter-spacing:0.2pt;">&#8221;), will be held virtually at www.virtualshareholdermeeting.com/APDN2025 on Thursday, May&#160;22, 2025 at 11:00&#160;a.m., Eastern Time, for the following purposes: </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">to elect six directors, constituting the entire board of directors of the Company (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Board of Directors</span><span style="letter-spacing:0.2pt;">&#8221; or &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Board</span><span style="letter-spacing:0.2pt;">&#8221;), to serve until the Company&#8217;s next annual meeting of stockholders, or until their respective successors are duly elected and qualified; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">to ratify the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending September&#160;30, 2025; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">to grant the Board of Directors discretionary authority for 12&#160;months to amend the Company&#8217;s certificate of incorporation, as amended (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Certificate of Incorporation</span><span style="letter-spacing:0.2pt;">&#8221;), to authorize a reverse stock split of common stock, at a ratio in the range from one-for-five to one-for-fifty, with such specific ratio to be determined by the Company&#8217;s Board of Directors following the Annual Meeting (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Reverse Split Proposal</span><span style="letter-spacing:0.2pt;">&#8221;); </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">to approve, in accordance with Nasdaq Listing Rule&#160;5635(d), the exercisability of certain common stock purchase warrants, and the issuance of the common stock underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on October&#160;30, 2024 (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Warrant Exercise Proposal</span><span style="letter-spacing:0.2pt;">&#8221;); </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">to approve an amendment to the Company&#8217;s 2020 Equity Incentive Plan (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Plan&#160;Amendment</span><span style="letter-spacing:0.2pt;">&#8221;) to increase the number of authorized shares of common stock reserved for issuance by 3&#160;million shares (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Plan&#160;Amendment Proposal</span><span style="letter-spacing:0.2pt;">&#8221;); </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">to approve, on a non-binding advisory basis, the compensation of the Company&#8217;s named executive officers (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Say on Pay Proposal</span><span style="letter-spacing:0.2pt;">&#8221;); </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">to approve, on a non-binding advisory basis, the frequency of the stockholder vote on the compensation of the Company&#8217;s named executive officers (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Say on Frequency Proposal</span><span style="letter-spacing:0.2pt;">&#8221;); and </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">to consider and act upon such other matters as may properly come before the meeting or any postponement or adjournment of the meeting. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">These matters are more fully described in the accompanying Proxy Statement. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Only stockholders of record at the close of business on April&#160;3, 2025 are entitled to notice of and to vote at the Annual Meeting and any adjournment or postponement thereof. The Annual Meeting will be held in a virtual format only, via the Internet, with no physical in-person meeting. Stockholders will have the ability to attend, vote and submit questions before and during the virtual meeting from any location via the Internet at www.virtualshareholdermeeting.com/APDN2025. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">A complete list of these stockholders will be available in electronic form at the Annual Meeting and will be accessible for ten days prior to the Annual Meeting. All stockholders are cordially invited to virtually attend the Annual Meeting. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Your vote is very important. Whether or not you plan to attend the Annual Meeting, we encourage you to read the Proxy Statement and submit your proxy or voting instructions as soon as possible by Internet, telephone or mail. For specific instructions on how to vote your shares, please refer to the section entitled &#8220;About the Annual Meeting&#8221; beginning on page 1 of the Proxy Statement or your enclosed proxy card. Please note that shares held beneficially in street name may be voted by you in person at the Annual Meeting only if you obtain a legal proxy from the broker, bank, trustee, or other nominee that holds your shares giving you the right to vote the shares. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:240pt; width:216pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Very truly yours, </span>
        </div>
        <div style="margin-left:240pt; margin-top:8pt; width:216pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">/s/ James A. Hayward</span>
        </div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">James A. Hayward
          <br/>
          Chairman and Chief Executive Officer </span>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Stony Brook, New York  <br/>April&#160;15, 2025 </span></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">This Notice of Annual Meeting and the enclosed Proxy Statement and proxy card are first being mailed on or about April&#160;15, 2025 to stockholders entitled to notice of and to vote at the Annual Meeting. </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Important Notice Regarding the Availability of Proxy
          <br/>
          Materials for the Annual Meeting of Stockholders
          <br/>
          To Be Held on May&#160;22, 2025</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">The Proxy Statement, along with our 2024 Annual Report is available free of charge at the following website: </span><span style="font-style:italic;letter-spacing:-0.2pt;">www.proxyvote.com</span><span style="letter-spacing:-0.2pt;">.</span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:119pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Table of Contents</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPRST"><span style="letter-spacing:0.2pt;">PROXY STATEMENT </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tPRST">1</a></span> <a href="#tPRST"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATAM"><span style="letter-spacing:0.2pt;">ABOUT THE ANNUAL MEETING </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tATAM">1</a></span> <a href="#tATAM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPN1E"><span style="letter-spacing:0.2pt;">PROPOSAL NO. 1: ELECTION OF DIRECTORS </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tPN1E">8</a></span> <a href="#tPN1E"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.96pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tPN2R"><span style="letter-spacing:0.2pt;">PROPOSAL NO. 2: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tPN2R">13</a></span> <a href="#tPN2R"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.96pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tPN3"><span style="letter-spacing:0.2pt;">PROPOSAL NO. 3: GRANTING THE BOARD OF DIRECTORS DISCRETIONARY
                  <br/>
                  AUTHORITY FOR 12 MONTHS TO AMEND THE COMPANY&#8217;S CERTIFICATE OF
                  <br/>
                  INCORPORATION TO AUTHORIZE A REVERSE STOCK SPLIT OF COMMON STOCK,
                  <br/>
                  AT A RATIO IN THE RANGE FROM ONE-FOR-FIVE TO ONE-FOR-FIFTY, WITH SUCH
                  <br/>
                  SPECIFIC RATIO TO BE DETERMINED BY THE COMPANY&#8217;S BOARD OF DIRECTORS
                  <br/>
                  FOLLOWING THE ANNUAL MEETING </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tPN3">16</a></span> <a href="#tPN3"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.96pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tPN4"><span style="letter-spacing:0.2pt;">PROPOSAL NO. 4: APPROVAL, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(d),
                  <br/>
                  OF THE EXERCISABILITY OF CERTAIN COMMON STOCK PURCHASE WARRANTS,
                  <br/>
                  AND THE ISSUANCE OF THE COMMON STOCK UNDERLYING SUCH WARRANTS,
                  <br/>
                  WHICH WARRANTS WERE ISSUED IN CONNECTION WITH AN OFFERING OF
                  <br/>
                  SECURITIES OF THE COMPANY THAT OCCURRED ON OCTOBER&#160;30, 2024 </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tPN4">25</a></span> <a href="#tPN4"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.96pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tPN5"><span style="letter-spacing:0.2pt;">PROPOSAL NO. 5: APPROVAL OF AN AMENDMENT TO THE COMPANY&#8217;S 2020 EQUITY
                  <br/>
                  INCENTIVE PLAN TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF
                  <br/>
                  COMMON STOCK RESERVED FOR ISSUANCE BY THREE MILLION SHARES </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tPN5">28</a></span> <a href="#tPN5"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.96pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tPN6A"><span style="letter-spacing:0.2pt;">PROPOSAL NO. 6: NON-BINDING ADVISORY APPROVAL OF THE COMPENSATION OF THE COMPANY&#8217;S NAMED EXECUTIVE OFFICERS </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tPN6A">36</a></span> <a href="#tPN6A"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.96pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tPN7A"><span style="letter-spacing:0.2pt;">PROPOSAL NO. 7: NON-BINDING ADVISORY APPROVAL OF THE FREQUENCY OF THE
                  <br/>
                  STOCKHOLDER VOTE ON THE COMPENSATION OF THE COMPANY&#8217;S NAMED
                  <br/>
                  EXECUTIVE OFFICERS </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tPN7A">38</a></span> <a href="#tPN7A"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tMACG"><span style="letter-spacing:0.2pt;">MANAGEMENT AND CORPORATE GOVERNANCE </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tMACG">39</a></span> <a href="#tMACG"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXCO"><span style="letter-spacing:0.2pt;">EXECUTIVE COMPENSATION </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tEXCO">45</a></span> <a href="#tEXCO"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.96pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tSOOC"><span style="letter-spacing:0.2pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tSOOC">54</a></span> <a href="#tSOOC"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tHOPM"><span style="letter-spacing:0.2pt;">HOUSEHOLDING OF PROXY MATERIALS </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tHOPM">57</a></span> <a href="#tHOPM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tOTBU"><span style="letter-spacing:0.2pt;">OTHER BUSINESS </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tOTBU">58</a></span> <a href="#tOTBU"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSPAN"><span style="letter-spacing:0.2pt;">STOCKHOLDER PROPOSALS AND NOMINATIONS </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tSPAN">59</a></span> <a href="#tSPAN"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tAROF"><span style="letter-spacing:0.2pt;">ANNUAL REPORT ON FORM 10-K AND OTHER INFORMATION </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tAROF">60</a></span> <a href="#tAROF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tAPA"><span style="letter-spacing:0.2pt;">APPENDIX A </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tAPA">A-1</a></span> <a href="#tAPA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tAPB"><span style="letter-spacing:0.2pt;">APPENDIX B </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tAPB">B-1</a></span> <a href="#tAPB"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tAPC"><span style="letter-spacing:0.2pt;">APPENDIX C </span></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:14.25pt; text-align:right; white-space:nowrap;">
              <span style="letter-spacing:0.2pt;"><a href="#tAPC">C-1</a></span>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">i</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tPRST">&#8203;</a><a id="tATAM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">APPLIED DNA SCIENCES, INC.
          <br/>
          50 HEALTH SCIENCES DRIVE
          <br/>
          STONY BROOK, NEW YORK 11790</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">PROXY STATEMENT</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">Our Board of Directors has delivered printed proxy materials to you by mail, in connection with the Board of Directors&#8217; solicitation of proxies for use at the 2025 Annual Meeting of Stockholders (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Annual Meeting</span><span style="letter-spacing:0.2pt;">&#8221;) of Applied DNA Sciences, Inc. to be held online on Thursday, May&#160;22, 2025, beginning at 11:00&#160;a.m., Eastern Time, and at any postponements or adjournments of the Annual Meeting. As a stockholder, you are invited to attend the Annual Meeting and are requested to vote on the items of business described in this Proxy Statement. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">Except as otherwise indicated, all share and per share information in this Proxy Statement gives effect to the reverse stock split of the Company&#8217;s outstanding common stock at a ratio of one-for-fifty shares, which was approved by our Board of Directors on March&#160;3, 2025 and was effected as of 12:01&#160;a.m., Eastern Time, on Friday, March&#160;14, 2025. </span>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">ABOUT THE ANNUAL MEETING</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Why did you send me this Proxy Statement?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">We sent you this Proxy Statement in connection with the solicitation by the Board of Directors of the Company (referred to herein as the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Board of Directors</span><span style="letter-spacing:0.2pt;">&#8221; or the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Board</span><span style="letter-spacing:0.2pt;">&#8221;) of proxies, in the accompanying form, to be used at the Annual Meeting to be held at 11:00&#160;a.m., Eastern Time, on May&#160;22, 2025 and any postponements or adjournments thereof. This Proxy Statement along with the accompanying Notice of Annual Meeting of Stockholders summarizes the purposes of the Annual Meeting and the information you need to know to vote at the Annual Meeting. This Proxy Statement is being mailed on or about April&#160;15, 2025 to all stockholders entitled to notice of and to vote at the Annual Meeting. You can also find a copy of our Annual Report on Form 10-K, as amended, for the year ended September&#160;30, 2024 (the &#8220;Annual Report&#8221;), which includes our financial statements for the fiscal year ended September&#160;30, 2024 by following the instructions contained in the Notice of Annual Meeting mailed to stockholders entitled to notice of and to vote at the Annual Meeting along with this Proxy Statement on April&#160;15, 2025. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">What is the purpose of the Annual Meeting?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">At our Annual Meeting, stockholders will act upon the matters outlined in the notice of meeting accompanying this Proxy Statement, consisting of (i)&#160;the election of six directors; (ii)&#160;the ratification of the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending September&#160;30, 2025; (iii)&#160;the authorization of a reverse stock split of our common stock, $0.001 par value (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Common Stock</span><span style="letter-spacing:0.2pt;">&#8221;), at a ratio in the range from one-for-five to one-for-fifty, with such specific ratio to be determined by the Company&#8217;s Board of Directors following the Annual Meeting (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Reverse Split Proposal</span><span style="letter-spacing:0.2pt;">&#8221;); (iv)&#160;the approval, in accordance with Nasdaq Listing Rule&#160;5635(d), of the exercisability of certain common stock purchase warrants, and the issuance of Common Stock, underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on October&#160;30, 2024 (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Warrant Exercise Proposal</span><span style="letter-spacing:0.2pt;">&#8221;); (v)&#160;the approval of an amendment to the Company&#8217;s 2020 Equity Incentive Plan (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Plan&#160;Amendment</span><span style="letter-spacing:0.2pt;">&#8221;) to increase the number of authorized shares of common stock reserved for issuance by three million shares (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Plan&#160;Amendment Proposal</span><span style="letter-spacing:0.2pt;">&#8221;); (vi)&#160;the approval, on a non-binding advisory basis, of the compensation of the Company&#8217;s named executive officers (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Say on Pay Proposal</span><span style="letter-spacing:0.2pt;">&#8221;); (vii)&#160;the approval, on a non-binding advisory basis, of the frequency of the stockholder vote on the compensation of the Company&#8217;s named executive officers (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Say on Frequency Proposal</span><span style="letter-spacing:0.2pt;">&#8221;); and (viii)&#160;such other business that may properly come before the meeting or any postponement or adjournment thereof. In addition, management will report on our performance during the fiscal year ended September&#160;30, 2024 and more recent developments and respond to questions from stockholders. Our Board of Directors is not currently aware of any other matters which will come before the meeting. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">1</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">How do proxies work and how are votes counted?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Board of Directors is asking for your proxy. Giving us your proxy means that you authorize us to vote your shares at the Annual Meeting in the manner you direct. You may vote for all of our director nominees or withhold your vote as to some or all of our director nominees. You may also vote for the ratification of our selection of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending September&#160;30, 2025 or against such ratification. You may also vote for or against, or abstain from voting on the Reverse Split Proposal, the Warrant Exercise Proposal, the Plan&#160;Amendment Proposal and the Say on Pay Proposal. You may vote on the frequency of or abstain from voting on the Say on Frequency Proposal. If a stockholder of record does not indicate instructions with respect to one or more matters on his, her or its proxy, the shares represented by that proxy will be voted as recommended by the Board of Directors (for more information, see &#8220;&#8212; What are the Board of Directors&#8217; recommendations as to the proposals to be voted on?&#8221;). If a beneficial owner of shares held in street name does not provide instructions to the bank, broker, or other nominee holding those shares, please see the information below under the caption &#8220;&#8212; What if I am a beneficial owner and do not give voting instructions to my broker or other nominee?&#8221; </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Who is entitled to vote at the Annual Meeting?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Only stockholders of record at the close of business on April&#160;3, 2025, the record date for the meeting, are entitled to receive notice of and to participate in the Annual Meeting, or any postponements and adjournments of the meeting. If you were a stockholder of record on that date, you will be entitled to vote all of the shares you held on that date at the meeting, or any postponements or adjournments of the meeting. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">On April&#160;3, 2025, the record date for the meeting, there were 6,497,790 shares of Common Stock outstanding. Each outstanding share of Common Stock is entitled to one vote on each of the matters presented at the Annual Meeting or postponements and adjournments of the meeting. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">What constitutes a quorum?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The presence at the meeting, in person or by proxy, of the holders of one-third of the outstanding shares of Common Stock as of the record date will constitute a quorum, permitting the Annual Meeting to conduct its business. As of the record date, 6,497,790 shares of Common Stock, representing the same number of votes, were outstanding. Thus, the presence of holders representing at least 2,165,930 shares will be required to establish a quorum. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">If a stockholder abstains from voting as to any matter or matters, the shares held by such stockholder shall be deemed present at the Annual Meeting for purposes of determining a quorum. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">What vote is required to approve each matter and how are votes counted?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">Proposal No. 1: Election of Directors</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The six nominees who receive the highest number of affirmative votes of the shares present in person or represented by proxy and entitled to vote on the election of directors will be elected as our directors. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Abstentions, broker non-votes and instructions on the accompanying proxy card to withhold authority to vote for one or more nominees will not be counted as votes in favor of the relevant nominee or nominees and will result in the relevant nominee or nominees receiving fewer total votes. However, the number of votes cast in favor of such nominee will not be reduced by any abstention, broker non-vote or instructions to withhold authority. </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The affirmative vote of a majority of the outstanding shares of our Common Stock present in person or represented by proxy at the Annual Meeting and entitled to vote on this proposal is required for the approval of this proposal. An abstention from voting by a stockholder present in person or represented by proxy at the meeting or a broker non-vote by a broker who elects to non-vote instead of using its voting discretion has the same legal effect as a vote &#8220;against&#8221; the matter. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">2</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">Proposal No. 3: Grant of Discretionary Authority to the Board for 12 Months to Amend the Company&#8217;s Certificate of Incorporation to Effect the Reverse Split Proposal.</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The votes cast for the proposal must exceed the votes cast against the proposal in order for the proposal to be approved. An abstention from voting by a stockholder present in person or represented by proxy at the meeting or a broker non-vote by a broker who elects to non-vote instead of using its voting discretion will be excluded entirely from the vote and will therefore have no effect on the outcome of the vote for this matter. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">Proposal No. 4: Approval, in Accordance with Nasdaq Listing Rule&#160;5635(d), of the Exercisability of Certain Common Stock Purchase Warrants, and the Issuance of the Common Stock Underlying such Warrants, which Warrants were Issued in Connection with an Offering of Securities of the Company that Occurred on October&#160;30, 2024.</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The affirmative vote of a majority of the outstanding shares of our Common Stock present in person or represented by proxy at the Annual Meeting and entitled to vote on this proposal is required for the approval of the Warrant Exercise Proposal. An abstention from voting by a stockholder present in person or represented by proxy at the meeting has the same legal effect as a vote &#8220;against&#8221; the matter. A broker non- vote for which the broker does not have voting discretion will be excluded entirely from the vote and will therefore have no effect on the outcome of the vote for this matter. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">Proposal No. 5: Approval of an Amendment to the Company&#8217;s 2020 Equity Incentive Plan to Increase the Number of Authorized Shares of Common Stock Reserved for Issuance by Three Million Shares.</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The affirmative vote of a majority of the outstanding shares of our Common Stock present in person or represented by proxy at the Annual Meeting and entitled to vote on this proposal is required for the approval of this proposal. An abstention from voting by a stockholder present in person or represented by proxy at the meeting has the same legal effect as a vote &#8220;against&#8221; the matter. A broker non-vote for which the broker does not have voting discretion will be excluded entirely from the vote and will therefore have no effect on the outcome of the vote for this matter. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">Proposal No. 6: Approval, on a Non-binding Advisory Basis, of the Compensation of the Company&#8217;s Named Executive Officers</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The affirmative vote of a majority of the outstanding shares of our common stock present in person or represented by proxy at the Annual Meeting and entitled to vote on this proposal is required for the approval of this proposal. An abstention from voting by a stockholder present in person or represented by proxy at the meeting has the same legal effect as a vote &#8220;against&#8221; the matter. A broker non- vote for which the broker does not have voting discretion will be excluded entirely from the vote and will therefore have no effect on the outcome of the vote for this matter. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">Proposal No. 7: Approval, on a Non-binding Advisory Basis, of the Frequency of the Stockholder Vote on the Compensation of the Company&#8217;s Named Executive Officers</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">On this proposal, a stockholder may vote to set the frequency of the say-on-pay vote to occur every year, every two&#160;years, or every three&#160;years, or the stockholder may vote to abstain. The choice among those four choices that receives the highest number of votes will be deemed the choice of the stockholders. A broker non- vote for which the broker does not have voting discretion will be excluded entirely from the vote and will therefore have no effect on the outcome of the vote for this matter. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">How can I attend the Annual Meeting?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We will be hosting the Annual Meeting live via audio webcast. Any stockholder can attend the Annual Meeting live online at www.virtualshareholdermeeting.com/APDN2025. If you were a stockholder as of the record date, or you hold a valid proxy for the Annual Meeting, you can vote at the Annual Meeting. A summary of the information you need to attend the Annual Meeting online is provided below: </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Instructions on how to attend and participate via the Internet, including how to demonstrate proof of stock ownership, are posted at www.virtualshareholdermeeting.com/APDN2025. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">3</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Assistance with questions regarding how to attend and participate via the Internet will be provided at www.virtualshareholdermeeting.com/APDN2025 on the day of the Annual Meeting. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Webcast will start on May&#160;22, 2025, at 11:00&#160;a.m., Eastern Time. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">You will need your 16-digit control number to enter the Annual Meeting. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Stockholders may submit questions while attending the Annual Meeting via the Internet. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Webcast replay of the Annual Meeting will be available until May&#160;22, 2026. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">To attend and participate in the Annual Meeting, you will need the 16-digit control number included on your proxy card, on your proxy card, or on the instructions that accompanied your proxy materials. If your shares are held in &#8220;street name,&#8221; you should contact your bank or broker to obtain your 16-digit control number or otherwise vote through the bank or broker. If you lose your 16-digit control number, you may join the Annual Meeting as a &#8220;Guest&#8221;, but you will not be able to vote, ask questions or access the list of stockholders as of the record date. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Why hold a virtual meeting?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">We are excited to use the latest technology to provide expanded access, improved communication and cost savings for our stockholders and the Company while providing stockholders the same rights and opportunities to participate as they would have at an in-person meeting. We believe the virtual meeting format enables increased stockholder attendance and participation because stockholders can participate from any location around the world. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">How do I ask questions at the virtual Annual Meeting?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">During the virtual Annual Meeting, you may only submit questions in the question box provided at www.virtualshareholdermeeting.com/APDN2025. We will respond to as many inquiries at the virtual Annual Meeting as time allows. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">What if during the check-in time or during the virtual Annual Meeting I have technical difficulties or trouble accessing the virtual meeting website?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual meeting website. If you encounter any difficulties accessing the virtual Annual Meeting during the check-in or meeting time, please call the technical support number that will be posted on the Annual Meeting website log-in page. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">How can I vote my shares?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Record Owners and Beneficial Owners Who Have Been Provided With a 16 Digit Control Number</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">If you are a record holder, meaning your shares are registered in your name and not in the name of a broker, trustee, or other nominee, or a beneficial owner who has been provided by your broker with a 16- digit control number, you may vote: </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">1.</span>
          <br/>
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Over the Internet&#8201;&#8212;&#8201;If you have Internet access, you may authorize the voting of your shares by accessing www.proxyvote.com and following the instructions set forth in the proxy materials. You must specify how you want your shares voted or your vote will not be completed, and you will receive an error message. Your shares will be voted according to your instructions. You can also vote during the meeting by visiting www.virtualshareholdermeeting.com/APDN2025 and having available the control number included on your proxy card or on the instructions that accompanied your proxy materials. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">2.</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">By Telephone&#8201;&#8212;&#8201;If you are a registered stockholder or a beneficial owner who has been provided with a control number on the voting instruction form that accompanied your proxy materials, you may call </span><span style="letter-spacing:0.2pt;white-space:nowrap;">1-800-690-6903</span><span style="letter-spacing:0.2pt;"> in the United States (toll-free) or from foreign countries (tolls may apply) to vote by telephone. Your shares will be voted according to your instructions. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">4</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">3.</span>
          <br/>
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">By Mail&#8201;&#8212;&#8201;Complete and sign the attached WHITE proxy card and mail it in the enclosed postage prepaid envelope. Your shares will be voted according to your instructions. If you sign your WHITE proxy card but do not specify how you want your shares voted, they will be voted as recommended by our Board of Directors. Unsigned proxy cards will not be voted. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Beneficial Owners</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">As the beneficial owner, you have the right to direct your broker, trustee, or other nominee on how to vote your shares. In most cases, when your broker provides you with proxy materials, they will also provide you with a 16-digit control number, which will allow you to vote as described above or at the Annual Meeting. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">If your broker has not provided you with a 16-digit control number, please contact your broker for instructions on how to vote your shares. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Stockholders who submit a proxy by Internet or telephone need not return a proxy card or any form forwarded by your broker, bank, trust or nominee. Stockholders who submit a proxy through the Internet or telephone should be aware that they may incur costs to access the Internet or telephone, such as usage charges from telephone companies or Internet service providers, and that these costs must be borne by the stockholder.</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">What am I voting on at the Annual Meeting?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The following proposals are scheduled for a vote at the Annual Meeting: </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proposal No. 1:</span><span style="letter-spacing:0.2pt;"> to elect six directors, constituting the entire Board of Directors, to serve until the Company&#8217;s next annual meeting of stockholders, or until their respective successors are duly elected and qualified; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proposal No. 2:</span><span style="letter-spacing:0.2pt;"> to ratify the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending September&#160;30, 2025; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proposal No. 3:</span><span style="letter-spacing:0.2pt;"> to grant discretionary authority to the Board of Directors for 12&#160;months to amend the Company&#8217;s Certificate of Incorporation to effect the Reverse Split Proposal; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proposal No. 4:</span><span style="letter-spacing:0.2pt;"> to approve, in accordance with Nasdaq Listing Rule&#160;5635(d), the exercisability of certain common stock purchase warrants, and the issuance of the Common Stock underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on October&#160;30, 2024; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proposal No. 5:</span><span style="letter-spacing:0.2pt;"> to approve an amendment to the Company&#8217;s 2020 Equity Incentive Plan to increase the number of authorized shares of Common Stock reserved for issuance by three million shares; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proposal No. 6:</span><span style="letter-spacing:0.2pt;"> to approve, on a non-binding advisory basis, the compensation of the Company&#8217;s named executive officers; and </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proposal No. 7:</span><span style="letter-spacing:0.2pt;"> to approve, on a non-binding advisory basis, the frequency of the stockholder vote on the compensation of the Company&#8217;s named executive officers. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Each of these proposals is described in further detail below. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">What happens if additional matters are presented at the Annual Meeting?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Other than the items of business described in this Proxy Statement, we are not currently aware of any other business to be acted upon at the Annual Meeting. If you grant a proxy, the persons named as proxy holders, Ms.&#160;Beth Jantzen and Ms.&#160;Judith Murrah, will have the discretion to vote your shares on any additional matters properly presented for a vote at the meeting. If for any reason any of the nominees is not available as a candidate for director, the persons named as proxies will vote your proxy for such other candidate or candidates as may be nominated by the Board of Directors. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">How does the Board of Directors recommend that I vote?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">As to the proposals to be voted on at the Annual Meeting, the Board of Directors unanimously recommends that you vote: </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">5</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">FOR</span><span style="letter-spacing:0.2pt;"> Proposal No. 1, for the election of each of the six nominated candidates for director; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">FOR</span><span style="letter-spacing:0.2pt;"> Proposal No. 2, for the ratification of the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending September&#160;30, 2025; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">FOR</span><span style="letter-spacing:0.2pt;"> Proposal No. 3, to grant discretionary authority to the Board of Directors for 12&#160;months to effect the Reverse Split Proposal; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">FOR</span><span style="letter-spacing:0.2pt;"> Proposal No. 4, to approve, in accordance with Nasdaq Listing Rule&#160;5635(d), the exercisability of certain common stock purchase warrants, and the issuance of the Common Stock underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on October&#160;30, 2024; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">FOR</span><span style="letter-spacing:0.2pt;"> Proposal No. 5, to approve an amendment to the Company&#8217;s 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by three million shares; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">FOR</span><span style="letter-spacing:0.2pt;"> Proposal No. 6, for the approval, on a non-binding advisory basis, of the compensation of the Company&#8217;s named executive officers; and </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">FOR</span><span style="letter-spacing:0.2pt;"> Proposal No. 7, for the approval, on a non-binding advisory basis, to hold advisory votes on the compensation of the Company&#8217;s named executive officers every three&#160;years. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">What if I am a stockholder of record and do not indicate voting instructions on my proxy?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">If you are a stockholder of record and provide specific instructions on your proxy with regard to certain items, your shares will be voted as you instruct on such items. If no instructions are indicated on your proxy for one or more of the proposals to be voted on, the shares will be voted as recommended by the Board of Directors: (i)&#160;in favor of each of our director nominees; (ii)&#160;for the ratification of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending September&#160;30, 2025; (iii)&#160;for the granting of discretionary authority to the Board of Directors for 12&#160;months to effect the Reverse Split Proposal; (iv)&#160;for the approval of the Warrant Exercise Proposal, to approve, in accordance with Nasdaq Listing Rule&#160;5635(d), the exercisability of certain common stock purchase warrants, and the issuance of the Common Stock underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on October&#160;30, 2024; (v)&#160;for the approval of an amendment to the Company&#8217;s 2020 Equity Incentive Plan to increase the number of authorized shares of Common Stock reserved for issuance by three million; (vi)&#160;for the approval, on a non-binding advisory basis, of the compensation of the Company&#8217;s named executive officers; and (vii)&#160;for the approval, on a non-binding advisory basis, to hold advisory votes on the compensation of the Company&#8217;s named executive officers every three&#160;years. If any other matters are properly presented for consideration at the meeting, the individuals named as proxy holders, Ms.&#160;Beth Jantzen and Ms.&#160;Judith Murrah, will vote the shares that they represent on those matters as recommended by the Board of Directors. If the Board of Directors does not make a recommendation, then they will vote in accordance with their best judgment. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">What if I am a beneficial owner and do not give voting instructions to my broker or other nominee?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">As a beneficial owner, in order to ensure your shares are voted in the way you would like, you must provide voting instructions to your bank, broker, or other nominee by the deadline provided in the materials you receive from your bank, broker, or other nominee or vote by mail, telephone or Internet according to instructions provided by your bank, broker, or other nominee. If you do not provide voting instructions to your bank, broker, or other nominee, whether your shares can be voted by such person or entity depends on the type of item being considered for vote. </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Non-Discretionary Items.&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;">The election of directors, the Warrant Exercise Proposal, the Plan&#160;Amendment Proposal, the Say on Pay Proposal and the Say on Frequency Proposal are non- discretionary items and may not be voted on by brokers, banks or other nominees who have not received specific voting instructions from beneficial owners. A broker non-vote occurs when a broker holding shares for a beneficial owner does not vote on a particular proposal because the broker does not have discretionary voting authority and has not received voting instructions from the beneficial owner. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">6</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Discretionary Items.&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;">The ratification of the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending September&#160;30, 2025 and the Reverse Split Proposal are discretionary items. Generally, brokers, banks and other nominees that do not receive voting instructions from beneficial owners may vote on this proposal in their discretion if they so choose. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">We encourage you to provide instructions to your broker regarding the voting of your shares.</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Can I change my vote or revoke my proxy?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">If you are a stockholder of record, you may revoke your proxy by (i)&#160;entering a new vote by telephone or over the Internet up until 11:59&#160;P.M. Eastern Time on May&#160;21, 2025, (ii)&#160;attending the Annual Meeting and voting in person (although attendance at the Annual Meeting will not in and of itself revoke a proxy) or (iii)&#160;entering a new vote by mail. Any written notice of revocation or subsequent proxy card must be received by the Secretary of the Company prior to the holding of the vote at the Annual Meeting at 11:00&#160;a.m., Eastern Time, on May&#160;22, 2025. Such written notice of revocation or subsequent proxy card should be hand delivered to the Secretary of the Company or sent to the Company&#8217;s principal executive offices at 50 Health Sciences Drive, Stony Brook, New York 11790, Attention: Corporate Secretary. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">If a broker, bank, or other nominee holds your shares, you must contact them in order to find out how to change your vote. </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">The last proxy or vote that we receive from you will be the vote that is counted.</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Who will bear the cost of soliciting votes for the Annual Meeting?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We will pay the entire cost of preparing, assembling, printing, mailing, and distributing these proxy materials and soliciting votes. If you choose to access the proxy materials and/or vote over the Internet, you are responsible for Internet access charges you may incur. If you choose to vote by telephone, you are responsible for telephone charges you may incur. In addition to the mailing of these proxy materials, the solicitation of proxies or votes may be made in person, by telephone, or by electronic communication by our directors, officers, and employees, who will not receive any additional compensation for such solicitation activities. We have engaged Kingsdale Advisors to assist in soliciting proxies on our behalf. Kingsdale Advisors may solicit proxies personally, electronically or by telephone. We have agreed to pay Kingsdale Advisors a fee of $10,500 and to reimburse them for certain out-of-pocket disbursements and expenses. We have also agreed to indemnify Kingsdale Advisors and its employees against certain liabilities arising from or in connection with the engagement. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">What is &#8220;householding&#8221; and where can I get additional copies of proxy materials?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">For information about householding and how to request additional copies of proxy materials, please see the section captioned &#8220;Householding of Proxy Materials.&#8221; </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Whom may I contact if I have other questions about the Annual Meeting or voting?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">You may contact the Company at 50 Health Sciences Drive, Stony Brook, New York 11790, Attention: Beth Jantzen, or by telephone at 631-240-8800, or you may contact Kingsdale Advisors by telephone at&#160;</span><span style="letter-spacing:0.2pt;white-space:nowrap;">1-855-682-9644</span><span style="letter-spacing:0.2pt;">. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Where can I find the voting results of the Annual Meeting?</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We will announce preliminary voting results at the Annual Meeting. Final voting results will be disclosed on a Form 8-K filed with the SEC within four business days after the Annual Meeting, which will also be available on our website. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">We encourage you to vote by proxy over the Internet, by mail or telephone pursuant to instructions provided on the proxy card.</span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">7</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tPN1E">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">PROPOSAL NO. 1 ELECTION OF DIRECTORS</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Six directors (constituting the entire Board of Directors) are to be elected at the Annual Meeting to serve until the 2025 Annual Meeting of Stockholders, or until their respective successors are elected and qualified. All of the nominees are our current directors and have been nominated for re-election by our Board of Directors. The Company intends that the proxy in the form presented will be voted, unless otherwise indicated, for the election of these nominees to serve until the 2025 Annual Meeting of Stockholders, or until their successors are elected and qualified. Our Certificate of Incorporation provides that the number of directors that constitute the whole Board of Directors shall be fixed exclusively in the manner designated in the Company&#8217;s Bylaws. The Company&#8217;s Bylaws provide that the number of directors is determined by resolution of the Board of Directors, provided that the Board of Directors shall consist of at least one member. As of the Annual Meeting, the number of directors shall be fixed at six. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Should one or more of these nominees be unable to accept nomination or election as a director, the individuals named as proxy holders, Ms.&#160;Beth Jantzen and Ms.&#160;Judith Murrah, will vote the shares that they represent for such other persons as the Board of Directors may recommend. The Board of Directors has no present knowledge that any of the nominees for director named below will be unavailable to serve. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The directors standing for re-election, together with their ages as of April&#160;3, 2025, and certain other information, are: </span>
        </div>
        <table style="width:456pt;margin-bottom:5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Director </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:13.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.16pt;">Age </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:27.99pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Year
                <br/>
                First
                <br/>
                Became
                <br/>
                Director </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:282.75pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Principal Occupation and Other Board of
                <br/>
                Directors Service During the Past Five Years </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:96pt;">
              <span style="letter-spacing:0.2pt;">James A. Hayward,
              <br/>
              Ph.D., Sc.D. </span>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">71 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:27.99pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">2006 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 2.167pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Dr.&#160;James A. Hayward has been our Chief Executive Officer since March&#160;17, 2006, a director on the Board of Directors since September&#160;28, 2005 and the Chairman of the Board of Directors since June&#160;12, 2007. He was previously our acting Chief Executive Officer from October&#160;5, 2005 until March&#160;17, 2006 and our President from June&#160;12, 2007 until December&#160;13, 2024. He also served as Acting Chief Financial Officer from August&#160;20, 2013 through October&#160;13, 2013. Dr.&#160;Hayward received his Ph.D. in Molecular Biology from the State University of New York at Stony Brook (&#8220;Stony Brook&#8221;) in 1983 and an honorary Doctor of Science from the same institution in 2000. His experience with public companies began with the co-founding of one of England&#8217;s first biotechnology companies&#8201;&#8201;&#8212;&#8201;&#8201;Biocompatibles, Ltd. Following this, Dr.&#160;Hayward was at the Estee Lauder companies for five&#160;years, eventually becoming Head of Product Development. In 1990, he founded The Collaborative Group, a provider of products and services to the biotechnology, pharmaceutical and consumer-product industries based in Stony Brook, where he served as Chairman, President and Chief Executive Officer for 14&#160;years. During this period, The Collaborative Group created several businesses, including The Collaborative BioAlliance, a contract developer and manufacturer of human protein products that was sold to Dow Chemical in 2002, and Collaborative Labs, a service provider and manufacturer of ingredients for skincare and dermatology that was sold to Engelhard (now BASF) in 2004. He is the winner of the first Helix Award from BIO and has been twice elected Entrepreneur of the Year by Inc. Magazine and the Long Island Technology Hall of Fame. He has served on the Boards of The Stony Brook Foundation, the NYS Research Foundation, and the NYS Regents Advisory Board. Dr.&#160;Hayward also serves on the advisory board of the Manufacturing and Technology Resource Consortium of Stony Brook University, and </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">8</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Director </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:13.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.16pt;">Age </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:27.99pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Year
                <br/>
                First
                <br/>
                Became
                <br/>
                Director </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:282.75pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Principal Occupation and Other Board of
                <br/>
                Directors Service During the Past Five Years </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">on the boards of NeoMatrix Formulations, Inc. and the TNPO2 Foundation. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Dr.&#160;Hayward&#8217;s experience and senior leadership positions in companies in the biotechnology, pharmaceutical and consumer-product industries, and specifically his qualifications and skills in the areas of general operations, financial operations and administration, as well as his role as the Company&#8217;s Chief Executive Officer, led the Board of Directors to conclude that Dr.&#160;Hayward should serve as a director of the Company. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:96pt;">
              <span style="letter-spacing:0.2pt;">Robert B. Catell </span>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">88 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">2016 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Robert B. Catell has been a member of the Board of Directors since October&#160;7, 2016. Mr.&#160;Catell serves as Chairman of the Advanced Energy Research and Technology Center at Stony Brook and Chair Emeritus of the Cristo Rey Brooklyn High School. He also serves on the board of several businesses and not-for-profit organizations, including Alternative Packaging Solutions, Colin Powell School for Civic and Global Leadership, Department of Education: Diocese of Rockville Centre, Feinstein Institute for Medical Research, Futures in Education Endowment Fund, Long Island Association, National Petroleum Council, St.&#160;Francis Hospital Foundation, and Utility Technology Solutions. Mr.&#160;Catell was formerly Chairman and CEO of KeySpan Corporation and KeySpan Energy Delivery (formerly Brooklyn Union Gas), Chairman of National Grid, U.S. and Deputy Chairman of National Grid plc, upon National Grid&#8217;s acquisition of KeySpan, and has served on numerous boards. Mr.&#160;Catell chaired the New York State Business Council from 2002 to 2003 and the Brooklyn Chamber of Commerce from 1994 to 1995. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Mr.&#160;Catell holds both a Master&#8217;s and a Bachelor&#8217;s degree in Mechanical Engineering from City College of New York and is a registered Professional Engineer. He has attended Columbia University&#8217;s Executive Development Program, and the Advanced Management Program at the Harvard Business School. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">The Board of Directors believe that Mr.&#160;Catell&#8217;s extensive executive-level management experience, including as a director at other private and public companies and within regulated and technical industries, qualifies him to serve as one of our directors. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:96pt;">
              <span style="letter-spacing:0.2pt;">Joseph D. Ceccoli </span>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">62 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">2014 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Joseph D. Ceccoli has been a member of the Board of Directors since December&#160;3, 2014. Since 2010, Mr.&#160;Ceccoli has been the Founder, President and CEO of Biocogent, LLC (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Biocogent</span><span style="letter-spacing:0.2pt;">&#8221;), a bioscience company located at the Stony Brook Long Island High Technology Incubator. Biocogent is focused on the invention, development and commercialization of skin-active molecules and treatment products used in regulated (over-the-counter / med-care), personal care and consumer products. Prior to starting Biocogent, Mr.&#160;Ceccoli was Global Director of Operations for BASF Corporation, a global Fortune 100 company and the world&#8217;s largest global chemical company, where he was responsible for the integration, operations and growth of domestic and overseas business&#160;units from 2007 to 2008. Prior to BASF, </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">9</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Director </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:13.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.16pt;">Age </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:27.99pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Year
                <br/>
                First
                <br/>
                Became
                <br/>
                Director </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:282.75pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Principal Occupation and Other Board of
                <br/>
                Directors Service During the Past Five Years </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Mr.&#160;Ceccoli was a General Manager for Engelhard Corporation, a U.S.-based Fortune 500 company and chief operating officer of Long Island-based The Collaborative Group from 2004 to 2007. Mr.&#160;Ceccoli holds a Bachelor of Science (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">B.S.</span><span style="letter-spacing:0.2pt;">&#8221;) degree in Biotechnology from Rochester Institute of Technology and advanced professional training in various pharmaceutical sciences, emulsion chemistry, engineering and management disciplines. He is a member of numerous professional organizations such as the American Chemical Society and the Society of Cosmetic Chemists. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Mr.&#160;Ceccoli has authored and co-authored 16 technical papers that have appeared in peer reviewed and industry specific journals and magazines and is inventor on 16 patents. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">The Board of Directors believes that Mr.&#160;Ceccoli&#8217;s experience across the bioscience and chemical markets, including in global and U.S.-based operations and management, enriches our Board of Directors. Mr.&#160;Ceccoli&#8217;s experience as an executive officer and director of several bioscience and chemical companies and organizations led the Board of Directors to conclude that he should serve as a director of the Company. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:96pt;">
              <span style="letter-spacing:0.2pt;">Yacov A. Shamash </span>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">75 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">2006 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Dr.&#160;Yacov A. Shamash has been a member of the Board of Directors since March&#160;17, 2006. Dr.&#160;Shamash is a Professor of Electrical and Computer Engineering at Stony Brook, a position he has held since 1992. From 1992 to 2015, he was the Dean of Engineering and Applied Sciences, and from 1995 to 2004, Dr.&#160;Shamash was also the Dean of the Harriman School for Management and Policy at Stony Brook. He served as Vice President for Economic Development at Stony Brook from 2001&#8201;to&#8201;2019. He was founder of the New York State Center for Excellence in Wireless and Information Technology, and the New York State Center for Excellence in Advanced Energy Research, at Stony Brook. Dr.&#160;Shamash developed and directed the NSF Industry/University Cooperative Research Center for the Design of Analog/Digital Integrated Circuits from 1989 to 1992 and also served as Chairman of the Electrical and Computer Engineering Department at Washington State University from 1985 until 1992. Dr.&#160;Shamash serves on the board of directors of public companies Comtech Telecommunications Corp. and Keytronic Corp. He is on the boards of several not for profit organizations: the Long Island First Robotics and Listnet. Dr.&#160;Shamash holds a Ph.D. degree in Electrical Engineering from the Imperial College of Science and Technology in London, England. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Dr.&#160;Shamash encounters leaders of businesses large and small, regional and global in their reach, on a daily basis and, as a member of our Board of Directors, Dr.&#160;Shamash brings to our Board of Directors his valuable experience gained from serving as a director at other private and public companies. The Board of Directors believes that Dr.&#160;Shamash&#8217;s technical experience and other abilities make him a valuable member of the Board of Directors. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">10</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:1.80999999999995pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Director </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:13.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.16pt;">Age </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:27.99pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Year
                <br/>
                First
                <br/>
                Became
                <br/>
                Director </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:282.75pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Principal Occupation and Other Board of
                <br/>
                Directors Service During the Past Five Years </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:96pt;">
              <span style="letter-spacing:0.2pt;">Sanford R. Simon </span>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">82 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:27.99pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">2006 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Dr.&#160;Sanford R. Simon has been a member of the Board of Directors since March&#160;17, 2006. Dr.&#160;Simon was a Professor of Biochemistry, Cell Biology and Pathology at Stony Brook from 1969 to January&#160;2022. He joined the faculty at Stony Brook as an Assistant Professor in 1969 and was promoted to Associate Professor with tenure in 1975. Dr.&#160;Simon was a member of the board of directors of The Collaborative Group from 1995 to 2004. From 1967 to 1969, Dr.&#160;Simon was a Guest Investigator at Rockefeller University. Dr.&#160;Simon received a B.A. in Zoology and Chemistry from Columbia University in 1963 and, a Ph.D. in Biochemistry from Rockefeller University in 1967, and he studied as a postdoctoral fellow with Nobel Prize winner Max Perutz in Cambridge, England. He has maintained an active research laboratory studying aspects of cell invasion in cancer and inflammation, the uses of small molecules in modulating diverse cell functions, and novel strategies of drug delivery; he also teaches undergraduate, graduate, medical and dental students. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Dr.&#160;Simon has worked in the use of large biomolecules in commercial media, and we have made use of his expertise in formulating DNA into commercial carriers for specific customers. As a member of our Board of Directors, Dr.&#160;Simon has advised us on patents, provided technical advice, and introduced us to corporate partners and customers. The Board of Directors believes that Dr.&#160;Simon&#8217;s advice makes him a valuable member of the Board of Directors. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:96pt;">
              <span style="letter-spacing:0.2pt;">Elizabeth Schmalz
              <br/>
              Shaheen </span>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">74 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:27.99pt;text-align:center;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">2017 </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Ms.&#160;Elizabeth M. Schmalz Shaheen has been a member of the Board of Directors since June&#160;1, 2017. She has served as President of American Flavors &amp; Fragrances LLC, a fragrance company, since 2003. Ms.&#160;Schmalz Shaheen also serves as President of her own consulting firm, Betsy Schmalz &amp; Associates. She served as Senior Vice President of Corporate Product Development at Est&#233;e Lauder. Ms.&#160;Schmalz Shaheen&#8217;s responsibilities included overseeing product development for some of the company&#8217;s most prominent brands. Subsequently, she was Executive Vice President of Product Development at Bath and Body Works and Victoria&#8217;s Secret for The Limited. Ms.&#160;Schmalz Shaheen started her senior management career at Revlon with responsibility for new product development for brands including Borghese, Ultima II and Prestige fragrances. She is an active member of Cosmetic Executive Women. She earned a bachelor&#8217;s degree in psychology from Georgian Court University and serves on their Board of Trustees. </span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:27.99pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:282.75pt;white-space:normal;">
              <span style="letter-spacing:0.2pt;">Ms.&#160;Schmalz Shaheen&#8217;s track record of accomplishments as a strategist and products leader led the Board of Directors to conclude she should serve as a director of the Company.</span>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:17.19pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">There are no family relationships between any director, executive officer, or person nominated or chosen by us to become a director or executive officer. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">11</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:460pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Section&#160;16(a) Beneficial Ownership Reporting Compliance</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Section&#160;16(a) of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Exchange Act</span><span style="letter-spacing:0.2pt;">&#8221;), requires our officers and directors and persons who beneficially own more than 10% of any class of our equity securities registered pursuant to Section&#160;12 of the Exchange Act to file reports of securities ownership and changes in such ownership with the SEC. Officers, directors and greater than 10% beneficial owners (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">10% stockholders</span><span style="letter-spacing:0.2pt;">&#8221;) also are required by SEC rules to furnish us with copies of all Section&#160;16(a) forms they file. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Based solely upon a review of such forms filed with the SEC with respect to the fiscal year ended September&#160;30, 2024, as the case may be, and upon written representations from these reporting persons, we believe that none of our officers, directors or 10% stockholders failed to file on a timely basis, reports required by Section&#160;16(a) during fiscal 2024. </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">The Board of Directors unanimously recommends a vote &#8220;FOR&#8221; the election of each of the nominees to the Board of Directors named in this Proposal No. 1.</span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">12</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tPN2R">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">PROPOSAL NO. 2</span>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">RATIFICATION OF APPOINTMENT OF
          <br/>
          INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Our Board of Directors has appointed CBIZ CPAs P.C. (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">CBIZ</span><span style="letter-spacing:0.2pt;">,&#8221; the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">principal accountant</span><span style="letter-spacing:0.2pt;">&#8221; or the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">independent accountant</span><span style="letter-spacing:0.2pt;">&#8221;) as the independent registered public accounting firm to audit our consolidated financial statements as of and for the fiscal year ending September&#160;30, 2025. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">CBIZ has served as our independent registered public accounting firm since January&#160;24, 2025. Since that date, CBIZ has also provided us certain tax and other audit-related services. Previously, Marcum LLP (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Marcum</span><span style="letter-spacing:0.2pt;">&#8221;) served as our independent registered accounting firm from June&#160;23, 2014 until January&#160;24, 2025. On November&#160;1, 2024, CBIZ acquired the attest business of Marcum. On January&#160;24, 2025, we were notified by Marcum that Marcum was declining to serve as the Company&#8217;s independent registered public accounting firm due to CBIZ&#8217;s acquisition of the attest business of Marcum. On January&#160;24, 2025, Marcum resigned as auditors of the Company and, with the approval of the Audit Committee of the Company&#8217;s Board of Directors (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Audit Committee</span><span style="letter-spacing:0.2pt;">&#8221;), CBIZ was engaged as the Company&#8217;s independent registered public accounting firm for the fiscal year ending September&#160;30, 2025. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The reports of Marcum regarding the Company&#8217;s financial statements for the fiscal&#160;years ended September&#160;30, 2024 and 2023, did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except for the inclusion of an explanatory paragraph as to the Company&#8217;s ability to continue as a going concern. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">During the&#160;years ended September&#160;30, 2024 and 2023, and through January&#160;24, 2025, the date of Marcum&#8217;s resignation, there were (a)&#160;no disagreements (as defined in Item&#160;304(a)(1)(iv) of Regulation&#160;S-K and the related instructions) with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Marcum, would have caused Marcum to make reference to such disagreement in its report and (b)&#160;no &#8220;reportable events&#8221; &#8203;(as defined in Item&#160;304(a)(1)(v) of Regulation&#160;S-K and the related instructions). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Prior to engaging CBIZ, the Company did not consult with CBIZ regarding the application of accounting principles to a specific completed or contemplated transaction or regarding the type of audit opinions that might be rendered by CBIZ on the Company&#8217;s financial statements, and CBIZ did not provide any written or oral advice that was an important factor considered by the Company in reaching a decision as to any such accounting, auditing, or financial reporting issue. The Company provided Marcum with a copy of the above disclosure. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Board of Directors has directed that management submit the selection of our independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. Representatives of CBIZ are expected to be present virtually at the Annual Meeting, will have an opportunity to make a statement if they so desire, and will be available to respond to appropriate questions. </span>
        </div>
        <div style="margin-top:11.91pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Audit and Other Fees</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The following table sets forth fees billed to us by our former independent audit firm Marcum during the fiscal&#160;years ended September&#160;30, 2024 and 2023 for: (i)&#160;services rendered for the audit of our annual financial statements and the review of our quarterly financial statements, (ii)&#160;services by our auditor that are reasonably related to the performance of the audit or review of our financial statements and that are not reported as Audit Fees, (iii)&#160;services rendered in connection with tax compliance, tax advice and tax planning, and (iv)&#160;all other fees for services rendered. </span>
        </div>
        <table style="width:456pt;height:93pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:301.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Fiscal year ended
                <br/>
                September&#160;30, 2024 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Fiscal year ended
                <br/>
                September&#160;30, 2023 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">(i) Audit Fees </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">460,204</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">278,105</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">(ii) Audit Related Fees </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">(iii) Tax Fees </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">50,985</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">26,265</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">(iv)&#160;All Other Fees </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:301.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Total Fees </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">511,189</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">304,370</td>
            <td style="padding:0pt;padding-left:13.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">13</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <span style="font-style:italic;letter-spacing:0.2pt;">Audit Fees &#8212;</span><span style="letter-spacing:0.2pt;"> Consists of fees billed for professional services rendered for the audit of our consolidated financial statements, review of the interim consolidated financial statements included in quarterly reports, and services that are normally provided by our independent auditors in connection with statutory and regulatory filings or engagements, including registration statements. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="font-style:italic;letter-spacing:0.2pt;">Audit Related Fees &#8212;</span><span style="letter-spacing:0.2pt;"> Consists of fees billed for assurance and related services that are reasonably related to the performance of the audit or review of our consolidated financial statements and are not reported under &#8220;Audit Fees,&#8221; such as accounting consultation and audits in connection with acquisitions. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="font-style:italic;letter-spacing:0.2pt;">Tax Fees &#8212;</span><span style="letter-spacing:0.2pt;"> Consists of fees billed for professional services for tax compliance, tax advice and tax planning. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-style:italic;letter-spacing:0.2pt;">All Other Fees &#8212;</span><span style="letter-spacing:0.2pt;"> Consists of fees for products and services other than the services reported above. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Board of Directors has considered whether the provision of non-audit services is compatible with maintaining the principal accountant&#8217;s independence and has determined that independence has been maintained. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Audit Committee Report</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Audit Committee operates under a written charter approved by the Board of Directors, which provides that its responsibilities include assisting the Board of Directors in monitoring the integrity of the Company&#8217;s financial statements, the qualifications and independence of the Company&#8217;s independent auditors, the performance of the Company&#8217;s internal audit function and independent auditors and the compliance by the Company with legal and regulatory requirements. For more information on the Audit Committee, see &#8220;Management and Corporate Governance&#8201;&#8212;&#8201;Board of Directors Structure and Committee Composition&#8201;&#8212;&#8201;Audit Committee.&#8221; </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Audit Committee oversees the Company&#8217;s financial reporting process on behalf of the Board of Directors. Management is responsible for the Company&#8217;s internal controls, financial reporting process, and compliance with laws and regulations and ethical business standards. Marcum was responsible for performing an independent audit of the Company&#8217;s consolidated financial statements for the fiscal year ending September&#160;30, 2024 in accordance with the standards of the Public Company Accounting Oversight Board of Directors (United States) (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">PCAOB</span><span style="letter-spacing:0.2pt;">&#8221;). The Audit Committee&#8217;s main responsibility is to monitor and oversee this process. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Audit Committee reviewed and discussed our audited consolidated financial statements as of and for the fiscal year ended September&#160;30, 2024 with management. The Audit Committee discussed with Marcum the matters required to be discussed by PCAOB Auditing Standard No. 16. The Audit Committee has received the written disclosures and the letter from the independent accountant required by applicable requirements of the PCAOB regarding the independent accountant&#8217;s communications with the Audit Committee concerning independence, and has discussed with the independent accountant the independent accountant&#8217;s independence. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Audit Committee considered any fees paid to Marcum for the provision of non-audit related services and does not believe that these fees compromised Marcum&#8217;s independence in performing the audit. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Based on the review and discussions referred to above in this report, the Audit Committee recommended to the Board of Directors that such audited financial statements be included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024 for filing with the SEC. </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">THE AUDIT COMMITTEE </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Yacov Shamash (Chairperson)
          <br/>
          Joseph Ceccoli
          <br/>
          Robert B. Catell </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditors</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services provided by the independent auditors. These services may include audit services, audit-related </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">14</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:512pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">services, tax services and other services. Pre-approval is generally provided for up to one year and any pre- approval is detailed as to the particular service or category of services and is generally subject to a specific budget. The independent auditors and management are required to periodically report to our Audit Committee regarding the extent of services provided by the independent auditors in accordance with this pre-approval, and the fees for the services performed to date. The Audit Committee may also pre-approve particular services on a case-by-case basis. </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:-0.2pt;">The Board of Directors deems Proposal No. 2 &#8220;Ratification of Appointment of Independent Registered Accounting Firm&#8221; to be in the Company and its stockholders&#8217; best interests and unanimously recommends a vote &#8220;FOR&#8221; approval thereof. </span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">15</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tPN3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">PROPOSAL NO. 3 </span>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">GRANTING THE BOARD OF DIRECTORS DISCRETIONARY AUTHORITY FOR 12 MONTHS TO AMEND THE COMPANY&#8217;S CERTIFICATE OF INCORPORATION TO AUTHORIZE A REVERSE STOCK SPLIT OF COMMON STOCK, AT A RATIO IN THE RANGE FROM ONE-FOR-FIVE TO ONE- FOR-FIFTY, WITH SUCH SPECIFIC RATIO TO BE DETERMINED BY THE COMPANY&#8217;S BOARD OF DIRECTORS FOLLOWING THE ANNUAL MEETING</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Introduction</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">At the Annual Meeting, stockholders will be asked to grant the Board of Directors discretionary authority to the Board of Directors for 12&#160;months to amend the Company&#8217;s Certificate of Incorporation (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Reverse Split Amendment</span><span style="letter-spacing:0.2pt;">&#8221;) to effect a reverse stock split (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Reverse Stock Split</span><span style="letter-spacing:0.2pt;">&#8221;) within a range of one-for-five to one-for-fifty, under the Nasdaq Capital Market (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Nasdaq</span><span style="letter-spacing:0.2pt;">&#8221;) listing rules, with the exact ratio, if any, to be determined by the Company&#8217;s Board of Directors (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Reverse Stock Split Ratio</span><span style="letter-spacing:0.2pt;">&#8221;) at any time prior to the one-year anniversary date of the Annual Meeting. Upon the effectiveness of the Reverse Split Amendment (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Split Effective Time</span><span style="letter-spacing:0.2pt;">&#8221;), the issued shares of Common Stock outstanding immediately prior to the Split Effective Time will be reclassified into a smaller number of shares. The ultimate Reverse Stock Split Ratio will be based on a number of factors, including market conditions, existing and expected trading prices for the Common Stock and the listing requirements of Nasdaq. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The proposed Reverse Split Amendment to effect the Reverse Stock Split is attached as </span><span style="font-style:italic;letter-spacing:0.2pt;">Appendix&#160;A</span><span style="letter-spacing:0.2pt;"> to this Proxy Statement. The form of the Reverse Split Amendment, as more fully described below, will effect the reverse stock split but will not change the number of authorized shares of Common Stock or preferred stock, or the par value of the Common Stock or preferred stock. The following discussion is qualified in its entirety by the full text of the Reverse Split Amendment, which is incorporated herein by reference. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Even if stockholders approve the Reverse Split Proposal, we reserve the right not to effect the Reverse Stock Split if the Board of Directors does not deem it to be in the best interests of the Company and its stockholders. The Board of Directors believes that granting this discretion provides the Board of Directors with maximum flexibility to act in the best interests of the Company and its stockholders. If this Reverse Split Proposal is approved by the stockholders, the Board of Directors will have the authority, in its sole discretion, without further action by the stockholders, to effect the Reverse Stock Split within the ratios and during the period set forth above. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Board of Directors&#8217; decision as to whether and when to effect the Reverse Stock Split will be based on a number of factors, including prevailing market conditions, existing and expected trading prices for our Common Stock, Nasdaq listing requirements, actual or forecasted results of operations, and the likely effect of such results on the market price of our Common Stock. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Purpose</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Board approved the proposal approving the Reverse Split Amendment for the following reasons: </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the Board believes that the Reverse Stock Split is the best option available to the Company to increase its stock price should it be required for continued listing on Nasdaq; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the Board believes a higher stock price may help generate investor interest in the Company and help the Company attract and retain employees; and </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">if the Reverse Stock Split successfully increases the per share price of the Common Stock, the Board believes this increase may increase trading volume in the Common Stock and facilitate future financings by the Company. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Reasons for the Reverse Split Proposal and Nasdaq Listing Requirements</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">We believe that the Reverse Stock Split will make our Common Stock more attractive to a broader range of institutional and other investors, and we believe that the current per share trading price of our Common Stock may affect its acceptability to certain institutional investors, professional investors and other members of the investing public. Many brokerage houses and institutional investors have internal policies </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">16</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. In addition, some of those policies and practices may function to make the processing of trades in low-priced stocks economically unattractive to brokers. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">If we were unable to maintain compliance with the minimum bid price of $1.00 per share as set forth in Nasdaq Listing Rule&#160;5550(a)(2) (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Minimum Bid Price Requirement</span><span style="letter-spacing:0.2pt;">&#8221;) and our Common Stock were delisted from Nasdaq, trading of our Common Stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQX, the OTCQB or the OTC Pink markets maintained by OTC Markets Group Inc. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our Common Stock on an over-the-counter market, and many investors would likely not buy or sell our Common Stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our Common Stock would be subject to SEC rules as a &#8220;penny stock,&#8221; which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher&#160;percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our Common Stock. Under new Nasdaq Rule&#160;5810(c)(3)(A)(iv), if the price of our Common Stock fails to satisfy the Minimum Bid Price Requirement (A)&#160;within one year after effectiveness of a reverse stock split or (B)&#160;if the Company has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more -to -one, then the Company shall not be eligible for any compliance period specified in Rule&#160;5810(c)(3)(A) and the Listing Qualifications Department will issue a Staff Delisting Determination under Rule&#160;5810 with respect to that security, and the Common Stock would be subject to delisting by Nasdaq without any opportunity for a cure period. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Company completed a reverse stock split March&#160;14, 2025 (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">March&#160;2025 Reverse Stock Split</span><span style="letter-spacing:0.2pt;">&#8221;). If the Company implements the Reverse Stock Split after the price of our Common Stock fails to satisfy the Minimum Bid Price Requirement and on or before March&#160;14, 2026, the Company will not be eligible for any compliance period specified in Rule&#160;5810(c)(3)(A) and the Listing Qualifications Department will issue a Staff Delisting Determination under Rule&#160;5810 with respect to our Common Stock, which would then be subject to delisting by Nasdaq. In addition, if the Company implements the Reverse Stock Split after the price of our Common Stock fails to satisfy the Minimum Bid Price Requirement and on or before March&#160;14, 2027 with a cumulative ratio combined with the March&#160;2025 Reverse Stock Split of 250 shares or more -to -one, the Company will not be eligible for any compliance period specified in Rule&#160;5810(c)(3)(A) and the Listing Qualifications Department will issue a Staff Delisting Determination under Rule&#160;5810 with respect to our Common Stock, which would then be subject to delisting by Nasdaq. If the Company effects the Reverse Stock Split while its Common Stock satisfies the Minimum Bid Price Requirement, the Reverse Stock Split would not trigger delisting under new Nasdaq Rule&#160;5810(c)(3)(A)(iv). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">For these reasons and others, delisting would adversely affect the liquidity, trading volume, investor interest and price of our Common Stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise capital. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Reverse Stock Split Ratio</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">If approved by stockholders, this Reverse Split Proposal would permit but not require the Board to effect the Reverse Stock Split at any time prior to the one-year anniversary date of the Annual Meeting by the Reverse Stock Split Ratio, with the specific ratio to be fixed within this range by the Board in its sole discretion without further stockholder approval. We believe that enabling the Board to fix the specific Reverse Stock Split Ratio within the stated range will provide us with the flexibility to implement it in a manner designed to maximize the anticipated benefits for our stockholders. In fixing the Reverse Stock Split Ratio, the Board may consider, among other things, factors such as: </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the total number of shares of Common Stock outstanding; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Nasdaq requirements for the continued listing of Common Stock; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">17</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the historical trading price and trading volume of Common Stock; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the then prevailing trading price and trading volume for Common Stock; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the anticipated impact of the Reverse Stock Split on the trading price of and market for Common Stock; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the administrative and transaction costs associated with potential exchange ratios; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">potential financing opportunities; and </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">prevailing general market and economic conditions. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Board will have sole discretion as to the Reverse Stock Split Ratio, within the range specified in this proposal, and any implementation and the exact timing of the Reverse Stock Split prior to the one-year anniversary date of the Annual Meeting. The Board may also determine that the Reverse Stock Split is no longer in the best interests of the Company and its stockholders and decide to abandon the Reverse Stock Split at any time before, during or after the Annual Meeting and prior to its effectiveness, without further action by the stockholders. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Effectiveness of the Reverse Stock Split</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">If approved by our stockholders, the Reverse Stock Split would become effective upon the filing of the Reverse Split Amendment with the Secretary of State of the State of Delaware, or at the later time set forth in the Reverse Split Amendment, which will constitute the Split Effective Time. The exact timing of the Reverse Split Amendment will be determined by the Board based on its evaluation as to when such action will be the most advantageous to the Company and its stockholders. In addition, the Board reserves the right, notwithstanding stockholder approval and without further action by the stockholders, to abandon the Reverse Split Amendment and the Reverse Stock Split if, at any time prior to the effectiveness of the filing of the Reverse Split Amendment with the Secretary of State of the State of Delaware, the Board, in its sole discretion, determines that it is no longer in the best interests of the Company and its stockholders to proceed. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The proposed form of Reverse Split Amendment to effect the Reverse Stock Split is attached as </span><span style="font-style:italic;letter-spacing:0.2pt;">Appendix&#160;A</span><span style="letter-spacing:0.2pt;"> to this Proxy Statement. Any Reverse Split Amendment to effect the Reverse Stock Split will include the Reverse Stock Split Ratio fixed by the Board, within the range approved by the stockholders. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Potential Market Effects of the Reverse Stock Split</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Reducing the number of outstanding shares of Common Stock through the Reverse Stock Split is intended, absent other factors, to increase the per share market price of our Common Stock. The market price of our Common Stock will also be based on, and may be adversely affected by, our performance, financial results market conditions, the market&#8217;s perception of our business and other factors which are unrelated to the number of shares outstanding. As a result, there can be no assurance that the Reverse Stock Split, if completed, will result in the intended benefits described above, that the market price of our Common Stock will increase following the Reverse Stock Split or that the market price of the Common Stock will not decrease in the future. Additionally, Applied DNA Sciences cannot assure you that the market price per share of Common Stock after the Reverse Stock Split will increase in proportion to the reduction in the number of shares of Common Stock outstanding before the Reverse Stock Split. In addition, the Reverse Stock Split may not result in a market price per share that will attract certain segments of the institutional investor community and the investing public that previously refrained from investing in Applied DNA Sciences because of the low market price of the Common Stock, especially if we are listed on the OTCQB or OTC Pink markets. If the Reverse Stock Split is effected and the market price of the Common Stock declines, the&#160;percentage decline as an absolute number and as a&#160;percentage of the overall market capitalization of the Company may be greater than would occur in the absence of the Reverse Stock Split. Furthermore, the liquidity of the Common Stock could be adversely affected by the reduced number of shares that would be outstanding after the Reverse Stock Split. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">In evaluating the Reverse Split Proposal, in addition to the considerations described above, the Board also took into account various negative factors associated with reverse stock splits generally. These factors </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">18</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">include: the negative perception of reverse stock splits held by some investors, analysts and other stock market participants; the fact that the stock price of some companies that have effected reverse stock splits has subsequently declined in share price and corresponding market capitalization; the adverse effect on liquidity that might be caused by a reduced number of shares outstanding; the costs associated with implementing a reverse stock split; and the fact that the Company recently completed the March&#160;2025 Reverse Stock Split and how it is affected by new Nasdaq Rule&#160;5810(c)(3)(A)(iv), as described above. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Potential Increased Investor Interest</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">On April&#160;3, 2025, the Company&#8217;s Common Stock closed at $1.66 per share. An investment in the Common Stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a&#160;percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide coverage of lower priced stocks. Also, the Board believes that most investment funds are reluctant to invest in lower priced stocks. The Board believes that the anticipated higher market price expected to result from the Reverse Stock Split will reduce, to some extent, the negative effects of the practices of brokerage houses and investors described above on the liquidity and marketability of the Common Stock. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">There are risks associated with the Reverse Stock Split, including that the Reverse Stock Split may not result in an increase in the per share price of the Common Stock. The Company cannot predict whether the Reverse Stock Split will increase the market price for the Common Stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that: </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the market price per share of the Common Stock after the Reverse Stock Split will rise in proportion to the reduction in the number of shares of the Common Stock outstanding before the Reverse Stock Split; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the Reverse Stock Split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the Reverse Stock Split will result in a per share price that will increase the ability of the Company to attract and retain employees; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the market price per share will either exceed or remain in excess of $1.00, the Minimum Bid Price Requirement by Nasdaq for continued listing; or </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">the Company would otherwise meet the Nasdaq listing requirements even if the per share market price of the Common Stock after the Reverse Stock Split meets the Minimum Bid Price Requirement. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The market price of the Common Stock will also be based on the Company&#8217;s performance and other factors, some of which are unrelated to the number of shares outstanding. If the Reverse Stock Split is effected and the market price of the Common Stock declines, the&#160;percentage decline as an absolute number and as a&#160;percentage of the overall market capitalization of the Company may be greater than would occur in the absence of a Reverse Stock Split. Furthermore, the liquidity of the Common Stock could be adversely affected by the reduced number of shares that would be outstanding after the Reverse Stock Split. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Potential Effects of Proposed Reverse Split Amendment</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">If our stockholders approve the Reverse Split Proposal and the Board effects the Reverse Stock Split, the number of shares of Common Stock issued and outstanding will be reduced, depending upon the Reverse Stock Split Ratio determined by the Board. The Reverse Stock Split will affect all holders of our Common Stock uniformly and will not affect any stockholder&#8217;s&#160;percentage ownership interest in the Company, except that, as described below in &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Fractional Shares</span><span style="letter-spacing:0.2pt;">,&#8221; holders of our Common Stock otherwise entitled to a fractional share as a result of the Reverse Stock Split because they hold a number of shares not evenly divisible by the Reverse Stock Split Ratio will, in lieu of a fractional share, receive one whole share of Common Stock. In addition, the Reverse Stock Split will not affect any stockholder&#8217;s proportionate voting power (subject to the treatment of fractional shares). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Reverse Stock Split alone would have no effect on our authorized capital stock, and the total number of authorized shares would remain the same as before the Reverse Stock Split. This would have the </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">19</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">effect of increasing the number of shares of our Common Stock available for issuance. The additional available shares would be available for issuance from time to time at the discretion of the Board when opportunities arise, without further stockholder action or the related delays and expenses, except as may be required for a particular transaction by law, the rules of any exchange on which our securities may then be listed, or other agreements or restrictions. Any issuance of additional shares of our Common Stock would increase the number of outstanding shares of our Common Stock and (unless such issuance was pro-rata among existing stockholders) the&#160;percentage ownership of existing stockholders would be diluted accordingly. In addition, any such issuance of additional shares of our Common Stock could have the effect of diluting the earnings per share and book value per share of outstanding shares of our Common Stock. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">In addition to sales of our Common Stock, if our stockholders approve the Reverse Split Proposal and the Board effects the Reverse Stock Split, the additional available shares of our Common Stock would also be available for conversions of convertible securities that we may issue, acquisition transactions, strategic relationships with corporate and other partners, stock splits, stock dividends and other transactions that may contribute to the growth of our business. Any decision to issue equity will depend on, among other things, our evaluation of funding needs, developments in business and technologies, current and expected future market conditions and other factors. There can be no assurance, however, even if the Reverse Split Proposal is approved and the Reverse Stock Split is implemented, that any financing transaction or other transaction would be undertaken or completed. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Reverse Stock Split will not change the terms of our Common Stock. After the Reverse Stock Split, the shares of Common Stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to Common Stock now authorized. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Reverse Stock Split may result in some stockholders owning &#8220;odd-lots&#8221; of less than 100 shares of Common Stock. Brokerage commissions and other costs of transactions in odd-lots are generally higher than the costs of transactions in &#8220;round-lots&#8221; of even multiples of 100 shares. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">After the Split Effective Time, the Company will continue to be subject to the periodic reporting and other requirements of the Exchange Act. Subject to compliance with applicable continued listing requirements, our Common Stock will continue to be listed on Nasdaq and traded under the symbol &#8220;APDN,&#8221; although the exchange will add the letter &#8220;D&#8221; to the end of the trading symbol for a period of 20 trading days after the Split Effective Time to indicate that a reverse stock split has occurred. After the Split Effective Time, it is expected that our Common Stock will have a new CUSIP number. The Reverse Stock Split is not intended as, and will not have the effect of, a &#8220;going private transaction&#8221; as described by Rule&#160;13e-3 under the Exchange Act. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">After the Split Effective Time, the post-split market price of our Common Stock may be less than the pre-split price multiplied by the Reverse Stock Split Ratio. In addition, a reduction in the number of shares outstanding may impair the liquidity for our Common Stock, which may reduce the value of the Common Stock. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Beneficial Holders of Common Stock</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Upon the implementation of the Reverse Stock Split, the Company intends to treat shares held by stockholders through a stockbroker, bank or other nominee in the same manner as registered stockholders whose shares are registered in their names. Stockbrokers, banks or other nominees will be instructed to effect the Reverse Stock Split for their beneficial holders holding Common Stock in street name. However, these stockbrokers, banks or other nominees may have different procedures than registered stockholders for processing the Reverse Stock Split. Stockholders who hold shares of Common Stock with a stockbroker, bank or other nominee and who have any questions in this regard are encouraged to contact their stockbrokers, banks or other nominees. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Registered &#8220;Book-Entry&#8221; Holders of Common Stock</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Certain registered holders of Common Stock may hold some or all of their shares electronically in book- entry form with our transfer agent. These stockholders do not have stock certificates evidencing their ownership of the Common Stock. They are, however, provided with statements reflecting the number of </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">20</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">shares registered in their accounts. Stockholders who hold shares electronically in book-entry form with our transfer agent will not need to take action to receive evidence of their shares of post-Reverse Stock Split Common Stock. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Fractional Shares</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Company will not issue fractional shares in connection with the Reverse Stock Split. Instead, stockholders who would otherwise be entitled to receive a fractional share as a result of the Reverse Stock Split will receive one whole share of our Common Stock in lieu of such fractional share. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Effect of the Reverse Stock Split on Stock Option Awards and Equity Incentive Plans</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">If the Reverse Stock Split is implemented, proportionate adjustments will be made to the per share exercise price, and the number of shares of our Common Stock issuable upon the exercise, of all outstanding options and to the number of shares of our Common Stock issuable upon the vesting and settlement of all outstanding restricted stock&#160;units (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">RSUs</span><span style="letter-spacing:0.2pt;">&#8221;). These adjustments would result in approximately the same aggregate exercise price being paid upon the exercise of such options, and approximately the same value of shares of our Common Stock being delivered upon the exercise of such options and upon the vesting and settlement of such RSUs, immediately preceding and immediately following the Reverse Stock Split. However, to comply with certain regulations under the Internal Revenue Code of 1986, as amended (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Code</span><span style="letter-spacing:0.2pt;">&#8221;), the per share exercise price of each outstanding option would be rounded up to the nearest whole cent, and the number of shares of our Common Stock that could be acquired upon the exercise of each outstanding option would be rounded down to the nearest whole share. The number of shares of our Common Stock reserved for issuance pursuant to the 2005 Incentive Stock Plan, as amended (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">2005 Plan</span><span style="letter-spacing:0.2pt;">&#8221;), and the Company&#8217;s current 2020 Equity Incentive Plan (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Current Plan</span><span style="letter-spacing:0.2pt;">&#8221;) will be reduced proportionately based upon the Reverse Stock Split Ratio. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Effect of the Reverse Stock Split on Warrants</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">In addition to adjusting the number of shares of our Common Stock, we would adjust all shares underlying any of our outstanding warrants as a result of the Reverse Stock Split, as required by the terms of these securities. In particular, we would reduce the conversion ratio for each instrument, and would increase the applicable exercise price or conversion price in accordance with the terms of each instrument and based on the Reverse Stock Split Ratio. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The company has certain Series&#160;A warrants, Series&#160;B warrants (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Series&#160;B Warrants</span><span style="letter-spacing:0.2pt;">&#8221;) and Series&#160;D Warrants (as defined in Proposal No. 4 below) that include a provision that resets their respective exercise price, conditioned upon the receipt of Warrant Stockholder Approval with respect to the Series&#160;D Warrants as more fully described in Proposal No. 4, in the event of a reverse split of Common Stock, to a price equal to the lesser of (i)&#160;the then exercise price and (ii)&#160;the daily lowest volume weighted average price (VWAP) during the period commencing five trading days immediately preceding and the five trading days commencing on the date we effect a reverse stock split with a proportionate adjustment to the number of shares underlying such warrants. Solely with respect to the Series&#160;D Warrants, the exercise price reset mechanism is subject to a floor of $3.17. Such a reset which results in the issuance of additional shares could result in our shareholders suffering substantial dilution. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Accounting Matters</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The proposed Reverse Split Amendment will not affect the par value of $0.001 of our Common Stock. As a result, at the Split Effective Time, the stated capital on our balance sheet attributable to the Common Stock will be reduced in the same proportion as the Reverse Stock Split Ratio, and the additional paid-in capital account will be credited with the amount by which the stated capital is reduced. The per share net income or loss and net book value of the Common Stock will be reclassified for prior periods to conform to the post-Reverse Stock Split presentation. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Pro Forma Capitalization of Common Stock</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The table below summarizes the Company&#8217;s pro&#160;forma capitalization of Common Stock, as of April&#160;3, 2025, before and after giving effect to a hypothetical reverse stock split of one-for-five (1-for-5), one- for-ten </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">21</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">(1-for-10), one-for-twenty (1-for-20), one-for-twenty-five (1-for-25), one-for-thirty (1-for-30), one- for- thirty-five (1-for-35), one-for-forty (1-for-40), one-for-forty-five (1-for-45) and one-for-fifty (1-for-50). Pursuant to Nasdaq Rule&#160;5550(a)(4), the Company is required to have at least 500,000 publicly held shares. The table below does not include the 10,000,000 shares of preferred stock authorized under the Certificate of Incorporation, none of which is currently outstanding. The Reverse Stock Split alone would have no effect on our authorized capital stock, including our authorized preferred stock. For purposes of the figures below, share numbers have been rounded down to the nearest whole share. </span>
        </div>
      </div>
      <div style="margin-top:12pt;margin-bottom:12pt;margin-left:27.16pt;width:541pt;">
        <table style="width:541pt;margin-bottom:5.61000000000001pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
          <tr style="line-height:7.5pt;height:12.63pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:79.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.875pt 0pt;">
              <div style="text-align:center; line-height:8.44pt; padding-bottom:0pt;">
                <span style="letter-spacing:-0.15pt;">Prior to
                <br/>
                Reverse Stock
                <br/>
                Split </span>
              </div>
            </td>
            <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="52" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.875pt 0pt; width:0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.15pt;">After Reverse Stock Split </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.5pt;height:13.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:79.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.875pt 0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.15pt;">1-for-5 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.875pt 0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.15pt;">1-for-10 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.875pt 0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.15pt;">1-for-20 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.875pt 0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.15pt;">1-for-25 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.875pt 0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.15pt;">1-for-30 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.875pt 0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.15pt;">1-for-35 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.875pt 0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.15pt;">1-for-40 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.875pt 0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.15pt;">1-for-45 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.875pt 0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.15pt;">1-for-50 </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.187pt 0pt 0.5pt 0pt; width:79.2pt;white-space:normal;text-align:left;">
              <div style="margin-left:8pt; text-indent:-8pt; line-height:9.59pt;font-weight:bold;">
                <span style="letter-spacing:-0.16pt;">Authorized Shares of Common Stock</span>
              </div>
            </td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.187pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">200,000,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:79.2pt;white-space:normal;text-align:left;">
              <div style="margin-left:8pt; text-indent:-8pt; line-height:9.59pt;font-weight:bold;">
                <span style="letter-spacing:-0.16pt;">Shares of Common Stock Issued and Outstanding</span><span style=" position:relative; bottom:3.25pt;font-size:5pt;letter-spacing:-0.12pt;">&#65279;(1)</span>
              </div>
            </td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">6,497,790</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">1,299,558</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">649,779</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">324,890</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">259,912</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">216,593</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">185,651</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">162,445</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">144,395</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">129,956</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.447pt 0pt 0.5pt 0pt; width:79.2pt;white-space:normal;text-align:left;">
              <div style="margin-left:8pt; text-indent:-8pt; line-height:9.59pt;font-weight:bold;">
                <span style="letter-spacing:-0.16pt;">Shares of Common Stock Reserved for Future Issuance but not Issued and Outstanding</span><span style=" position:relative; bottom:3.25pt;font-size:5pt;letter-spacing:-0.12pt;">&#65279;(1)(2)</span>
              </div>
            </td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">12,726,817</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">2,545,363</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">1,272,682</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">636,641</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">509,073</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">424,227</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">363,623</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">318,170</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">282,818</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.447pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">254,536</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:2.437pt 0pt 0.5pt 0pt; width:79.2pt;white-space:normal;text-align:left;">
              <div style="margin-left:8pt; text-indent:-8pt; line-height:9.59pt;font-weight:bold;">
                <span style="letter-spacing:-0.16pt;">Shares of Common Stock Available for Future Issuance</span><span style=" position:relative; bottom:3.25pt;font-size:5pt;letter-spacing:-0.12pt;">&#65279;(1)</span>
              </div>
            </td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">180,775,393</td>
            <td style="padding:0pt;padding-left:1.725pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">196,155,079</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">198,077,539</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">199,038,769</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">199,231,015</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">199,359,180</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">199,450,726</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">199,519,385</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">199,572,787</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.437pt 0pt 0.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">199,615,508</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">(1)</span>
          <br/>
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">These estimates do not reflect the potential effects of rounding up of fractional shares that may result from the Reverse Stock Split. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">(2)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes, as of April&#160;3, 2025, (i)&#160;12,719,465 shares issuable upon the exercise of outstanding warrants at a weighted average exercise price of $3.91 (which includes 2,477,035 Private Placement Warrants whose exercise is subject to Warrant Stockholder Approval and excluding the warrant price protection reset included in the Series&#160;Warrants, which is subject to Warrant Stockholder Approval, as more fully described in Proposal No. 4); (ii)&#160;2,027 shares issuable upon the exercise of outstanding stock options, at a weighted average exercise price of $8,540; and (iii)&#160;5,325 shares reserved for future issuance under the 2005 Plan and the Current Plan. Does not include any shares of Common Stock issuable upon the exercise or conversion of securities that may have been issued since April&#160;3, 2025. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">(3)</span>
          <br/>
        </div>
        <div style=" margin-top:3.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-size:10pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The table above does not take into account (i)&#160;the alternative cashless exercise mechanism of the Series&#160;B Warrants, which allows holders of such warrants to receive an aggregate number of shares equal to the product of (x)&#160;the aggregate number of shares of Common Stock that would be issuable upon a cash exercise of the Series&#160;B Warrant and (y)&#160;3.0, and (ii)&#160;the alternative cashless exercise mechanism of the Series&#160;D Warrants, as more fully described in Proposal No. 4 below. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <span style="letter-spacing:-0.2pt;">Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">The following discussion is a general summary of the material U.S. federal income tax consequences of the Reverse Stock Split to U.S. Holders (as defined below) of our Common Stock. This discussion is based on the Code, U.S. Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the Internal Revenue Service (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">IRS</span><span style="letter-spacing:0.2pt;">&#8221;), in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a holder of our Common Stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the Reverse Stock Split. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of our Common Stock that, for U.S. federal income tax purposes, is or is treated as: </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;font-size:10pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">an individual who is a citizen or resident of the United States; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000006pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">22</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">a corporation (or any other entity or arrangement treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any state thereof or the District of Columbia; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">a trust that (1)&#160;is subject to the primary supervision of a U.S. court and all substantial decisions of which are subject to the control of one or more &#8220;United States persons&#8221; &#8203;(within the meaning of Section&#160;7701(a)(30) of the Code) or (2)&#160;has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">This discussion is limited to U.S. Holders who hold our Common Stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to the particular circumstances of a U.S. Holder, including the impact of the Medicare contribution tax on net investment income. In addition, it does not address consequences relevant to U.S. Holders that are subject to special rules, including, without limitation, banks, insurance companies and other financial institutions, real estate investment trusts, regulated investment companies, grantor trusts, tax-exempt organizations or governmental organizations, brokers, dealers or traders in securities, commodities or currencies, stockholders who hold our Common Stock as part of a position in a straddle or as part of a hedging, conversion or integrated transaction for U.S. federal income tax purposes, U.S. Holders that have a functional currency other than the U.S. dollar, U.S. Holders who actually or constructively own 5% or more of our stock, U.S. expatriates and former citizens or long-term residents of the United States, and persons for whom Common Stock constitutes &#8220;qualified small business stock&#8221; within the meaning of Section&#160;1202 of the Code. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">If a partnership (or other entity or arrangement treated as a partnership for U.S. federal income tax purposes) is the beneficial owner of our Common Stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner and the activities of the partnership. Accordingly, partnerships (and other entities or arrangements treated as partnerships for U.S. federal income tax purposes) holding our Common Stock and the partners in such entities should consult their tax advisors regarding the U.S. federal income tax consequences of the proposed Reverse Stock Split to them. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">In addition, the following discussion does not address the U.S. federal estate and gift tax, alternative minimum tax, or state, local and non-U.S. tax law consequences of the Reverse Stock Split. Furthermore, the following discussion does not address any tax consequences of transactions effected before, after or at the same time as the Reverse Stock Split, whether or not they are in connection with the Reverse Stock Split. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Each stockholder should consult his, her or its own tax advisors concerning the particular U.S. federal tax consequences of the Reverse Stock Split, as well as the consequences arising under the laws of any other taxing jurisdiction, including any state, local or foreign income tax consequences. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Reverse Stock Split is intended to constitute as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code for U.S. federal income tax purposes. Assuming that such treatment is correct, the Reverse Stock Split generally will not result in the recognition of gain or loss for U.S. federal income tax purposes, except potentially with respect to any additional fractions of a share of our Common Stock received as a result of the rounding up of any fractional shares that otherwise would be issued, as discussed below. Subject to the following discussion regarding a U.S. Holder&#8217;s receipt of a whole share of our Common Stock in lieu of a fractional share, the adjusted basis of the new Common Stock will be the same as the adjusted basis of the Common Stock exchanged. The holding period of the new, post-Reverse Stock Split Common Stock resulting from implementation of the Reverse Stock Split will include the U.S. Holder&#8217;s respective holding periods for the pre-Reverse Stock Split Common Stock. U.S. Holders who acquired our Common Stock on different dates or at different prices should consult their tax advisors regarding the allocation of the tax basis of such Common Stock. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">As noted above, no fractional shares of our Common Stock will be issued as a result of the Reverse Stock Split. Instead, we will issue one (1)&#160;full share of the post-Reverse Stock Split Common Stock to any U.S. Holder who would have been entitled to receive a fractional share as a result of the process. The U.S. federal income tax consequences of the receipt of such additional fraction of a share of our Common Stock are not clear. A U.S. Holder who receives one (1)&#160;whole share of our Common Stock in lieu of a </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">23</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:412pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">fractional share may recognize income or gain in an amount not to exceed the excess of the fair market value of such share over the fair market value of the fractional share to which such U.S. Holder was otherwise entitled. We are not making any representation as to whether the receipt of one (1)&#160;whole share in lieu of a fractional share will result in income or gain to any U.S. Holder, and U.S. Holders are urged to consult their own tax advisors as to the possible tax consequences of receiving a whole share in lieu of a fractional share in the Reverse Stock Split. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The U.S. federal income tax discussion set forth above does not discuss all aspects of U.S. federal income taxation that may be relevant to a particular stockholder in light of such stockholder&#8217;s circumstances and income tax situation. Accordingly, we urge you to consult with your own tax advisor with respect to all of the potential U.S. federal, state, local and non-U.S. tax consequences to you of the Reverse Stock Split. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Appraisal Rights</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Under the General Corporation Law of the State of Delaware, our stockholders will not be entitled to dissenter&#8217;s rights with respect to the proposed Reverse Split Amendment to effect the Reverse Stock Split, and Applied DNA Sciences does not intend to independently provide stockholders with such rights. </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">The Board of Directors unanimously recommends a vote &#8220;For&#8221; the Reverse Split Proposal.</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">24</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tPN4">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">PROPOSAL NO. 4 </span>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">APPROVAL, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(d), OF THE EXERCISABILITY OF CERTAIN COMMON STOCK PURCHASE WARRANTS, AND THE ISSUANCE OF THE COMMON STOCK UNDERLYING SUCH WARRANTS, WHICH WARRANTS WERE ISSUED IN CONNECTION WITH AN OFFERING OF SECURITIES OF THE COMPANY THAT OCCURRED ON OCTOBER 30, 2024</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">We are seeking stockholder approval, for purposes of complying with Nasdaq Listing Rule&#160;5635(d), for the exercisability of an aggregate of 832,813 warrants, consisting of (i)&#160;406,250 Series&#160;C warrants, each to purchase one share of the Company&#8217;s Common Stock (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Series&#160;C Warrants</span><span style="letter-spacing:0.2pt;">&#8221;), (ii)&#160;406,250 Series&#160;D warrants, each to purchase one share of the Company&#8217;s Common Stock (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Series&#160;D Warrants</span><span style="letter-spacing:0.2pt;">&#8221;, and, together with the Series&#160;C Warrants, the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">October Series&#160;Warrants</span><span style="letter-spacing:0.2pt;">&#8221;) and (iii)&#160;20,313 Placement Agent Warrants, each to purchase one share of the Company&#8217;s Common Stock (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Placement Agent Warrants</span><span style="letter-spacing:0.2pt;">&#8221;, and, together with the October Series&#160;Warrants, the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Private Placement Warrants</span><span style="letter-spacing:0.2pt;">&#8221;), and the issuance of the Common Stock underlying such Private Placement Warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on October&#160;30, 2024. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The information set forth in this Proposal No. 4 is qualified in its entirety by reference to the full text of the form of Purchase Agreement (as defined below), form of Series&#160;C Warrant, form of Series&#160;D Warrant and form of Placement Agent Warrant, attached as exhibits 10.1, 4.2, 4.3 and 4.4, respectively, to our Current Report on Form 8-K filed with the SEC on October&#160;31, 2024. </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Stockholders are urged to carefully read these documents. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Background</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">On October&#160;30, 2024, the Company entered into a securities purchase agreement (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Purchase Agreement</span><span style="letter-spacing:0.2pt;">&#8221;) with certain institutional investors (each, a &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Purchaser</span><span style="letter-spacing:0.2pt;">&#8221; and, collectively, the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Purchasers</span><span style="letter-spacing:0.2pt;">&#8221;), pursuant to which the Company agreed to issue and sell (i)&#160;in a registered direct public offering (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Registered Direct Offering</span><span style="letter-spacing:0.2pt;">&#8221;) of 406,250 shares (&#8220;Shares&#8221;) of the Company&#8217;s Common Stock and pre-funded warrants (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Pre-Funded Warrants</span><span style="letter-spacing:0.2pt;">&#8221;) to purchase up to 406,250 shares of Common Stock, and (ii)&#160;in a concurrent private placement (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Private Placement</span><span style="letter-spacing:0.2pt;">&#8221;, and together with the Registered Direct Offering the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Offering</span><span style="letter-spacing:0.2pt;">&#8221;), unregistered Series&#160;C Warrants to purchase up to 406,250 shares of Common Stock and unregistered Series&#160;D Warrants to purchase up to 406,250 shares of Common Stock. The purchase price for each Share and accompanying Series&#160;C Warrant and Series&#160;D Warrant was $16.00 and the purchase price for each Pre-Funded Warrant and accompanying Series&#160;C Warrant and Series&#160;D Warrant was $16.00. Craig-Hallum Capital Group LLC (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Craig-Hallum</span><span style="letter-spacing:0.2pt;">&#8221; or the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Placement Agent</span><span style="letter-spacing:0.2pt;">&#8221;) acted as placement agent in connection with the Offering. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Pursuant to that certain engagement letter, dated August&#160;23, 2024, by and between the Company and the Placement Agent (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Engagement Letter</span><span style="letter-spacing:0.2pt;">&#8221;), the Company paid the Placement Agent a cash placement fee equal to 6.0% of the aggregate gross proceeds raised in the Offering from sales arranged for by the Placement Agent. Subject to certain conditions, the Company also reimbursed certain expenses of the Placement Agent in connection with the Offering, including but not limited to legal fees, up to a maximum of $100,000. The Company also issued to the Placement Agent, or its respective designees, Placement Agent Warrants (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Placement Agent Warrants</span><span style="letter-spacing:0.2pt;">&#8221;) to purchase up to 20,313 shares of Common Stock (which equals 5.0% of the number of shares of Common Stock and Pre-Funded Warrants offered in the Offering). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Offering closed and the Private Placement Warrants were issued on October&#160;31, 2024. The Company received gross proceeds from the Offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, of approximately $6.5&#160;million. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The exercisability of the Private Placement Warrants will be available only upon receipt of such stockholder approval (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Warrant Stockholder Approval</span><span style="letter-spacing:0.2pt;">&#8221;) as may be required by the applicable rules and regulations of The Nasdaq Stock Market LLC. Each Series&#160;C Warrant has an exercise price of $16.00 per share of Common Stock, will become exercisable upon the first trading day following the Company&#8217;s notice to warrantholders of Warrant Stockholder Approval (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Stockholder Approval Date</span><span style="letter-spacing:0.2pt;">&#8221;), and will expire on the five-year anniversary of the Stockholder Approval Date. Each Series&#160;D Warrant has an exercise </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">25</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">price of $16.00 per share of Common Stock, will become exercisable upon the Stockholder Approval Date, and will expire on the 18-month anniversary of the Stockholder Approval Date. Each Placement Agent Warrant has an exercise price of $16.00 per share of Common Stock, will become exercisable upon the Stockholder Approval Date and will expire on October&#160;30, 2029. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Upon the receipt of Warrant Stockholder Approval, if all Private Placement Warrants are exercised as described in the immediately preceding paragraph (including if the Series&#160;D Warrants are exercised pursuant to the alternative cashless exercise mechanism described below), the Company will have 19,219,282 shares of Common Stock outstanding (based on 6,497,790 shares of Common Stock outstanding as of the Record Date and including 12,719,465 warrants and 2,027 options to purchase Common Stock outstanding as of the Record Date). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">If at the time of exercise there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of, the common stock underlying the Private Placement Warrants, then the Private Placement Warrants may also be exercised, in whole or in part, at such time by means of a cashless exercise, in which case the holder would receive upon such exercise the net number of common shares determined according to the formula set forth in the Private Placement Warrants. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Under the alternate cashless exercise option of the Series&#160;D Warrants, the holder of a Series&#160;D Warrant, has the right to receive, without payment of additional consideration, an aggregate number of shares equal to the product of (x)&#160;the aggregate number of shares of common stock that would be issuable upon a cash exercise of the Series&#160;D Warrant and (y)&#160;1.0. In addition, the Series&#160;D Warrants include a provision that resets their exercise price in the event of a reverse split of our common stock, to a price equal to the lesser of (i)&#160;the then exercise price and (ii)&#160;lowest volume weighted average price (VWAP) during the period commencing five trading days immediately preceding and the five trading days commencing on the date we effect a reverse stock split in the future with a proportionate adjustment to the number of shares underlying the Series&#160;D Warrants, subject to a floor of $3.17. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">On March&#160;14, 2025, we completed the March&#160;2025 Reverse Stock Split. As a result, the exercise price reset mechanism was triggered, which resulted in the number of shares of Common Stock issuable upon exercise of the Series&#160;D Warrants increasing from 406,250 to 2,050,472. The exercise price of the Series&#160;D Warrants was adjusted from $16.00 per share to $3.17 per share. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">In the case of certain fundamental transactions affecting the Company, a holder of Private Placement Warrants, upon exercise of such Private Placement Warrants after such fundamental transaction, will have the right to receive, in lieu of shares of the Common Stock, the same amount and kind of securities, cash or property that such holder would have been entitled to receive upon the occurrence of the fundamental transaction, had the Private Placement Warrants been exercised immediately prior to such fundamental transaction. In lieu of such consideration, a holder of Private Placement Warrants may instead, without exercise, elect to receive a cash payment based upon the Black-Scholes value of their Private Placement Warrants. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Company carefully considered its financing alternatives and the expense of conducting one or more special stockholder meetings to approve the exercise of the Private Placement Warrants pursuant to Nasdaq listing Rule&#160;5635(d) and concluded that the Offering, including the issuance of the Private Placement Warrants, was the best available financing alternative. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We are seeking approval for Proposal No. 4 because, pursuant to the Purchase Agreement, the Engagement Letter and the Private Placement Warrants, we issued the Private Placement Warrants in the Offering, and the Private Placement Warrants are not exercisable until we receive Warrant Stockholder Approval, and we are obligated pursuant to the Purchase Agreement to obtain Warrant Stockholder Approval, as described below. In addition, in the event Warrant Stockholder Approval is obtained and the Private Placement Warrants are exercised for cash, the Company would receive approximately $13,325,000 if the holders of the Series&#160;D warrants do not elect to utilize the alternate cashless exercise option. Alternatively, in the event that Warrant Stockholder Approval is obtained, and the holders of the Series&#160;D Warrants elect to utilize the alternate cashless exercise option, the Company would only receive $6,825,000 if the remaining Private Placement Warrants were exercised for cash. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">26</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:268pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Pursuant to the Purchase Agreement, the Company agreed to file a preliminary proxy statement with respect to obtaining Warrant Stockholder Approval at a special meeting of stockholders (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Special Meeting</span><span style="letter-spacing:0.2pt;">&#8221;) within 20&#160;days following the closing date of the Purchase Agreement and, in the event the Company did not obtain Warrant Stockholder Approval at the Special Meeting, to call a meeting every ninety (90) days after each Special Meeting until either Warrant Stockholder Approval is obtained or the October Series&#160;Warrants are no longer outstanding, whichever is earlier. The Company held the Special Meeting on January&#160;23, 2025, but the meeting was adjourned until February&#160;14, 2025 and then subsequently adjourned until February&#160;28, 2025 as a result of a failure to receive the required quorum to hold such meeting. At the February&#160;28, 2025 re-convening of the Special Meeting, the Company again failed to receive the required quorum to hold the meeting. As such, the Company is now seeking to obtain approval for Proposal No. 4 at the Annual Meeting. If we are able to obtain approval for Proposal No. 4 at the Annual Meeting, we will save time and avoid the expense of having additional meetings to obtain approval. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Nasdaq Stockholder Approval Requirement; Reasons for the Warrant Exercise Proposal</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Nasdaq Listing Rule&#160;5635(d) requires stockholder approval in connection with a transaction, other than a public offering, involving the sale or issuance by the issuer of common stock (or securities convertible into or exchangeable for common stock) equal to 20% or more of the common stock or 20% or more of the voting power of such company outstanding before the issuance for a price that is less than the lower of: (i)&#160;the closing price of the common stock immediately preceding the signing of the binding agreement for the issuance of such securities and (ii)&#160;the average closing price of the common stock for the five trading days immediately preceding the signing of the binding agreement for the issuance of such securities (such price, the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Nasdaq Minimum Price</span><span style="letter-spacing:0.2pt;">&#8221;). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Private Placement Warrants were issued in a private placement which is not a public offering and which resulted in the issuance of securities convertible into our Common Stock equal to more than 20% of the voting power of our outstanding Common Stock below the Nasdaq Minimum Price. Because of this, the Private Placement Warrants provide that they may not be exercised, and therefore have no value, unless stockholder approval of their exercise is obtained. </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">The Board of Directors unanimously recommends a vote &#8220;For&#8221; the Warrant Exercise Proposal.</span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">27</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tPN5">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">PROPOSAL NO. 5 </span>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">APPROVAL OF AN AMENDMENT TO THE COMPANY&#8217;S 2020 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK RESERVED FOR ISSUANCE BY THREE MILLION SHARES</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">We are asking you to approve an amendment to the Company&#8217;s 2020 Equity Incentive Plan, a copy of which is attached as </span><span style="font-style:italic;letter-spacing:0.2pt;">Appendix&#160;B</span><span style="letter-spacing:0.2pt;"> hereto (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Plan&#160;Amendment</span><span style="letter-spacing:0.2pt;">&#8221;), to increase the number of shares of Common Stock authorized for issuance by an additional three million. In this proxy statement, we refer to the Company&#8217;s current 2020 Equity Incentive Plan as the &#8220;Current Plan,&#8221; and we refer to the Current Plan, as modified by the Plan&#160;Amendment, as the &#8220;Amended Plan&#8221;. All shares listed in this section are calculated post Company reverse splits conducted on April&#160;25, 2024 and March&#160;14, 2025 (collectively, the &#8220;Previous Reverse Stock Splits&#8221;). On March&#160;30, 2025, our Board approved the Plan&#160;Amendment, subject to stockholder approval, and directed that the Amended Plan be submitted to our stockholders for their approval at the Annual Meeting. The Amended Plan does not contain any modifications, alterations or revisions of any other term or provision of our Current Plan except with respect to the increase in the share reserve, and for the avoidance of doubt, pursuant to the terms of the Amended Plan, if any potential reverse stock split is approved and implemented pursuant to Proposal No. 3, the number of shares of Common Stock available in the share reserve will be adjusted accordingly. </span>
        </div>
        <div style="text-indent:20pt; margin-top:7.12pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">As of April&#160;3, 2025 and as a result of the Previous Reverse Stock Splits we had only 5,325 shares of Common Stock that remained available for issuance under the Current Plan. If Proposal No. 5 is approved, the Plan&#160;Amendment will become effective with respect to the increase in the number of authorized shares of Common Stock reserved for issuance upon stockholder approval at the Annual Meeting. Without approval by stockholders of the Plan&#160;Amendment, the Company will be unable to continue to grant equity awards once the share pool is depleted, potentially resulting in the loss of employees and difficulties in recruiting new employees. The Company did not grant any equity awards under the Current Plan during the fiscal year ended September&#160;30, 2024 due to the small number of shares of Common Stock available under the Current Plan. If the Plan&#160;Amendment is not approved, the Company will become increasingly reliant on cash-based compensation, which will deplete the Company&#8217;s finite cash resources. Accordingly, our Board recommends the approval of the Plan&#160;Amendment. </span>
        </div>
        <div style="text-indent:20pt; margin-top:7.11pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">We recognize the dilutive impact that our equity compensation program has on our stockholders and continuously strive to balance this concern with the competition for talent in the competitive business environment and talent market, as well as the current market conditions, in which we operate. In determining the appropriate number of shares to request and add to the pool of shares available for issuance, our Board and the Compensation Committee of our Board of Directors (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Compensation Committee</span><span style="letter-spacing:0.2pt;">&#8221;) worked with management to evaluate a number of factors and carefully considered (i)&#160;the potential dilutive impact that the increase would have on our stockholders, (ii)&#160;our historical burn rate and overhang, (iii)&#160;the number of shares remaining available under the Current Plan, (iv)&#160;the realities of equity awards being a key component of designing competitive compensation packages necessary for retaining key talent and directors in a competitive marketplace, specifically in light of our negative operating cashflows and historical operating losses, (v)&#160;our strategic growth plans, and (vi)&#160;the interests of our stockholders. The Compensation Committee of our Board monitors our equity award process to ensure that we maximize stockholder value by granting only the appropriate number of equity awards necessary to attract, reward and retain employees and directors. In addition, the Current Plan includes, and the Amended Plan will include, provisions designed to be less dilutive to stockholders. As described further below, the Current Plan does not, and the Amended Plan will not, contain an &#8220;evergreen&#8221; provision, so the number of shares available for issuance under the Current Plan does not automatically increase each year and likewise will not automatically increase under the Amended Plan. The below table summarizes grants under our Current Plan for the last three fiscal&#160;years. </span>
        </div>
        <table style="width:456pt;height:80.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:305.52pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Options
                <br/>
                Granted </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">RSUs
                <br/>
                Granted </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Weighted Average
                <br/>
                Common Shares
                <br/>
                Outstanding Each
                <br/>
                Year </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:305.52pt;text-align:left;">
              <div style="font-weight:bold;">
                <span style="letter-spacing:-0.2pt;">2022</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">588</td>
            <td style="padding:0pt;padding-left:2.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,968</td>
            <td style="padding:0pt;padding-left:16.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:305.52pt;text-align:left;">
              <div style="font-weight:bold;">
                <span style="letter-spacing:-0.2pt;">2023</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">1,003 </td>
            <td style="padding:0pt;padding-left:2.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">283</td>
            <td style="padding:0pt;padding-left:6.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">13,075</td>
            <td style="padding:0pt;padding-left:16.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:305.52pt;text-align:left;">
              <div style="font-weight:bold;">
                <span style="letter-spacing:-0.2pt;">2024</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.265pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.265pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:16.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">79,321</td>
            <td style="padding:0pt;padding-left:16.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">28</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Maintaining our current equity compensation program is particularly critical at this time when competition for quality personnel is intense in the highly competitive biotechnology marketplace in which we operate, and our ability to successfully execute, compete and deliver value to stockholders could be significantly negatively impacted if we cannot maintain our current equity award practices in support of retaining and attracting key talent. If we are limited in our ability to grant desired equity awards to our employees and other eligible individuals, we may not be able to compete for or retain key talent, and/or we may have to increase cash-based compensation incentives, which could work against our current philosophy of aligning the interests of our personnel with the interests of our stockholders. This course of action could also be a distraction for our management team and employees because it would disrupt the normal and scheduled operations of our compensation programs and restrict their ability to utilize equity grants to retain and motivate our employees and other key talent. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Historically, our ability to offer competitive equity compensation packages was integral to hiring and retaining key performers who are instrumental in the operations of the Company. For these reasons, we believe it is critically important to approve the Plan&#160;Amendment at this time to ensure we have a sufficient number of shares authorized for issuance under the Amended Plan. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Reasons for the Plan&#160;Amendment</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">We are proposing to implement the Plan&#160;Amendment to motivate and retain key employees and to reinforce the alignment of our employees&#8217; interests with those of our shareholders at this critical time as we focus on building our new business focusing on the manufacturing of DNA for biotherapeutic applications. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The number of shares available for issuance under our Current Plan has been significantly decreased due to the Previous Reverse Stock Splits. Considering this fact, our ability to grant equity-based compensation to our employees as a form of pay-for-performance long-term incentives has been greatly diminished, resulting in no equity-based compensation being issued to any employee in Fiscal 2024. The shares available for issuance under our Current Plan would also be impacted by any potential future reverse stock splits. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Over the past twelve&#160;months we have undertaken a number of actions to transform and reinvigorate our business and improve our performance, such as divesting certain operations, realigning our segments and installing new segment management and building our first GMP facility to support our DNA manufacturing for biotherapeutic applications. We have also responded to the most recent conditions by implementing significant cost reduction programs, and reducing the size of our workforce. Equity compensation under the Current Plan is offered to our employees in order to emphasize pay-for-performance in long-term incentives and to more closely align our employees&#8217; interests with our shareholders&#8217; interests. We believe that it is critical to our success to retain and motivate key employees throughout our operations and particularly important as we focus on our new business opportunity relating to the manufacture of DNA for biotherapeutic applications. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">History of the Current Plan</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">On June&#160;30, 2020, our Compensation Committee recommended that our Board approve the Current Plan and submit the Current Plan to a vote of our stockholders. On June&#160;30, 2020, our Board approved the Current Plan, subject to stockholder approval, and directed that the Current Plan be submitted to our stockholders for their approval at the Company&#8217;s annual meeting of stockholders held on September&#160;16, 2020 (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">2020 Annual Meeting</span><span style="letter-spacing:0.2pt;">&#8221;). Our stockholders approved the Current Plan at the 2020 Annual Meeting. The purposes of the Current Plan are to enable the Company to recruit and retain highly qualified employees, directors and consultants; provide them with an incentive for productivity; and provide them with an opportunity to share in the growth and value of the Company. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Current Plan, as originally adopted and adjusted for the Previous Reverse Stock Splits, made 3,500 shares of our Common Stock available for issuance to eligible participants. At a Special Meeting of Stockholders of the Company which took place April&#160;15, 2024, our stockholders approved an amendment to the Current Plan to increase the number of authorized shares of Common Stock available for issuance by 4,000, as adjusted for the Previous Reverse Stock Splits. The maximum number of shares of Common Stock that presently may be issued under the Current Plan in connection with awards is 7,500. On March&#160;30, 2025, the Board approved and adopted the Plan&#160;Amendment, subject to stockholder approval at the </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">29</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Annual Meeting, to increase the number of authorized shares of Common Stock reserved for issuance pursuant to the Current Plan by 3,000,000. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Remaining Share Reserve</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">As of April&#160;3, 2025, there were 6,497,790 shares of our Common Stock outstanding. Upon the receipt of Warrant Stockholder Approval, if all Private Placement Warrants are exercised as described in Proposal No. 4 (including if the Series&#160;D Warrants are exercised pursuant to the alternative cashless exercise mechanism described below), the Company will have 19,219,282 shares of Common Stock outstanding (based on 6,497,790 shares of Common Stock outstanding as of the Record Date and including 12,719,465 warrants and 2,027 options to purchase Common Stock outstanding as of the Record Date).As of the date hereof, the Company has awarded grants of options to purchase shares of our Common Stock and grants of restricted stock&#160;units settled in our Common Stock, in each case, pursuant to the Current Plan, with the number of shares of our Common Stock underlying such grants totaling 1,672 in the aggregate, and there are currently 5,325 authorized shares remaining under the Current Plan. The increase of the Current Share Pool by 3,000,000 authorized shares of Common Stock will result in additional potential dilution of our outstanding Common Stock. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">With respect to options or stock appreciation rights that expire, terminate or are canceled or forfeited for any reason without having been exercised in full, the shares of Common Stock associated with such awards will again become available for grant under the Amended Plan. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Awards that are assumed or substituted by us in connection with an acquisition will not reduce the Current Share Pool. In the event of any merger, consolidation, reorganization, recapitalization, stock split, reverse stock split, split up, spin-off, combination of shares, exchange of shares, stock dividend, dividend in kind or other like change in capital structure (other than ordinary cash dividends) to our stockholders, or other similar corporate event or transaction that affects our Common Stock, the Compensation Committee shall make appropriate adjustments in the number and kind of shares authorized by the Amended Plan and covered under outstanding awards as it determines appropriate and equitable. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Additionally, with respect to awards previously granted under the 2005 Plan, that expire, terminate, are canceled or are forfeited for any reason after the effective date of the Current Plan, the shares subject to such awards will be added to the Current Share Pool so that they can be utilized for new grants under the Current Plan. As of April&#160;3, 2025, awards with respect to 207 shares of our Common Stock were outstanding under the 2005 Plan. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The term of the Current Plan will expire on September&#160;15, 2030. Subject to the approval of the Reverse Split Proposal at the Annual Meeting, the number of shares of our Common Stock reserved for issuance pursuant to the 2005 Plan and the Current Plan will be reduced proportionately based upon the Reverse Stock Split Ratio, and if the Plan&#160;Amendment Proposal is approved at the Annual Meeting and the Reverse Stock Split is implemented, then the Amended Plan will be reduced proportionately based upon the Reverse Stock Split Ratio. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Summary of the Amended Plan</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The principal provisions of the Amended Plan are summarized below. This summary is qualified in its entirety by reference to the actual Amended Plan, a copy of which is attached as </span><span style="font-style:italic;letter-spacing:0.2pt;">Appendix&#160;C</span><span style="letter-spacing:0.2pt;"> hereto. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Administration</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Amended Plan vests broad powers in a committee to administer and interpret the Amended Plan, provided, that, the Board itself may at any time exercise any rights and duties of the committee under the Amended Plan. Our Board will designate the Compensation Committee as the committee authorized to administer the Amended Plan. In this capacity, the Compensation Committee has the authority to, among other things: select the persons to be granted awards; determine the type, size and terms and conditions of such awards, and approve forms of award agreement to be used for awards under the Amended Plan. The Compensation Committee may amend any outstanding award at any time; provided, however, that no such amendment may materially impair a participant&#8217;s rights without the participant&#8217;s consent. Subject to </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">30</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">requirements of applicable law, the Compensation Committee may delegate to one or more of our officers the authority to grant awards to participants who are not subject to Section&#160;16 of the Exchange Act. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">In order to comply with foreign law, the Compensation Committee may modify the terms of outstanding awards, establish subplans and take other actions that it deems advisable, provided that no subplans or modifications may increase the number of shares available for grant under the Amended Plan. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Unless stockholder approval is required under applicable law or exchange listing requirements, the Board may amend or terminate the Amended Plan at any time. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Eligibility</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Any of our employees, directors, consultants and other service providers, and those of our affiliates, will be eligible to participate in the Amended Plan. As of April&#160;3, 2024, the Company employed or engaged approximately 36 employees, 5 nonemployee directors and 2 consultants who would be eligible to participate in the Amended Plan. Participants will be selected in the discretion of the Compensation Committee. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Vesting</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Compensation Committee determines the vesting conditions for awards. Vesting conditions may include the continued employment or service of the participant, the attainment of specified individual or corporate performance goals and/or other factors in the Compensation Committee&#8217;s discretion. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Shares of Stock Available for Issuance</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Subject to certain adjustments, including but not limited to the Previous Reverse Stock Splits, the maximum number of shares of Common Stock that may be issued under the Amended Plan in connection with awards is 3,007,500 (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Share Pool</span><span style="letter-spacing:0.2pt;">&#8221;). However, if any award previously granted under the 2005 Plan expires, terminates, is canceled or is forfeited for any reason after the effective date of the Amended Plan, the shares subject to that award will be added to the Share Pool so that they can be utilized for new grants under the Amended Plan. As of April&#160;3, 2025, awards with respect to 207 shares of our Common Stock were outstanding under the 2005 Plan. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">If any award granted under the Amended Plan expires, terminates, is canceled or is forfeited, the shares of our Common Stock underlying the award will be available for new grants under the Amended Plan. However, shares of our Common Stock that are withheld for the payment of taxes or in satisfaction of the exercise price for an option award will not become available for re-issuance under the Amended Plan. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Any shares of our Common Stock issued by the Company through the assumption or substitution of outstanding grants in connection with the acquisition of another entity will not reduce the Share Pool. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The maximum aggregate number of shares under the Amended Plan that may be issued in respect of incentive stock options is 3,007,500. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The maximum total grant date fair value of awards granted under the Amended Plan to individuals in their capacity as non-employee directors may not exceed $250,000 in any single calendar year. </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The market value of a share of our Common Stock was $1.66 as of April&#160;3, 2025. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Adjustments</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">In the event of any merger, consolidation, reorganization, recapitalization, stock split, reverse stock split, split up, spin-off, combination of shares, exchange of shares, stock dividend, dividend in kind or other like change in capital structure (other than ordinary cash dividends) to stockholders of the Company, or other similar corporate event or transaction that affects our Common Stock, the Compensation Committee shall make such adjustments to the number and kind of shares authorized by the Amended Plan, the number and kind of shares subject to outstanding awards, the exercise prices of outstanding awards and any other affected term or condition of the Amended Plan or outstanding awards, in each case, as it determines to be equitable. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">31</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Accordingly, if the Reverse Stock Split is approved and implemented pursuant to Proposal No. 3, the number of shares of Common Stock available in the Share Pool will be adjusted accordingly. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Unless otherwise provided in an award agreement or determined by the Compensation Committee, if a participant terminates employment with us (or our affiliates) due to death or disability, the participant&#8217;s unexercised options and stock appreciation rights may be exercised, to the extent they were exercisable at the time of the participant&#8217;s death or disability (or on such accelerated basis as the Compensation Committee may determine at or after grant), for a period of twelve&#160;months from the termination date or until the expiration of the original award term, whichever period is shorter. If a participant&#8217;s employment with us (or our affiliates) is terminated for cause (as defined in the Amended Plan), (i)&#160;all unexercised options and stock appreciation rights (whether vested or unvested) shall terminate and be forfeited on the termination date, and (ii)&#160;any shares in respect of exercised options or stock appreciation rights for which we have not yet delivered shares will be forfeited and we will refund to the participant the option exercise price paid for those shares, if any. Unless otherwise provided in an award agreement or determined by the Compensation Committee, if a participant&#8217;s employment terminates for any other reason, the participant&#8217;s unexercised options and stock appreciation rights may be exercised, to the extent they were exercisable at the time of the participant&#8217;s termination (or on such accelerated basis as the Compensation Committee may determine at or after grant), for a period of ninety days from the termination date or until the expiration of the original option or stock appreciation right term, whichever period is shorter. Unless otherwise provided by the Compensation Committee, any options and stock appreciation rights that are not exercisable at the time of termination of employment shall terminate and be forfeited on the termination date. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Types of Awards</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Amended Plan provides for the grant of the following equity-based and cash-based incentive awards to participants: (i)&#160;stock options, (ii)&#160;stock appreciation rights, (iii)&#160;restricted stock, (iv)&#160;RSUs and (v)&#160;cash or other stock-based awards. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stock Options</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;An option entitles the holder to purchase from us a stated number of shares of Common Stock. An incentive stock option (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">ISO</span><span style="letter-spacing:0.2pt;">&#8221;) may only be granted to our employees or the employees of our affiliates. The Compensation Committee will specify the number of shares of Common Stock subject to each option and the exercise price for such option, provided that the exercise price per share may not be less than the fair market value of a share of Common Stock on the date the option is granted. However, for an ISO granted to any 10% stockholder, the exercise price per share shall not be less than 110% of the fair market value of a share of Common Stock on the date the option is granted. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Generally, options may be exercised in whole or in part through a cash payment. The Compensation Committee, however, may in its discretion permit payment of the exercise price through other methods. For example, the Compensation Committee may permit the option holder to surrender previously acquired shares, or to &#8220;net settle&#8221; the option, which involves the cancellation of a portion of the option to cover the cost of exercising the balance of the option. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">All options shall be exercisable in accordance with the terms of the applicable award agreement. The maximum term of an option shall be determined by the Compensation Committee on the date of grant but shall not exceed 10&#160;years (5&#160;years in the case of ISOs granted to any 10% stockholder). In the case of ISOs, the aggregate fair market value (determined as of the date of grant) of Common Stock with respect to which such ISOs become exercisable for the first time during any calendar year cannot exceed $100,000. ISOs granted in excess of this limitation will be treated as non-qualified stock options. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Stock Appreciation Rights</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;A stock appreciation right represents the right to receive, upon exercise, any appreciation in a share of Common Stock realized over a particular time period. The base price of a stock appreciation right shall not be less than the fair market value of a share of Common Stock on the date the stock appreciation right is granted. The maximum term of a stock appreciation right shall be determined by the Compensation Committee on the date of grant but shall not exceed 10&#160;years. Distributions with respect to stock appreciation rights may be made in cash, shares of Common Stock or a combination of both, at the Compensation Committee&#8217;s discretion. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Restricted Stock</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;A restricted stock award is a grant of shares of Common Stock, which are subject to forfeiture restrictions during a restriction period. The Compensation Committee will determine the price, </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">32</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">if any, to be paid by the participant for each share of Common Stock subject to a restricted stock award. If the specified vesting conditions are not attained, the underlying Common Stock will be forfeited to us. Conversely, if and when the vesting conditions are satisfied, the restrictions imposed will lapse. During the restriction period, a participant will have the right to vote the shares of Common Stock underlying the restricted stock award and receive dividends with respect to the shares of Common Stock underlying the restricted stock award. However, the Compensation Committee may specify that any such dividends are subject to the same vesting conditions as the shares of Common Stock underlying the restricted stock award to which they relate, and may also require that the dividends be invested in additional restricted shares of Common Stock. Unless otherwise provided in an award agreement or determined by the Compensation Committee, upon termination, a participant will forfeit all shares of Common Stock underlying the portion of the restricted stock award that then remains subject to forfeiture. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Restricted Stock Units</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;An RSU represents a right to receive, on the achievement of specified vesting conditions, an amount equal to the fair market value (at the time of distribution) of one share of our Common Stock. An RSU may be settled in shares of our Common Stock, cash, or a combination of both, at the discretion of the Compensation Committee. Unless otherwise provided in an award agreement or determined by the Compensation Committee, upon a termination of service, a participant will forfeit all of the participant&#8217;s RSUs that then remain subject to forfeiture. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Cash or Other Stock Based Awards</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Cash or other stock -based awards (including awards to receive unrestricted shares of our Common Stock or immediate cash payments) may be granted to participants. The Compensation Committee will determine the terms and conditions of each such award, including, as applicable, the term, any exercise or purchase price, vesting conditions and other terms and conditions. Payment in respect of a cash or other stock -based award may be made in cash, shares of our Common Stock or a combination of both, at the discretion of the Compensation Committee. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Change in Control</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">In the event of a &#8220;change in control&#8221; &#8203;(as defined in the Amended Plan), the Compensation Committee may, in its sole and absolute discretion, on a participant-by-participant basis: (i)&#160;cause any or all outstanding awards to become vested and immediately exercisable (as applicable), in whole or in part; (ii)&#160;cause any outstanding option or stock appreciation right to become fully vested and immediately exercisable for a reasonable period in advance of the change in control and, to the extent not exercised prior to that change in control, cancel that option or stock appreciation right upon closing of the change in control; (iii)&#160;cancel any unvested award or unvested portion thereof, with or without consideration; (iv)&#160;cancel any award in exchange for a substitute award; (v)&#160;redeem any restricted stock or RSU for cash and/or other substitute consideration with value equal to the fair market value of an unrestricted share on the date of the change in control; (vi)&#160;cancel any outstanding option or stock appreciation right with respect to all Common Stock for which the award remains unexercised in exchange for a cash payment equal to the excess (if any) of the fair market value of the Common Stock subject to the option or stock appreciation right over the exercise price of the option or stock appreciation right (and if the fair market value does not exceed the exercise or base price of the award, cancel the award without payment of any consideration); or (vii)&#160;take such other action as the Compensation Committee shall determine to be reasonable under the circumstances. In the discretion of the Compensation Committee, any cash or substitute consideration payable upon cancellation of an award may be subject to vesting terms substantially identical to those that applied to the cancelled award immediately prior to the change in control, or earn-out, escrow, holdback or similar arrangements, to the extent such arrangements are applicable to any consideration paid to stockholders in connection with the change in control. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Repricing</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Neither the Board nor the Compensation Committee may, without obtaining prior approval of our stockholders: (i)&#160;implement any cancellation/re-grant program pursuant to which outstanding options or stock appreciation rights under the Amended Plan are cancelled and new options or stock appreciation rights are granted in replacement with a lower exercise or base price per share; (ii)&#160;cancel outstanding options or stock appreciation rights under the Amended Plan with an exercise or base price per share in excess of the </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">33</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:28.43pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">then current fair market value per share for consideration payable in our equity securities; or (iii)&#160;otherwise directly reduce the exercise or base price in effect for outstanding options or stock appreciation rights under the Amended Plan. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Federal Income Tax Consequences</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">The federal income tax consequences arising with respect to grants awarded under the Amended Plan will depend on the type of grant. The following provides only a general description of the application of federal income tax laws to certain grants under the Amended Plan. This discussion is intended for the information of stockholders considering how to vote at the meeting and not as tax guidance to participants in the Amended Plan, as the consequences may vary with the types of grants made, the identity of the recipients and the method of payment or settlement. The summary does not address the effects of other federal taxes (including possible &#8220;golden parachute&#8221; excise taxes) or taxes imposed under state, local or foreign tax laws. Tax laws are subject to change. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">Under the Internal Revenue Code of 1986, as amended (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Code</span><span style="letter-spacing:0.2pt;">&#8221;), as currently in effect, a grant under the Amended Plan of options, stock appreciation rights, restricted stock or RSUs would have no federal income tax consequence at the time of grant. Generally, all amounts taxable as ordinary income to participants under the Amended Plan in respect of awards are expected to be deductible by the Company as compensation at the same time the participant recognizes the ordinary income, subject to the limitations of Section&#160;162(m) of the Code. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Options and Stock Appreciation Rights</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Upon exercise of a nonqualified stock option, the excess of the fair market value of the stock at the date of exercise over the exercise price is taxable to a participant as ordinary income. Similarly, upon exercise of a Stock Appreciation Right, the value of the shares or cash received is taxable to the participant as ordinary income. Upon exercise of an ISO, the participant will not have taxable income, except that alternative minimum tax may apply. When there is a disposition of the shares subject to the ISO, provided that such disposition occurs at least two&#160;years after the date of ISO grant and at least one year after the date of exercise, the difference, if any, between the sale price of the shares and the exercise price of the option is treated as long-term capital gain or loss. If the participant does not satisfy these holding period requirements, a &#8220;disqualifying disposition&#8221; occurs, and the participant will recognize ordinary income in the year of the disposition in an amount equal to the excess of the fair market value of the shares at the time the option was exercised over the exercise price of the option. In that case, any gain realized in excess of the fair market value at the time of exercise will be short or long-term capital gain, depending on whether the shares were sold more than one year after the option was exercised. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Restricted Stock</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Unless the participant elects to recognize its value as income at the time of the grant, by filing an election under Section&#160;83(b) of the Code, restricted stock is taxable to a participant as ordinary income when it becomes vested. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Restricted Stock Units</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;When shares of Common Stock or cash with respect to RSU awards are delivered to the participant, the value of the shares or cash is taxable to the participant as ordinary income. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Miscellaneous</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">Generally, awards granted under the Amended Plan shall be nontransferable except by will or by the laws of descent and distribution. The awards will be subject to our recoupment and stock ownership policies, as may be in effect from time to time. Awards will be subject to applicable tax withholding requirements, and the Compensation Committee may authorize the withholding of shares subject to the award to satisfy required tax withholding. The Amended Plan will expire on September&#160;15, 2030. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">34</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:406pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The following table provides information as of September&#160;30, 2024 with respect to shares of our common stock that may be issued under our existing equity compensation plans. </span>
        </div>
        <table style="width:456pt;height:165pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:210.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Plan&#160;Category </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Number of Securities
                <br/>
                to be issued upon
                <br/>
                exercise of
                <br/>
                outstanding options,
                <br/>
                warrants and rights
                <br/>
                (a)</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Weighted-average
                <br/>
                exercise price of
                <br/>
                outstanding
                <br/>
                options, warrants
                <br/>
                and rights
                <br/>
                (b) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Number of securities
                <br/>
                available for future issuance
                <br/>
                under equity compensation
                <br/>
                plans (excluding securities
                <br/>
                reflected in column (a))
                <br/>
                (c) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:210.45pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <span style="letter-spacing:0.2pt;">Equity compensation plans approved by security
                <br/>
                holders </span>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:210.45pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;font-style:italic;">
                <span style="letter-spacing:0.2pt;">Applied DNA Sciences, Inc.2005 Incentive Stock Plan, as amended</span>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">233</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.815pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">61,463.50</td>
            <td style="padding:0pt;padding-left:6.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.585pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">44</td>
            <td style="padding:0pt;padding-left:34.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:210.45pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <span style="letter-spacing:0.2pt;">Applied DNA Sciences, Inc. 2020 Incentive Plan</span>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,940</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,018.00</td>
            <td style="padding:0pt;padding-left:6.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,328</td>
            <td style="padding:0pt;padding-left:34.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:210.45pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <span style="letter-spacing:0.2pt;">Equity&#160;compensation plans not approved by security holders </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.815pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.815pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:34.585pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.833pt 0pt; width:210.45pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">TOTAL </span>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,173</td>
            <td style="padding:0pt;padding-left:23.965pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.815pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9,289.00</td>
            <td style="padding:0pt;padding-left:6.815pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:34.585pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.833pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">5,372</td>
            <td style="padding:0pt;padding-left:34.585pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">The Board of Directors unanimously recommends a vote &#8220;For&#8221; the Plan&#160;Amendment Proposal.</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">35</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tPN6A">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">PROPOSAL NO. 6</span>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">NON-BINDING ADVISORY APPROVAL OF THE COMPENSATION
          <br/>
          OF THE COMPANY&#8217;S NAMED EXECUTIVE OFFICERS</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We are providing our stockholders the opportunity to vote to approve, on a non-binding advisory basis, the compensation of our &#8220;named executive officers&#8221; disclosed in this Proxy Statement in accordance with the SEC&#8217;s rules. This proposal, which is commonly referred to as &#8220;say-on-pay,&#8221; is required under Section&#160;14A of the Exchange Act, which was added by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. As indicated in this Proxy Statement under the heading &#8220;Executive Compensation,&#8221; our &#8220;named executive officers&#8221; for the most recently completed fiscal year consist of (i)&#160;James Hayward, our President and Chief Executive Officer, (ii)&#160;Beth Jantzen, our Chief Financial Officer, (iii)&#160;Judith Murrah, our Chief Information Officer and Secretary, and (iv)&#160;Clay Shorrock, our Chief Legal Officer and Executive Director of Business Development. On December&#160;17, 2024, the Company announced that Ms.&#160;Murrah was named the President of the Company and Dr.&#160;Hayward stepped down as President of the Company, effective on December&#160;13, 2024. Concurrently on December&#160;13, 2024, Mr.&#160;Shorrock was named President of LineaRx, our 98% owned subsidiary. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our executive compensation programs are designed to attract, motivate, and retain our executive officers, who are critical to our success, as more fully described in the &#8220;Executive Compensation&#8221; section of this Proxy Statement. Under these programs, as approved by our compensation committee, our named executive officers are rewarded for the achievement of our near-term and longer-term financial and strategic goals, for driving corporate financial performance and stability and for increasing stockholder value. The programs contain elements of both cash and equity-based compensation. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The &#8220;Executive Compensation&#8221; section beginning on page <a href="#tEXCO">45</a> describes in detail our executive compensation programs and the decisions made by our compensation committee and our Board of Directors with respect to the fiscal year ended September&#160;30, 2024. As discussed in those disclosures, we believe that our compensation program provides a competitive overall compensation that is designed to attract and retain top performers. To achieve this goal, our compensation program is structured to: </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">provide total compensation and compensation elements that are competitive with those companies that are competing for available employees; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">hold our executive officers accountable for results over the long term and maintain integrity in all of the business dealings of our executive officers; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">align the interest of our executives with our stockholders; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">reward exceptional performance by individual employees; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">provide a mix of compensation that offers (i)&#160;a meaningful base compensation, with a potential to earn additional amounts based on achievement of corporate and personal goals, and (ii)&#160;the opportunity to share in the long-term growth of our company through equity compensation; and </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">establish a clear connection between rewards and performance. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our Board of Directors believes this link between compensation and the achievement of our near- and long-term business goals has helped drive our performance over time. At the same time, we believe our program does not encourage excessive risk-taking by management. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">This proposal is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described under &#8220;Executive Compensation.&#8221; Our Board of Directors is asking stockholders to indicate their support for the compensation of our named executive officers as described in this Proxy Statement by casting a non-binding advisory vote &#8220;FOR&#8221; the following resolution: </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">RESOLVED</span><span style="letter-spacing:0.2pt;">, that the Company&#8217;s stockholders hereby approve, on a non-binding advisory basis, the compensation paid to the Company&#8217;s named executive officers, as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables and any related material disclosed in the Company&#8217;s Proxy Statement. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">36</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:336pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">As an advisory vote, this proposal is not binding. The outcome of this advisory vote will not affect any compensation already paid or awarded to any named executive officer and does not overrule any decision by us or our Board of Directors (or any committee thereof) or create or imply any change to our fiduciary duties or the fiduciary duties of our Board of Directors (or any committee thereof). However, our compensation committee and Board of Directors value the opinions expressed by our stockholders in their vote on this proposal and will consider the outcome of the vote when making future compensation decisions for named executive officers. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Vote Required</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The affirmative vote of a majority of the outstanding shares of our Common Stock present in person or represented by proxy at the Annual Meeting and entitled to vote is required for the approval of Proposal No. 6. Broker non-votes, if any, with respect to this matter will be treated as neither a vote &#8220;for&#8221; nor a vote &#8220;against&#8221; the matter and will not be counted in determining the number of votes necessary for approval. However, abstentions will be considered in determining the total number of votes required to attain a majority of the shares present in person or represented by proxy at the meeting entitled to vote. Accordingly, an abstention from voting by a stockholder present in person or represented by proxy at the meeting has the same legal effect as a vote &#8220;against&#8221; the matter because it represents a share present in person or represented by proxy at the meeting and entitled to vote, thereby increasing the number of affirmative votes required to approve this proposal. It is intended that the proxy in the form presented will be voted, unless otherwise indicated, &#8220;FOR&#8221; Proposal No. 6. If no instructions are indicated, the shares will be voted &#8220;FOR&#8221; Proposal&#160;No. 6. </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">The Board of Directors unanimously recommends that stockholders vote to approve, on a non-binding
          <br/>
          advisory basis, the compensation of our named executive officers by voting &#8220;FOR&#8221; Proposal No. 6.</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">37</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tPN7A">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:134pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">PROPOSAL NO. 7</span>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">NON-BINDING ADVISORY APPROVAL OF THE FREQUENCY OF THE STOCKHOLDER VOTE ON THE COMPENSATION OF THE COMPANY&#8217;S NAMED EXECUTIVE OFFICERS</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">In this Proposal No. 7, we are asking our stockholders to cast a non-binding advisory vote regarding the frequency of future executive compensation advisory votes. Stockholders may vote for a frequency of every one, two, or three&#160;years, or may abstain. In Proposal No. 6, we are providing our stockholders the opportunity to vote to approve, on a non-binding advisory basis, the compensation of our &#8220;named executive officers&#8221; disclosed in this Proxy Statement. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Section&#160;14A of the Exchange Act requires that, at least once every six&#160;years, stockholders be given the opportunity to vote regarding how often the advisory vote on executive compensation should be held. Our Board of Directors will take into consideration the outcome of this vote in making a determination about the frequency of future executive compensation advisory votes. However, our Board of Directors may decide that it is in the best interests of our stockholders and the Company to hold the advisory vote to approve executive compensation more or less frequently. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">At our 2019 annual meeting of stockholders, the majority of stockholders voted to advise us to include a say-on-pay proposal every three&#160;years, and the Board of Directors determined that the Company will hold an advisory say-on-pay vote every three&#160;years. Our Board of Directors believes that stockholders should continue to have the opportunity to vote on the compensation of our named executive officers every three&#160;years. While parts of our compensation programs are designed to incentivize our employees on a long-term basis, we review our executive compensation programs annually, and we describe those programs to our stockholders in our proxy statement each year. Conducting an advisory vote on executive compensation every year or every two&#160;years does not give our stockholders sufficient time to evaluate the effectiveness of our long-term compensation programs. We believe that a three-year cycle will provide our stockholders sufficient time to evaluate the effectiveness of both our short- and long-term compensation programs. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our board of directors values the opinions expressed by stockholders and will consider implementing the frequency which receives the greatest level of support from our stockholders. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Vote Required</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">On this non-binding matter, a stockholder may vote to set the frequency of the say-on-pay vote to occur every year, every two&#160;years, or every three&#160;years, or the stockholder may vote to abstain. The choice among those four choices that receives the highest number of votes will be deemed the choice of the stockholders. </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">The Board of Directors unanimously recommends that stockholders vote to hold advisory votes on
          <br/>
          the compensation of the Company&#8217;s named executive officers &#8220;EVERY THREE YEARS&#8221;.</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">38</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tMACG">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">MANAGEMENT AND CORPORATE GOVERNANCE</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Information Regarding the Board of Directors</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Members</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Our Board of Directors currently consists of six members: James A. Hayward, Robert B. Catell, Joseph D. Ceccoli, Yacov A. Shamash, Sanford R. Simon, and Elizabeth M. Schmalz Shaheen. Our Board of Directors has nominated six incumbent directors for re-election at the Annual Meeting. Please see &#8220;Proposal No. 1&#8201;&#8212;&#8201;Election of Directors&#8221; for the names, ages and business experience of each of the Company&#8217;s director nominees for election at the Annual Meeting. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Director Independence</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Board of Directors has determined that at all times during the fiscal year ended September&#160;30, 2024, each of our directors other than Dr.&#160;Hayward &#8201;&#8212;&#8201;consisting of Robert B. Catell, Joseph D. Ceccoli, Yacov A. Shamash, Sanford R. Simon, and Elizabeth M. Schmalz Shaheen&#8201;&#8212;&#8201;are and were &#8220;independent&#8221; as defined by the listing standards of Nasdaq, constituting a majority of independent directors on our Board of Directors as required by the rules of Nasdaq. The Board of Directors considers in its evaluation of independence whether any director has a relationship with us that would interfere with the exercise of independent judgment in carrying out his or her responsibilities of a director. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Board of Directors Leadership Structure and Role in Risk Oversight</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Our Board of Directors does not have a policy on whether the same person should serve as both the Chief Executive Officer and Chairman of the Board of Directors or, if the roles are separate, whether the Chairman should be selected from the non-employee directors or should be an employee. The Board of Directors believes that Dr.&#160;Hayward&#8217;s dual role as both Chairman of the Board of Directors and Chief Executive Officer serves the best interests of both us and our stockholders. His combined role enables decisive leadership, ensures clear accountability, and enhances our ability to communicate our message and strategy clearly and consistently to our stockholders, employees, customers and suppliers. Dr.&#160;Hayward possesses detailed and in-depth knowledge of the issues, opportunities and challenges facing us and our business and is thus best positioned to develop agendas that ensure that the time and attention of the Board of Directors are focused on the most critical matters. This structure also enables our Chief Executive Officer to act as a bridge between management and the Board of Directors, helping both to act with a common purpose. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Board of Directors appreciates that the advantages gained by having a single Chairman and Chief Executive Officer must be viewed in light of potential independence concerns. The Board of Directors considers, however, that we have adequate safeguards in place to address those concerns, including, for example, our Board of Directors consisting of a supermajority of independent directors. In addition, our audit, compensation and nominating committees, which oversee critical matters such as the integrity of our financial statements, the compensation of executive management, the selection and evaluation of directors, and the development and implementation of corporate governance policies, each consist entirely of independent directors. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Our risk management program is overseen by our Chief Executive Officer. Material risks are identified and prioritized by management, and each prioritized risk is referred to a Board of Directors committee or the full Board of Directors for oversight. For example, strategic risks are referred to the full Board of Directors while financial risks are referred to the Audit Committee. The Board of Directors regularly reviews information regarding our liquidity and operations, as well as the risks associated with each. Also, the Compensation Committee periodically reviews the most important risks to our business to ensure that compensation programs do not encourage excessive risk-taking and promote our goals and objectives. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Board of Directors Structure and Committee Composition</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">In June&#160;2008, our Board of Directors established a standing Compensation Committee and in September&#160;2011, our Board of Directors established an Audit Committee and a nominating committee (the </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">39</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Nominating Committee</span><span style="letter-spacing:0.2pt;">&#8221;). Each of the committees operates under a written charter adopted by the Board of Directors. All of the committee charters are available on our web site at </span><span style="font-style:italic;letter-spacing:0.2pt;">www.adnas.com/adnas_home/</span>&#8203;<span style="font-style:italic;letter-spacing:0.2pt;">investors/</span>&#8203;<span style="letter-spacing:0.2pt;"> or by writing to Applied DNA Sciences, Inc., 50 Health Sciences Drive, Stony Brook, New York&#160;11790, c/o&#160;Investor Relations. The information found on, or accessible through, our website is not incorporated into, and does not form a part of, this Proxy Statement or any other report or document we file with or furnish to the SEC. </span></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">During fiscal 2024, the Board of Directors held ten formal meetings (including regularly scheduled and special meetings) and acted by unanimous written consent nine times. During fiscal 2024, each director attended at least 75% of all meetings of the Board of Directors during the time such director was a member of the Board of Directors and of all meetings of the committee or committees on which he served, Directors are strongly encouraged to attend our annual meetings of stockholders. All directors then serving on the Board of Directors attended the Company&#8217;s annual meeting of stockholders held in 2024. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The membership of each of the Audit Committee, the Compensation Committee, and the Nominating Committee is composed, and was composed during the fiscal year ended September&#160;30, 2024, entirely of independent directors. In addition, the members of the Audit Committee meet the heightened standards of independence for Audit Committee members required by SEC rules and Nasdaq rules. The committee membership and the responsibilities of each of the committees during the fiscal year ended September&#160;30, 2024 are described below. </span>
        </div>
        <table style="width:456pt;height:170.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;min-height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:314.99pt;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Name </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:18.35pt;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Audit </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:47.33pt;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Compensation </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:39.33pt;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Nominating </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;min-height:15.25pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:314.99pt;text-align:left;">
              <span style="letter-spacing:0.2pt;">James A. Hayward </span>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:18.35pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">&#8212;</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:47.33pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">&#8212;</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:39.33pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:0.2pt;">&#8212;</span>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="min-height:27pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4pt 0pt 5pt 0pt; width:314.99pt;text-align:left;">
              <div style="line-height:12pt;">
                <span style="letter-spacing:0.2pt;">Robert B. Catell</span><span style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(I)</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 12pt 0pt; width:18.35pt;white-space:normal;">
              <div style="position:relative;text-align:center;">
                <img alt="[MISSING IMAGE: ic_member-bw.jpg]" src="ic_member-bw.jpg" style="height: 15px; width: 9px;"/>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 5pt 0pt; width:47.33pt;">
              <div style="text-align:center; line-height:12pt;">
                <span style="letter-spacing:0.2pt;">&#8212;</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 5pt 0pt; width:39.33pt;">
              <div style="text-align:center; line-height:12pt;">
                <span style="letter-spacing:0.2pt;">&#8212;</span>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="min-height:27pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4pt 0pt 5pt 0pt; width:314.99pt;text-align:left;">
              <div style="line-height:12pt;">
                <span style="letter-spacing:0.2pt;">Joseph D. Ceccoli</span><span style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(I)</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 12pt 0pt; width:18.35pt;white-space:normal;">
              <div style="position:relative;text-align:center;">
                <img alt="[MISSING IMAGE: ic_member-bw.jpg]" src="ic_member-bw.jpg" style="height: 15px; width: 9px;"/>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 12pt 0pt; width:47.33pt;white-space:normal;">
              <div style="position:relative;text-align:center;">
                <img alt="[MISSING IMAGE: ic_member-bw.jpg]" src="ic_member-bw.jpg" style="height: 15px; width: 9px;"/>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 5pt 0pt; width:39.33pt;">
              <div style="text-align:center; line-height:12pt;">
                <span style="letter-spacing:0.2pt;">&#8212;</span>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="min-height:27pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4pt 0pt 5pt 0pt; width:314.99pt;text-align:left;">
              <div style="line-height:12pt;">
                <span style="letter-spacing:0.2pt;">Sanford R. Simon</span><span style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(I)</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 5pt 0pt; width:18.35pt;">
              <div style="text-align:center; line-height:12pt;">
                <span style="letter-spacing:0.2pt;">&#8212;</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 5pt 0pt; width:47.33pt;">
              <div style="text-align:center; line-height:12pt;">
                <span style="letter-spacing:0.2pt;">&#8212;</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 12pt 0pt; width:39.33pt;white-space:normal;">
              <div style="position:relative;text-align:center;">
                <img alt="[MISSING IMAGE: ic_member-bw.jpg]" src="ic_member-bw.jpg" style="height: 15px; width: 9px;"/>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="min-height:27pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4pt 0pt 5pt 0pt; width:314.99pt;white-space:nowrap;text-align:left;">
              <div style="line-height:12pt;">
                <span style="letter-spacing:0.2pt;">Yacov A. Shamash</span><span style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(I)</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 12pt 0pt; width:18.35pt;">
              <div style="position:relative;text-align:center;">
                <img alt="[MISSING IMAGE: ic_chairper-bw.jpg]" src="ic_chairper-bw.jpg" style="height: 15px; width: 9px;"/>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 12pt 0pt; width:47.33pt;">
              <div style="position:relative;text-align:center;">
                <img alt="[MISSING IMAGE: ic_chairper-bw.jpg]" src="ic_chairper-bw.jpg" style="height: 15px; width: 9px;"/>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 12pt 0pt; width:39.33pt;">
              <div style="position:relative;text-align:center;">
                <img alt="[MISSING IMAGE: ic_chairper-bw.jpg]" src="ic_chairper-bw.jpg" style="height: 15px; width: 9px;"/>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="min-height:43pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4pt 0pt 5pt 0pt; width:314.99pt;text-align:left;">
              <div style="line-height:12pt;">
                <span style="letter-spacing:0.2pt;">Elizabeth M. Schmalz Shaheen</span><span style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(I)</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 5pt 0pt; width:18.35pt;">
              <div style="text-align:center; line-height:12pt;">
                <span style="letter-spacing:0.2pt;">&#8212;</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 0.5pt 0pt; width:47.33pt;white-space:normal;">
              <div style="position:relative;text-align:center;">
                <img alt="[MISSING IMAGE: ic_member-bw.jpg]" src="ic_member-bw.jpg" style="height: 15px; width: 9px;"/>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4pt 0pt 0.5pt 0pt; width:39.33pt;white-space:normal;">
              <div style="position:relative;text-align:center;">
                <img alt="[MISSING IMAGE: ic_member-bw.jpg]" src="ic_member-bw.jpg" style="height: 15px; width: 9px;"/>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:1.7pt; width:456pt;">
          <img alt="[MISSING IMAGE: ic_chairper-bw.jpg]" src="ic_chairper-bw.jpg" style="height: 15px; width: 9px;"/>
        </div>
        <div style="margin-top:-12pt; position:relative; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;&#160;&#160;&#160;&#160;&#160;Chairperson</span>
        </div>
        <div style="position:relative;margin-top:2.2pt; width:456pt;">
          <img alt="[MISSING IMAGE: ic_member-bw.jpg]" src="ic_member-bw.jpg" style="height: 15px; width: 9px;"/>
        </div>
        <div style="margin-top:-12pt; position:relative; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;&#160;&#160;&#160;&#160;&#160;Member </span>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(I)</span>
          <br/>
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Independent director </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Audit Committee</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Messrs. Catell, Ceccoli, and Shamash (Chairperson) served on the Audit Committee during the fiscal year ended September&#160;30, 2024 and continue to serve on the Audit Committee. The Board of Directors has determined that each member of the Audit Committee is independent within the meaning of the director independence standards of the Company and Nasdaq as well as the heightened director independence standards of the SEC for Audit Committee members, including Rule&#160;10A-3(b)(1) under the Exchange Act. The Board of Directors has also determined that each of the members of the Audit Committee is financially sophisticated and is able to read and understand consolidated financial statements and that Dr.&#160;Shamash is an &#8220;Audit Committee expert&#8221; as defined in the Exchange Act. During fiscal 2024, the Audit Committee held four formal meetings. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The composition and responsibilities of the Audit Committee and the attributes of its members, as reflected in the charter, are intended to be in accordance with applicable requirements for corporate Audit Committees. The Audit Committee charter will be reviewed, and amended if necessary, on an annual basis. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">40</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Audit Committee assists the Board of Directors in fulfilling its oversight responsibility relating to our financial statements and the disclosure and financial reporting process, our system of internal controls, our internal audit function, the qualifications, independence and performance of our independent registered public accounting firm, compliance with our code of ethics and legal and regulatory requirements. The Audit Committee has the sole authority to appoint, retain, terminate, compensate and oversee the work of the independent registered public accounting firm, as well as to pre-approve all audit and non-audit services to be provided by the independent registered public accounting firm. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Compensation Committee</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Messrs. Ceccoli and Shamash (Chairperson) and Ms.&#160;Schmalz Shaheen served on the Compensation Committee during the fiscal year ended September&#160;30, 2024 and continue to serve on the Compensation Committee. The Compensation Committee reviews and approves salaries and bonuses for all officers, reviews and approves non-employee directors&#8217; compensation, administers options outstanding under our stock incentive plan, provides advice and carries out the responsibilities required by SEC rules. The Compensation Committee believes that its processes and oversight should be directed toward attracting, retaining and motivating employees and non-employee directors to promote and advance our interests and strategic goals. As requested by the Compensation Committee, the Chief Executive Officer will provide information and may participate in discussions regarding compensation for other executive officers. The Compensation Committee considers other general industry information and trends if available. During fiscal 2023, the Compensation Committee held two formal meetings. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Nominating Committee</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Messrs. Shamash (Chairperson) and Simon and Ms.&#160;Schmalz Shaheen served on the Nominating Committee during the fiscal year ended September&#160;30, 2024 and continue to serve on the Nominating Committee. The Board of Directors has determined that each member of the Nominating Committee is independent within the meaning of the director independence standards of the Company, Nasdaq and the SEC. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Nominating Committee is responsible for, among other things: reviewing the Board of Directors&#8217; composition, procedures and committees, and making recommendations on these matters to the Board of Directors; and reviewing, soliciting and making recommendations to the Board of Directors and stockholders with respect to candidates for election to the Board of Directors. During fiscal 2024, the Nominating Committee held one formal meeting. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Process for Identifying and Evaluating Nominees for the Board of Directors</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Director Qualifications.&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;">The Nominating Committee has not formally established any specific, minimum qualifications that must be met by each candidate for the Board of Directors or specific qualities or skills that are necessary for one or more of the members of the Board of Directors to possess. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Identifying Nominees.&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;">The Nominating Committee has two primary methods for identifying director candidates (other than those proposed by our stockholders, as discussed below). First, on a periodic basis, the Nominating Committee will solicit ideas for possible candidates from a number of sources, including members of the Board of Directors, our executive officers and individuals personally known to the members of the Board of Directors. Second, the Nominating Committee is authorized to use its authority under its charter to retain at our expense one or more search firms to identify candidates (and to approve such firms&#8217; fees and other retention terms). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Stockholder Candidates.&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;">The Nominating Committee will consider candidates for nomination as a director submitted by stockholders. Although the Nominating Committee does not have a separate policy that addresses the consideration of director candidates recommended by stockholders, the Board of Directors does not believe that such a separate policy is necessary because our bylaws permit stockholders to nominate candidates and one of the duties set forth in the Nominating Committee charter is to consider director candidates submitted by stockholders in accordance with our bylaws. The Nominating Committee will evaluate individuals recommended by stockholders for nomination as directors according to the criteria </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">41</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">discussed above and in accordance with our bylaws and the procedures described under &#8220;Stockholder Proposals and Nominations&#8221; below. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Review of Director Nominees.&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;">The Nominating Committee will evaluate any candidates recommended by stockholders against the same criteria and pursuant to the same policies and procedures applicable to the evaluation of candidates proposed by our directors, executive officers, third-party search firms or other sources. In evaluating proposed director candidates, the Nominating Committee may consider, in addition to any minimum qualifications and other criteria for Board of Directors membership approved by the Board of Directors from time to time, all facts and circumstances that it deems appropriate or advisable, including, among other things, the proposed director candidate&#8217;s understanding of our business and industry on a technical level, his or her judgment and skills, his or her depth and breadth of professional experience or other background characteristics, his or her independence, his or her willingness to devote the time and effort necessary to be an effective board member, and the needs of the Board of Directors. We do not have a formal policy with regard to the consideration of diversity in identifying director nominees. However, the Board of Directors believes that it is essential that its members represent diverse viewpoints, with a broad array of experiences, professions, skills, and backgrounds that, when considered as a group, provide a sufficient mix of perspectives to allow the Board of Directors to best fulfill its responsibilities to the long- term interests of our stockholders. The Nominating Committee considers at least annually, and recommends to the Board of Directors suggested changes to, if any, the size, composition, organization and governance of the Board of Directors and its committees. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Stockholder Proposals and Nominations.&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;">In order for a stockholder to nominate a person for election as a director at the 2026 Annual Meeting of stockholders, you must provide written notice to Applied DNA Sciences, Inc., 50 Health Sciences Drive, Stony Brook, New York 11790, c/o&#160;Corporate Secretary. The notice of a proposed director nomination must provide information and documentation as required in our bylaws which, in general, require that the notice of a director nomination include the information about the nominee that would be required to be disclosed in the solicitation of proxies for the election of a director under federal securities laws; the nominee&#8217;s written consent to be named in the proxy statement as a nominee and to serve as a director if elected; a description of any transaction or arrangement during the last three&#160;years between the stockholder making the nomination and the nominee in which the nominee had a direct or indirect material interest; and a completed and signed questionnaire (after such form has been provided by the Company), together with a written representation and agreement that such nominee is not and will not become a party to certain voting commitments. A copy of the bylaw requirements will be provided upon request to the Corporate Secretary at the address above. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Effective September&#160;1, 2022, Rule&#160;14a-19 under the Exchange Act requires the use of a universal proxy card in contested director elections. Under this &#8220;universal proxy rule,&#8221; a stockholder intending to engage in a director election contest with respect to an annual meeting of stockholders must give the Company notice of its intent to solicit proxies by providing the name(s) of the stockholder&#8217;s nominee(s) and certain other information at least 60 calendar days prior to the anniversary of the previous year&#8217;s annual meeting date (except that, if the Company did not hold an annual meeting during the previous year, or if the date of the meeting has changed by more than 30 calendar days from the previous year, then notice must be provided by the later of 60 calendar days prior to the date of the annual meeting or the 10th calendar day following the day on which public announcement of the date of the annual meeting is first made by the Company). </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Stockholder Communications with the Board of Directors</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Stockholders and other interested parties may make their concerns known confidentially to the Board of Directors or the independent directors by submitting a communication in an envelope addressed to the &#8220;Board of Directors,&#8221; a specifically named independent director or the &#8220;Independent Directors&#8221; as a group, in care of the Corporate Secretary. All such communications will be conveyed, as applicable, to the full Board of Directors, the specified independent director or the independent directors as a group. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Code of Ethics</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">Our Board of Directors has adopted a &#8220;code of ethics&#8221; as defined by regulations promulgated under the Securities Act and the Exchange Act (our &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Code of Business Conduct and Ethics</span><span style="letter-spacing:0.2pt;">&#8221;) that applies to all of our employees, officers and directors, including our chief executive officer, our chief financial officer and </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">42</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">those officers and employees responsible for financial reporting. The Code of Business Conduct and Ethics is designed to codify the ethical standards that we believe are reasonably designed to deter wrong-doing and promote honest and ethical conduct. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We have established procedures to ensure that suspected violations of the Code of Business Conduct and Ethics may be reported anonymously. A current copy of our Code of Business Conduct and Ethics is available on our website at </span><span style="font-style:italic;letter-spacing:0.2pt;">www.adnas.com/adnas_home/investors/</span>&#8203;<span style="letter-spacing:0.2pt;">. A copy may also be obtained, free of charge, from us upon a request directed to Applied DNA Sciences, Inc., 50 Health Sciences Drive, Stony Brook, New York 11790, c/o&#160;Investor Relations. We intend to disclose any amendments to or waivers of a provision of the Code of Business Conduct and Ethics granted to directors and officers by posting such information on our website available at </span><span style="font-style:italic;letter-spacing:0.2pt;">www.adnas.com</span><span style="letter-spacing:0.2pt;"> and/or in our public filings with the SEC. </span></div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Insider Trading Policy</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"> <span style="letter-spacing:0.2pt;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-7947">We have adopted an insider trading policy</ix:nonNumeric> (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Insider Trading Policy</span><span style="letter-spacing:0.2pt;">&#8221;) applicable to our employees, officers, directors and consultants (collectively, the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">APDN Insiders</span><span style="letter-spacing:0.2pt;">&#8221;), which we believe is reasonably designed to promote compliance with insider trading laws, rules, and regulations, and the Nasdaq listing standards. </span> </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our Insider Trading Policy prohibits APDN Insiders from trading in our securities and other companies while in possession of material, nonpublic information (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">MNPI</span><span style="letter-spacing:0.2pt;">&#8221;), subject to limited exceptions, such as trading pursuant to a Rule&#160;10b5-1 plan. Our Insider Trading Policy also generally prohibits our officers, directors, and employees from disclosing material, nonpublic information regarding the Company or its customers, prospective customers or other entities with which it conducts business or contemplates dealings. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our Insider Trading Policy requires that our executive officers and directors, as well as members of our finance and sales group, be subject to a &#8220;trading blackout period&#8221; during which they are prohibited from buying or selling our securities even if they are not in possession of MNPI (the &#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">Trading Blackout Period</span><span style="letter-spacing:0.2pt;">&#8221;). There are four quarterly Trading Blackout Periods each year, which begin on the tenth business day of the last month of each fiscal quarter and end at the close of trading on the second full day after issuance of our quarterly earnings release for the corresponding concluded fiscal quarter. The fiscal quarters end on December&#160;31, March&#160;31, June&#160;30 and September&#160;30 of each year. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">In addition to the above, the Insider Trading Policy reserves the right for the Company to impose a special trading blackout period applicable to all or some of our personnel. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our Insider Trading Policy does not apply to the acceptance or receipt of stock options, shares of restricted stock or similar grants of securities under one of the company&#8217;s benefit plans, or to exercises of employee stock options, so long as the stock is not sold during a Trading Blackout Period or at a time when the APDN Insider possesses material nonpublic information about Applied DNA Sciences, Inc. or our securities. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Hedging Policy</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our Board of Directors has not adopted a hedging policy with respect to transactions by our directors, officers and employees that hedge or offset, or are designed to hedge or offset, any decrease in the market value of our equity securities. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Executive Officers</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our current executive officers, and their ages and positions as of April&#160;3, 2025, are set forth below. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Dr.&#160;James A. Hayward</span><span style="letter-spacing:0.2pt;">, age 71, has been our Chief Executive Officer since March&#160;17, 2006, a director on the Board of Directors since September&#160;28, 2005 and the Chairman of the Board of Directors since June&#160;12, 2007. He was previously our acting Chief Executive Officer from October&#160;5, 2005 until March&#160;17, 2006 and our President from June&#160;12, 2007 until December&#160;13, 2024. He also served as Acting Chief Financial Officer from August&#160;20, 2013 through October&#160;13, 2013. Dr.&#160;Hayward received his Ph.D. in Molecular Biology from the State University of New York at Stony Brook (&#8220;Stony Brook&#8221;) in 1983 and an honorary </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">43</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Doctor of Science from the same institution in 2000. His experience with public companies began with the co-founding of one of England&#8217;s first biotechnology companies&#8201;&#8212;&#8201;Biocompatibles, Ltd. Following this, Dr.&#160;Hayward was at the Estee Lauder companies for five&#160;years, eventually becoming Head of Product Development. In 1990, he founded The Collaborative Group, a provider of products and services to the biotechnology, pharmaceutical and consumer-product industries based in Stony Brook, where he served as Chairman, President and Chief Executive Officer for 14&#160;years. During this period, The Collaborative Group created several businesses, including The Collaborative BioAlliance, a contract developer and manufacturer of human protein products that was sold to Dow Chemical in 2002, and Collaborative Labs, a service provider and manufacturer of ingredients for skincare and dermatology that was sold to Engelhard (now BASF) in 2004. He is the winner of the first Helix Award from BIO and has been twice elected Entrepreneur of the Year by Inc. Magazine and the Long Island Technology Hall of Fame. He has served on the Boards of The Stony Brook Foundation, the NYS Research Foundation, and the NYS Regents Advisory Board. Dr.&#160;Hayward also serves on the advisory board of the Manufacturing and Technology Resource Consortium of Stony Brook University, and on the boards of NeoMatrix Formulations, Inc. and the TNPO2 Foundation. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Beth Jantzen</span><span style="letter-spacing:0.2pt;">, age 48, Beth Jantzen has been our Chief Financial Officer since February&#160;15, 2015. Previously, Ms.&#160;Jantzen held the position of Controller from May&#160;2013 to her appointment as Chief Financial Officer. Prior to joining the Company, Ms.&#160;Jantzen was a senior manager at Marcum LLP, formerly our independent registered accounting firm, from January&#160;2000 until May&#160;2013, where she managed multiple engagements and specialized in SEC policies, practices and procedures, including Sarbanes-Oxley compliance. Ms.&#160;Jantzen holds a B.S. in Accounting from the State University of New York at Binghamton and is also a Certified Public Accountant (CPA). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Judith Murrah</span><span style="letter-spacing:0.2pt;">, age 67, has been our President since December&#160;13, 2024, our Chief Operating Officer since January&#160;19, 2021, our Chief Information Officer since June&#160;1, 2013, and our Secretary since December&#160;22, 2017. Ms.&#160;Murrah is responsible for the operational management of the Company supporting the achievement of its stated goals and initiatives. Ms.&#160;Murrah was previously the Senior Director of Information Technology at Motorola Solutions, which had acquired her former firm, Symbol Technologies. Her role at Motorola Solutions included overseeing the global IT program management office, financial and supplier operations and quality assurance. At Symbol Technologies, Ms.&#160;Murrah held leadership positions in product line management, global account sales, corporate and marketing communications and IT. Ms.&#160;Murrah holds an MBA from Harvard Business School, and a B.S. in Industrial Engineering from the University of Rhode Island. She is an inventor on 14 U.S. patents. Ms.&#160;Murrah is active in Long Island&#8217;s business and academic community. She has co-founded and volunteers with non-profits engaging students in science, technology, engineering, and math disciplines. She serves on the boards of the Middle Country (N.Y.) Library Foundation, the Tesla Science Center at Wardenclyffe, and Stony Brook University&#8217;s Center for Corporate Education. Ms.&#160;Murrah was named to the Top 50 Women of Long Island Hall of Fame in 2023 and received the inaugural 2001 Diamond Award for Long Island Women Leaders in Technology. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Clay Shorrock</span><span style="letter-spacing:0.2pt;">, age 41, has been our Chief Legal Officer and Executive Director of Business Development since April&#160;2021, and has served as the President of LRx since December&#160;13, 2024. Mr.&#160;Shorrock leads Applied DNA&#8217;s legal, regulatory, risk mitigation, intellectual property, and business development functions. Mr.&#160;Shorrock previously served as general and intellectual property counsel to Applied DNA from November&#160;2016 through April&#160;2019. Prior to rejoining the Company in April&#160;2021, Mr.&#160;Shorrock was a member of the intellectual property groups of Florida-based Lowndes, Drosdick, Doster, Kantor &amp; Reed, P.A. and Allen, Dyer, Doppelt &amp; Gilchrist, P.A. Earlier in his career Mr.&#160;Shorrock was an associate at several New Jersey-based law firms where he focused on intellectual property and complex commercial transactions. Mr.&#160;Shorrock holds a B.A. in Biology from Franklin and Marshall College and a J.D. with a concentration in intellectual property from Seton Hall University Law School. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our executive officers are elected by, and serve at the discretion of, our Board of Directors. There are no family relationships between any director, executive officer, or person nominated or chosen by us to become a director or executive officer.</span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">44</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tEXCO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">EXECUTIVE COMPENSATION</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Compensation Overview</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">The Compensation Committee has overall responsibility for approving and evaluating the compensation arrangements for our named executive officers. Our named executive officers for fiscal 2024 are our Chairman and Chief Executive Officer, Dr.&#160;James Hayward, our Chief Financial Officer, Beth Jantzen, our President, Chief Operating Officer, our Chief Information Officer, Judith Murrah, and our Chief Legal Officer, Executive Director of Business Development and President of LineaRx, Inc., our 98% owned subsidiary (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">LRx</span><span style="letter-spacing:0.2pt;">&#8221;), Clay Shorrock. Our Chairman and Chief Executive Officer, Dr.&#160;Hayward, provides recommendations to the Compensation Committee with respect to the compensation of the named executive officers other than for Dr.&#160;Hayward himself. However, the Compensation Committee is free to make decisions that are contrary to the Chief Executive Officer&#8217;s recommendations. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">On December&#160;13, 2024, Dr.&#160;Hayward stepped down as President of the Company and Judith Murrah was appointed President of the Company. Also on December&#160;13, 2024, Clay Shorrock was named President of LRx. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Our Executive Compensation Philosophy and Objectives</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">General</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">The fundamental purpose of our executive compensation program is to assist us in achieving our financial and operating performance objectives. Specifically, we attempt to tailor an executive&#8217;s compensation to (1)&#160;retain and motivate the executive, (2)&#160;reward him or her upon the achievement of Company-wide and individual performance, and (3)&#160;align the executive&#8217;s interest with the creation of long- term stockholder value, without encouraging excessive risk taking. To that end, and within the context of the stage of our company, we have historically compensated our named executive officers through a mix of base salary, equity-based incentives and cash bonuses. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our business model is based on our ability to establish long-term relationships with clients and to maintain our strong mission, client focus, entrepreneurial spirit and team orientation. We have sought to create an executive compensation package that balances short-term versus long-term components, in ways we believe are most appropriate to motivate senior management and reward them for achieving key business goals. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Base Salary</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Except, as noted below, we did not change the annual base salary for any of our named executive officers in fiscal 2024, and their respective annual base salaries remained as follows: Dr.&#160;Hayward, $450,000, Ms.&#160;Jantzen, $300,000, Ms.&#160;Murrah, $325,000 and Mr.&#160;Shorrock, $300,000. Effective as of January&#160;1, 2024, Dr.&#160;Hayward and Ms.&#160;Murrah voluntarily reduced their annual base salaries to $250,000 and $243,750, respectively, in response to the cash position of the Company. This voluntary reduction was effective until May&#160;25, 2024. Effective November&#160;25, 2024, the base salaries for Ms.&#160;Murrah and Mr.&#160;Shorrock were increased to $400,000 and $385,000 respectively. Also, Ms.&#160;Murrah was named the President of Applied DNA Sciences, Inc. and Mr.&#160;Shorrock was named the President of LineaRx, Inc, effective on December&#160;13, 2024. Concurrently on December&#160;13, 2024 Dr.&#160;Hayward stepped down as the President of the Company. Dr.&#160;Hayward remains as the CEO and Chairman of the Board. Effective December&#160;7, 2024 Ms.&#160;Jantzen&#8217;s base salary was increased to $385,000. On January&#160;24, 2025 Dr.&#160;Hayward voluntarily reduced his salary by 11% to an annual base salary of $400,000, effective as of January&#160;18, 2025 through December&#160;31, 2025. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Bonuses</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">As of the date hereof, the Compensation Committee and the Board of Directors have determined that no cash incentive bonuses will be granted to Dr.&#160;Hayward, Ms.&#160;Jantzen, Mr.&#160;Shorrock or Ms.&#160;Murrah in respect of fiscal 2024 performance. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">45</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Long-Term Stock-Based Compensation</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Our long-term compensation program has historically consisted solely of stock options. Stock option grants made to executive officers are designed to provide them with an incentive to execute their responsibilities in such a way as to generate long-term benefit to us and our stockholders. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We believe that, by only rewarding the creation of stockholder value, stock options provide our executive officers with an effective risk and reward profile. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">There was no stock-based compensation granted to Dr.&#160;Hayward, Ms.&#160;Jantzen, Ms.&#160;Murrah, or Mr.&#160;Shorrock during the fiscal year ended September&#160;30, 2024. </span>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Benefits</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We provide the following benefits to our named executive officers on the same basis as the benefits provided to all employees: </span>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">health and dental insurance; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">life insurance; </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">short-and long-term disability; and </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">&#8226;</span>
          <br/>
        </div>
        <div style=" margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">401(k) Plan (currently there is no employer match) </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We believe these benefits are generally consistent with those offered by other companies and specifically with those companies with which we compete for employees. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Compensation Committee Interlocks and Insider Participation</span><span style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">None of the members of our Compensation Committee is or has been an officer or employee of our Company. None of our executive officers currently serves, or in the past year has served, as a member of the Compensation Committee or director (or other board committee performing equivalent functions or, in the absence of any such committee, the entire Board of Directors) of any entity that has one or more executive officers who currently serves, or will serve, on our Compensation Committee or our Board of Directors. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Summary Compensation Table</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The following table sets forth the compensation of our named executive officers for the fiscal&#160;years ended September&#160;30, 2024 and 2023. </span>
        </div>
        <table style="width:456pt;height:164.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:150.1pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Name and Principal Position </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.16pt;">Year </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Salary
                <br/>
                ($) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Bonus
                <br/>
                ($) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Stock
                <br/>
                Awards
                <br/>
                ($) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Option
                <br/>
                Awards
                <br/>
                ($) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Nonequity
                <br/>
                Incentive Plan
                <br/>
                Compensation
                <br/>
                ($) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">All Other
                <br/>
                Compensation
                <br/>
                ($)</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Total
                <br/>
                ($) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7.25pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td rowspan="2" style="padding:3.25pt 0pt 1.5pt 0pt; width:150.1pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify; line-height:12.0000000000001pt; padding-bottom:0pt;">
                <span style="letter-spacing:0.2pt;">James A. Hayward </span>
                <br/>
                <span style="font-style:italic;letter-spacing:0.2pt;">Chairman, President and CEO</span><span style=" position:relative; bottom:4.25pt;font-size:6.5pt;font-style:italic;letter-spacing:0.15pt;">&#65279;(2)</span>
              </div>
            </td>
            <td rowspan="2" style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:24.75pt; text-align:right; white-space:nowrap;">369,623</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:21pt; text-align:right; white-space:nowrap;">18,000</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12.0000000000001pt; min-width:24.75pt; text-align:right; white-space:nowrap;">387,623</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">450,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">18,000</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">468,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td rowspan="2" style="padding:3.5pt 0pt 1.5pt 0pt; width:150.1pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify; line-height:12pt; padding-bottom:0pt;">
                <span style="letter-spacing:0.2pt;">Beth M. Jantzen </span>
                <br/>
                <span style="font-style:italic;letter-spacing:0.2pt;">CFO</span>
              </div>
            </td>
            <td rowspan="2" style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">300,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">300,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">300,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">99,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">102,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">501,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td rowspan="2" style="padding:3.5pt 0pt 1.5pt 0pt; width:150.1pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify; line-height:12pt; padding-bottom:0pt;">
                <span style="letter-spacing:0.2pt;">Judith Murrah </span>
                <br/>
                <span style="font-style:italic;letter-spacing:0.2pt;">CIO, COO</span><span style=" position:relative; bottom:4.25pt;font-size:6.5pt;font-style:italic;letter-spacing:0.15pt;">&#65279;(2)</span>
              </div>
            </td>
            <td rowspan="2" style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">292,055</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">292,055</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">325,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">107,250</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">110,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">542,750</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td rowspan="2" style="padding:3.5pt 0pt 5pt 0pt; width:150.1pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify; line-height:12pt; padding-bottom:0.666666666666667pt;">
                <span style="letter-spacing:0.2pt;">Clay Shorrock </span>
                <br/>
                <span style="font-style:italic;letter-spacing:0.2pt;">CLO, Executive Director of
                <br/>
                Business Development</span><span style=" position:relative; bottom:4.25pt;font-size:6.5pt;font-style:italic;letter-spacing:0.15pt;">&#65279;(2)</span>
              </div>
            </td>
            <td rowspan="2" style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:15pt; text-align:right; white-space:nowrap;">2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">300,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:24.75pt; text-align:right; white-space:nowrap;">300,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">300,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.205pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">99,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">102,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">501,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.69pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(1)</span>
          <br/>
        </div>
        <div style=" margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Represents reimbursement payments to Dr.&#160;Hayward for costs associated with an automobile used by Dr.&#160;Hayward. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">46</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(2)</span>
          <br/>
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">On December&#160;13, 2024, Dr.&#160;Hayward stepped down as President of the Company and Judith Murrah was appointed President of the Company. Also on December&#160;13, 2024, Clay Shorrock was named President of LRx. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Outstanding Equity Awards at Fiscal Year-End</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The following table shows information concerning outstanding equity awards held by our named executive officers as of September&#160;30, 2024, the last day of fiscal 2024. </span>
        </div>
        <table style="width:456pt;height:511pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:129.6pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td colspan="22" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.16pt;">Option Awards </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td colspan="10" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.16pt;">Stock Awards </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:129.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Name </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Number of
                <br/>
                Securities
                <br/>
                Underlying
                <br/>
                Unexercised
                <br/>
                Options (#)
                <br/>
                Exercisable</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Number of
                <br/>
                Securities
                <br/>
                Underlying
                <br/>
                Unexercised
                <br/>
                Options (#)
                <br/>
                Unexercisable</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Option
                <br/>
                Exercise
                <br/>
                Price
                <br/>
                ($) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Option
                <br/>
                Expiration
                <br/>
                Date </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Number of
                <br/>
                Shares or
                <br/>
                Units of Stock
                <br/>
                That Have
                <br/>
                Not Yet
                <br/>
                Vested
                <br/>
                (#) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3.5pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Market Value
                <br/>
                of Shares
                <br/>
                or Units of
                <br/>
                Stock That
                <br/>
                Have Not
                <br/>
                Vested
                <br/>
                ($) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7.25pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td rowspan="10" style="padding:3.25pt 0pt 1.5pt 0pt; width:129.6pt;text-align:left;">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <span style="letter-spacing:0.2pt;">Dr.&#160;James A. Hayward </span>
              </div>
            </td>
            <td rowspan="10" style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:11.25pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">232,800.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10/17/2027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">114,400.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/21/2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">119,600.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/21/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">82,000.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/20/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">16</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">140,400.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7/10/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">47,600.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">08/29/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,360.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">06/02/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,540.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10/18/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">80</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,440.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1/5/2031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">219</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,580.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10/31/2031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td rowspan="9" style="padding:3.5pt 0pt 1.5pt 0pt; width:129.6pt;text-align:left;">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <span style="letter-spacing:0.2pt;">Beth M. Jantzen </span>
              </div>
            </td>
            <td rowspan="9" style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">114,400</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/21/2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">138,000.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">2/14/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">119,600.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/21/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">82,000.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/20/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">47,600.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">08/29/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,360.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">06/02/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,540.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10/18/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,580.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10/31/2031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">76</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,080.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/23/2033</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td rowspan="8" style="padding:3.5pt 0pt 1.5pt 0pt; width:129.6pt;text-align:left;">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <span style="letter-spacing:0.2pt;">Judith Murrah </span>
              </div>
            </td>
            <td rowspan="8" style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:11.25pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">114,400.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/21/2024</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">119,600.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/21/2025</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">82,000.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/20/2026</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">47,600.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">08/29/2028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">8,360.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">06/02/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">7,540.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10/18/2030</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">52</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,580.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10/31/2031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:15pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">28</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,080.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/23/2033</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:7pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td rowspan="2" style="padding:3.5pt 0pt 0.5pt 0pt; width:129.6pt;text-align:left;">
              <div style="white-space:nowrap; line-height:12pt; padding-bottom:0pt;">
                <span style="letter-spacing:0.2pt;">Clay Shorrock </span>
              </div>
            </td>
            <td rowspan="2" style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:11.25pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">5,580.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:34.5pt; text-align:right; white-space:nowrap;">10/31/2031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; line-height:12pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;height:19pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:15.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">76</td>
            <td style="padding:0pt;padding-left:21.67pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,080.00</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3/23/2033</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:19.355pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt; width:3.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:18.01pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(1)</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">All Option grants reflected in this column are fully vested and exercisable. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">47</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; line-height:12pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(2)</span>
          <br/>
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Each of the Option grants made in fiscal 2023 vests in equal 25% installments on each of the first four anniversaries of the date of grant (i.e., March&#160;23rd of each of 2024, 2025, 2026 and 2027), subject to the relevant named executive officer&#8217;s continued employment with the Company through each applicable vesting date. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Employment Agreement with Dr.&#160;James A. Hayward</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">The following is a discussion of our employment agreement with Dr.&#160;Hayward as of April&#160;3, 2025 and, where indicated, compensation actions prior to such date.</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Chairman and Chief Executive Officer is the only named executive officer with an employment agreement. Effective as of January&#160;1, 2024, Dr.&#160;Hayward voluntarily reduced his salary to $250,000 in response to the then current cash position of the Company. This voluntary reduction was effective until May&#160;25, 2024. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The initial term of Dr.&#160;Hayward&#8217;s employment agreement was from July&#160;1, 2016 to July&#160;1, 2017, and the term of the employment agreement renews automatically on an annual basis thereafter, unless either party provides the other with 90&#160;days&#8217; advance written notice of non-renewal. The employment agreement provides for an annual base salary, which is described above in the section entitled &#8220;Base Salary,&#8221; and the Board of Directors, acting in its discretion, may also grant annual bonuses and annual equity awards to Dr.&#160;Hayward, provided that Dr.&#160;Hayward may not be treated less favorably with respect to annual bonuses or annual equity awards than other executives of the Company. Dr.&#160;Hayward will be eligible to participate in retirement, welfare and incentive plans available to the Company&#8217;s other employees. The employment agreement also provides for the following limited perquisites: an automobile allowance of up to $1,500 per month, a gas allowance, the use of an outside driver for up to 20 hours per week, a gym membership and an airline club membership. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The employment agreement with Dr.&#160;Hayward also provides that if he is terminated by the Company without &#8220;cause&#8221; &#8203;(as defined in the employment agreement and summarized below) or if Dr.&#160;Hayward terminates his employment for &#8220;good reason&#8221; &#8203;(as defined in the employment agreement and summarized below), then, in addition to payment or provision of any earned and unpaid base salary, bonus and benefits, and subject to his delivery of an executed general release and continuing compliance with restrictive covenants, Dr.&#160;Hayward will be entitled to receive: (i)&#160;a pro&#160;rata portion (based on the number of days elapsed from the beginning of the Company&#8217;s fiscal year to the date of his termination of employment) of the greater of (A)&#160;the annual bonus he would have received if his employment had continued through the end of the fiscal year of termination and (B)&#160;the prior year&#8217;s annual bonus; (ii)&#160;installment payments for two&#160;years following termination in an aggregate amount equal to the greater of (A)&#160;2.99 times Dr.&#160;Hayward&#8217;s base salary and (B)&#160;two times the sum of (I)&#160;Dr.&#160;Hayward&#8217;s base salary and (II)&#160;Dr.&#160;Hayward&#8217;s prior year&#8217;s annual bonus (or, if greater, Dr.&#160;Hayward&#8217;s target bonus (if any) for the fiscal year of termination); (iii)&#160;Company-paid COBRA continuation coverage for 18&#160;months post-termination; (iv)&#160;continuing life insurance benefits (if any) for two&#160;years post-termination; and (v)&#160;extended exercisability of any outstanding vested stock options and stock appreciation rights (until three&#160;years from the termination date or, if earlier, until the expiration of the fixed stock option or stock appreciation right term). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">If termination of Dr.&#160;Hayward&#8217;s employment is triggered by the Company without cause or by Dr.&#160;Hayward for good reason, in each case, within six&#160;months before or two&#160;years after a &#8220;change in control of the Company&#8221; &#8203;(as defined in the employment agreement), then, the severance payments that would otherwise have been paid in installments will be paid in a lump sum. Further, unless assumed or continued by the acquiror, all of Dr.&#160;Hayward&#8217;s outstanding stock options and other equity incentive awards will become fully vested upon the occurrence of a change in control of the Company (whether or not his employment is terminated in connection with such change in control). The exercisability period of outstanding stock options and stock appreciation rights would be extended until three&#160;years following the change in control (or, if later, until three&#160;years following a qualifying termination after a change in control), or, if earlier, until the earlier expiration of the fixed stock option or stock appreciation right term. In addition, the employment agreement provides that if the payments and benefits due to Dr.&#160;Hayward in connection with a change in control would be subject to an excise tax under Section&#160;280G of the Code, they will be reduced to the </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">48</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">maximum amount that would not trigger the excise tax, unless Dr.&#160;Hayward would be better off (on an after- tax basis) receiving all of the payments and benefits and paying all necessary applicable taxes. Additionally, if, following a change in control, the Company fails to comply with any of its obligations under the employment agreement or the Company takes any action to declare the employment agreement void or unenforceable or institutes any litigation or other legal action designed to deny, diminish or to recover from Dr.&#160;Hayward (or his beneficiary) the payments and benefits intended to be provided, then Dr.&#160;Hayward (or his beneficiary, as the case may be) shall be entitled to select and retain counsel at the expense of the Company to represent him (or his beneficiary) in connection with the good faith initiation or defense of any litigation or other legal action, whether by or against the Company or any director, officer, stockholder or other person affiliated with the Company or any successor thereto in any jurisdiction. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Upon a termination of his employment due to death or &#8220;disability&#8221; &#8203;(as defined in the employment agreement), Dr.&#160;Hayward will generally be entitled to receive the same payments and benefits he would have received if his employment had been terminated by the Company without cause, other than the installment payments and the continuing life insurance benefits, and additionally, the extended exercisability provisions would apply to any outstanding stock options only. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">For purposes of the employment agreement, &#8220;cause&#8221; means Dr.&#160;Hayward: (i)&#160;is convicted of or pleads nolo contendere to a felony, (ii)&#160;commits fraud or a material act or omission involving dishonesty affecting the assets, business or reputation of the Company or any of its subsidiaries or affiliates, (iii)&#160;willfully fails or refuses to carry out the material responsibilities of his employment, as reasonably determined by the Board of Directors, (iv)&#160;engages in gross negligence, willful misconduct or a pattern of behavior that has had or is reasonably likely to have a significant adverse effect on the Company or his ability to perform the duties and responsibilities of his employment, or (v)&#160;willfully engages in any act or omission that is in material violation of Company policy, including, without limitation, Company policy on business ethics and conduct, and Company policy on the use of inside information and insider trading; provided, however, that, if the conduct giving rise to termination for Cause is curable without material harm to the business or assets of the Company, Dr.&#160;Hayward will be afforded an opportunity to effect such a cure within 30&#160;days after notice of termination and thereby avoid a termination for Cause based upon such conduct. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">For purposes of the employment agreement, &#8220;good reason&#8221; is defined as any of the following: (i)&#160;a material adverse change by the Company of Dr.&#160;Hayward&#8217;s status or position as the Chief Executive Officer, including, without limitation, a material diminution of his position, duties, responsibilities or authority or the assignment to him of duties or responsibilities that are materially inconsistent with his status or position; (ii)&#160;a non-voluntary reduction by the Company of his annual base salary or failure to pay same; (iii)&#160;a breach by the Company of any of its material obligations under the employment agreement; (iv)&#160;relocation of Dr.&#160;Hayward without his consent beyond a 75-mile radius of his then principal place of employment in violation of the employment agreement; or (v)&#160;in connection with a change in control, the failure or refusal by the successor or acquiring company to expressly assume the obligations of the Company under the employment agreement. As a condition to terminating his employment for Good Reason, Dr.&#160;Hayward must, within 60&#160;days after the occurrence of the event or condition giving rise to such termination, provide written notice to the Company (or the successor or acquiring company) of his desire to terminate for Good Reason, specifying the nature of the act or omission that he deems to constitute Good Reason. The Company shall have 30&#160;days after receipt of such notice to review and, if required, correct the situation (and thus prevent his termination for Good Reason). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Dr.&#160;Hayward is subject to standard restrictive covenants, including a two-year post-employment non- compete and a two-year post-employment non-solicit of employees or customers. In his capacity as a Chief Executive Officer, Dr.&#160;Hayward&#8217;s position at the Company is a policy-making position in which he has the authority to make policy decisions that control significant aspects of the Company. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Director Compensation: Fiscal 2024</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Due to the financial state of the Company, the Board waived their compensation for fiscal 2024. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">None of the members of our Board of Directors received any other compensation in respect of fiscal 2024. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">49</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:0.0299999999999727pt;margin-left:69.66pt;width:456pt;">
        <table style="width:416pt;height:101.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:350.13pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:-0.16pt;">Name </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Option
                <br/>
                Awards
                <br/>
                ($) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Total
                <br/>
                ($) </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:350.13pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <span style="letter-spacing:0.2pt;">Sanford R. Simon</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.13pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <span style="letter-spacing:0.2pt;">Yacov A. Shamash</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.13pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <span style="letter-spacing:0.2pt;">Joseph D. Ceccoli</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.13pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <span style="letter-spacing:0.2pt;">Robert C. Catell</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.13pt;text-align:left;">
              <div style="white-space:nowrap;font-style:italic;">
                <span style="letter-spacing:0.2pt;">Elizabeth M. Schmalz Shaheen</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.19pt; width:456pt; line-height:12pt;font-size:10pt;">
          <span style="letter-spacing:-0.2pt;">Policies and Practices for Granting Certain Equity Awards</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <ix:nonNumeric contextRef="c0" escape="true" name="ecd:AwardTmgMnpiDiscTextBlock" id="ixv-5937"><ix:nonNumeric contextRef="c0" escape="true" name="ecd:AwardTmgMethodTextBlock" id="ixv-5938"><ix:nonNumeric contextRef="c0" escape="true" name="ecd:AwardTmgHowMnpiCnsdrdTextBlock" id="ixv-5939"><div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-weight:normal;font-size:10pt;"> <span style="letter-spacing:0.2pt;">The Company did not grant equity awards to any executive officer or Board member during fiscal year 2024 due to the small number of shares available under the Current Plan. The Compensation Committee and the Board have a historical practice of not granting equity awards to executive officers during closed quarterly trading windows as determined under the Company&#8217;s Insider Trading Policy. Annual grants of equity awards, which historically have included stock options, are typically made to the Corporation&#8217;s executive officers, including named executive officers, during the open-trading-window period of the fiscal quarter in which they are awarded. Consequently, the <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:AwardTmgMnpiCnsdrdFlag" id="ixv-7948">Company has not granted</ix:nonNumeric>, and does not expect to grant, any equity awards to any named executive officers during the period commencing four business days prior to and ending one business day following the filing with the SEC of any Company report on Forms 10-K, 10-Q or 8-K that discloses material non-public information about the Company. The Compensation Committee and the Board <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:AwardTmgPredtrmndFlag" id="ixv-7949">do not</ix:nonNumeric> take material non-public information into account when determining the timing of equity awards, and the Company has <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="ecd:MnpiDiscTimedForCompValFlag" id="ixv-7950">not timed</ix:nonNumeric> the disclosure of material non-public information in order to affect the value of executive compensation. </span> </div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-size:10pt;">
          <span style="letter-spacing:-0.2pt;">Pay Versus Performance</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-weight:normal;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">As required by Section&#160;953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act, and Item&#160;402(v) of Regulation&#160;S-K, we are providing the following information about the relationship between executive compensation actually paid and certain financial performance of the Company. </span>
        </div>
        <ix:nonNumeric contextRef="c0" continuedAt="_PvpTableTextBlock-c0_cont_1" escape="true" name="ecd:PvpTableTextBlock" id="ixv-5947"><table style="width:456pt;height:95.56pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <tr style="line-height:9pt;height:31.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:left;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Summary <br/> Compensation <br/> Table Total <br/> for PEO</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Compensation <br/> Actually Paid <br/> to PEO</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Average <br/> Summary <br/> Compensation <br/> Table Total <br/> for Non-PEO <br/> NEOs</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(3)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Average <br/> Compensation <br/> Actually Paid <br/> to Non-PEO <br/> NEOs</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(4)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Value of Initial <br/> Fixed $100 <br/> Investment Based On</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(6)</span><span style="letter-spacing:-0.16pt;">: </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Net (Loss) <br/> (thousands)</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(6)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;"><ix:nonNumeric contextRef="c0" name="ecd:CoSelectedMeasureName" id="ixv-7951">Revenues</ix:nonNumeric> <br/> (thousands)</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(7)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td> </tr> <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:60pt;"> <div style="white-space:nowrap;"> <span style="letter-spacing:-0.16pt;">Year</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;text-align:center;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Total Shareholder <br/> Return</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(5)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> </tr> <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="padding:3.25pt 0pt 2.5pt 0pt; width:60pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:-0.16pt;">(a) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(b) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(c) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(d) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(e) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(f) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(g) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(h) </span> </div> </td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;"> <td style="padding:3.27pt 0pt 1.79pt 0pt; width:60pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.18pt;">2024 </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd" id="ixv-7952">387,623</ix:nonFraction></td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd" id="ixv-7953">387,623</ix:nonFraction></td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-7954">297,352</ix:nonFraction></td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-7955">297,352</ix:nonFraction></td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:25.02pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ecd:TotalShareholderRtnAmt" scale="0" unitRef="usd" id="ixv-7956">107.08</ix:nonFraction></td> <td style="padding:0pt;padding-left:25.02pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7957">7,088</ix:nonFraction><span style="position:absolute;">)</span></td> <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:7.85pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ecd:CoSelectedMeasureAmt" scale="3" unitRef="usd" id="ixv-7958">3,431</ix:nonFraction></td> <td style="padding:0pt;padding-left:7.85pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;"> <td style="padding:3.52pt 0pt 1.79pt 0pt; width:60pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.18pt;">2023 </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd" id="ixv-7959">468,000</ix:nonFraction></td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd" id="ixv-7960">468,000</ix:nonFraction></td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-7961">514,917</ix:nonFraction></td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-7962">308,333</ix:nonFraction></td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:25.02pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="ecd:TotalShareholderRtnAmt" scale="0" unitRef="usd" id="ixv-7963">107.08</ix:nonFraction></td> <td style="padding:0pt;padding-left:25.02pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-7964">10,023</ix:nonFraction><span style="position:absolute;">)</span></td> <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:7.85pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="ecd:CoSelectedMeasureAmt" scale="3" unitRef="usd" id="ixv-7965">13,367</ix:nonFraction></td> <td style="padding:0pt;padding-left:7.85pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> </table>
        <div style="margin-top:14.01pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <ix:nonNumeric contextRef="c0" continuedAt="_NamedExecutiveOfficersFnTextBlock-c0_cont_1" escape="true" name="ecd:NamedExecutiveOfficersFnTextBlock" id="ixv-6163"><div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;"> <span style="letter-spacing:0.2pt;">(1)</span> <br/> </div></ix:nonNumeric>
        <ix:continuation continuedAt="_NamedExecutiveOfficersFnTextBlock-c0_alt_0_cont_2" id="_NamedExecutiveOfficersFnTextBlock-c0_cont_1"><div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;"> <!--blacklining:none;--> <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (b)&#160;are the amounts of total compensation reported for the principal executive officer (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">PEO</span><span style="letter-spacing:0.2pt;">&#8221;), <ix:nonNumeric contextRef="c0" name="ecd:PeoName" id="ixv-7966">Dr.&#160;Hayward</ix:nonNumeric> (our Chairman, Chief Executive Officer and President), for each corresponding year in the &#8220;Total&#8221; column of the Summary Compensation Table. Refer to &#8220;Executive Compensation&#8201;&#8212;&#8201;Executive Compensation Tables&#8201;&#8212;&#8201;Summary Compensation Table.&#8221; </span> </div></ix:continuation>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <ix:nonNumeric contextRef="c0" continuedAt="_AdjToPeoCompFnTextBlock-c0_cont_1" escape="true" name="ecd:AdjToPeoCompFnTextBlock" id="ixv-6173"><div style=" float:left; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;"> <span style="letter-spacing:0.2pt;">(2)</span> <br/> </div></ix:nonNumeric>
        <ix:continuation continuedAt="_AdjToPeoCompFnTextBlock-c0_cont_2" id="_AdjToPeoCompFnTextBlock-c0_cont_1"><div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (c)&#160;represent the amount of &#8220;compensation actually paid&#8221; to Dr.&#160;Hayward, as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr.&#160;Hayward during the applicable year. In accordance with the requirements of Item&#160;402(v) of Regulation&#160;S-K, the following adjustments were made to Dr.&#160;Hayward&#8217;s total compensation for each year to determine the compensation actually paid which is reported above: </span>
        </div></ix:continuation>
        <ix:continuation continuedAt="_AdjToPeoCompFnTextBlock-c0_cont_3" id="_AdjToPeoCompFnTextBlock-c0_cont_2"><div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div></ix:continuation></ix:nonNumeric>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">50</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <ix:continuation id="_PvpTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_AdjToPeoCompFnTextBlock-c0_cont_4" id="_AdjToPeoCompFnTextBlock-c0_cont_3"><table style="width:436pt;height:74.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:183.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:-0.16pt;">Year </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Reported <br/> Summary <br/> Compensation <br/> Table Total for <br/> PEO </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Reported <br/> Value of Equity <br/> Awards</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(a)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Equity <br/> Award <br/> Adjustments</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(b)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Compensation <br/> Actually Paid to <br/> PEO </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.25pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2024 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd" id="ixv-7967">387,623</ix:nonFraction></td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-1">&#160;&#160;&#160;&#8212;</span></td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-2">&#160;&#160;&#160;&#8212;</span></td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd" id="ixv-7968">387,623</ix:nonFraction></td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.5pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2023 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoTotalCompAmt" scale="0" unitRef="usd" id="ixv-7969">468,000</ix:nonFraction></td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-4">&#8212;</span></td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-5">&#8212;</span></td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:PeoActuallyPaidCompAmt" scale="0" unitRef="usd" id="ixv-7970">468,000</ix:nonFraction></td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> </table></ix:continuation>
        <div style="margin-left:20pt; margin-top:12.3pt; width:436pt;">
          <ix:continuation continuedAt="_AdjToPeoCompFnTextBlock-c0_cont_5" id="_AdjToPeoCompFnTextBlock-c0_cont_4"><div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div></ix:continuation>
        </div>
        <ix:continuation continuedAt="_AdjToPeoCompFnTextBlock-c0_cont_6" id="_AdjToPeoCompFnTextBlock-c0_cont_5"><div style=" float:left; margin-left:20pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(a)</span>
          <br/>
        </div></ix:continuation>
        <ix:continuation continuedAt="_AdjToPeoCompFnTextBlock-c0_cont_7" id="_AdjToPeoCompFnTextBlock-c0_cont_6"><div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The grant date fair value of equity awards represents the total of the amounts reported in the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns in the Summary Compensation Table for the applicable year. </span>
        </div></ix:continuation>
        <ix:continuation continuedAt="_AdjToPeoCompFnTextBlock-c0_cont_8" id="_AdjToPeoCompFnTextBlock-c0_cont_7"><div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div></ix:continuation>
        <ix:continuation continuedAt="_AdjToPeoCompFnTextBlock-c0_cont_9" id="_AdjToPeoCompFnTextBlock-c0_cont_8"><div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(b)</span>
          <br/>
        </div></ix:continuation>
        <ix:continuation id="_AdjToPeoCompFnTextBlock-c0_cont_9"><div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">There was no equity award adjustment for each of the applicable&#160;years shown above, as all equity awards granted were fully vested on the date of grant. </span>
        </div></ix:continuation>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <ix:continuation continuedAt="_NamedExecutiveOfficersFnTextBlock-c0_alt_0_cont_3" id="_NamedExecutiveOfficersFnTextBlock-c0_alt_0_cont_2"><div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"> <span style="letter-spacing:0.2pt;">(3)</span> <br/> </div></ix:continuation>
        <ix:continuation id="_NamedExecutiveOfficersFnTextBlock-c0_alt_0_cont_3"><div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (d)&#160;represent the average of the amounts reported for the Company&#8217;s named executive officers as a group (excluding Dr.&#160;Hayward, who has served as our Chairman, Chief Executive Officer and President) in the &#8220;Total&#8221; column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers (excluding Dr.&#160;Hayward) included for purposes of calculating the average amounts in each applicable year are as follows: (i)&#160;for 2024 and 2023, Beth M. Jantzen, Clay Shorrock and Judith Murrah. </span>
        </div></ix:continuation>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <ix:nonNumeric contextRef="c0" continuedAt="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_1" escape="true" name="ecd:AdjToNonPeoNeoCompFnTextBlock" id="ixv-6330"><div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"> <span style="letter-spacing:0.2pt;">(4)</span> <br/> </div></ix:nonNumeric>
        <ix:continuation continuedAt="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_2" id="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_1"><div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (e)&#160;represent the average amount of &#8220;compensation actually paid&#8221; to the named executive officers as a group (excluding Dr.&#160;Hayward), as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the named executive officers as a group (excluding Dr.&#160;Hayward) during the applicable year. In accordance with the requirements of Item&#160;402(v) of Regulation&#160;S-K, the following adjustments were made to average total compensation for the named executive officers as a group (excluding Dr.&#160;Hayward) for each year to determine the compensation actually paid, using the same methodology described above in Note 3: </span>
        </div></ix:continuation>
        <ix:continuation continuedAt="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_3" id="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_2"><div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div></ix:continuation>
        <ix:continuation continuedAt="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_4" id="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_3"><table style="width:436pt;height:83.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:170.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:-0.16pt;">Year </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average <br/> Reported <br/> Summary <br/> Compensation <br/> Table Total for <br/> Non-PEO NEOs </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average <br/> Reported <br/> Value of Equity <br/> Awards </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average Equity <br/> Award <br/> Adjustments</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(a)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average <br/> Compensation <br/> Actually Paid to <br/> Non-PEO NEOs </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.25pt 0pt 1.5pt 0pt; width:170.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2024 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-7971">297,352</ix:nonFraction></td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-6">&#8212;</span></td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-3">&#160;&#160;&#160;&#8212;</span></td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-7972">297,352</ix:nonFraction></td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2023 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgTotalCompAmt" scale="0" unitRef="usd" id="ixv-7973">514,917</ix:nonFraction></td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="ecd:AdjToCompAmt" scale="0" sign="-" unitRef="usd" id="ixv-7974">206,583</ix:nonFraction></td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-7">&#8212;</span></td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" scale="0" unitRef="usd" id="ixv-7975">308,333</ix:nonFraction></td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> </table></ix:continuation>
        <div style="margin-left:20pt; margin-top:12.3pt; width:436pt;">
          <ix:continuation continuedAt="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_5" id="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_4"><div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div></ix:continuation>
        </div>
        <ix:continuation continuedAt="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_6" id="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_5"><div style=" float:left; margin-left:20pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(a)</span>
          <br/>
        </div></ix:continuation>
        <ix:continuation id="_AdjToNonPeoNeoCompFnTextBlock-c0_cont_6"><div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">There was no equity award adjustment for each of the applicable&#160;years shown above, as all equity awards granted were fully vested on the date of grant. </span>
        </div></ix:continuation>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(5)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Cumulative total shareholder return (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">TSR</span><span style="letter-spacing:0.2pt;">&#8221;) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company&#8217;s share price at the end and the beginning of the measurement period by the Company&#8217;s share price at the beginning of the measurement period. No dividends were paid on stock awards or Options in either of fiscal 2024 or 2023. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(6)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The dollar amounts reported represent the amount of net income reflected in the Company&#8217;s audited financial statements for the applicable year. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <ix:nonNumeric contextRef="c10" continuedAt="_NonGaapMeasureDescriptionTextBlock-c10_cont_1" escape="true" name="ecd:NonGaapMeasureDescriptionTextBlock" id="ixv-6466"><div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"> <span style="letter-spacing:0.2pt;">(7)</span> <br/> </div></ix:nonNumeric>
        <ix:continuation id="_NonGaapMeasureDescriptionTextBlock-c10_cont_1"><div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The dollar amounts reported represent the amount of consolidated revenues reflected in the Company&#8217;s audited financial statements for the applicable year. </span>
        </div></ix:continuation></ix:continuation>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">Analysis of the Information Presented in the Pay versus Performance Table</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Company&#8217;s executive compensation program reflects a variable pay-for-performance philosophy. While the Company utilizes several performance measures to align executive compensation with Company performance, all of those Company measures are not presented in the Pay versus Performance table. Moreover, the Company generally seeks to incentivize long-term performance, and therefore does not specifically </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">51</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:137.45pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">align the Company&#8217;s performance measures with compensation that is actually paid (as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K) for a particular year. In accordance with Item&#160;402(v) of Regulation&#160;S-K, the Company is providing the following descriptions of the relationships between information presented in the Pay versus Performance table. </span>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">Compensation Actually Paid and Cumulative TSR</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">The following graph addresses the amount of compensation actually paid to Dr.&#160;Hayward and the average amount of compensation actually paid to the Company&#8217;s named executive officers as a group (excluding Dr.&#160;Hayward) with the Company&#8217;s cumulative TSR over the two&#160;years presented in the table. The Company does not use cumulative TSR as a performance measure in the overall executive compensation program. </span>
        </div>
        <ix:nonNumeric contextRef="c0" escape="true" name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock" id="ixv-6504"><div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img alt="[MISSING IMAGE: bc_tsr-bw.jpg]" src="bc_tsr-bw.jpg" style="height: 315px; width: 556px;"/>
        </div></ix:nonNumeric>
        <div style="margin-top:18.69pt; width:456pt; line-height:12pt;font-style:italic;">
          <span style="letter-spacing:0.2pt;">Compensation Actually Paid and Net Loss</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">The following table addresses the amount of compensation actually paid to Dr.&#160;Hayward and the average amount of compensation actually paid to the Company&#8217;s named executive officers as a group (excluding Dr.&#160;Hayward) with the Company&#8217;s net loss over the two&#160;years presented in the table. The Company does not use net loss as a performance measure in the overall executive compensation program, particularly when determining the size of incentive equity awards. </span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">52</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:34pt;margin-left:69.66pt;width:456pt;">
        <ix:nonNumeric contextRef="c0" escape="true" name="ecd:CompActuallyPaidVsNetIncomeTextBlock" id="ixv-6530"><div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img alt="[MISSING IMAGE: bc_netloss-bw.jpg]" src="bc_netloss-bw.jpg" style="height: 315px; width: 556px;"/>
        </div></ix:nonNumeric>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">Compensation Actually Paid and Revenues</span><span style="font-style:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">As demonstrated by the following graph, the amount of compensation actually paid to Dr.&#160;Hayward and the average amount of compensation actually paid to the Company&#8217;s named executive officers as a group (excluding Dr.&#160;Hayward) is aligned with the Company&#8217;s revenues over the two&#160;years presented in the table. The Company utilizes revenues when setting goals for the certain performance-based bonuses and incentive equity compensation grants that are awarded to the named executive officers. </span>
        </div>
        <ix:nonNumeric contextRef="c0" escape="true" name="ecd:CompActuallyPaidVsCoSelectedMeasureTextBlock" id="ixv-6538"><div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img alt="[MISSING IMAGE: bc_revenues-bw.jpg]" src="bc_revenues-bw.jpg" style="height: 315px; width: 556px;"/>
        </div></ix:nonNumeric>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">53</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tSOOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The following table sets forth certain information regarding the shares of our Common Stock beneficially owned as of the Record Date, by (i)&#160;each person, or group of affiliated persons, who is known to us to beneficially own 5% or more of the outstanding Common Stock, (ii)&#160;each of our named executive officers and current executive officers, (iii)&#160;each of our directors and (iv)&#160;all of our current executive officers and directors as a group. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections&#160;13(d) and 13(g) of the Exchange Act. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">We have based our calculation of the&#160;percentage of beneficial ownership on 6,497,790 shares of our Common Stock outstanding on the Record Date. We have deemed shares of Common Stock subject to stock options that are currently exercisable or exercisable within 60&#160;days of the Record Date to be outstanding and to be beneficially owned by the person holding the stock option for the purpose of computing the&#160;percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the&#160;percentage ownership of any other person. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Unless otherwise indicated below, the address of each beneficial owner listed in the table below is c/o&#160;50 Health Sciences Drive, Stony Brook, New York 11790. The information in the table below is based solely on a review of Schedules 13D and 13G as well as the Company&#8217;s knowledge of holdings with respect to its employees and directors. </span>
        </div>
        <table style="width:456pt;height:288pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:255.99pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:-0.16pt;">Title of Class </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Number of Shares
                <br/>
                Owned</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;">
              <div style="text-align:center;">
                <span style="letter-spacing:-0.16pt;">Percentage
                <br/>
                of Class</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <span style="letter-spacing:-0.2pt;">Executive Officers and Directors:</span>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:66.97pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">James A. Hayward </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">504<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(3)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Yacov A. Shamash </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">180<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(4)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Joseph D. Ceccoli </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">172<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(5)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Sanford R. Simon </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">167<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(6)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Robert B. Catell </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">169<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(7)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Elizabeth Schmalz Shaheen </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">168<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(8)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Beth M. Jantzen </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">163<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(9)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Judith Murrah </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">182<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(10)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Clay Shorrock </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">151<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(11)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <span style="letter-spacing:-0.2pt;">All directors and officers as a group (9 persons)</span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,856<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(12)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <span style="letter-spacing:0.2pt;">5% Stockholders: </span>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:66.97pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Altium Growth Fund, LP </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">420,972<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(13)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.17<span style="position:absolute;">%</span></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Anson Master Funds </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">399,115<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(14)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.84<span style="position:absolute;">%</span></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Michael Bigger </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">394,466<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(15)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.79<span style="position:absolute;">%</span></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">L1 Capital Global Opportunities Master Fund </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">371,103<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(16)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.45<span style="position:absolute;">%</span></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">Sabby Volatility Warrant Master Fund, Ltd. </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">104,484<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(17)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.61<span style="position:absolute;">%</span></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:255.99pt;text-align:left;">
              <div style="white-space:nowrap;">
                <span style="letter-spacing:0.2pt;">S.H.N. Financial Investments Ltd </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:66.97pt;">
              <div style="white-space:nowrap; text-align:center;">
                <span style="letter-spacing:0.2pt;">Common Stock </span>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">379,103<span style="position:absolute;"><span style=" position:relative; bottom:3.25pt;font-size:6.5pt;">(18)</span> </span></td>
            <td style="padding:0pt;padding-left:13.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.57<span style="position:absolute;">%</span></td>
            <td style="padding:0pt;padding-left:9.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">*</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">indicates less than one&#160;percent </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(1)</span>
          <br/>
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to the shares shown. Except as indicated by footnote and subject </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">54</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">to community property laws where applicable, to our knowledge, the stockholders named in the table have sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned by them. A person is deemed to be the beneficial owner of securities that can be acquired by such person within 60&#160;days upon the exercise of options, warrants or convertible securities (in any case, the &#8220;Currently Exercisable Options&#8221;). </span>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:3.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(2)</span>
          <br/>
        </div>
        <div style=" margin-top:3.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Based upon 6,497,790 shares of Common Stock outstanding as of the Record Date. Each beneficial owner&#8217;s&#160;percentage ownership is determined by assuming that the Currently Exercisable Options that are beneficially held by such person (but not those held by any other person) have been exercised and converted. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(3)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes 370 shares underlying currently exercisable options. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(4)</span>
          <br/>
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes 178 shares underlying currently exercisable options. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(5)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes 171 shares underlying currently exercisable options. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(6)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes 167 shares underlying currently exercisable options. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(7)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes 167 shares underlying currently exercisable options. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(8)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes 167 shares underlying currently exercisable options. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(9)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes 122 shares underlying currently exercisable options. Excludes 50 shares underlying options that were granted on March&#160;23, 2023 and vest 25% per year commencing on the first anniversary of grant date. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(10)</span>
          <br/>
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes 135 shares underlying currently exercisable options. Excludes 54 shares underlying options that were granted on March&#160;23, 2023 and vest 25% per year commencing on the first anniversary of grant date. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(11)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes 95 shares underlying currently exercisable options. Excludes 50 shares underlying options that were granted on March&#160;23, 2023 and vest 25% per year commencing on the first anniversary of grant date. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(12)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">Includes 1,572 shares underlying currently exercisable options. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(13)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The securities are directly held as of November&#160;6, 2024, by Altium Growth Fund, LP (&#8220;Altium&#8221;), and may be deemed to be beneficially owned by Jacob Gottlieb, who exercises investment and voting control over the securities. The address of Altium is c/o&#160;Altium Capital Management, LP, 152 West 57</span><span style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</span><span style="letter-spacing:0.2pt;">&#160;Street, 20</span><span style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</span><span style="letter-spacing:0.2pt;"> Floor, New York, NY 10019. Consists of (i)&#160;97,548 shares of Common Stock, (ii)&#160;warrants to purchase up to 316,936 shares of Common Stock and (iii)&#160;Pre-Funded Warrants to purchase up to 6,488&#160;shares of Common Stock. Certain of the warrants held by Altium are subject to a beneficial ownership limitation of 4.99% or 9.99%, as applicable, which such limitation restricts Altium from exercising that portion of the warrants that would result in Altium and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The beneficial ownership of Altium reported in this table does not reflect this limitation. Excludes (i)&#160;Series&#160;C Warrants to purchase up to 75,000 shares of Common Stock and (ii)&#160;Series&#160;D Warrants to purchase up to 378,549 shares of Common Stock, whose exercise are subject to Warrant Stockholder Approval. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(14)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The securities are directly held as of November&#160;6, 2024, by (i)&#160;Anson East Master Fund&#160;LP (&#8220;Anson East&#8221;) and (ii)&#160;Anson Investments Master Fund&#160;LP (&#8220;Anson Investments&#8221;, and, collectively with Anson East, the &#8220;Anson Master Funds&#8221;). Anson Advisors Inc and Anson Funds Management LP, the Co-Investment Advisers of the Anson Master Funds, hold voting and dispositive power over the shares of Common Stock held by the Anson Master Funds. Tony Moore is the managing member of Anson Management GP LLC, which is the general partner of Anson Funds Management LP. Moez Kassam and Amin Nathoo are directors of Anson Advisors Inc. Mr.&#160;Moore, Mr.&#160;Kassam and Mr.&#160;Nathoo each disclaim beneficial ownership of these shares of Common Stock except to the extent of their pecuniary interest therein. The principal business address of the Anson Master Funds is Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. Consists of (i)&#160;68,512 shares of Common Stock, (ii)&#160;warrants to purchase up to 324,115 shares of Common Stock and (iii)&#160;Pre-Funded Warrants to purchase up to 6,488 shares of Common Stock. Certain of the warrants held by the Anson Master Funds are subject to a beneficial ownership limitation of 4.99% or 9.99%, as applicable, which such limitation restrict the Anson Master Funds from exercising that portion of the warrants that would result in the Anson Master Funds and their affiliates </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">55</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The beneficial ownership of the Anson Master Funds reported in this table do not reflect this limitation. Excludes (i)&#160;Series&#160;C Warrants to purchase up to 75,000 shares of Common Stock and (ii)&#160;Series&#160;D Warrants to purchase up to 378,549 shares of Common Stock, whose exercise are subject to Warrant Stockholder Approval. </span>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(15)</span>
          <br/>
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The securities are directly held as of November&#160;6, 2024, by (i)&#160;Bigger Capital Fund, LP (&#8220;Bigger&#8221;) and (ii)&#160;District 2 Capital Fund&#160;LP (&#8220;District 2&#8221;), and may be deemed to be beneficially owned by Michael&#160;Bigger, who exercises investment and voting control over the securities. The address of Bigger is 11700 W.&#160;Charleston Blvd. 170-659, Las Vegas, NV 89135, and the address of District 2 is 14 Wall Street, Huntington, NY 11743. Consists of (i)&#160;75,000 shares of Common Stock and (ii)&#160;warrants to purchase up to 319,466 shares of Common Stock. Certain of the warrants held by Bigger and District 2 are subject to a beneficial ownership limitation of 4.99% or 9.99%, as applicable, which such limitation restrict Bigger and District 2 from exercising that portion of the warrants that would result in Bigger and District&#160;2 and their affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The beneficial ownership of Bigger and District 2 reported in this table do not reflect this limitation. Excludes (i)&#160;Series&#160;C Warrants to purchase up to 75,000 shares of Common Stock and (ii)&#160;Series&#160;D Warrants to purchase up to 378,549 shares of Common Stock, whose exercise are subject to Warrant Stockholder Approval. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(16)</span>
          <br/>
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The securities are directly held as of November&#160;6, 2024, by L1 Capital Global Opportunities Master Fund (&#8220;L1&#8221;), and may be deemed to be beneficially owned by David Feldman and Joel Arber. The address of L1 is 161A Shedden Road, 1 Artillery Court, PO Box 10085, Grand Cayman KY1-1001, Cayman Islands. Consists of (i)&#160;62,500 shares of Common Stock and (ii)&#160;warrants to purchase up to 308,603 shares of Common Stock. Certain of the warrants held by L1 are subject to a beneficial ownership limitation of 4.99% or 9.99%, as applicable, which such limitation restrict L1 from exercising that portion of the warrants that would result in L1 and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The beneficial ownership of L1 reported in this table does not reflect this limitation. Excludes (i)&#160;Series&#160;C Warrants to purchase up to 62,500 shares of Common Stock and (ii)&#160;Series&#160;D Warrants to purchase up to 315,457 shares of Common Stock, whose exercise are subject to Warrant Stockholder Approval. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(17)</span>
          <br/>
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The securities are directly held as of December&#160;31, 2024, by Sabby Volatility Warrant Master Fund, Ltd. (&#8220;Sabby&#8221;). Sabby Management, LLC is the investment manager of Sabby and shares voting and investment power with respect to these shares in this capacity. As manager of Sabby Management, LLC, Hal Mintz also shares voting and investment power on behalf of Sabby. Each of Sabby Management, LLC and Hal Mintz disclaims beneficial ownership over the securities listed except to the extent of their pecuniary interest therein. The address of Sabby is Captiva (Cayman) Ltd., Governors Square, Bld. 4, 2nd Floor, 23 Lime Tree Bay Avenue, P.O. Box 32315, Grand Cayman KY1-1209, Cayman Islands. Consists of (i)&#160;104,484 shares of Common Stock . Certain of the warrants held by Sabby are subject to a beneficial ownership limitation of 4.99% or 9.99%, as applicable, which such limitation restricts Sabby from exercising that portion of the warrants that would result in Sabby and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The beneficial ownership of Sabby reported in this table does not reflect this limitation. Excludes (i)&#160;Series&#160;C Warrants to purchase up to 75,000 shares of Common Stock and (ii)&#160;Series&#160;D Warrants to purchase up to 378,549 shares of Common Stock, whose exercise are subject to Warrant Stockholder Approval. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(18)</span>
          <br/>
        </div>
        <div style=" margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">The securities are directly held as of November&#160;6, 2024, by S.H.N. Financial Investments Ltd. (&#8220;SHN&#8221;), and may be deemed to be beneficially owned by Nir Shamir and Hadar Shamir. The address of SHN is Arik Einstein 3, Herzliya, Israel. Consists of (i)&#160;75,500 shares of Common Stock and (ii)&#160;warrants to purchase up to 303,603 shares of Common Stock. Certain of the warrants held by SHN are subject to a beneficial ownership limitation of 4.99% or 9.99%, as applicable, which such limitation restricts SHN from exercising that portion of the warrants that would result in SHN and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The beneficial ownership of SHN reported in this table does not reflect this limitation. Excludes (i)&#160;Series&#160;C Warrants to purchase up to 43,750 shares of Common Stock and (ii)&#160;Series&#160;D Warrants to purchase up to 220,820 shares of Common Stock, whose exercise are subject to Warrant Stockholder Approval. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">56</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tHOPM">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:360pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">HOUSEHOLDING OF PROXY MATERIALS</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The SEC has adopted rules that permit companies and intermediaries such as brokers to satisfy delivery requirements for proxy materials with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially provides extra convenience for stockholders and cost savings for companies. The Company, as well as some brokers (or other nominees), household the Company&#8217;s proxy materials, which means that we or they deliver a single proxy statement to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker (or other nominee) or from or us that they or we will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate proxy statement in the future, or if you are receiving multiple copies of the proxy statement and wish for only one copy to be delivered to your household in the future, please notify (i)&#160;your broker (or other nominee) if your shares are held in a brokerage or similar account or (ii)&#160;the Company if you hold registered shares in your own name. We will promptly deliver a separate proxy statement to record stockholders upon written or oral request. You can notify us of your instructions by telephone at 631-240-8800 or by sending a written request to: </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Corporate Secretary
          <br/>
          Applied DNA Sciences, Inc.
          <br/>
          50 Health Sciences Drive
          <br/>
          Stony Brook, New York 11790 </span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">57</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tOTBU">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:560pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:-0.2pt;">OTHER BUSINESS</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">We do not know of any matters that are to be presented for action at the Annual Meeting other than those set forth above. If any other matters properly come before the Annual Meeting, the person named in the enclosed proxy card will vote the shares represented by proxies in accordance with their best judgment on such matters. </span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <span style="letter-spacing:0.2pt;">58</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tSPAN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:36pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">STOCKHOLDER PROPOSALS AND NOMINATIONS</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">In order for a stockholder proposal to be considered for inclusion in the proxy statement for the 2026 annual meeting of stockholders, the written proposal must have been received by the Corporate Secretary at the address below no earlier than </span><span style="font-weight:bold;letter-spacing:-0.2pt;">January&#160;22, 2026</span><span style="letter-spacing:0.2pt;"> and no later than </span><span style="font-weight:bold;letter-spacing:-0.2pt;">February&#160;21, 2026</span><span style="letter-spacing:0.2pt;">. In the event that the annual meeting of stockholders is called for a date that is not within 30&#160;days before or after the first anniversary of the date of this year&#8217;s annual meeting, the proposal must be received no later than a reasonable time before the Company begins to print and mail its proxy materials. The proposal will also need to comply with the SEC&#8217;s regulations under Rule&#160;14a-8 under the Exchange Act regarding the inclusion of stockholder proposals in company sponsored proxy materials. Proposals should have been addressed to: </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Corporate Secretary
          <br/>
          Applied DNA Sciences, Inc.
          <br/>
          50 Health Sciences Drive
          <br/>
          Stony Brook, New York 11790 </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">For a stockholder proposal that is not intended to be included in the proxy statement for the 2026 annual meeting of stockholders, or if you want to nominate a person for election as a director, you must provide written notice to the Corporate Secretary at the address above. The Secretary must receive this notice not earlier than </span><span style="font-weight:bold;letter-spacing:-0.2pt;">January&#160;22, 2026</span><span style="letter-spacing:0.2pt;"> and no later than </span><span style="font-weight:bold;letter-spacing:-0.2pt;">February&#160;21, 2026</span><span style="letter-spacing:0.2pt;">. However, if our 2026 annual meeting of stockholders is held </span><span style="font-style:italic;letter-spacing:0.2pt;">more than 30&#160;days before or more than 60&#160;days after May&#160;22, 2026</span><span style="letter-spacing:0.2pt;">, then the Secretary must receive this notice not earlier than the close of business on the 120th day prior to the date of our 2025 annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which we make a public announcement of the date of the meeting. The notice of a proposed item of business must provide information as required in our bylaws which, in general, require that the notice include for each matter a brief description of the matter to be brought before the meeting; the reason for bringing the matter before the meeting; the text of the proposal or matter; your name, address, and number of shares you own beneficially or of record; and any material interest you have in the proposal. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Effective September&#160;1, 2022, Rule&#160;14a-19 under the Exchange Act requires the use of a universal proxy card in contested director elections. Under this &#8220;universal proxy rule,&#8221; a stockholder intending to engage in a director election contest with respect to an annual meeting of stockholders must give the Company notice of its intent to solicit proxies by providing the name(s) of the stockholder&#8217;s nominee(s) and certain other information at least 60 calendar days prior to the anniversary of the previous year&#8217;s annual meeting date, or </span><span style="font-weight:bold;letter-spacing:-0.2pt;">March&#160;23, 2026</span><span style="letter-spacing:0.2pt;"> (except that, if the Company did not hold an annual meeting during the previous year, or if the date of the meeting has changed by more than 30 calendar days from the previous year, then notice must be provided by the later of 60 calendar days prior to the date of the annual meeting or the 10th calendar day following the day on which public announcement of the date of the annual meeting is first made by the Company). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The notice of a proposed director nomination must provide information and documentation as required in our bylaws which, in general, require that the notice of a director nomination include the information about the nominee that would be required to be disclosed in the solicitation of proxies for the election of a director under federal securities laws; the nominee&#8217;s written consent to be named in the proxy statement as a nominee and to serve as a director if elected; a description of any transaction or arrangement during the last three&#160;years between the stockholder making the nomination and the nominee in which the nominee had a direct or indirect material interest; and a completed and signed questionnaire, together with a written representation and agreement that such nominee is not and will not become a party to certain voting commitments. A copy of the bylaw requirements will be provided upon request to the Corporate Secretary at the address above. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">59</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tAROF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:434pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">ANNUAL REPORT ON FORM 10-K AND OTHER INFORMATION</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">A copy of our Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2024, including financial statements and any financial statement schedules required to be filed in accordance with SEC rules, will be sent without charge to any stockholder of the Company requesting it in writing from: Applied DNA Sciences, Inc., 50 Health Sciences Drive, Stony Brook, New York 11790, Attention: Beth Jantzen. We also make available, free of charge on our website, all of our filings that are publicly filed on the SEC&#8217;s EDGAR website, including Forms 10-K, 10-Q and 8-K, at </span><span style="font-style:italic;letter-spacing:-0.2pt;">www.adnas.com</span><span style="letter-spacing:-0.2pt;">.</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-left:220pt; margin-top:8pt; width:236pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">By Order of the Board of Directors </span>
        </div>
        <div style="margin-left:220pt; margin-top:12pt; width:236pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">/s/ James A. Hayward</span>
        </div>
        <div style="margin-left:220pt; margin-top:2.5pt; width:236pt;">
          <div style="margin-left: 0pt; width: 236pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:220pt; margin-top:2pt; width:236pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">James A. Hayward</span>
          <br/>
          <span style="font-style:italic;letter-spacing:0.2pt;">Chairman and Chief Executive Officer</span><span style="letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Stony Brook, New York  <br/>April&#160;15, 2025</span></div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">60</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tAPA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:33pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Appendix&#160;A</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">PROPOSED FORM OF
          <br/>
          CERTIFICATE OF
          <br/>
          AMENDMENT TO THE
          <br/>
          CERTIFICATE OF INCORPORATION
          <br/>
          OF
          <br/>
          APPLIED DNA SCIENCES, INC.</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Applied DNA Sciences, Inc. (the &#8220;</span><span style="font-weight:bold;letter-spacing:-0.2pt;">Corporation</span><span style="letter-spacing:0.2pt;">&#8221;), a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">FIRST:&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;">Article&#160;IV of the Certificate of Incorporation, as amended (the &#8220;</span><span style="font-weight:bold;letter-spacing:-0.2pt;">Certificate of Incorporation</span><span style="letter-spacing:0.2pt;">&#8221;), of the Corporation is hereby amended by adding the following paragraph at the end thereof: </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#8220;Upon the effectiveness (the &#8220;Reverse Split Effective Time&#8221;) pursuant to the General Corporation Law of the State of Delaware of this Certificate of Amendment to the Certificate of Incorporation of the Corporation, each [&#8199;&#8199;&#8199;&#8199;]</span><span style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">1</span><span style="letter-spacing:0.2pt;"> shares of Common Stock, par value $0.001 per share, issued and outstanding (or held in treasury) immediately prior to the Reverse Split Effective Time, shall automatically be reclassified and combined into one (1)&#160;validly issued, fully paid, and non-assessable share of Common Stock, par value $0.001 per share, without any action by any holder thereof, subject to the treatment of fractional shares set forth below (the &#8220;Reverse Stock Split&#8221;). No fractional shares shall be issued as a result of the Reverse Stock Split. Any stockholder of record of Common Stock immediately prior to the Reverse Split Effective Time that would otherwise be entitled to fractional share as a result of the Reverse Stock Split shall be entitled, upon the Reverse Split Effective Time, to receive one whole share of Common Stock in lieu of such fractional share. </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">From and after the Reverse Split Effective Time, certificates that, immediately prior to the Reverse Split Effective Time, represented shares of Common Stock shall thereafter represent the number of shares of Common Stock into which such shares shall have been reclassified and combined as a result of the Reverse Stock Split, including the treatment of fractional shares set forth above.&#8221; </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">SECOND:&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;">This Certificate of Amendment shall become effective on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2025, at 12:01&#160;a.m. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">THIRD:&#160;&#160;&#160;</span><span style="letter-spacing:0.2pt;">That the foregoing amendment was duly adopted in accordance with Section&#160;242 of the General Corporation Law of the State of Delaware. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">IN WITNESS WHEREOF</span><span style="letter-spacing:0.2pt;">, the Corporation has caused this Certificate of Amendment of Certificate of Incorporation to be signed by its [&#8199;&#8199;], on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2025. </span>
        </div>
        <div style="margin-left:220pt; margin-top:12pt; width:236pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">APPLIED DNA SCIENCES, INC.</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">By:</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:240pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">&#8199;</span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Name: </span>
        </div>
      </div>
      <div style="margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">1</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">This shall be a whole number between (and including) five (5)&#160;and fifty (50) to be determined by the Board of Directors pursuant to authority granted by the stockholders, as described in the accompanying proxy statement (the &#8220;Reverse Stock Split Ratio&#8221;). The stockholders are approving all amendments with such Reverse Stock Split Ratio range and each Reverse Stock Split Ratio within such range shall, together with the remaining provisions of this Certificate of Amendment not appearing in brackets, constitute a separate amendment being approved and adopted by the Board of Directors and stockholders in accordance with Section&#160;242 of the General Corporation Law of the State of Delaware. Any proposed amendments reflecting a Reverse Stock Split Ratio not selected by the Board of Directors shall be deemed abandoned in accordance with Section&#160;242(c) of the General Corporation Law of the State of Delaware.</span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">A-1</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tAPB">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:230pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Appendix&#160;B</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">AMENDMENT TO THE
          <br/>
          APPLIED DNA SCIENCES, INC.
          <br/>
          2020 EQUITY INCENTIVE PLAN</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Applied DNA Sciences, Inc. 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) is hereby amended, effective as of the date of adoption of this Amendment by the Board of Directors of Applied DNA Sciences, Inc. (the &#8220;Company&#8221;): </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">1. </span><span style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3(a) of the Plan is amended in its entirety; provided that Section&#160;3(a), as amended, is subject to approval by the Company&#8217;s stockholders in accordance with Section&#160;11 of the Plan</span><span style="letter-spacing:0.2pt;">: </span>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(a) Shares Subject to the Plan. Subject to adjustment as provided in Section&#160;3(d) of the Plan, the maximum number of Shares that may be issued in respect of Awards under the Plan is 3,007,500 (the &#8220;Plan&#160;Limit&#8221;). Subject to adjustment as provided in Section&#160;3(d) of the Plan, the maximum aggregate number of Shares that may be issued under the Plan in respect of Incentive Stock Options is 3,007,500. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued Shares or treasury shares. Any Shares issued by the Company through the assumption or substitution of outstanding grants in connection with the acquisition of another entity shall not reduce the maximum number of Shares available for delivery under the Plan. The maximum total grant date fair value of Awards (as measured by the Company for financial accounting purposes) granted to any Participant in his or her capacity as a Non-Employee Director in any single calendar year shall not exceed $250,000. </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">*&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;*&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;* </span>
        </div>
        <div style="margin-left:40pt; text-indent:20pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Except as amended hereby, the terms and conditions of the Plan shall otherwise continue in full force and effect. </span>
        </div>
        <div style="margin-left:220pt; margin-top:12pt; width:236pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">APPLIED DNA SCIENCES, INC.</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">By:</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:240pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">&#8199;</span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Name: James A. Hayward </span>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Title: Chairman and Chief Executive Officer </span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">B-1</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a><a id="tAPC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">Appendix&#160;C</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">APPLIED DNA SCIENCES, INC.
          <br/>
          2020 EQUITY INCENTIVE PLAN</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;1.&#160;&#160;&#160;Purpose; Definitions.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;The purposes of the Applied DNA Sciences, Inc. 2020 Equity Incentive Plan (as amended from time to time, the &#8220;Plan&#8221;) are to: (a)&#160;enable Applied DNA Sciences, Inc. (the &#8220;Company&#8221;) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b)&#160;provide those employees, directors and consultants with an incentive for productivity; and (c)&#160;provide those employees, directors and consultants with an opportunity to share in the growth and value of the Company. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">For purposes of the Plan, the following terms will have the meanings defined below, unless the context clearly requires a different meaning: </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(a) &#8220;Affiliate&#8221; means, with respect to a Person, a Person that directly or indirectly controls, is controlled by, or is under common control with such Person. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(b) &#8220;Applicable Law&#8221; means the legal requirements relating to the administration of and issuance of securities under stock incentive plans, including, without limitation, the requirements of state corporations law, federal, state and foreign securities law, federal, state and foreign tax law, and the requirements of any stock exchange or quotation system upon which the Shares may then be listed or quoted. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(c) &#8220;Award&#8221; means an award of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Cash or Other Stock Based Awards made under this Plan. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(d) &#8220;Award Agreement&#8221; means, with respect to any particular Award, the written document that sets forth the terms of that particular Award. </span>
        </div>
        <div style="text-indent:40pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(e) &#8220;Board&#8221; means the Board of Directors of the Company, as constituted from time to time. </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(f) &#8220;Cash or Other Stock Based Award&#8221; means an award that is granted under Section&#160;10. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(g) &#8220;Cause&#8221; means (i)&#160;Participant&#8217;s refusal to comply with any lawful directive or policy of the Company which refusal is not cured by the Participant within ten (10) days of such written notice from the Company; (ii)&#160;the Company&#8217;s determination that Participant has committed any act of dishonesty, embezzlement, unauthorized use or disclosure of confidential information or other intellectual property or trade secrets, common law fraud or other fraud against the Company or any Subsidiary or Affiliate; (iii)&#160;a material breach by the Participant of any written agreement with or any fiduciary duty owed to any Company or any Subsidiary or Affiliate; (iv)&#160;Participant&#8217;s conviction (or the entry of a plea of a nolo contendere or equivalent plea) of a felony or any misdemeanor involving material dishonesty or moral turpitude; or (v)&#160;Participant&#8217;s habitual or repeated misuse of, or habitual or repeated performance of Participant&#8217;s duties under the influence of, alcohol, illegally obtained prescription controlled substances or non-prescription controlled substances. Notwithstanding the foregoing, if a Participant and the Company (or any of its Affiliates) have entered into an employment agreement, consulting agreement or other similar agreement that specifically defines &#8220;cause,&#8221; then with respect to such Participant, &#8220;Cause&#8221; shall have the meaning defined in such other agreement. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(h) &#8220;Change in Control&#8221; shall mean the occurrence of any of the following events: (i)&#160;any &#8220;person&#8221; (as such term is used in Sections&#160;13(d) and 14(d) of the Exchange Act) is or becomes a &#8220;beneficial owner&#8221; (as defined in Rule&#160;13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the total power to vote for the election of directors of the Company; (ii)&#160;during any twelve month period, individuals who at the beginning of such period constitute the Board and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Section&#160;1(h)(i), Section&#160;1(h)(iii), Section&#160;1(h)(iv) or Section&#160;1(h)(v) hereof) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the period of whose election or nomination for election was </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-1</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">previously approved, cease for any reason to constitute a majority thereof; (iii)&#160;the merger or consolidation of the Company with another corporation where the stockholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to 50% or more of all votes to which all stockholders of the surviving corporation would be entitled in the election of directors (without consideration of the rights of any class of stock to elect directors by a separate class vote); (iv)&#160;the sale or other disposition of all or substantially all of the assets of the Company; (v)&#160;a liquidation or dissolution of the Company; or (vi)&#160;such other event deemed to constitute a &#8220;Change in Control&#8221; by the Board. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Notwithstanding anything in the Plan or an Award Agreement to the contrary, to the extent necessary to comply with Section&#160;409A of the Code, no event that, but for the application of this paragraph, would be a Change in Control as defined in the Plan or the Award Agreement, as applicable, shall be a Change in Control unless such event is also a &#8220;change in control event&#8221; as defined in Section&#160;409A of the Code. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(i) &#8220;Code&#8221; means the Internal Revenue Code of 1986, as amended from time to time, and any successor thereto. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(j) &#8220;Committee&#8221; means the committee designated by the Board to administer the Plan under Section&#160;2. To the extent required under Applicable Law, the Committee shall have at least two members and each member of the Committee shall be a Non-Employee Director. </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(k) &#8220;Director&#8221; means a member of the Board. </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(l) &#8220;Disability&#8221; means a condition rendering a Participant Disabled. </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(m) &#8220;Disabled&#8221; will have the same meaning as set forth in Section&#160;22(e)(3) of the Code. </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(n) &#8220;Exchange Act&#8221; means the Securities Exchange Act of 1934, as amended. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(o) &#8220;Fair Market Value&#8221; means, as of any date, the value of a Share determined as follows: (i)&#160;if the Shares are listed on any established stock exchange or a national market system, including, without limitation, the Nasdaq Capital Market, the Fair Market Value of a Share will be the closing sales price for such stock as quoted on that system or exchange (or the system or exchange with the greatest volume of trading in Shares) at the close of regular hours trading on the day of determination; (ii)&#160;if the Shares are regularly quoted by recognized securities dealers but selling prices are not reported, the Fair Market Value of a Share will be the mean between the high bid and low asked prices for Shares at the close of regular hours trading on the day of determination; or (iii)&#160;if Shares are not traded as set forth above, the Fair Market Value will be determined in good faith by the Committee taking into consideration such factors as the Committee considers appropriate, such determination by the Committee to be final, conclusive and binding. Notwithstanding the foregoing, in connection with a Change in Control, Fair Market Value shall be determined in good faith by the Committee, such determination by the Committee to be final conclusive and binding. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(p) &#8220;Incentive Stock Option&#8221; means any Option intended to be an &#8220;Incentive Stock Option&#8221; within the meaning of Section&#160;422 of the Code. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(q) &#8220;Non-Employee Director&#8221; will have the meaning set forth in Rule&#160;16b-3(b)(3)(i) promulgated by the Securities and Exchange Commission under the Exchange Act, or any successor definition adopted by the Securities and Exchange Commission. </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(r) &#8220;Non-Qualified Stock Option&#8221; means any Option that is not an Incentive Stock Option. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(s) &#8220;Option&#8221; means any option to purchase Shares (including an option to purchase Restricted Stock, if the Committee so determines) granted pursuant to Section&#160;5 hereof. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(t) &#8220;Parent&#8221; means, in respect of the Company, a &#8220;parent corporation&#8221; as defined in Section&#160;424(e) of the Code. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-2</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(u) &#8220;Participant&#8221; means an employee, consultant, Director, or other service provider of or to the Company or any of its respective Affiliates to whom an Award is granted. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(v) &#8220;Person&#8221; means an individual, partnership, corporation, limited liability company, trust, joint venture, unincorporated association, or other entity or association. </span>
        </div>
        <div style="text-indent:40pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(w) &#8220;Restricted Stock&#8221; means Shares that are subject to restrictions pursuant to Section&#160;8 hereof. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(x) &#8220;Restricted Stock Unit&#8221; means a right granted under and subject to restrictions pursuant to Section&#160;9 hereof. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(y) &#8220;Shares&#8221; means shares of the Company&#8217;s common stock, par value $0.001, subject to substitution or adjustment as provided in Section&#160;3(d) hereof. </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(z) &#8220;Stock Appreciation Right&#8221; means a right granted under and subject to Section&#160;6 hereof. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(aa) &#8220;Subsidiary&#8221; means, in respect of the Company, a subsidiary company as defined in Sections&#160;424(f) and (g)&#160;of the Code. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;2.&#160;&#160;&#160;Administration.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;The Plan shall be administered by the Committee; provided that, notwithstanding anything to the contrary herein, in its sole discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Committee under the Plan except with respect to matters which under Applicable Law are required to be determined in the sole discretion of the Committee. Any action of the Committee in administering the Plan shall be final, conclusive and binding on all persons, including the Company, its Subsidiaries, Affiliates, their respective employees, the Participants, persons claiming rights from or through Participants and stockholders of the Company. The Committee will have full authority to grant Awards under this Plan and determine the terms of such Awards. Such authority will include the right to: </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(a) select the individuals to whom Awards are granted (consistent with the eligibility conditions set forth in Section&#160;4); </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(b) determine the type of Award to be granted; </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(c) determine the number of Shares, if any, to be covered by each Award; </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(d) establish the other terms and conditions of each Award; </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(e) approve forms of agreements (including Award Agreements) for use under the Plan; and </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(f) modify or amend each Award, subject to the Participant&#8217;s consent if such modification or amendment would materially impair such Participant&#8217;s rights. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">The Committee will have the authority to adopt, alter and repeal such administrative rules, guidelines and practices governing the Plan as it, from time to time, deems advisable; to interpret the terms and provisions of the Plan and any Award issued under the Plan (and any Award Agreement); and to otherwise take any action that may be necessary or desirable to facilitate the administration of the Plan. The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any Award Agreement in the manner and to the extent it deems necessary to carry out the intent of the Plan. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">To the extent permitted by Applicable Law, the Committee may delegate to one or more officers of the Company the authority to grant Awards to Participants who are not subject to the requirements of Section&#160;16 of the Exchange Act and the rules and regulations thereunder. Any such delegation shall be subject to the applicable corporate laws of the State of Delaware. The Committee may revoke any such allocation or delegation at any time for any reason with or without prior notice. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">No Director will be liable for any good faith determination, act or omission in connection with the Plan or any Award. </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;3.&#160;&#160;&#160;Shares Subject to the Plan</span><span style="letter-spacing:0.2pt;">. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(a) Shares Subject to the Plan. Subject to adjustment as provided in Section&#160;3(d) of the Plan, the maximum number of Shares that may be issued in respect of Awards under the Plan is 7,500 (the </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-3</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">&#8220;Plan&#160;Limit&#8221;). Subject to adjustment as provided in Section&#160;3(d) of the Plan, the maximum aggregate number of Shares that may be issued under the Plan in respect of Incentive Stock Options is 7,500. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued Shares or treasury shares. Any Shares issued by the Company through the assumption or substitution of outstanding grants in connection with the acquisition of another entity shall not reduce the maximum number of Shares available for delivery under the Plan. The maximum total grant date fair value of Awards (as measured by the Company for financial accounting purposes) granted to any Participant in his or her capacity as a Non-Employee Director in any single calendar year shall not exceed $250,000. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(b) Effect of the Expiration or Termination of Awards. If and to the extent that an Option or a Stock Appreciation Right expires, terminates or is canceled or forfeited for any reason without having been exercised in full, the Shares associated with that Award will again become available for grant under the Plan. Similarly, if and to the extent an Award of Restricted Stock or Restricted Stock Units is canceled or forfeited for any reason, the Shares subject to that Award will again become available for grant under the Plan. In addition, if any award granted under the Applied DNA Sciences, Inc. 2005 Incentive Stock Plan (as amended) expires, terminates, is canceled or is forfeited for any reason after the Effective Date, the Shares subject to that award will be added to the Plan&#160;Limit and become available for issuance hereunder. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(c) Shares Withheld in Satisfaction of Taxes or Exercise Price. Shares withheld in settlement of a tax withholding obligation associated with an Award, or in satisfaction of the exercise price payable upon exercise of an Option, will not again become available for grant under the Plan. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(d) Other Adjustment. In the event of any corporate event or transaction such as a merger, consolidation, reorganization, recapitalization, stock split, reverse stock split, split up, spin-off, combination of shares, exchange of shares, stock dividend, dividend in kind, or other like change in capital structure (other than ordinary cash dividends) to stockholders of the Company, or other similar corporate event or transaction affecting the Shares, the Committee, to prevent dilution or enlargement of Participants&#8217; rights under the Plan, shall, in such manner as it may deem equitable, substitute or adjust, in its sole discretion, the number and kind of shares that may be issued under the Plan or under any outstanding Awards, the number and kind of shares subject to outstanding Awards, the exercise price, grant price or purchase price applicable to outstanding Awards, and/or any other affected terms and conditions of this Plan or outstanding Awards. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(e) Change in Control. Notwithstanding anything to the contrary set forth in the Plan, upon or in anticipation of any Change in Control, the Committee may, in its sole and absolute discretion and without the need for the consent of any Participant, take one or more of the following actions contingent upon the occurrence of that Change in Control: </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(i) cause any or all outstanding Awards to become vested and immediately exercisable (as applicable), in whole or in part; </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(ii) cause any outstanding Option or Stock Appreciation Right to become fully vested and immediately exercisable for a reasonable period in advance of the Change in Control and, to the extent not exercised prior to that Change in Control, cancel that Option or Stock Appreciation Right upon closing of the Change in Control; </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(iii) cancel any unvested Award or unvested portion thereof, with or without consideration; </span>
        </div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(iv) cancel any Award in exchange for a substitute award; </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(v) redeem any Restricted Stock or Restricted Stock Unit for cash and/or other substitute consideration with value equal to the Fair Market Value of an unrestricted Share on the date of the Change in Control; </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(vi) cancel any Option or Stock Appreciation Right in exchange for cash and/or other substitute consideration with a value equal to: (A)&#160;the number of Shares subject to that Option or Stock Appreciation Right, multiplied by (B)&#160;the difference, if any, between the Fair Market Value per Share on the date of the Change in Control and the exercise price of that Option or the base price of the Stock Appreciation Right; </span><span style="font-style:italic;letter-spacing:0.2pt;">provided,</span><span style="letter-spacing:0.2pt;"> that if the Fair Market Value per Share on the date of the Change in Control does not exceed the exercise price of any such Option or the base price of any such Stock </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-4</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Appreciation Right, the Committee may cancel that Option or Stock Appreciation Right without any payment of consideration therefor; and/or </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(vii) take such other action as the Committee shall determine to be reasonable under the circumstances. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">In the discretion of the Committee, any cash or substitute consideration payable upon cancellation of an Award may be subjected to (i)&#160;vesting terms substantially identical to those that applied to the cancelled Award immediately prior to the Change in Control, or (ii)&#160;earn-out, escrow, holdback or similar arrangements, to the extent such arrangements are applicable to any consideration paid to stockholders in connection with the Change in Control. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Notwithstanding any provision of this Section&#160;3(e), in the case of any Award subject to Section&#160;409A of the Code, the Committee shall only be permitted to take actions under this Section&#160;3(e) to the extent that such actions would be consistent with the intended treatment of such Award under Section&#160;409A of the Code. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(f) Foreign Holders. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in countries other than the United States in which the Company and its Subsidiaries operate or have employees, directors and consultants, or in order to comply with the requirements of any foreign securities exchange or other Applicable Law, the Committee, in its sole discretion, shall have the power and authority to: (i)&#160;modify the terms and conditions of any Award granted to employees, directors and consultants outside the United States to comply with Applicable Law (including, without limitation, applicable foreign laws or listing requirements of any foreign securities exchange); (ii)&#160;establish subplans and modify exercise procedures and other terms and procedures, to the extent such actions may be necessary or advisable; provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section&#160;3(a); and (iii)&#160;take any action, before or after an Award is made, that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals or listing requirements of any foreign securities exchange. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;4.&#160;&#160;&#160;Eligibility.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;Employees, Directors, consultants, and other individuals who provide services to the Company or its Affiliates are eligible to be granted Awards under the Plan; </span><span style="font-style:italic;letter-spacing:0.2pt;">provided, however</span><span style="letter-spacing:0.2pt;">, that only employees of the Company, any Parent or a Subsidiary are eligible to be granted Incentive Stock Options. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;5.&#160;&#160;&#160;Options.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;Options granted under the Plan may be of two types: (i)&#160;Incentive Stock Options or (ii)&#160;Non-Qualified Stock Options. The Award Agreement shall state whether such grant is an Incentive Stock Option or a Non-Qualified Stock Option. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Award Agreement evidencing any Option will incorporate the following terms and conditions and will contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee deems appropriate in its sole and absolute discretion: </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(a) Option Price.&#160;&#160;&#160;The exercise price per Share under an Option will be determined by the Committee and will not be less than 100% of the Fair Market Value of a Share on the date of the grant. However, any Incentive Stock Option granted to any Participant who, at the time the Option is granted, owns, either directly and/or within the meaning of the attribution rules contained in Section&#160;424(d) of the Code, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, will have an exercise price per Share of not less than 110% of Fair Market Value per Share on the date of the grant. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(b) Option Term.&#160;&#160;&#160;The term of each Option will be fixed by the Committee, but no Option will be exercisable more than 10&#160;years after the date the Option is granted. However, any Incentive Stock Option granted to any Participant who, at the time such Option is granted, owns, either directly and/or within the meaning of the attribution rules contained in Section&#160;424(d) of the Code, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, may not have a term of more than 5&#160;years. No Option may be exercised by any Person after expiration of the term of the Option. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-5</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(c) Exercisability.&#160;&#160;&#160;Options will vest and be exercisable at such time or times and subject to such terms and conditions as determined by the Committee. Such terms and conditions may include the continued employment or service of the Participant, the attainment of specified individual or corporate performance goals, or such other factors as the Committee may determine in its sole discretion (the &#8220;Vesting Conditions&#8221;). The Committee may provide in the terms of an Award Agreement that the Participant may exercise the unvested portion of an Option in whole or in part in exchange for shares of Restricted Stock subject to the same vesting terms as the portion of the Option so exercised. Restricted Stock acquired upon the exercise of an unvested Option shall be subject to such additional terms and conditions as determined by the Committee. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(d) Method of Exercise.&#160;&#160;&#160;Subject to the terms of the applicable Award Agreement, the exercisability provisions of Section&#160;5(c) and the termination provisions of Section&#160;7, Options may be exercised in whole or in part from time to time during their term by the delivery of written notice to the Company specifying the number of Shares to be purchased. Such notice will be accompanied by payment in full of the purchase price, either by certified or bank check, or such other means as the Committee may accept. The Committee may, in its sole discretion, permit payment of the exercise price of an Option in the form of previously acquired Shares based on the Fair Market Value of the Shares on the date the Option is exercised or by means of a &#8220;net settlement,&#8221; whereby the Option exercise price will not be due in cash and where the number of Shares issued upon such exercise will be equal to: (A)&#160;the product of (i)&#160;the number of Shares as to which the Option is then being exercised, and (ii)&#160;the excess, if any, of (a)&#160;the then current Fair Market Value per Share over (b)&#160;the Option exercise price, divided by (B)&#160;the then current Fair Market Value per Share. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">No Shares will be issued upon exercise of an Option until full payment therefor has been made. A Participant will not have the right to distributions or dividends or any other rights of a stockholder with respect to Shares subject to the Option until the Participant has given written notice of exercise, has paid in full for such Shares, if requested, has given the representation described in Section&#160;17(a) hereof and fulfills such other conditions as may be set forth in the applicable Award Agreement. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(e)&#160;&#160;&#160;Incentive Stock Option Limitations. In the case of an Incentive Stock Option, the aggregate Fair Market Value (determined as of the time of grant) of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year under the Plan and/or any other plan of the Company, its Parent or any Subsidiary will not exceed $100,000. For purposes of applying the foregoing limitation, Incentive Stock Options will be taken into account in the order granted. To the extent any Option does not meet such limitation, that Option will be treated for all purposes as a Non-Qualified Stock Option. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(f)&#160;&#160;&#160;Termination of Service. Unless otherwise specified in the applicable Award Agreement or as otherwise provided by the Committee at or after the time of grant, Options will be subject to the terms of Section&#160;7 with respect to exercise upon or following termination of employment or other service. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;6.&#160;&#160;&#160;Stock Appreciation Right.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;Subject to the other terms of the Plan, the Committee may grant Stock Appreciation Rights to eligible individuals. Each Stock Appreciation Right shall represent the right to receive, upon exercise, an amount equal to the number of Shares subject to the Award that is being exercised multiplied by the excess of (i)&#160;the Fair Market Value of a Share on the date the Award is exercised, over (ii)&#160;the base price specified in the applicable Award Agreement. Distributions may be made in cash, Shares, or a combination of both, at the discretion of the Committee. The Award Agreement evidencing each Stock Appreciation Right shall indicate the base price, the term and the Vesting Conditions for such Award. A Stock Appreciation Right base price may never be less than the Fair Market Value of the underlying common stock of the Company on the date of grant of such Stock Appreciation Right. The term of each Stock Appreciation Right will be fixed by the Committee, but no Stock Appreciation Right will be exercisable more than 10&#160;years after the date the Stock Appreciation Right is granted. Subject to the terms and conditions of the applicable Award Agreement, Stock Appreciation Rights may be exercised in whole or in part from time to time during their term by the delivery of written notice to the Company specifying the portion of the Award to be exercised. Unless otherwise specified in the applicable Award Agreement or as otherwise provided by the Committee at or after the time of grant, Stock Appreciation Rights will be subject to the terms of Section&#160;7 with respect to exercise upon or following termination of employment or other service. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-6</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:11.5pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;7.&#160;&#160;&#160;Termination of Service.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;Unless otherwise specified with respect to a particular Option or Stock Appreciation Right in the applicable Award Agreement or otherwise determined by the Committee, any portion of an Option or Stock Appreciation Right that is not exercisable upon termination of service will expire immediately and automatically upon such termination and any portion of an Option or Stock Appreciation Right that is exercisable upon termination of service will expire on the date it ceases to be exercisable in accordance with this Section&#160;7. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(a) Termination by Reason of Death.&#160;&#160;&#160;If a Participant&#8217;s service with the Company or any Affiliate terminates by reason of death, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised, to the extent it was exercisable at the time of his or her death or on such accelerated basis as the Committee may determine at or after grant, by the legal representative of the estate or by the legatee of the Participant, for a period expiring (i)&#160;at such time as may be specified by the Committee at or after grant, or (ii)&#160;if not specified by the Committee, then 12&#160;months from the date of death, or (iii)&#160;if sooner than the applicable period specified under (i)&#160;or (ii)&#160;above, upon the expiration of the stated term of such Option or Stock Appreciation Right. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(b) Termination by Reason of Disability.&#160;&#160;&#160;If a Participant&#8217;s service with the Company or any Affiliate terminates by reason of Disability, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised by the Participant or his or her personal representative, to the extent it was exercisable at the time of termination, or on such accelerated basis as the Committee may determine at or after grant, for a period expiring (i)&#160;at such time as may be specified by the Committee at or after grant, or (ii)&#160;if not specified by the Committee, then 12&#160;months from the date of termination of service, or (iii)&#160;if sooner than the applicable period specified under (i)&#160;or (ii)&#160;above, upon the expiration of the stated term of such Option or Stock Appreciation Right. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(c) Cause.&#160;&#160;&#160;If a Participant&#8217;s service with the Company or any Affiliate is terminated for Cause or if a Participant resigns at a time that there was a Cause basis for such Participant&#8217;s termination: (i)&#160;any Option or Stock Appreciation Right, or portion thereof, not already exercised will be immediately and automatically forfeited as of the date of such termination, and (ii)&#160;any Shares for which the Company has not yet delivered share certificates will be immediately and automatically forfeited and the Company will refund to the Participant the Option exercise price paid for such Shares, if any. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(d) Other Termination.&#160;&#160;&#160;If a Participant&#8217;s service with the Company or any Affiliate terminates for any reason other than death, Disability or Cause, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised by the Participant, to the extent it was exercisable at the time of such termination, or on such accelerated basis as the Committee may determine at or after grant, for a period expiring (i)&#160;at such time as may be specified by the Committee at or after grant, or (ii)&#160;if not specified by the Committee, then 90&#160;days from the date of termination of service, or (iii)&#160;if sooner than the applicable period specified under (i)&#160;or (ii)&#160;above, upon the expiration of the stated term of such Option or Stock Appreciation Right. </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;8. &#160;&#160;&#160;Restricted Stock</span><span style="letter-spacing:0.2pt;">. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(a) Issuance.&#160;&#160;&#160;Restricted Stock may be issued either alone or in conjunction with other Awards. The Committee will determine the time or times within which Restricted Stock may be subject to forfeiture, and all other conditions of such Awards. The purchase price for Restricted Stock may, but need not, be zero. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(b) Certificates.&#160;&#160;&#160;Upon the Award of Restricted Stock, the Committee may direct that a certificate or certificates representing the number of Shares subject to such Award be issued to the Participant or placed in a restricted stock account (including an electronic account) with the transfer agent and in either case designating the Participant as the registered owner. The certificate(s), if any, representing such shares shall be physically or electronically legended, as applicable, as to sale, transfer, assignment, pledge or other encumbrances during the Restriction Period. If physical certificates are issued, they will be held in escrow by the Company or its designee during the Restriction Period. As a condition to any Award of Restricted Stock, the Participant may be required to deliver to the Company a share power, endorsed in blank, relating to the Shares covered by such Award. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <span style="letter-spacing:0.2pt;">(c) Restrictions and Conditions.&#160;&#160;&#160;The Award Agreement evidencing the grant of any Restricted Stock will incorporate the following terms and conditions and such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee deems appropriate in its sole and absolute discretion: </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-7</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; text-indent:20pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(i) During a period commencing with the date of an Award of Restricted Stock and ending at such time or times as specified by the Committee (the &#8220;Restriction Period&#8221;), the Participant will not be permitted to sell, transfer, pledge, assign or otherwise encumber Restricted Stock awarded under the Plan. The Committee may condition the lapse of restrictions on Restricted Stock upon one or more Vesting Conditions. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(ii) While any Share of Restricted Stock remains subject to restriction, the Participant will have, with respect to the Restricted Stock, the right to vote the Shares. If any cash distributions or dividends are payable with respect to the Restricted Stock, the Committee, in its sole discretion, may require the cash distributions or dividends to be subjected to the same Restriction Period as is applicable to the Restricted Stock with respect to which such amounts are paid, or, if the Committee so determines, reinvested in additional Restricted Stock to the extent Shares are available under Section&#160;3(a) of the Plan. A Participant shall not be entitled to interest with respect to any dividends or distributions subjected to the Restriction Period. Any distributions or dividends paid in the form of securities with respect to Restricted Stock will be subject to the same terms and conditions as the Restricted Stock with respect to which they were paid, including, without limitation, the same Restriction Period. </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(iii) Subject to the provisions of the applicable Award Agreement or as otherwise determined by the Committee, if a Participant&#8217;s service with the Company and its Affiliates terminates prior to the expiration of the applicable Restriction Period, the Participant&#8217;s Restricted Stock that then remains subject to forfeiture will then be forfeited automatically. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;9.&#160;&#160;&#160;Restricted Stock Units.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;Subject to the other terms of the Plan, the Committee may grant Restricted Stock Units to eligible individuals and may impose one or more Vesting Conditions on such&#160;units. Each Restricted Stock Unit will represent a right to receive from the Company, upon fulfillment of any applicable conditions, an amount equal to the Fair Market Value (at the time of the distribution) of one Share. Distributions may be made in cash, Shares, or a combination of both, at the discretion of the Committee. The Award Agreement evidencing a Restricted Stock Unit shall set forth the Vesting Conditions and time and form of payment with respect to such Award. The Participant shall not have any stockholder rights with respect to the Shares subject to a Restricted Stock Unit Award until that Award vests and the Shares are actually issued thereunder; provided, however, that an Award Agreement may provide for the inclusion of dividend equivalent payments or unit credits with respect to the Award in the discretion of the Committee. Subject to the provisions of the applicable Award Agreement or as otherwise determined by the Committee, if a Participant&#8217;s service with the Company terminates prior to the Restricted Stock Unit Award vesting in full, any portion of the Participant&#8217;s Restricted Stock Units that then remain subject to forfeiture will then be forfeited automatically. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;10.&#160;&#160;&#160;Cash or Other Stock Based Awards</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Subject to the other terms of the Plan, the Committee may grant Cash or Other Stock Based Awards (including Awards to receive unrestricted Shares or immediate cash payments) to eligible individuals. The Award Agreement evidencing a Cash or Other Stock Based Award shall set forth the terms and conditions of such Cash or Other Stock Based Award, including, as applicable, the term, any exercise or purchase price, performance goals, Vesting Conditions and other terms and conditions. Payment in respect of a Cash or Other Stock Based Award may be made in cash, Shares, or a combination of cash and Shares, as determined by the Committee. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;11.&#160;&#160;&#160;Amendments and Termination.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;Subject to any stockholder approval that may be required under Applicable Law, the Plan may be amended or terminated at any time or from time to time by the Board. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;12.&#160;&#160;&#160;Prohibition on Repricing Programs</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;Neither the Committee nor the Board shall (i)&#160;implement any cancellation/re-grant program pursuant to which outstanding Options or Stock Appreciation Rights under the Plan are cancelled and new Options or Stock Appreciation Rights are granted in replacement with a lower exercise or base price per share, (ii)&#160;cancel outstanding Options or Stock Appreciation Rights under the Plan with exercise prices or base prices per share in excess of the then current Fair Market Value per Share for consideration payable in equity securities of the Company or (iii)&#160;otherwise directly reduce the exercise price or base price in effect for outstanding Options or Stock Appreciation Rights under the Plan, without in each such instance obtaining stockholder approval. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-8</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;13.&#160;&#160;&#160;Conditions Upon Grant of Awards and Issuance of Shares</span><span style="letter-spacing:0.2pt;">. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(a) The implementation of the Plan, the grant of any Award and the issuance of Shares in connection with the issuance, exercise or vesting of any Award made under the Plan shall be subject to the Company&#8217;s procurement of all approvals and permits required by regulatory authorities having jurisdiction over the Plan, the Awards made under the Plan and the Shares issuable pursuant to those Awards. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(b) No Shares or other assets shall be issued or delivered under the Plan unless and until there shall have been compliance with all applicable requirements of Applicable Law. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;14.&#160;&#160;&#160;Limits on Transferability; Beneficiaries</span><span style="letter-spacing:0.2pt;">.&#160;&#160;&#160;No Award or other right or interest of a Participant under the Plan shall be pledged, encumbered, or hypothecated to, or in favor of, or subject to any lien, obligation, or liability of such Participant to, any party, other than the Company, any Subsidiary or Affiliate, or assigned or transferred by such Participant other than by will or the laws of descent and distribution, and such Awards and rights shall be exercisable during the lifetime of the Participant only by the Participant or his or her guardian or legal representative. Notwithstanding the foregoing, the Committee may, in its discretion, provide that Awards or other rights or interests of a Participant granted pursuant to the Plan (other than an Incentive Stock Option) be transferable, without consideration, to immediate family members (i.e., children, grandchildren or spouse), to trusts for the benefit of such immediate family members and to partnerships in which such family members are the only partners. The Committee may attach to such transferability feature such terms and conditions as it deems advisable. In addition, a Participant may, in the manner established by the Committee, designate a beneficiary (which may be a person or a trust) to exercise the rights of the Participant, and to receive any distribution, with respect to any Award upon the death of the Participant. A beneficiary, guardian, legal representative or other person claiming any rights under the Plan from or through any Participant shall be subject to all terms and conditions of the Plan and any Award Agreement applicable to such Participant, except as otherwise determined by the Committee, and to any additional restrictions deemed necessary or appropriate by the Committee. </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;15.&#160;&#160;&#160;Withholding of Taxes</span><span style="letter-spacing:0.2pt;">. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(a) Required Withholding. All Awards under the Plan shall be subject to applicable federal (including FICA), state and local tax withholding requirements. The Company may require that the Participant or other person receiving or exercising Awards pay to the Company the amount of any federal, state or local taxes that the Company is required to withhold with respect to such Awards, or the Company may deduct from other wages paid by the Company the amount of any withholding taxes due with respect to such Awards. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(b) Election to Withhold Shares. If the Committee so permits, Shares subject to an Award may be withheld to satisfy tax withholding obligations arising with respect thereto based on the Fair Market Value of such Shares at the time of withholding, to the extent that such withholding would not result in liability classification of such Award (or any portion thereof) under applicable accounting rules. </span>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;16.&#160;&#160;&#160;Liability of Company</span><span style="letter-spacing:0.2pt;">. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(a) Inability to Obtain Authority.&#160;&#160;&#160;If the Company cannot, by the exercise of commercially reasonable efforts, obtain authority from any regulatory body having jurisdiction for the sale of any hares under this Plan, and such authority is deemed by the Company&#8217;s counsel to be necessary to the lawful issuance of those Shares, the Company will be relieved of any liability for failing to issue or sell those Shares. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(b) Grants Exceeding Allotted Shares.&#160;&#160;&#160;If Shares subject to an Award exceed, as of the date of grant, the number of Shares which may be issued under the Plan without additional stockholder approval, that Award will be contingent with respect to such excess Shares, on the effectiveness under Applicable Law of a sufficient increase in the number of Shares subject to this Plan. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(c) Rights of Participants and Beneficiaries.&#160;&#160;&#160;The Company will pay all amounts payable under this Plan only to the applicable Participant, or beneficiaries entitled thereto pursuant to this Plan. The Company will not be liable for the debts, contracts, or engagements of any Participant or his or her beneficiaries, and rights to cash payments under this Plan may not be taken in execution by attachment or garnishment, or by any other legal or equitable proceeding while in the hands of the Company. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-9</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;17.&#160;&#160;&#160;General Provisions</span><span style="letter-spacing:0.2pt;">. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">(a) The Board may require each Participant to represent to and agree with the Company in writing that the Participant is acquiring securities of the Company for investment purposes and without a view to distribution thereof and as to such other matters as the Board believes are appropriate. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">(b) The Awards shall be subject to the Company&#8217;s stock ownership policies, as in effect from time to time. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">(c) All certificates for Shares or other securities delivered under the Plan will be subject to such share-transfer orders and other restrictions as the Board may deem advisable under the rules, regulations and other requirements of the Securities Act of 1933, as amended, the Exchange Act, any stock exchange upon which the Shares are then listed, and any other Applicable Law, and the Board may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">(d) Nothing contained in the Plan will prevent the Board from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">(e) Neither the adoption of the Plan nor the execution of any document in connection with the Plan will: (i)&#160;confer upon any employee or other service provider of the Company or an Affiliate any right to continued employment or engagement with the Company or such Affiliate, or (ii)&#160;interfere in any way with the right of the Company or such Affiliate to terminate the employment or engagement of any of its employees or other service providers at any time. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="letter-spacing:0.2pt;">(f) The Awards (whether vested or unvested) shall be subject to rescission, cancellation or recoupment, in whole or in part, under any current or future &#8220;clawback&#8221; or similar policy of the Company that is applicable to the Participant. Notwithstanding any other provisions in this Plan, any Award which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;18.&#160;&#160;&#160;Effective Date of Plan.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;The Plan will become effective upon its approval by the holders of a majority of the voting power of the shares deemed present and entitled to vote at the meeting of stockholders of the Company (the &#8220;Effective Date&#8221;). </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;19.&#160;&#160;&#160;Term of Plan.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;Unless the Plan shall theretofore have been terminated in accordance with Section&#160;11, the Plan shall terminate on the 10-year anniversary of the Effective Date, and no Awards under the Plan shall thereafter be granted. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;20.&#160;&#160;&#160;Invalid Provisions.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;In the event that any provision of this Plan is found to be invalid or otherwise unenforceable under any Applicable Law, such invalidity or unenforceability will not be construed as rendering any other provisions contained herein as invalid or unenforceable, and all such other provisions will be given full force and effect to the same extent as though the invalid or unenforceable provision was not contained herein. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;21.&#160;&#160;&#160;Governing Law.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;The Plan and all Awards granted hereunder will be governed by and construed in accordance with the laws and judicial decisions of the State of Delaware, without regard to the application of the principles of conflicts of laws. </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <span style="font-weight:bold;letter-spacing:-0.2pt;">Section&#160;22.&#160;&#160;&#160;Notices.</span><span style="letter-spacing:0.2pt;">&#160;&#160;&#160;Any notice to be given to the Company pursuant to the provisions of this Plan must be given in writing and addressed, if to the Company, to its principal executive office to the attention of its Chief Financial Officer (or such other Person as the Company may designate in writing from time to time), and, if to a Participant, to the address contained in the Company&#8217;s personnel files, or at such other address as that Participant may hereafter designate in writing to the Company. Any such notice will be deemed duly given: if delivered personally or via recognized overnight delivery service, on the date and at the time so delivered; if sent via telecopier or email, on the date and at the time telecopied or emailed with confirmation of delivery; or, if mailed, five (5)&#160;days after the date of mailing by registered or certified mail. </span>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-10</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
    </div><div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a href="#TOC" style="text-decoration:none;color:#003366;">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:254pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">AMENDMENT TO THE
          <br/>
          APPLIED DNA SCIENCES, INC.
          <br/>
          2020 EQUITY INCENTIVE PLAN</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">The Applied DNA Sciences, Inc. 2020 Equity Incentive Plan (the &#8220;Plan&#8221;) is hereby amended, effective as of the date of adoption of this Amendment by the Board of Directors of Applied DNA Sciences, Inc. (the &#8220;Company&#8221;): </span>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">1. </span><span style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Section&#160;3(a) of the Plan is amended in its entirety; provided that Section&#160;3(a), as amended, is subject to approval by the Company&#8217;s stockholders in accordance with Section&#160;11 of the Plan</span><span style="letter-spacing:0.2pt;">: </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">(a) Shares Subject to the Plan.&#160;&#160;&#160;Subject to adjustment as provided in Section&#160;3(d) of the Plan, the maximum number of Shares that may be issued in respect of Awards under the Plan is 3,007,500 (the &#8220;Plan&#160;Limit&#8221;). Subject to adjustment as provided in Section&#160;3(d) of the Plan, the maximum aggregate number of Shares that may be issued under the Plan in respect of Incentive Stock Options is 3,007,500. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued Shares or treasury shares. Any Shares issued by the Company through the assumption or substitution of outstanding grants in connection with the acquisition of another entity shall not reduce the maximum number of Shares available for delivery under the Plan. The maximum total grant date fair value of Awards (as measured by the Company for financial accounting purposes) granted to any Participant in his or her capacity as a Non-Employee Director in any single calendar year shall not exceed $250,000. </span>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">*&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;*&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;* </span>
        </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Except as amended hereby, the terms and conditions of the Plan shall otherwise continue in full force and effect. </span>
        </div>
        <div style="margin-left:220pt; margin-top:12pt; width:236pt; line-height:12pt;font-weight:bold;">
          <span style="letter-spacing:-0.2pt;">APPLIED DNA SCIENCES, INC.</span><span style="font-weight:normal;letter-spacing:0.2pt;"> </span>
        </div>
        <div style=" float:left; margin-left:220pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">By:</span>
          <br/>
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:240pt;">
          <!--blacklining:none;-->
          <span style="letter-spacing:0.2pt;">&#8199;</span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:240pt; margin-top:2.5pt; width:216pt;">
          <div style="margin-left: 0pt; width: 216pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Name: James A. Hayward </span>
        </div>
        <div style="margin-left:240pt; margin-top:2pt; width:216pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">Title: Chairman, President and Chief Executive Officer</span>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">&#160;</span>
          <br/>
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <span style="letter-spacing:0.2pt;">C-11</span>
          <br/>
        </div>
      </div>
      <hr/>
    </div><div>
  </div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">PRE 14A</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-3" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-6" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-7" name="ecd:AdjToCompAmt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-7986">0000744452</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-7987">false</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="apdn-20240930.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tC7CvZHOJjSUEJbYlSz0QmT1AzchKAjg5AqVJioVI5FtUHo07BdwqKaKppMJSlnYwXCaHdYwu3AIF454azm2PFRPQOUT0DHwG0wyGbCQ3UiYIEhFqlkO9g27q0o2g9mU0H+3Ka18hnq6AobAViuV0GCReq6KaDkFuuPX4qsEDGlMeLNkCU3ZmvgERekUKgpIP66KhvuABJBIYRHzx6miZpo4PAM8CS3mUw9juNpPy9PnlgNnr+zbywRlJulDUMCw=] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-10-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000744452</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:typedMember dimension="ecd:MeasureAxis">
        <ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain>
      </xbrldi:typedMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>apdn-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Apr 04 20:42:12 UTC 2025 -->
<xs:schema elementFormDefault="qualified" targetNamespace="http://adnas.com/20240930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://xbrl.us/us-types/2009-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:apdn="http://adnas.com/20240930" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="apdn-20240930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="apdn-20240930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:roleType roleURI="http://adnas.com/role/AdditionalDimensions" id="apdn_r_AdditionalDimensions">
        <link:definition>999000 - Disclosure - Pay vs Performance Disclosure - Additional Dimensions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tC7CvZHOJjSUEJbYlSz0QmT1AzchKAjg5AqVJioVI5FtUHo07BdwqKaKppMJSlnYwXCaHdYwu3AIF454azm2PFRPQOUT0DHwG0wyGbCQ3UiYIEhFqlkO9g27q0o2g9mU0H+3Ka18hnq6AobAViuV0GCReq6KaDkFuuPX4qsEDGlMeLNkCU3ZmvgERekUKgpIP66KhvuABJBIYRHzx6miZpo4PAM8CS3mUw9juNpPy9LOmB+HURXpUNFFzHlV2sOo=] CSR-->
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:element name="EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember"/>
  <xs:element name="EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember"/>
  <xs:element name="EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember"/>
  <xs:element name="EquityAwardsAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_EquityAwardsAdjustmentsMember"/>
  <xs:element name="EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember"/>
  <xs:element name="EquityAwardsValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_EquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
  <xs:element name="NetAdjustmentsForEquityAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_NetAdjustmentsForEquityAwardsMember"/>
  <xs:element name="NetAdjustmentsForPensionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_NetAdjustmentsForPensionMember"/>
  <xs:element name="PensionAdjustmentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_PensionAdjustmentsMember"/>
  <xs:element name="PensionAdjustmentsPriorServiceCostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_PensionAdjustmentsPriorServiceCostMember"/>
  <xs:element name="PensionAdjustmentsServiceCostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_PensionAdjustmentsServiceCostMember"/>
  <xs:element name="PensionValueInCompensationTableForTheApplicableYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="apdn_PensionValueInCompensationTableForTheApplicableYearMember"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>apdn-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Apr 04 20:42:12 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="apdn-20240930.xsd#apdn_r_AdditionalDimensions" roleURI="http://adnas.com/role/AdditionalDimensions"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tC7CvZHOJjSUEJbYlSz0QmT1AzchKAjg5AqVJioVI5FtUHo07BdwqKaKppMJSlnYwXCaHdYwu3AIF454azm2PFRPQOUT0DHwG0wyGbCQ3UiYIEhFqlkO9g27q0o2g9mU0H+3Ka18hnq6AobAViuV0GCReq6KaDkFuuPX4qsEDGlMeLNkCU3ZmvgERekUKgpIP66KhvuABJBIYRHzx6miZpo4PAM8CS3mUw9juNpPy9LRGEUKOfO6aBCozmm4Ylyk=] CSR-->
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://adnas.com/role/AdditionalDimensions" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>apdn-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Apr 04 20:42:12 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="apdn_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:href="apdn-20240930.xsd#apdn_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl" xml:lang="en-US">Adjustments For Equity Awards Failed To Meet Performance Conditions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:to="apdn_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on adjustments for equity awards that failed to meet performance conditions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember" xlink:to="apdn_EquityAwardsAdjustmentsAdjustmentsForEquityAwardsFailedToMeetPerformanceConditionsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:href="apdn-20240930.xsd#apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Current Year Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:to="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of current  year awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember" xlink:to="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:href="apdn-20240930.xsd#apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Prior Year Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:to="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of prior year awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember" xlink:to="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:href="apdn-20240930.xsd#apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl" xml:lang="en-US">Change In Fair Value As Of Vesting Date Of Awards Vested During Current Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:to="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value (as of vesting date) of awards vested during current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember" xlink:to="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfVestedAwardsDuringCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:href="apdn-20240930.xsd#apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl" xml:lang="en-US">Change In Fair Value Of Outstanding And Unvested Awards Granted In Prior Fiscal Years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:to="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the change in fair value from the end of the prior fiscal year of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember" xlink:to="apdn_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:href="apdn-20240930.xsd#apdn_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl" xml:lang="en-US">Dividends Or Other Earnings Paid On Equity Awards Not Otherwise Reflected In Fair Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:to="apdn_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on dividends or other earnings paid on equity awards not otherwise reflected in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember" xlink:to="apdn_EquityAwardsAdjustmentsDividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInFairValueMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_EquityAwardsAdjustmentsMember" xlink:href="apdn-20240930.xsd#apdn_EquityAwardsAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_EquityAwardsAdjustmentsMember_lbl" xml:lang="en-US">Total Equity Awards Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsMember" xlink:to="apdn_EquityAwardsAdjustmentsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_EquityAwardsAdjustmentsMember_lbl0" xml:lang="en-US">This member presents the total equity awards adjustments, which may be comprised of adjustments for (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the change in fair value from the end of the prior fiscal year of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards granted in prior years that vest in the applicable year, the amount equal to the change in value as of the vesting date (from the end of the prior fiscal year); (iv) adjustments for equity awards that failed to meet performance conditions; and (v) dividends or other earnings paid on equity awards not otherwise reflected in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsMember" xlink:to="apdn_EquityAwardsAdjustmentsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:href="apdn-20240930.xsd#apdn_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl" xml:lang="en-US">Year-end Fair Value Of Awards Granted In The Current Fiscal Year [Member]</label>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tC7CvZHOJjSUEJbYlSz0QmT1AzchKAjg5AqVJioVI5FtUHo07BdwqKaKppMJSlnYwXCaHdYwu3AIF454azm2PFRPQOUT0DHwG0wyGbCQ3UiYIEhFqlkO9g27q0o2g9mU0H+3Ka18hnq6AobAViuV0GCReq6KaDkFuuPX4qsEDGlMeLNkCU3ZmvgERekUKgpIP66KhvuABJBIYRHzx6miZpo4PAM8CS3mUw9juNpPy9OWWW3TMNhS770SaS8hX0Wk=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:to="apdn_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl0" xml:lang="en-US">This member presents the equity awards adjustments on the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember" xlink:to="apdn_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:href="apdn-20240930.xsd#apdn_EquityAwardsValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Equity Awards Value In Summary Compensation Table (Grant Date Value) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="apdn_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the adjustment (deduction) for equity awards value from summary compensation table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_EquityAwardsValueInCompensationTableForTheApplicableYearMember" xlink:to="apdn_EquityAwardsValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_NetAdjustmentsForEquityAwardsMember" xlink:href="apdn-20240930.xsd#apdn_NetAdjustmentsForEquityAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_NetAdjustmentsForEquityAwardsMember_lbl" xml:lang="en-US">Total Net Adjustments For Equity Awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_NetAdjustmentsForEquityAwardsMember" xlink:to="apdn_NetAdjustmentsForEquityAwardsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_NetAdjustmentsForEquityAwardsMember_lbl0" xml:lang="en-US">This member presents the net compensation adjustment for equity awards, which is comprised of equity awards value from summary compensation table, net of total equity awards adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_NetAdjustmentsForEquityAwardsMember" xlink:to="apdn_NetAdjustmentsForEquityAwardsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_NetAdjustmentsForPensionMember" xlink:href="apdn-20240930.xsd#apdn_NetAdjustmentsForPensionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_NetAdjustmentsForPensionMember_lbl" xml:lang="en-US">Total Net Adjustments For Pension [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_NetAdjustmentsForPensionMember" xlink:to="apdn_NetAdjustmentsForPensionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_NetAdjustmentsForPensionMember_lbl0" xml:lang="en-US">This member presents the net compensation adjustment for pension, which is comprised of pension value from summary compensation table, net of total pension adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_NetAdjustmentsForPensionMember" xlink:to="apdn_NetAdjustmentsForPensionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_PensionAdjustmentsMember" xlink:href="apdn-20240930.xsd#apdn_PensionAdjustmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_PensionAdjustmentsMember_lbl" xml:lang="en-US">Total Pension Adjustments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_PensionAdjustmentsMember" xlink:to="apdn_PensionAdjustmentsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_PensionAdjustmentsMember_lbl0" xml:lang="en-US">This member presents the total pension adjustments, which may be comprised of adjustments for service cost and prior service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_PensionAdjustmentsMember" xlink:to="apdn_PensionAdjustmentsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_PensionAdjustmentsPriorServiceCostMember" xlink:href="apdn-20240930.xsd#apdn_PensionAdjustmentsPriorServiceCostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apdn_PensionAdjustmentsPriorServiceCostMember_lbl" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_PensionAdjustmentsPriorServiceCostMember" xlink:to="apdn_PensionAdjustmentsPriorServiceCostMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_PensionAdjustmentsPriorServiceCostMember_lbl0" xml:lang="en-US">This member presents the total pension adjustments, prior service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_PensionAdjustmentsPriorServiceCostMember" xlink:to="apdn_PensionAdjustmentsPriorServiceCostMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_PensionAdjustmentsServiceCostMember" xlink:href="apdn-20240930.xsd#apdn_PensionAdjustmentsServiceCostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="apdn_PensionAdjustmentsServiceCostMember_lbl" xml:lang="en-US">Pension Adjustments Service Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_PensionAdjustmentsServiceCostMember" xlink:to="apdn_PensionAdjustmentsServiceCostMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_PensionAdjustmentsServiceCostMember_lbl0" xml:lang="en-US">This member presents the pension adjustments, service cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_PensionAdjustmentsServiceCostMember" xlink:to="apdn_PensionAdjustmentsServiceCostMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="apdn_PensionValueInCompensationTableForTheApplicableYearMember" xlink:href="apdn-20240930.xsd#apdn_PensionValueInCompensationTableForTheApplicableYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_PensionValueInCompensationTableForTheApplicableYearMember_lbl" xml:lang="en-US">Pension Adjustments Pension Value In Summary Compensation Table [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_PensionValueInCompensationTableForTheApplicableYearMember" xlink:to="apdn_PensionValueInCompensationTableForTheApplicableYearMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="apdn_PensionValueInCompensationTableForTheApplicableYearMember_lbl0" xml:lang="en-US">This member presents the adjustment (deduction) for pension value from summary compensation table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_PensionValueInCompensationTableForTheApplicableYearMember" xlink:to="apdn_PensionValueInCompensationTableForTheApplicableYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_PensionAdjustmentsPriorServiceCostMember_lbl1" xml:lang="en-US">Pension Adjustments Prior Service Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_PensionAdjustmentsPriorServiceCostMember" xlink:to="apdn_PensionAdjustmentsPriorServiceCostMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="apdn_PensionAdjustmentsServiceCostMember_lbl1" xml:lang="en-US">Pension Adjustments Service Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="apdn_PensionAdjustmentsServiceCostMember" xlink:to="apdn_PensionAdjustmentsServiceCostMember_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>bc_netloss-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_netloss-bw.jpg
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M Q$!_\0 I0 !  (# 0$! 0            0% P8' @$("0$! 0$
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M?/R@'8U9U=/OGY0#L:LZNGWS\H!V-6=73[Y^4 [&K.KI]\_* =C5G5T^^?E
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MOJR/\4_PF(J<
M
M                                  *+\I^T_P!&*B?3?5D?XI_A,14X
M
M
M                      47Y3]I_HQ43Z;ZLC_%/\)B*G
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M#SRD*.H"                    "B_*?M/]&*B?3?5D?XI_A,14X
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MEY?G\?$HBTG[ABX+:PV!M!&SI&WTUD9->U$6A#O-HYQ*DH,R=UXSKSYVK/*
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MI(@'WNHK:YC8VWY[,-AJ<[ ;)V2AI"75D?$]2R(C/)EX3#14=PG]@2_7Y?\
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M[NJ6NV]WK[ZJ:EGH]>RS"6RP1F:4<^@G5$G/(G4L\%X"#1V 10
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M5CDU*3@U?? 6]94UE+$3 J(;,&$@S-+$="6D9/E/"2+B?A,!,
M          0+6EJKMIAFVB-RVHSZ)3"'2R2'VLZ5E[I9,!/
M                    5]E15%P]"D6D-N4]7.E(A*=+5S3Q8PM)<F2P L
M                              47Y3]I_HQ43Z;ZLC_%/\)B*G
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M_:?Z,5$^F^K(_P 4_P )B*G
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MFR.\B_B5&ZCW'63*N>;3LVG;BZ4,LKP;B$/H4I?.H(\:5\-7 P'31
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MO<S-=*_L)S7:%5!)XH3D(^+JGVG$DELD\/%@LG@L9%'Z%&5
M                                %%^4_:?Z,5$^F^K(_P 4_P )B*G
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MO$ QM18S"UN,LH;6YQ6I"22:ONF1<0&4
M                  47Y3]I_HQ43Z;ZLC_%/\)B*G
M
M
M    "B_*?M/]&*B?3?5D?XI_A,14X
M
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MLJ/)H<29H6C."SI4DRSCB(+D
M
M              ?%*)*34>3(BS@N)\ '.-J7.]-UV$'>D7H:=HSFE14U'27#
M?:;)X_\ >5X0;9O%ITFWX"X:LBCI @          "B_*?M/]&*B?3?5D?XI_
MA,14X        !2[JG08%,\Y:5C]M6.&34R+'8*69,KSJ6MHSRI"<>=@C/W
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M1S_39^<$*W/NY[X*GO(L9E=75TF&N&R4A;DA39I,C62,%H,SSQ"#HXB@
M
M                           (\>!#B/2I$9E+;\UPGI2RY7'$H2V2E?<2
MA*?O )            *+\I^T_P!&*B?3?5D?XI_A,14X   &J;YL+2J;IK&(
MF4NKCV"%W2:]OGI!Q>:<TEH(C,T<[S?.:2SC[XHT]A[>*K"EW?(E6+$F\N4Q
M6=LN$?16:19*+4\R1'H>)".>4YJX&>G (ZV(H               "#=?4]C^
MK/?FU /YV#;(       #O?\ "S_::]_4$?GDB:N/U,,J
M
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M@     !!NOJ>Q_5GOS:@'\[!MD       !WO^%G^TU[^H(_/)$U<?J894
M
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M,O\ RKONB:8_;0RT
M                          "B_*?M/]&*B?3?5D?XI_A,14X   &F=X=,
MY>-T$-Z([84?:K)W,)C/G,*;<2A;A$9&;:'30I9>+CX!1SRNVA&I]U0(%;M9
MUB]@[@=F(M4L*.O.D>4M99=/*-2&U)0A/PDK26/#DCNPB@
M (-U]3V/ZL]^;4 _G8-L@       .]_PL_VFO?U!'YY(FKC]3#*@
M              _!G>E_W&W1_P!1D?SS&F6HB@      .A]QO_=7;O\ K)'_
M *5X33'[>&6@
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M9$E*2+)F9GR$0"GV_NJEW.S+D5$E+S4*0[%>42T*\YE1IUEH4KS%8RA7A+B
MDUU_16[ST>JM(DZ1'_KVHS[;RT>#SB0HS+CXP!R_HF;)%,]9Q&[=S'-P%/MI
MD*R62PV:M1Y+DX /ME?4=.MENWLHL!R0>&$2GVV369</-):BS]X!8$9&1&1Y
M(^0P       0;KZGL?U9[\VH!_.P;9        =[_A9_M->_J"/SR1-7'ZF&
M5                      !^#.]+_N-NC_J,C^>8TRU$4      !T/N-_[J
M[=_UDC_TKPFF/V\,M
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M%G+9$9%]W)D(,':3O49'HI^< =I.]1D>BGYP!VD[U&1Z*?G ':3O49'HI^<
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MNBU5<T3,&&TEB.T63TH06"XGQ,_&9\H@E@     "#=?4UC^K/?FU /YV#;(
M      #H7=!]<VOZFC\Z ZV"@       .V[6_L]6_P"H2,ZJW$
M  'X,[TO^XVZ/^HR/YYC3+410      &R]WW]LZGX[GYI0#O *        ZK
MW<?4#GZRO^8@9T;>(H
M    (';->=T>WR=S:E%Z<;.#X1^<YK4:N3X7@ 9>T8/:/9/2&^T^9Z5T347.
M\QKT<YIY=.KAGQ@,I28QOG%)Y!R2+4;.HM9%X].<@,AF22,S/!%Q,SY, /#+
M[$ALG8[B'6CX$MM1*3P]TL@#<AAY3B&G4.+:/2ZE"B4:5>)1%R& =(C\]T;G
M4=(QJYG46O3X]/+@!BCSX4MZ5&C/H=D0EDU+:2HC6TM2261*+E+*5$9 )(
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M242%&3FDU85I\>!43J"?W,NW<!NDI"9MU/)*$]V9(:T._BGK4V1)QXS!761
M  &)F3'DDLX[J'B;6IIPVU$K2X@\*2>#/"B/E(!E           !!NOJ>Q_5
MGOS:@'\[!MD       !T+N@^N;7]31^= =;!0       ';=K?V>K?]0D9U5N
M(            /P9WI?]QMT?]1D?SS&F6HB@      -E[OO[9U/QW/S2@'>
M4       !U7NX^H'/UE?\Q SHV\10
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M,DEDOZ-7N /YW$1)(DI+"2X$7N$-LOH       .A=T'US:_J:/SH#K8*
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MW&E2JB6B4W)49I:-]*7FTI2:#4V6?--1$? P%[NG<C6V:]J4<9R;-F2&H-;
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MYI0#O *        ZKW<?4#GZRO\ F(&=&WB*
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M^&.31'J8VV[TA>/Q79R.;(S\9FA9@K>1  47Y3]I_HQ43Z;ZLC_%/\)B*G
M  YK/W S$M&9^\]A2>U(:C*)<P(S=LRE*3\U274$3J/&1*06!1[D[_I+:9#D
MUVU;FYM81K5 <*O6REE;J="C-V0:$HR7 S ;O2R;:77-2;N"BML7-1N0FWBD
MDV6H])&XE*24K&,X+&1!8                @W7U/8_JSWYM0#^=@VR
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MLO=]_;.I^.Y^:4 [P"@       .J]W'U Y^LK_F(&=&WB*
M                                "#!IX-=+L)T5LTRK1Y,B8LSR:EH:
M0RG'B(DH+@ C,;?C1MQS-R1W5MOSXS469&+3S3BHRE&TZ?#5K2E:D<N,>#@
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MTJ299$%T      (-U]3V'ZL]^;4 _G8-L@       .A=T'US:_J:/SH#K8*
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MFA:#XD:5%@R/[I /,6-'A1F8<1I+,2.A++#+9:4(;;(DI2DBY"(BP0#*
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M=@VR        Z%W0?7-K^IH_.@.M@H       #MNUO[/5O\ J$C.JMQ
M       !^#.]+_N-NC_J,C^>8TRU$4      !LO=]_;.I^.Y^:4 [P"@
M   .J]W'U Y^LK_F(&=&WB*
M                       HORG[3_1BHGTWU9'^*?X3$5.   !P:VG=V]IN
MC<JN\FS=8MX<XX=,V3DIOHL-IEHT.,DR6DE*6:S,U9XER>.HVKNX[U-NVU)1
MU%K<H=W8\@HSK*D.\XXZE1H2:E&C&I22)1GGE,-Q73Q      4>Y=SP]MLQR
M<9?FV,Y9LUU=#;YV0^ZE)K,DIR1$E*2U*4HR(B >=HW5A=U#;UQ7OUMPSI:L
M(S[1LIY\D)4HV3-2B6WD_-42C 7P       (-U]3V/ZL]^;4 _G8-L@
M  .A=T'US:_J:/SH#K8*        [;M;^SU;_J$C.JMQ            !^#.
M]+_N-NC_ *C(_GF-,M1%       ;+W??VSJ?CN?FE .\ H       #JO=Q]0
M.?K*_P"8@9T;>(H
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M9=79(7E+CC!)<-O1IX9:7SB59\!E@0;$ HORG[3_ $8J)]-]61_BG^$Q%3@
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M--FF?&/2K)+3'<B/J<(RY2P@TD8([&(JB_*?M/\ 1BHGTWU9'^*?X3$5.
M!K.^95%'IDHOZ=V^CR'DM,5L>+TUUQXTJ4G2CD3@B/SS,L>,!H%'L_?R)K<O
M:IKV-1()1=E3Y2K<G,GE)E&5E#)>,DNY%1U*A.^.M;+<J8I6R5*2ZJ :SCK2
M1^:I).><62Y2/PB*LP    %)NO:U7O"G>IK5LC9=TFEXDH4ZV:5$>6S6E6DS
M(L9+P +2'"AU\=$2OCM18C?!MAA"6FTYX\$I(B(!G
M
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M6S%*J)/K9DQM;U=VC%7%1+0T65FR:N4TI\XTJP>..!1M0@
M            "DW#N>)MWHZ'(<ZPERM9L1*V,N4Z:6].M1Z<)21:B^$HL^#(
M",UOO;;NW#W04A95R5G'4TII922DDOF^C\SC7SNOS=./Y.(#S5[ZIK%%@3S,
MRLEU;/2IL"PCK9E)CF1F3J6TZC6D])EYF3SPY0'FDWY4W5H5,<2?66+K:GXC
M-G%7$.0R@R)2VM7+C)9(\*]P!(MMYT=-?5>VYCJSM;8\1FFT:R22LDDW#_%)
M1I42?'@_$ V
M                    !1?E/VG^C%1/IOJR/\4_PF(J<   #5]YW5M5-U<'
M;[,=RZN9A0HSDW5T9HB:<>6XO1A2L);/"2/B8#3:K>&_DS:Z1=/4_8CUX]M^
M8<6/(*0E]IQ;*#(E.F1$XM&"/\741F6,XJ.M"*
M  U/>.XGH^G:]"27]V6K2BCMJ,B;B1S\U<M\_P 5MO/FERK5A)%RXHUUFJA[
M8WIL*G2[SE?&J9\&O>7CSY2"84L_$2EI(SP0#+2W%;4[L[Q]R3I*&:&.[6LN
MRC/+?2(T32ZE.,Y61J0C27'5PY0%IM./)?L+;?=\DJ]^S9::B0'E))<.LC:E
M(-\R/!..&HW%EGS."<\# 4<UFUJM^[6L=P63&X6IKDF'3M,M%#=AKD-&M;Z4
M(6LGD&VG0M2C+21Y+E =1$                           4>Y]S1MMQ&U
M<TJ9;35]'J:MHR)Z5(,N"2SP2DN5Q9^:A/$_$8<\M*->VZC:#EJ^W(D/[K9M
M+Z2UP83-FD\9J+/P6T.*0DC/W#X"C87WHY=[O22<0ANOVV[VE(49$AI+DM"V
MTN*/@G@A:^/@X@/E2ZO=^YFM[<VI-!41Y$?;;1^;(F+D8)^423,C2VHFR0RE
M7%7%? C(!S^7:SV)5+;7>WK=&XI^XV)TY1Q$Z.;9CR&V(<=6LC7S:#X9(LGK
M4*COR5:DDK!EDB/!\#+/C&5?0
M                                47Y3]I_HQ43Z;ZLC_%/\)B*G
MUO>BXS4&%)D44N_7%FLR8T> 1&\R^R2E(>XK;X)QI/CQU8,L&8#0XDK;LG?=
M;-F[+N:VXLY*GHSDQ2&X/2FV\+?-KGS0;J6RSDDZO"19XBH[ (H
M              "@M]C[1OY9S[FFBS9II)!OO-DI9I3R%GW 'MW9VUWZ9K;S
MM3'52L*-;$/1A#:S4:M2,<4GE1\2//$!Z/:&UU4R=NG4Q>PT*):8'-IYK61Y
MU8\*L\<\H##5[&V?2N/N5=+$BKE,JC2#0T6'&'#(U-J(\D:3P62,!ZIMD[3V
M]+7.I:B-#F+2:.?;1YY(/B:4F>=*3\2<$ O@
M   4]WM3;FY395?5D>P5')1,'(02S02\:L>+." >(>S]K0*N52PZB,U4S3U2
MH9-D;3BC(BRI)Y(S\TO> (&T-L5=;*J(%5'8K9I&F8PE&2>)1:3)PSR:N!XX
MF C5O=_LJHG-6591Q(D]@S4S(:;)*T&HC2>#^X9D NY==!GJC+FQT/JAO)DQ
M3<+/-OH(TDM/B41*,L@)(
M                             "B_*?M/]&*B?3?5D?XI_A,14X   %%N
MF7>1HL5O;LFMC6<F2EELK<W.:<(T+4:&R:4E1N'IR1>(C :I)IMY6=G1N;ZM
MJ:)5PK%B7$CUJ'FW9,UHEFTWKD+X9XGI3Q5R"CI @
M
M                                                       "B_*?
MM/\ 1BHGTWU9'^*?X3$5.   !S7O&VZ],M*.R7NB75LG91V8T)I*7"*0IIUM
M*HZ4M+/G3U<37YI(U&?(+@]2=J0:V[V^>ZMT6MH2IQ.5,69S9156#*%+:UJ:
M:3A1$2C02E%DR^\ Z0(
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M1$HR,RRHBX>$P$V+*C3HK,V&ZE^)(0EUAYL]2%MK(E)4DRY2,CR S
M                                                         HOR
MG[3_ $8J)]-]61_BG^$Q%3@   :YO#;TZ]BP7Z>6B%>5,I,^N?>1SC!N)0MM
M3;J2P>A:%J(S3Q+E(!IDMR_LMPT-?W@7%%7MQ)[,R%4U;CSDR7,:R3.KGL&E
MLE*S\'W#%'5A
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MDD-I(B2A)8(B+D(B(0>@
M                       47Y3]I_HQ43Z;ZLC_ !3_  F(J<   #DN[BWN
M=Y-[>5;)V-E/0OW5)KG]'XW2?_[C&/A<T6,"C#W1(V#VMN+L/HQRRL/_ &XY
M.KM'HW1F=7_F?Z;'.<YGW<AJ.P"*
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MC0@\>:D\<"X<A ,H
M                    "B_*?M/]&*B?3?5D?XI_A,14X    !5S=N4-C/C6
MDVNCO6<-:78LQ3:>?0M')A9>=CW,X 6@
M
M                                               *+\I^T_T8J)]-
M]61_BG^$Q%3@   <[[X)D.%25;EO-<B;<<LF6KEN.XMI]^,M"_,0:/.,B5A:
MTIXFE)XY!<%%MMON%3>UY[>D-JNR>3T!)2;!9F]^*1)=6:#_ -(/J.PB*
M
M
M           "B_*?M/\ 1BHGTWU9'^*?X3$5.   !J^]KN?5QJZ!316)=Y<R
MTPJ],S/1FU<VMU;KNGB:4(09X3Q/P"BA;G[QVI:5);J[,LJBVEMUR9,!A<:1
M&E2"/FCTJ-25MF9:3Y#+.0'1A
M
M                                        %%^4_:?Z,5$^F^K(_P 4
M_P )B*G    Y_O.^V+:TT@[>V=KBJ;4H;-C';>3(C6S"#67-8;4:C))JSYII
M,LD*-7V[;[5NMQU176^I>YID>02Z>N<KW(,=,HR-*'%DAA*5+21GI4HRP".T
M"*
M
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M%C&9<-UE27D<XT\THR(]#B>)$HLER&(-F
M                            !1?E/VG^C%1/IOJR/\4_PF(J<   #4-^
MV5M%11UE3/34KNK)N ]:*0ATVD*:==TH2YYNMPVR0DS(^7QBC0:RYW%!MZ[I
M^[Y-@XC<;M'-HUMQ6WELDXXAEWS4:M.DFW%\,&DSP9>$CMHB@
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MT"+>N1&:Z)*1S;_1H#1MDZM!\4\XI:C2E7$B ;P(
M                                   HORG[3_1BHGTWU9'^*?X3$5.
M  !K6[KIFJ=H8\EB,Y'LK-J.X_-,B98YMMQ\ED9\.<RV1-_YP#26-R]*W1%W
MDS1U3FW9UH6WH-P3>;9Y:C-@I*'?@*8-:301%YVGCR"HZV(H
M                          *VRHX-M+K)LO7S]3(.5$T*TESBFU-'J+PE
MA9@+(                    !5PZ"!"NK*_;-Q=C:(8:?4XO4E#49)I0AHO
MQ4Y4:E$7*H\@+0
M                         %%^4_:?Z,5$^F^K(_Q3_"8BIP   -2[P+&)
M%JXM8]2(W#*N)*(<*J>-"67'22IW4XMPE$E*"0:LXS^$45E>QNUZ541;+9U5
M$JJUY*HRV9VLHI$DT:VFB9264I,]) .@"
M
M                                                *+\I^T_T8J)]
M-]61_BG^$Q%3@   :=WEU\*;MYMZPO2V['KY3,TK/FT.+0XUG03>K!DHU&7P
M.)_!Y#,7!1[;<LI2J>[_ +QW+.FGR38C1W*Z-&3*<;UZF=1H2M)GH5X"/AP
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MNMDHC6@E\4ZB+B6<<,@,@  KBNZ\[Y6VR6KM5,1-@;>D]/1U.FR1ZN3.I)\
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M;G8<DT%@S.:95H>YI7GH4><$M!X4G..&2 6P
M          HORG[3_1BHGTWU9'^*?X3$5.   !JF^:FSG-T]I5146,JCGHL.
MRW5)04A)-.-&2%+\TG$<YK;-7#)"C1Z&MW7='54\K;\BHKX-^_N&98SEM9-/
M2GI#3+2$&:E*5SA)6KD+!^,$=C$4                         :'WF_\
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MLN[AU>WRN([5B;2E=));J<:F6VO,,D%G[X*^K<W)MMC:^XWMQ2+1R\G0(5I
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M%H6ZNC)>GU-FA@HQK)1)6_"6RV239U'I(DK/'#)9XAHZ&(
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M,*JB,P8:#,T1XS:&6B-1Y,R2@B+B?*()0
M
M                                               HORG[3_1BHGTW
MU9'^*?X3$5.   !H/>NEYZHJ8B7VZZ-(M8J)%XXG4JOP:E-O-GE.A9K)+>LS
MP1*,CX&+@S5='=,6,9Y_?TBP:0XE2X*F8*2>(OQ#-""5Q]SB W@0
M
M
M      !1?E/VG^C%1/IOJR/\4_PF(J<   #3^\9V@33Q6+RF/<#TF6VS55*2
M+4],6A>G!F9$DB1K-2U<"(7!IM#64-)?U?[Q]WL?;4B5(2U46C$IN<T4W!J0
MVLT:30L])Z#P9&8([$(H                         Y;OS^(GNB[M;U6V
MMVW_ $:\;;0Z_#8C292FDND2D<X;#:R2:DF2B29YQ@^0R!8U?_&3_#[_ /)'
M_P#[;/\ ]@!#_&3_  ^__)'_ /[;/_V $/\ &3_#[_\ )'__ +;/_P!@!#_&
M3_#[_P#)'_\ [;/_ -@!%WM+^)[N4WMN"'MB@W$:[FP5S4)F1$E1DNN^!!+=
M:2C4?XI&?$^!<0(V!3^X-Y;DNJ^NN'J/;] XW#-R$VTJ3*FJ;)UPU+>0LD(;
M)24Z4I\[CDQ464B_E;5BUM-9K?W+N>:;Q1FX3#3#S[31ZC<<2:TM-DA*DI4K
M41&?(7@ 8E]Y-(QM^POYL>7$*HDM0K6O=:(I<=UYQMM.4$HR4D^<2LE(49*3
MR9/@$&#^\MCIJZD]OVZ;Q3:9$*L4PV3LB,HS+GB5SFAM*3+SB=4DR,R+&3P$
M&5SO-HFZ>HN419SS=S(<A1XC3&J4B4T2]3*VM625J;-'#)9XYT\0@F5N]XT]
MFV2[63XMO2I0N;3K:2Y+-+R34T;1-+6EPEX,BTJY2XX *O>K4V?)J;"JFU%H
MQ$58MQ9B6CYZ*E6@UH6RXXG*5&1*29D99(05M5WI5-JNI=*LL8E3=.(C0+64
MRAN.N6XDS2SP6:\F9&DE:=)J+@9EQ%@L%[_I6MOW&XGFWVV*.2]!G1E)3S_2
M6%I;)"2)1I,W#6C1YW'47( ][]MI]3L:YN*]:HEA'AJ=869)4IM>"\!ZDF99
M]T0:A)WGN&/L:TCRY*6=Z[>G0(%D^VELR<;DRF2;D)3@TDE]E?B+CJQC HVZ
MWWJS7V4BIKJJ==S8+2)%FBN0TKHS;A&:"5SKC>IQ9%J2VC*C+[V8*&X[R);=
MWM5O;]9(MJ.]CR)1NL):YQY*&M:$L\Z\WI4V?%TED7#@7'(L&P=X-I/I]D7=
MM6NG&L(L53K#N$J4A98XX41D&"RLKR!143EY</<U"C,I<?<QDS-6"(B(N52E
M&24D7*9B"HJ]],3+1BGM:J=13IK3DFN18I:(I#;)$IPDFTXYA:$GJ4A6#(A1
MYJM^Q+.%(N5UDZ'MQJ*]8,W$A#?,.QH_PE$EMQ;B3,O.2E:"-2?> 3]M[E=W
M"V;RJ>;6QEM-R8C\PF=#[+V32:3:<<TJQQ-"L&62$%\
M
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MWGO%7N4&U7&$)CT+\M,W3,UFI;K)H6M+3>D].@E<3XX(!T 0
M
M    47Y3]I_HQ43Z;ZLC_%/\)B*G    Y>QN&'W:WNXF=V-OL5-S8*M8%XAE
MQ^.:7FFVS8<-I*E(4V:,)(RXD>> H\3=SP.\FZVY!V>A^7 J;-JVL;HV7&8K
M3<5#A<TE3J4&I;AKTX(N3^0.IB
M     ,$B%#E.QWI,=MYZ(OG8KCB24IIPTFG4@S+@>#,LD S@   CH@PFYCMB
MB.VF>\A+3LHDD3JFVS,TI-6,F1&9X(!(
M
M 47Y3]I_HQ43Z;ZLC_%/\)B*G     !$1<"X$
M
M                                                      HORG[3
M_1BHCP>WNB-=$T=&P?-ZM.<9/ER D?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !
M]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0
M ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_
MD 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z
M/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF
M^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]
MIOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0
M?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D
M 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/
MY !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^
MC^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]I
MOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?
M:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D
M'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y
: !]IOH_D ('_ +KJ_%U]+_S?_,:?P:0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>bc_revenues-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_revenues-bw.jpg
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M Q$!_\0 I0 !  (" P$!              0%!@<! @,("0$! 0$
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M?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G
M.YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSL
MZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G
M .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJS
MLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?
MG .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJ
MSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*
M?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .Y
MJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?
M*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .
MYJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ
M?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G
M.YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSL
MZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G .YJSLZ?*?G
M .YJSLZ?*?G 5/48N?+NBPZ_N<,3_H\F.7EY,146U-]61_BG[YB*G
M
M
M               "B^<_6?YL5$^F^K(_Q3]\Q%3@
M
M
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M4L3(L?">P089IFPZ]QBU*N-+.36.54)Z-NW3<CJ)26_31@9IV^,A1M 0
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MA*<_QP$G6L5Z)K[1VDZ^E[^JJ:K5)ATBGFH[;CK>9DEK-[T%9$MDHB/_ ,3
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MQG@GD+P; 5N 0                    47SGZS_ #8J)]-]61_BG[YB*G
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M32;222995&9GB>WP .E-H]^KUSJ+5RY2'&+MJ*VW%)!DMLXS:4&9JQP/'+B
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ML)1+T?PYD:6U18ZC?MW;1ZSB-M2G9)?CG))+S+<V>BE&PB0@O@ELQV!1GP@
M                   HOG/UG^;%1/IOJR/\4_?,14X
M          'F;#*GDR%-I-]!&E#II(UI2K#$B/E(CPV@/0
M      !C5KP]T1=S%3[2BAR)JSS./FV25K5XUFG#,?Q@%W7UM?4Q40:N*U"A
M-_ CQT):;+'Q)21%M 2@                    $"WI:J^B%!N(C<R&2TND
MRZ6*<[9XI/[P">                                 K[6BJ+Q,9-O#;
MF(AO)E1DNEF2AY&))7AR&98^$!8                                H
MOG/UG^;%1/IOJR/\4_?,14X
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MG@
M  *+YS]9_FQ43Z;ZLC_%/WS$5.
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M-!LJ:-25H\9JV@,R$
M %%\Y^L_S8J)]-]61_BG[YB*G
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M;N.TAEO''*VDDEB?N%@ ]
M      %%\Y^L_P V*B?3?5D?XI^^8BIP
M
M                                                      HOG/UG
M^;%1/IOJR/\ %/WS$5.
M
M                                         %%\Y^L_S8J)]-]61_BG
M[YB*G         ,?UGJ4]*4+MLAA+[V]9C,I=7NF2<DN):2IUS \B$FK%1X
M*RC/6E%6W4G4SL.P2E,BRAR(SCQDDU9G.KY74[&T;"09*Y!1YZ(M]<:@CU]U
M:KIBHYT9$G<PDR>MH-Y!+0E1N+-&)8X*V?< 4\CB!JI5/*US @P7=$1'W$=6
M4;O>3\2.\;#KZ%XDVG:DU);4GX)?" 6TW4>KK2[M:S1L>O./1H8*5(LC=/K,
MB0T3Z6F=RI))(D&G,M>.U7P=@#(-*:A8U7IRNU#&;-EN<T3ALJ/$T.),T+1C
M@6.523+'#:(+D
M
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M89M@#O/UGK%]O4-UI^# 7I_3;\B,\Q,-\IDQ4 L9)M*;/(V1&2DMYDKS&6W
M!GE78Q[>LA6L3$XLYAJ4QFV'NWD$M./NX&()8"B^<_6?YL5$^F^K(_Q3]\Q%
M3@        %+JJ=!@4SSEI6/VU8X9-3(L=@I9DRO',M;1GBI"</2P(S]P!@&
MC>KLS[.PTO7V/[LUU9N%7R&W5)D3%+S?\BR^9K-"FL2,DX)49D1"CI65]'*U
MC0S.'U)(J6XBGCOY?5'JZ*J*II228<0ZELG7#6:33@D\N&.("N9[T@\/)G"I
M%5-<U0:I-;&4<=WJ;D>3(6I,KK))-LFR;7B>*LV8L, 1D4>R7H+4.I6IM;.E
MQ+1<:;2N08SLOK"T16V%L&;25$A9*;V9S(L#Q!61<.:.;IS1-146*21/::6[
M*;+ \CLEU;ZD8EB7HFO+L#1D,F(F2:3-UUO*6&#2S01_=P$'AW4CM4GVR@#N
MI':I/ME '=2.U2?;* .ZD=JD^V4 =U([5)]LH [J1VJ3[90!W4CM4GVR@#NI
M':I/ME '=2.U2?;* .ZD=JD^V4 =U([5)]LH [J1VJ3[90!W4CM4GVR@#NI'
M:I/ME '=2.U2?;* .ZD=JD^V4 =U([5)]LH [J1VJ3[90!W4CM4GVR@#NI':
MI/ME '=2.U2?;* .ZD=JD^V4 =U([5)]LH [J1VJ3[90!W4CM4GVR@#NI':I
M/ME '=2.U2?;* .ZD=JD^V4 =U([5)]LH [J1VJ3[90!W4CM4GVR@#NI':I/
MME '=2.U2?;* .ZD=JD^V4 =U([5)]LH [J1VJ3[90!W4CM4GVR@#NI':I/M
ME '=2.U2?;* .ZD=JD^V4 =U([5)]LH [J1VJ3[90!W4CM4GVR@#NI':I/ME
M '=2.U2?;* .ZD=JD^V4 =U([5)]LH [J1VJ3[90!W4CM4GVR@#NI':I/ME
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MFG*BF=42W:^%'B.+3R*4PTE!F7N&9""T 47SGZS_ #8J)]-]61_BG[YB*G
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M,-3Q(L9E=75TF&Y#8*0MR0ILTF1K)&!9#,\=H*V.(
M
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M"/H8C)1$I)XD>TC+D,@1R
M
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M#W)L))Y_&D@9C= (
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M2Q^8OS@(EJFT*KGF\XP;75G\Q$A>/]&KW0'YZHSDA).'BO LQ^[X1I'8
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ML?F+]8 R7'2Q^8OU@#)<=+'YB_6 ,EQTL?F+]8 R7'2Q^8OS@&2XZ6/S%^<
MR7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%
M^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6
M/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2
MXZ6/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS
M@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^
M8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'
M2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%^< R7'2Q^8OS@&2XZ6/S%^<
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MKJIBSY,<L&79#2'%)3CCEQ46U..W ]@"W2E*$DA!$E*2P2DMA$1> @'(
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MO. =<E].YSU><!L'@?)D.<4].H6\M23<D8I-1F7_ $KONAH^VQE0
M
M  47SGZS_-BHGTWU9'^*?OF(J<   ##.(5*Y>(T_&>AN6-*BV85;P6OPF%-N
M(0MPL2S-MNJ0M:=NPL<-@HP"!I%%3JF!75NE'(]S!U ].;NT1R[O.E>4XO*;
MQ^CF0VLD(1\)*TD9>Z1O(10               $&Z^IK']&>_)J ?G6-(
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M\94
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MBOZ34]8Q=:=L(]I4R2S,3(CB7FE>YF29X&7A(]I>$&5B         ^"^*?\
MF-JC^\I'\\QI&(@       V'P,_S5T[_ ,21_P"E>#1]OC*@
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M5_S$#.C+Q%
M          47SGZS_-BHGTWU9'^*?OF(J<   #&M:44JWAPYM9-:K[JFDIGU
M\J0G-'SI0IM;;Q;#W:T+4E1D>)<H#%V&-3ZKMZ@M5V-'&K*N6U8-0ZE];[\J
M6P1[K$W,,J",\V!$9GR"C9H@                @W7U-8_HSWY-0#\ZQI
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M        VKPX^H'/TE?\Q SHR\10
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M?RFU*]W $CY>XI_YC:H_O&1_/,:98B       #)>'W^-*GX[GY)0J-\@H
M    #:O#CZ@<_25_S$#.C+Q%
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MSC/8%F+HU /SS2HEI)2=J5%B7W#&D<@       V%P@^N;7]#1^6(5&W 4
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M_M37.( [SK^U-<X@#O.O[4USB .\Z_M37.(!(;<0Z@G&U$I"MJ5%M(P'8
M         !1?.?K/\V*B?3?5D?XI^^8BIP   *NGH8=([9NQ%.*5;3%V,DG%
M$HB><0ALR3@18)P;+8 M    5.HWKV-5N2=/)BN3V#)U3,W>;MQE!&:T)-K%
M25F7P3P,L?  Q'3M5J>SGO<19T>'7W,ZF3$K*E!NY<7#*0A4UQ2$JSDHDHRI
M3Z*<?"*&C*;75+-6_<P*V1*LG=[=W*9CSDIW+CD)#9QTI2ALCRH;)1)27NX@
M('[#:O:H)7#R,N$C24E]W);;QSKK4"0^;ZV=P;9I4YZ2D$O>9</  N)5'K&C
MO+J?I)$"3$OB9<-$YUQCJ4IADF-X1-MKWJ%)2E1IQ2>) ,ATEIYK2NFZW3[+
MAO%!:)"WC+#>.*,UN+PVX9E*,\!!<+;;<P-:$J,N3,1'[X#KU>/T2.:0!U>/
MT2.:0!U>/T2.:0!U>/T2.:0"%<,M(J+!2&TI449[ R26)?BU>X _.U*221)2
M6"2+ B]PAI'(       -A<(/KFU_0T?EB%1MP%        ;JTPRRK3]::FTF
M>X1M-)#.JMNKQ^B1S2$#J\?HD<T@#J\?HD<T@#J\?HD<T@#J\?HD<T@#J\?H
MD<T@#J\?HD<T@#J\?HD<T@#J\?HD<T@#J['1(YI /@/C'4UEMK[5,2QBHD,=
MY2<I*+!23-9EBE1;4G]P:1HNXX:V5<]WAI62MPVSS(8-6[D(^(LL"5_L,2-5
MS3<2["O>[OU5&6M39Y5R$IW<A'QT'@2O]AA3?EL:NLZ^WCE+K)*)+'A-!^DD
MS\"DGM2?W164L   &2\/O\:5/QW/R2A4;Y!0       &TN'332Z%PUH2H^LK
MVF1'^ @9T9=U>/T2.:0BG5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_
M1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '
M5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(Y
MI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_
M1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '5X_1(YI '
M5X_1(YI '5X_1(YI '5X_1(YI .Y)))$E)$22Y"+80"DU3J5K3,.,]U5R=.L
M)3=?70FC2A3TIXE&E)K69)0G!)F:E<F "DK-1ZII](VUIK6K-NTIF7Y:E-.L
MJ9E-EO'4I;-O'*:$D2%9D^[MQ%%CIB_U-=+0[;:<*HKGF"?CRNO-2E*->4TH
M-M"$F6*3,\<? ()&I]2EIYF&W'AKL;>S?*)6U[:TMFZ[E-:C4M6)(0A*34I6
M!X *5'$9F#"OG-35SE79Z>0R[+A-N)E$\W+/+'4PX1()>\5Z&!D6"MABP>U=
MK:>FWCTVJZ4Z&1.C.RZ]WK3<MIQ,8B4\VM2$IR.(29*,MJ<.10"%%XDRW2K;
M290.Q-(W$AN+7VZGT*=QD*RL..QR21MMN'R*SGALQY0@S\0  !1?.?K/\V*B
M?3?5D?XI^^8BIP  \I)R$QWE14)<E$A1L(<4:$*<(CRDI1$9D1GRG@8#5\3B
M'*I8VLINKI+,;4%>^ENOTZEY+B21U9LV"9]%"W"?<6>*L/)@*(;C6I= HTWJ
M:RMK2ZM;B4W$OZ0S*0VI4EAQPRBL%AE4RI&!9/A%XN0$;:A2BG0V)B6G6$OM
MI=)F0@VGD9RQRK0K:E1>$C$5[@               @W7U-8_HSWY-0#\ZQI
M       &PN$'US:_H:/RQ"HVX"@       -VZ6_P]6_\!(SJK<0
M   ?!?%/_,;5']Y2/YYC2,1 5MS05%^UNK2,EU1%@V^GT7D?%66W[Q[ &N;'
M0>HM-OG9Z8E.2&V]OXKT)*4EMP-!;%E]SR"1JU/HN**<Q0]3,&TZD\IS&4X8
M&7+O&_!_]/D"F_+8<65%G,)E0GD2(R_@NM*)2?\ 9R'[ABLO8!DO#[_&E3\=
MS\DH5&^04       !M7AQ]0.?I*_YB!G1EXB@
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M _.L:0       !L+A!]<VOZ&C\L0J-N H       #=NEO\/5O_ 2,ZJW$
M         'P7Q3_S&U1_>4C^>8TC$0   4E[I.DU"DSG,9)>&"9C."'B^Z?(
MHOC 9K7DO2^KM%/JL*-]<F&6U;D<C,\OB=9/'$O*0C5S60:?XGU\W)&O6R@R
M3V=9;Q..H_=+::/]I!3?EN'ARXV]J^F>96EUEQ3AH<09*0HMTKD,MAC3#?8*
M        VKPX^H'/TE?\Q SHR\10
M              1;.OC6]=+JIJ35#G,N1I"4F:3-MY)H41&6TCP/E >K$=F-
M';B,H),=E"6FT> D)+*1>0!T5#9**[%CEU5#J5)SQR)M2366&9.!8$HO > "
M/44M=1U$:CKV21716]TAM7I9BY5&O'X2E&9J4?A,P$YMMMI!-M))#:=B4)(B
M(B]PB <-,LL$9,MI;)1YE$A))(U'X3P\( EEE+BGDMI)Y>!+<))$HR+DQ/E,
M!W   !1?.?K/\V*B?3?5D?XI^^8BIP   ,:=XAZ$8=6P]J.N0\VHT.(5*:)2
M5)/ R,LW@,!Z0]>:*L)3,&#J"!)F2%$VPPU);6M:SY"21'B9@,A  &/:UU*K
M2>GWK=ME#SV]9CLD\O=,(<DN):2MY>!Y6TFK%1@(NE(VLJU%A^TDB+9L/+<F
MPWH2W3<)3RC6<=*'L2)M)8):,E\G+XQ1XZ3U/?W%_>U%[7L5QUS4&1'CLN&^
MZE,TG3-+R]B#66[+X!8%XSY0%!(U]JM5++UY B07-&1'W$IA*)WO!^''>-AQ
M]+F8FTJQ2I24&CX/A 6\W4.K[>[MJS1K4!$:C0R4A^Q)U?6I,AHGTM-;I:<B
M20I.9:L=I\@"_P!):A9U7INNU"PV;*9S1+4R9XFAQ)FA:,=F.523+$070
M   @W7U/8?HSWY-0#\ZQI        &PN$'US:_H:/RQ"HVX"@       -VZ6
M_P /5O\ P$C.JMQ            !\%\4_P#,;5']Y2?YYC2,1     ",R/$M
MA@,:O]#4=_F>4WU.P5MZU'(BS'_OHV$K_881<V,:TU XG</M3P']),JLWUO9
M8K#*#DQWE*(RRN-<J<2Y3V8?RA%N:^YT&LVVU.I)MY2$*=;(\Q(<-)&I)'X2
M2>)8C3#D%      !M7AQ]0.?I*_YB!G1EXB@
M                                   *+YS]9_FQ43Z;ZLC_ !3]\Q%3
M@   :[XB:8AG%KK*%IYJRB1+!N7=0(<=KK<F,DEG@DL"-S!PT+4WCZ> HINL
MU^HM1Z<<T9I>563*^:F186LBO*O8;@FA27V5&I)9U.$9$DB+8>TC($;=$4 4
MVJ9\2OIGG;"K?MZY9DU,B1F4RE;E>.9:FE&69"?PB+$_< 8/P^::1?3+/2<.
M=!X=/5Y.-QI:74M.SE.$LG(;+IJ639MXXFG!*C,L"%'IIF_0_P 0;Z:=9:LQ
M+IFN8A/R*Z4RWGBH?WF=2T$2"+.G:K#$!0,IN(/#Z7PJ13SG-1FJ3717SCN=
M1<C2)"UIE')(C;)LFU[<3S9BPP!&0L6$C0>H=2-2:F?-A6JX\RF<@1W)1/.(
MBML+94;9&3:\S>S.9%@>.(*R/AU13--Z+J*>Q(DSV6EN2D),C)+LAQ;ZTXEB
M1Y37EV"#(),-$DTJ4XXC*6'XM9H+;X\ 'AW4UT\CVJ@#NIKIY'M5 '=373R/
M:J .ZFNGD>U4 B6M<TU5SW"=?4:8SWHJ=5@?XM0#\]4(R(2@CQ))$6/W!I'8
M       &PN$'US:_H:/RQ"HVX"@       C<.FZYIVAKEFZ\DS81L2XHB\@S
MJK3NIKIY'M5"*=U-=/(]JH [J:Z>1[50!W4UT\CVJ@#NIKIY'M5 '=373R/:
MJ .ZFNGD>U4 =U-=/(]JH [J:Z>1[50#GNIKIY'M5 /A;B<V3?$75"2,S_\
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MB       #)>'W^-*GX[GY)0J-\@H       #:O#CZ@<_25_S$#.C+Q%
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M%
M 47SGZS_ #8J)]-]61_BG[YB*G    T-;3^&MAJC4_[RYCK=Q'G'$J$GULNK
M0FF6S;<8W"32E1N&M1F?A+RZ1E'#CBIIZSIJ.DMK<W=6NH**ZRME_.XZE1I0
M:EFWES*21*,S4)N*VB(     "CU+J>'IMF.3C+\VQG+-FNKH;>]D/NI2:S)*
M<2(DI2692E&1$0#KI&ZL+NH;>N*]^MN&<K5A&?:-E._)"5*-DS4HEMXGZ*B4
M8"^       !!NOJ:Q_1GOR:@'YUC2        -A<(/KFU_0T?EB%1MP%
M    ;MTM_AZM_P" D9U5N(            /@OBG_ )C:H_O*1_/,:1B(
M   ,EX??XTJ?CN?DE"HWR"@       -J\./J!S])7_,0,Z,O$4
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M8EX %I#A0Z^.B)7QVHL1O8VPPA+3:<=NQ*2(B >X
M
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MJ5<2?6SI3:WX";**N*F4VUM6;1JY321D9I/!6'@%&4B
M          *;4&I(FGFV#>BS)TF4I28T.OCKDOKR%BH\$["(BY349 (477NF
MY.G96IU/KC5\%Q3$YJ0TMN2Q)09)-A;6&8G,5)(DERXE@ XJ-=T]J_+AO1YM
M580H_7G85E&7'?.(6PWD)]+,DC]$\NTCV&0#RI^(--;VS%,<6?72YB%NUJK&
M(Y%;EH:+,HV#7\+!/I&1X'AMP%$R\UG1:>M:FEL'5]XW+J68C32#<PSK2VE;
MF'P$FM1)(SY3^X8@R
M                          !1?.?K/\V*B?3?5D?XI^^8BIP   ,8UG=W
M%6BJ@:?1'.WN9I0F'IN<X[*2:<>6M1(,C49);,DIQ+$P&&5FK]>HEU\FYF52
MZ9V]>T]-3&C/)D)>;=<9;,LSIE@XI!>ZDE$>![11MH0
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MC?S+F^9;>R*;WB27NW"RK3F+'!1> R\(RKN
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M@6)& [TNBM*:=DKFTM1&ARUI-!OMH],D&>)I29XFE)^).! +X
M                %3>:8T]J5+*;ZM8L"C9C8ZP@EY-YAFRX\F.4L0'E T=I
M:K@RZROJ(K%=.+"9%2V6[=+##TTGB1[ "LT?IBFA2ZZKJH\:'.2;<UI*"/?(
M-)HRK,\34G S(B,\" 1(/#S0]9,9L*^AAQIL=1.,/MMDE2%%R&1^ !>3:V!9
M%'*?'1(**^W+CDX6;=OLGBAQ/B4D^0P$H
M                                         !1?.?K/\V*B?3?5D?XI
M^^8BIP   *'54JYCQ8C5!-KH5E*DI8:[U2XIMW%"U;MLFU(,W#RXE[A& Q:5
M2ZKGV5&YKR[JH]9#L6),*+7LNLN29[9*-ELUON*\.)Y4[5<@HV.(
M
M
M       HOG/UG^;%1/IOJR/\4_?,14X   &M>(^FNNVE'9NZFGUB%V,=B/!C
MX+3OU-.H)4=*6U&3IYCQ4L\I(S&8H[/Z2K*B[H%ZFU+<VI+FD=5'G.(5#[P:
M0I;6<VVDX+P)1MDI6TR ;($
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MP
M    *+YS]9_FQ43Z;ZLC_%/WS$5.   !CNK].S+^+">J9B8%W52D3JZ2XC>M
M;Q*%-J0XC$C-"T+4D\#Q+E 83(=N[#4=%6\0;VCB]4G,RX-/3F^Y*DS6L=SO
M-]Z2$$9YN3#P&8HVP(
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MD(0VA+;:20VDB)*$E@1$7(1$0@[
M                               HOG/UG^;%1/IOJR/\4_?,14X   &I
M-7Q];+O)JK[O9_0V9)PFM*J:0^2/PBDI/!]1>/='@*/+A&K0+5OJ)FD*,U+.
MPPKFI)*18]6*,SFP*3^.PWF?'W<0U&X!%
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M3NVE$DB-"#P]%)X;"V<A /4
M                           !1?.?K/\ -BHGTWU9'^*?OF(J<     K9
MM!1V,R+8SJ^._80UI=B2UMI-YM:-I&E>&8ON8@+(
M
M                                                       %%\Y^
ML_S8J)]-]61_BG[YB*G    UUQAEP8=)5+N9;C&G'+-EJXCL+6T])C+0YZ"3
M;](R(R)Q:2P,TI/ \<!<%#II7 #OZN+3BF>_2>3W>253S/??@X;P\O.#RC<8
MB@
M
M                HOG/UG^;%1/IOJR/\4_?,14X   &,:TO+*JCUU?1L,OW
MEU+3!@G+QZNT>[6ZMUPD[3)"$'Z);3,442;'6VDK.I+5$FOMZ:WF-UN_B1U1
M),:3((]R9)S*2MLU%E5R*+'$!L00
M
M                                          !1?.?K/\V*B?3?5D?X
MI^^8BIP   -?:TO]#6M+(*XL),%-9:E!8G16GRE1[9A!K2;.5M1J,DFK:232
M98BC&=.V>E;?4E4=OK"SU)-CODJH@R:]Z)%1),C2AQ9)CH2I:2,\JUGL!&YQ
M%
M
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MW6E&1'NW$GF3F+$O"(,E
M               !1?.?K/\ -BHGTWU9'^*?OF(J<   ##]?V%I&;HZRLL.Z
M.^K-N!(M"2A:VD*:=<)#9+Q22W5()M)F1X8^,4:_K+6[K[JN1,U=,L)3>HW:
M690N[A#RXQ+<2R]E2C-ERDVZL\,II,\#($;P$4
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MP3#:W4?@+7M4:#Y &;"
M              *+YS]9_FQ43Z;ZLC_%/WS$5.   !C.K[UJF<HF9+48XEC9
M-QGY,XR)AA*&W'R41GL)PS;(F\?P@&&1]4.2M1P]8M4M4O3MA:EI^OM":+O=
MXE&;!24/\ALFM*DDCER;11MD0
M   !765) M9=;-EDHWZE\Y4,TJ-)$XIM39YB\)95& L0
M    %9"H:^!;V=XR2U6-L3"93CBS41(C(-#:$)/8E)8F9D7*9X@+,
M
M    %%\Y^L_S8J)]-]61_BG[YB*G    Q/7]HS#K(E8JE;U!+NI2(,.KD9$Q
MUN95.FMU3B5$24$@U<F/B\8HK8$?6CTVH8M=+4T>KKG4J84Q*4LXI$DT9F6]
MRE.9*3,D@,^$
M
M                           47SGZS_-BHGTWU9'^*?OF(J<   ##N)5?
M7SM.H=L[P]/1($IF;WDE*%+2XSCD)!J+%*LQEAD](^3D,R%P4>G.LRE4]XGB
M+)LJF=)-F*P[#CQT2G6\^9G:VE:3/(KQ'LV -FB
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MU)(299E&?\DDX@.*#5NG-4$]W%8-RW(YD4ADLS;S>/(:FW"2LB/P&:0%T
M                               *+YS]9_FQ43Z;ZLC_ !3]\Q%3@
M8IKFILYS=/:545%C*HYZ+#NMU24%(233C1DA2_1)Q&\SMFK9B0HP>AK=5W1U
M5/*T_(J*^#?/ZAF6,Y;6)IZT](:9:0@S4I2MX25JY"P/Q@C<8B@
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M$D\"(B^^(J-04;BN*VJY?>T\BCHK9"HY.-[AW?HD8-.%N\3;;P_%D1D9>$S
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M14/V%9:;I4=2B5E7(A*:1E-K.>7!*MFS$L=H#8@@
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M#(0                                %%\Y^L_S8J)]-]61_BG[YB*G
M   Q+7UC$AP:^(Y1-:BL+&8F-65TDFB9W^[6LW%+=2I*"2A*MN&/@%&.5NGK
MAV='9L^'>G(U:MQ)2GVE,.+0WX5)1U<LQEX@&QX-? K(Z8=;%9AQ$&9I8CMI
M:;(U'B9DE!$6TQ!)
M
M                              %%\Y^L_P V*B?3?5D?XI^^8BIP   ,
M XLDX[3U44Y+=;"?M8J9=VM.*X!)-2FWFCQ3D6;A);WF."24>.PQ<':JII;-
ME$=7Q!E6*4.)4<%9PLKQ%^ >1!*P/W-H#/1
M
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M??\ Y(__ /;9_P#4 0_UD_P^_P#R1_\ ^VS_ .H A_K)_A]_^2/_ /VV?_4
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MCR"6J+()).MF?*E9)-18E[AF0@D
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M1X&HR+!)J/X6&/A$%R
M                                             "B^<_6?YL5$^F^K
M(_Q3]\Q%3@   :P8OF.&MYJ%K4\>2BFN9ZK:#>,LN26/QS3:%L.[I*E(4@V_
M1V;2\0H\YFI(O$JYT[#TFQ)?K*FS9M["Z<8<CQD(C(61,H-U*%*6X:\N!%L+
MW.0-IB
M
M                     *+YS]9_FQ43Z;ZLC_%/WS$5.
M
M
M       %%\Y^L_S8J(\'O[JC75,G5L#W>;+CAB?+B D?:;Z/Y !]IOH_D 'V
MF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !
M]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0
M ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_
MD 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z
M/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF
M^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]
MIOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0
M?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D
M 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/
MY !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^
MC^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]I
MOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?
M:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D 'VF^C^0 ?:;Z/Y !]IOH_D
E'VF^C^0 ?:;Z/Y !]IOH_D ('_NN;\'/UO\ W?\ J,OO90'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>bc_tsr-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bc_tsr-bw.jpg
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M Q$!_\0 I  !  (" P$!              0%!@<" P@!"0$! 0$
M          $"$   !@$" 04)"0H+!@4$ P$  0(#! 41$@8A,1-4%0=!49'1
M(I)3DQ1AL3*BTF,U)@AQ@4)R0\.%%A<84K(C,W.STW24-C>A8B0T576"PD0E
M5L'CE7;A@[0G$0$! 0$! 0$!            $0%!(3$"$O_:  P# 0 "$0,1
M #\ ]RUE9 ?@,//,$MQ9&:E&9Y,\G[HHE]35G1T^$_&('4U9T=/A/Q@'4U9T
M=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q
M@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9
MT=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/
MQ@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U
M9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A
M/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4
MU9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/
MA/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'
M4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=
M/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@
M'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T
M=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q
M@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9
MT=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/
MQ@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U
M9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A
M/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4
MU9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/
MA/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'4U9T=/A/Q@'
M4U9T=/A/Q@*GV&+KT\T6/;^9QD_YO1G3R\F146U-]&1_Q3]\Q%3@
M
M
M             !1?E/TG^;%1/IOHR/\ BG[YB*G
M
M
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M,MN8RPZN,\ME6HDO-XU(/W2R0@0;FJLWYL:!+:D/USO,3FVU$:F72_!7WCX
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M[X:('8;_ )=O?^_3_>:#1&[/G(3%WVH/6*DHKV[-Q<M:^""92APUFH^\2<Y
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M NYP ;@$4                   !1?E/TG^;%1/IOHR/^*?OF(J<
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MDGD)2TX,\>Z8"SJ:6HHHI0::"Q B$>KF8[:6TFH^Z>DBR?NF G
M           (%O2U5]$*#<1&YD,EI=)ETLIUMGE)_> 3P
M                 %?:T51>)C)MX;<Q$-Y,J,ETM24/(R25XY#,L]T!8
M                             HORGZ3_ #8J)]-]&1_Q3]\Q%3@
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ME/TG^;%1/IOHR/\ BG[YB*G
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M(S(O*]SAW2"TW_O/<E+?;2K]J,,S^OO:TG&>\E+AH;;-I9N<J4(UFM6.4BP
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M42#==6Z2,EDCT$K3PX<. FJRP0
M               %%^4_2?YL5$^F^C(_XI^^8BIP
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M1?E/TG^;%1/IOHR/^*?OF(J<
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M*5$:5$1I/@9'Q(R "(DD24EA)<"(N0B =2XL5UU+[C#:WD? <4A)J+[AF62
M=JDDHC2HB-)\#(^)&0 E*4I)*2)*2X$1<"(@'Q*$(SH22=1FI6"QDSY3/W0'
M(                                                  47Y3])_FQ
M43Z;Z,C_ (I^^8BIP
M
M                                       HORGZ3_-BHGTWT9'_ !3]
M\Q%3@
M
M                          !1?E/TG^;%1/IOHR/^*?OF(J<
MQ_>>Y3VI0NVR&$OO<ZS&92ZOFF2<DN):2IUS!Z$)-65'@!649[THJVZD[F=A
MV"4ID64.1&<>,DFK4Y[/I=3P;1P)!DKD%'7LBWWQN"/7W5JNF*CG1D2>9A)D
M^UH-Y!+0E1N+-&2SA7#[@"GD=H&ZE4\K?,"#!=V1$?<1[,HW>LGXD=XV'7T+
MR3:>*34EM2?@E\(!;3=Q[NM+NUK-FQZ\X]&A@I4BR-T_:9$AHGTM,\RI))(D
M&G4M>>*O@\ &0;4W"QNO;E=N&,V;+<YHG#94>30XDS0M&<%G2I)EG'$07(
M
M                                                      #&][;G
M=VM5,2XS"'YDV9'KHO/K-J,V[*5I)Q]PB4:6T\JC(O< =.UVMY5%;-9W0;%H
M\SSDF)(@N.*>?-U;CJF30^223HRE#?EXTXSC HZMG;HN[RVW!5WM>S72:AR*
M2([+IOJ2F6QSQ)<<X)4HB,LZ"Q]WE 5\_<V^*"QJY-]#K.H;6Q9JT18KCRIS
M*I:C0TM3B\-K(L96E*"]P!]G;IW?83;P]HQ8"ZW;KAQI)SS>-Z7*;;2\ZTSS
M9I)O2E1)U+)65>X RS;US'W%1U][%2:&+".W(2VKBI'.)(S29EW4GP,01/RG
MZ3_-BHGTWT9'_%/WS$5.         4NZIT&!3/.6E8_;5CADU,BQV"EF3*\Z
MEK:,\J0G'E8(S]P!@&S?9V9]G8;7K[']F:ZLW"KY#;JDR)BEZO\ @67S-9H4
MUDC).$J,R(A1PK*^CE;QH9G9]22*EN(IX[^7[(]71515-*23#B'4MDZX:S2:
M<)/3C.0%<SUI![/)G94BJFN;H-4FMC*..[[&Y'DR%J3*]I))MDV3:\GE6K46
M, C(H]DO86X=RM3:V=+B6BXTVE<@QG9?M"T16V%L&;25$A9*;X:S(L'D%9%V
M<T<W;FR:BHL4DB>TTMV4V6#T.R75OJ1DLEY)KT\ T92(   @JJT*4:O:9)9/
M."=41<0'SJI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4
MCI4GUR@#JI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4C
MI4GUR@#JI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI
M4GUR@#JI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI4
MGUR@#JI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI4G
MUR@#JI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI4GU
MR@#JI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI4GUR
M@#JI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI4GUR@
M#JI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI4GUR@#
MJI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI4GUR@#J
MI'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI4GUR@#JI
M'2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI4GUR@#JI'
M2I/KE '52.E2?7* .JD=*D^N4 =5(Z5)]<H ZJ1TJ3ZY0!U4CI4GUR@#JI'2
MI/KE '52.E2?7* .JD=*D^N4 YM5R&G$N%(?4:3SI6X:DG]T@$P  8_O&QJJ
MZD=7>UCUI2NGS<]IB.4M+;.DUFZZWG/-IT\5)(S+@?N@,1[/B*)/M9^WX]A&
M[."AM.P8TY+RE*E$:EK5";<U.DR;>GACRE?!X"C[LR\9?W[NE\X-BQ'O78*J
MY^1 E,-**)")#FI;C9$C"DF1:\9[@"$QNAJ^W4U;;AK+=B%5/K:H*HJR8I'.
MJ+FSFR%DWI-9DHR;3R-ED_A& D1;.3LB;O"KDU<Z7(MK!ZUHW(L9V0U*5-9;
M3S1.-I4E"D+1A7.&GAQY &9;&I9&W-H4M)+P4N'%;1())ZB)TRU+(C+E(E&9
M9$'/\I^D_P V*B?3?1D?\4_?,14X   &"NWW:/;*7^KNVXU9%(S)J7?R%)6X
M1'C/L\4EJ3_XED*.!3>V*#EZ95T-NT7'V>OD28CY^X2I*5(\)D RVELGK:N:
MFR8$BLD+-2784LDDZA2%&D^*%*2:3QE*B/B7$06 #@ZTV\VMEU)+:<2:%I/D
M-*BP9& X18L>#%8A0VDLQ(S:&6&4%A*&VTDE*2+N$1%@@'<
M      #56_.W.EV%N%S;T^KE2I#;3;QO,J;)!DZ62+RC(^ L&,_O3[8_Z%/\
M]GY01#]Z?;'_ $*?Y[/R@@?O3[8_Z%/\]GY00/WI]L?]"G^>S\H('[T^V/\
MH4_SV?E! _>GVQ_T*?Y[/R@@?O3[8_Z%/\]GY00/WI]L?]"G^>S\H('[T^V/
M^A3_ #V?E! _>GVQ_P!"G^>S\H(,CV/V\4>^MQQMMP:J7&D24NK2\\IHT))E
M!K/.E6>.,!%;8$
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MW1MW=U8W<[7M(UM5N_ E0W4O(S_!5I,]*B[J58,NZ#*V
M
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M[0*TK?9MU%N(/#6J,O+C9GR)=;5A;:O]U:2,&61
M
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M^8OQ@&BX]+'\Q?C -%QZ6/YB_& :+CTL?S%^, T7'I8_F+\8!HN/2Q_,7\H
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MH22$$24I+"4EP(B+N$ ^@             #QO]H__4R1_<XO\4QK$:E
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MW//5XP'Z+1/^58_HT?Q2&5=P
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MJ"@             _1R)_P JQ_1H_BD,J[@
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M[P"P(R,B,CR1\A@               \;_:/_ -3)']SB_P 4QK$:E
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M@#K)WH,CS4_* .LG>@R/-3\H ZR=Z#(\U/R@#K)WH,CS4_* .LG>@R/-3\H
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MI0>DEH,CP R*LK85/71:JN:)F##:2Q':+)Z4(+!<3XF??,^402P
M    !XW^T?\ ZF2/[G%_BF-8C4H            #+.S3_.<+^AD?U8J-Y H
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M7)]\O? >GD?S;?\ 1H_BD*CZ"@           -G=FGT5,_O'_D2,Z8S810
M                1:ZRA6L;VRO>)^-SCK).$1D1K8<4TX7E$7(M"D@)62SC
MN]X R6<=T   %%^4_2?YL5$^F^C(_P"*?OF(J<   #&MZ44JWAPYM9-:K[JF
MDIGU\J0G5'UI0IM;;Q<#YM:%J2HR/)<H#%V&-S[KMZ@MUV-'&K*N6U8-0ZE]
M;[\J6P1\UDW,:4$9ZL$1F?(*-FB                        #QO\ :/\
M]3)']SB_Q3&L1J4            !EG9I_G.%_0R/ZL5&\@4
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M7O@/3R/YMO\ HT?Q2%1]!0           &SNS3Z*F?WC_P B1G3&;"*
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M^> *VH(   ZF9,>22SCNH>)M:FG#;42M+B#PI)X,\*(^4@':
M       #QO\ :/\ ]3)']SB_Q3&L1J4            !EG9I_G.%_0R/ZL5&
M\@4             ;VIOH>O_ +LS_5I&%3@     !H[M0^REV4=I?/3DP/U<
MW$YE76M0E+)+6?=>8QS:_=/"5'_"!:\KW'8E]H_[.-@]N'L]L9%G1H/6]+I=
M3J%H3TNO7KSP+B>EQ)?P@6ULOLQ^W=6RC:J>UBI.NDEAM5Y6(4Y'R7 S>C&9
MN(]TVS7^*0$>M=L[LVSO.K;N=JVL:WK'.23#=2ZDC_@J(N*5%W4J(C(&5R
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M_P 8ME#W/IC+D&X9&V2^Z3>K!8R%&QA  47Y3])_FQ43Z;Z,C_BG[YB*G
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M:\X@#K.OZ4UYQ '6=?TIKSB >/OM%NM.]ICYMK)9>Q1%92>2PI*L>\-8C5
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MR/\ BG[YB*G    JZ>AATCMF[$4XI5M,78R2<42B)YQ"&S)."+"<-EP 6@
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M!8SR"">                       #QO]H__4R1_<XO\4QK$:E
M    99V:?YSA?T,C^K%1O(%             &]J;Z'K_ .[,_P!6D85.
M             8YO'8.S>T"M.IWE2Q;B%QYLI",N-F?*;3J<+;/W4*(P'D+M
M*^PI,AO+N^Q^Z43K2N=:I;-SFW4*2>2YB6@BXD?P2<27XX-5IO=/:GVY;3B1
MNS_M<BRY,:"\3\4K=LRF%I0:,M2RSSR,*/B9K_& W*[:3>%#?DE$2034L_\
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MM.A)(4G4M6>)\@"_VEN%G=>VZ[<+#9LIG-$M3)GDT.),T+1GAG2I)ED070
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MT?Q2%1]!0           &SNS3Z*E_P!X_P#(D9TQFPB@
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M9V:?YSA?T,C^K%1O(%             &]J;Z'K_[LS_5I&%3@
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MF_EG<>1'ELIDQ'4/QU\4NM*):#^^0K+FKD^^7O@/3R/YMO\ HT?Q2%1]!0
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M]#(_JQ4;R!0            !O:F^AZ_^[,_U:1A4X
M&B/M3?Y1IO\ N7YAP7$>5!0        (S+B1X,!CMYLC;][J==8]EF*_]5&P
MA1G_ +R?@J\&?=!<U@DC:F\MG/*G44A<F*7%2XN3,R^<9/.?]HBW-6U-VIL.
M8C[AC&PX1D1RHY&:<D?'4V?$O_#X I_+VQ3VM9>5<2VII;4ZLDMI-B4PK4VK
M26E1=PR-)D9&1\2,:8304           !L[LT^BIG]X_\B1G3&;"*
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M@#F[?T['JU?* .;M_3L>K5\H YNW].QZM7R@#F[?T['JU?* .;M_3L>K5\H
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MAU\=$2OCM18C?!MAA"6FTYX\$I(B(!W@
M
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M'9QJ]Z+81H\V1[%"M)$1QJ"]),S2EM#BL'E1D9)RDB5C@8HRX0
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M@,,K-W[]1+KY-S,JETSMZ]MZ:F-&>3(2\VZXRV9:G3+#BD%[J241X/B*-M"
M                                   "CW/N:-MN(VKFE3+::OV>IJVC
M(GI4@RX)+/!*2Y7%GY*$\3[QAKRTHU[;J-H.6K[<B0_NMFTOI+7!A,V:3QFH
ML_!;0XI"2,_</@*,A?>CEVN^TDXA#=?MMWK*0HR)#27):%MI<4?!/!"U\>YQ
M ?:12MY[JC[S-/,[?JV'XNW"7Y+TM4DTD_+-/ TM&2"0T2BRHLKX9(!4[[*R
MCO56Z)EM'NMK1;6*_%HF6R8<6ZMPFF5-/MK6;ZVE+U\V9$E6#SR -IB
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M6J9'LS\7_AFF^:E(YMW^302=6DC/@K&4^X(J]
M               %%^4_2?YL5$^F^C(_XI^^8BIP   ,;WFY&9@0I,BBE7ZH
MTUF1&CP4I4\R^R2EH>+*T8))EIY?PL&6#,!@L.9MR3ONMG3=D6];>6;ZEQY$
MS0W$]H;;\I\V^?-!N)07*2=6.)<14;>$4
M        !3W>U-N;E-E5]61[!4<E$P<A!+-!+QJQWLX(!PA[/VM JY5+#J(S
M53-/5*ADV1M.*,B+*DGDC/R2\ ! VAMBKK951 JH[%;-(TS&$HR3Q*+29.&>
M35P/'$P$:M[/]E4\YJRJZ.)$GL&9LR&FR2M)J(TG@_N&9 .4/8>S8%F5S"I(
MC%DE1N(?0T1:%JY5(3\%*C[Z2(P&1
M              (=I4UMW"776\5N9!=-)N1WDDM"C09*3DC[QED!6TVR=I[>
MEG/I*>-!F*0;1O,(TJ-"C(S3GO&9$ Y5NS=JT]BY;5=1%B6+NK5(:;)*BU_"
MT]Q.>[IQD!!D]FNPIDAV7*V]"=DOK4Z\ZIHM2EK,U*4?NF9BT9')A1)<-VOE
M,I=A/MJ8>8664*:6G2I)EWC(\"#L99:C,MQV$$VPTE+;3:2PE*$E@B(N\1$
MY@                                     "B_*?I/\ -BHGTWT9'_%/
MWS$5.   !0[JF7<6+$;V]*K8UG*DI8:*WYWFG<H6HT-DTI*C</3DB[Q& Q27
M4;QL;.B<WY;TT.KAV3$F''K4/(=DSFR6;+6N0L\9XGA/%7(*-DB
M
M
M      *+\I^D_P V*B?3?1D?\4_?,14X   &M>T?;7MMI1V;NYI]8A=C'8CP
M8^%IY]33J"5'2EM1DZ>H\J6>DD:C,4<G]I5E1=T"]S;EN;4ES2.JCSG$*A]8
M-(4MK6;;2<+P2C;)2N)D V0(
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MY_"Y "-NW;$R?'JXEO$?L91.''BM/(6XLF342\)(S/R30KS3[P"Y
M                                                     47Y3])_
MFQ43Z;Z,C_BG[YB*G    QW=^W9E_%A/5,Q,"[JI2)U=)<1SK7.)0IM2'$9(
MS0M"U)/!Y+E 89).^G[AHH':'>44-,6<S+@5%2IY4J5,:R3.OGSU)02CSP3[
MAF*-JB
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M<I$22P1%_P#4-5L@0
M                 47Y3])_FQ43Z;Z,C_BG[YB*G    U+NXM[G>3>OE6R=
MC93[%^JI-<_H_"]I_P#48Q\+FBQ@4=/9$C8/6VXNH_9CEE8?^W')U=8^S>S,
MZO\ F?Y;'.<YGW<AJ-P"*
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M2+!JP6>^ [V6&8Z.;8;2TWDU:4)))94>3/!=TS =@
M                                         "B_*?I/\V*B?3?1D?\
M%/WS$5.     5<W;E!8SXMI-KH[UG#6EV+,4VGGT+1R867E8]S. %H
M
M
M         "B_*?I/\V*B?3?1D?\ %/WS$5.   !KKMAEP8=)5+N9;C&W'+-E
MJXCL+6T])C+0YY"3;\HR(R)Q:2P9I2>#S@7!0[:5V =?5Q;<4SUZ3R>KR2J>
M9\]^#CG#T^<'J-QB*
M
M                               "B_*?I/\ -BHGTWT9'_%/WS$5.
M!C&]+RRJH]=7T;#+]Y=2TP8)R\^SM'S:W5NN$GB9(0@_)+B9BBB38[VVE9U)
M;HDU]O36\QNMY^)'5$DQI,@CYDR3J4E;9J+2KD46<@-B"
M
M
M*+\I^D_S8J)]-]&1_P 4_?,14X   &OMZ7^QK6ED%<6$F"FLM2@L3HK3Y2H]
MLP@UI-G2VHU&235Q))I,LBC&=NV>U;?<E4=OO"SW)-CODJH@R:]Z)%1),C2A
MQ9)CH2I:2,]*UGP!&YQ%
M
M                                  !1?E/TG^;%1/IOHR/^*?OF(J<
M  #67:1:;B9O-M,U^VW["+$M&9+$MJ0RA+SIQI"39TJ/*,$K.M>$\/=%P3>N
M.T>[L:J,UMQS;L)J8W(LYS\R))2N(V2N<9)MO4K*\E@RY &P!
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MS9ITJSRYX"P65=N^%&VE"W'N>SKFTR,DJ7!6X<-Q9K42$LDX7.*/!<4XSDC
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M)'J<YHBSW]?DX[X@B;YW!,VQMJ5<0&6I$QIR,RRT^:DM&J3(;8RHT\<%KSP
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MGEW;EI4W$1$'<=(\ABQC,N&ZRI+R.<:>:49$>AQ/$B462Y#$&3
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M$%6>QHLV;>[FWG*BO0(MZY$9KHDI'-O^S0&C;)U:#XIYQ2U&E*N)$ S@0
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M/J<7J2AJ,DTH0T7X*<J-2B+E4>0%H
M                                        "B_*?I/\V*B?3?1D?\4_
M?,14X   &)[_ +1F'61*Q5*WN"7=2D08=7(T)CK<TJ=-;JG$J(DH)!JY,][O
MBBM@1]Z/3:ABUVM31ZNN=2IA3$I2SBD231J9;YE*=24F9) 9\(
M
M
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M;;27(635@N)\" 5U!N[;.Z4NGM^S8GFSCGFVE8<01\AFA1$HB/N'C "Z
M      '6Z^RSHYYQ+?.*)MO6HDZEGR)+/*9XY $9%O6N6SM&B0D[5EA,IV-@
M]265J-"5YQC!F6.4!-   !!C7-5-L9E3%EM/65?S9S8J%9<:YTM2-1>Z0"<
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M<<<EU]G8VJ]P-M-.V%3=(:2XRLS4E3L=32$I4RM623I4HBQW &>"
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MLCIAUL5F'$09FEB.VEILC4>3,DH(BXF()(
M
M                                                HORGZ3_-BHGT
MWT9'_%/WS$5.   !@':R3CM/513DMUL)^UBIEW:TY7 ))J4V\T>4Z%FX26^<
MSA)*// Q<'*JII;-E$=7V@RK%*'$J."LX6EXB_ /0@E8/W.(#/1
M
M
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MM528[R?9SD+0L]+39.,$ALN<YQ2L=_E!&]Q%
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MDL'WA%
M                            !1?E/TG^;%1/IOHR/^*?OF(J<   #6#%
M\QV:WFX6MSQY**:YGJMH-XRRY)8_EFFT+8=YI*E(4@V_)X<2[PHZYFY(O:5<
M[=A[38DOUE39LV]A=.,.1XR$1D+(F4&ZE"E+<->G!%P+W.0-IB
M                             .E^'$DN,.R&&WG8R^=C+<0E2FW#2:=2
M#,O)/!F62[@#N   !T(A0VY;D]$=M,YY"6W9)(23JVVS,TI4K&3(LG@@'>
M
M                           HORGZ3_-BHGTWT9'_ !3]\Q%3@
M
M
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M9OF_B 'UF^;^( ?6;YOX@!]9OF_B 'UF^;^( ?6;YOX@!]9OF_B 'UF^;^(
J?6;YOX@!]9OF_B 'UF^;^( ?6;YOX@"!_P"ZZOP=?M?^[_S&GWM(#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ic_chairper-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ic_chairper-bw.jpg
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M%!04%!04%/_  !$( !8 #0,!$0 "$0$#$0'_Q !E  $  P
M   & P0% 0$! 0                   0(0  (" 00! P4!          (#
M 04$$1(3!P8A% @ ,2(R0A41 0 # 0                 !$2%!_]H # ,!
M  (1 Q$ /P %\PO*?,+/NBZI+O(R%4U1P+I*^2(<<<<T ?, _J1,(BDC^_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ic_member-bw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ic_member-bw.jpg
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M%!04%!04%/_  !$( !8 #0,!$0 "$0$#$0'_Q !C   # 0
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8Z;!-NDX^KNUM(@D@"@[FI=2KA,?(?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>lg_applieddna-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_applieddna-4c.jpg
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M%!04%!04%!04_\  $0@ 10'% P$1  (1 0,1 ?_$ +T  0 " 04!
M       '" 8" P0%"0$! 0 # 0$! 0             !!08$ @,'$  ! P,#
M @(&!08&#PD    ! @,$ !$%$@8'(0@Q$T%182(4%7&!0B,),E)BDQ87<C/3
M=5<8D:*RTD-3LR1$E+155C<XP9)S=(1E-D<9$0$  0," 0D&! 4#!0
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M!-[=0DJ]%Z"Y?=-$VO+X%WN-W!OY<SCUO1'' DK1D$D?"EHJ\'"Z4I%O&]O
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M-J[&OQS5IV3YOC<MSI\$4Z]L)'PW>DQGU(:QFV]NN27/R8SB7&G;^K2YIO\
M55_8Q\.[S7ZJ9_W<G^BCOY&9:_\ 335'9.OX:LV/.')P0ES]U$7RUBZ%B#**
M5#U@A-B/HKN]*QO[B>^%?ZMD_P!OX3Y.+DNX7?>&@/Y7,<:X['8J,+R)TR*^
MQ';OX:G%@)%_IKS5MF+3&LY$]\/=&Z954Z1C^_R4<[@N9'^:]ZM9\X^+C8./
MB(Q\)B&@MH4A"U.*<.H!5U*6;:O1:LA?FF:YX)F:>C7G:NS%441Q1$3TZ<RP
M';'F.0>*=BOIB;"5FF]QOIRB'YL-]82UY8;;\LH38A21KO?TU?[?MUJY:X[E
MW@F>B)CF46?N-VW=X+=KCB.G2>?N39^_/DW^BF+_ *A*_O:LO2L;[\]\*[U;
M)_M_"?(_?GR;_11%_P!0E?WM/2L;[\]\'JV3_;^$^1^_/DP__5$7_4)7][3T
MK&^_/?!ZMD_V_A/DYJ.XOF1M"6V^. E" $I2F-.  '0  "OGZ+B?>\:7N-YR
M_L>_R<QON&YA5BY$P\<+\YJ2PRA?DS WI<;=4H%)&HJ]Q-E#H/ ]2*^<[-B<
M41];HGY>Q[C>,K@F?H3KK'7V]BT%8]KB@P+F[_DYOW^8,G_LKE!5;\-7IM3?
MW\X0/\@[07FH*N]_W_3Y)'_N^/\ [I=!D?97_P!..T?_ %G^UNT$_P! H% H
M% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H,&WSPUQ=R
M4@C>VUH&6?\ 1,<:\N6.EA9]K0YT_A4%5^0?PY=I9 .2N-MR2<+)-M&/RP^,
MB7]-G4!+J1](705-Y-[4^:>*H\K*9W!B9MV(%+=S>-=1(BI;!L%+%TK;!_30
M*#']A=P',/&A:;VENV=&@,JUIQK[GQ4(]+6\A_6@#Z *C1.K7R9S=ROSEDX[
M>[<H]/;"PF!@H*"U#2X;)'EQF[ZEG\Y6I7MJ4+0=M?8OD9LJ)O;FV&8F.:4'
MH.SW/X]\BRDJFV_(;O\ X'\H_:L.A#T-:::8:0RRA+3+:0AMM "4I2D6  '0
M #PH-= H% H% H%!H>99D-+8D-I=8=24.-. *0I*NA!!Z$&@XN/Q&)Q*5HQ4
M"/!0X07$Q64,A1 L"0@"]J#FT'&G8^!DV/A<E%9F1B0HLR&TNMZAX'2L$7%!
MJAPH>/CHB0([46*W?0PPA+3:;FYLE( '6@WZ!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01%S#W)\6<(NL0-XY!YS.RFOB(^'Q
M[7Q$HLDE(6JY2A"24D K6+^B@IWR'^(UO#)AR'QKMV/@HY ",CDR)TOQ\4M)
MTM)Z?G:Z"KNY-_<L<QY9J/G\OE=TY%Y9^%QR2X^D$F]FH[0TCJ?LHH)TXJ["
MN6-ZJ9G[U*-E8)1NM,M/G9)2;F^F,D@)/_BK3]%!?'B'MJXIX8:;?VSB1+W"
M$Z7MPY&TB>HD65H40$M ^II*?;>@E[PH% H% H% H% H% H% H% H% H% H%
M H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%!Y8]_;>VCSP5
M,R9R<NK'04YAI<=M49"=!\M<=?G)4HE%M2%(2-7VNO0,'XKC]I3,R,>3,CNV
M<ZK3YB1!BP<:A5^NLQ9DJ0I/\$)-!Z7\*_N"^3H_<E\C^$\O[SY7H^.T7_TC
67_G'C_C:"5Q;T4"@4"@4"@4"@4'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">PRE 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Applied DNA Sciences, Inc<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000744452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance Disclosure, Table</a></td>
<td class="text"><table style="width:456pt;height:95.56pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <tr style="line-height:9pt;height:31.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:left;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Summary <br/> Compensation <br/> Table Total <br/> for PEO</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(1)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Compensation <br/> Actually Paid <br/> to PEO</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(2)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Average <br/> Summary <br/> Compensation <br/> Table Total <br/> for Non-PEO <br/> NEOs</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(3)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Average <br/> Compensation <br/> Actually Paid <br/> to Non-PEO <br/> NEOs</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(4)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Value of Initial <br/> Fixed $100 <br/> Investment Based On</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(6)</span><span style="letter-spacing:-0.16pt;">: </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Net (Loss) <br/> (thousands)</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(6)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"> <span style="letter-spacing:-0.16pt;">Revenues <br/> (thousands)</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(7)</span> </div> </td> <td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td> </tr> <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:60pt;"> <div style="white-space:nowrap;"> <span style="letter-spacing:-0.16pt;">Year</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;text-align:center;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Total Shareholder <br/> Return</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(5)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;">&#8203;</td> </tr> <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="padding:3.25pt 0pt 2.5pt 0pt; width:60pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:-0.16pt;">(a) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(b) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(c) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(d) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(e) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(f) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(g) </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"> <div style="white-space:nowrap; text-align:center;"> <span style="letter-spacing:-0.16pt;">(h) </span> </div> </td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> <tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;"> <td style="padding:3.27pt 0pt 1.79pt 0pt; width:60pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.18pt;">2024 </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">387,623</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">387,623</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">297,352</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">297,352</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:25.02pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">107.08</td> <td style="padding:0pt;padding-left:25.02pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(7,088<span style="position:absolute;">)</span></td> <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:7.85pt;width:0pt;">&#8203;</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">3,431</td> <td style="padding:0pt;padding-left:7.85pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> <tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;"> <td style="padding:3.52pt 0pt 1.79pt 0pt; width:60pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.18pt;">2023 </span> </div> </td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">468,000</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">468,000</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">514,917</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">308,333</td> <td style="padding:0pt;padding-left:6.695pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:25.02pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">107.08</td> <td style="padding:0pt;padding-left:25.02pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(10,023<span style="position:absolute;">)</span></td> <td style="padding:0pt;padding-left:6.355pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt; width:2.64pt;">&#8203;</td> <td style="padding:0pt;padding-left:7.85pt;width:0pt;">&#8203;</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;">13,367</td> <td style="padding:0pt;padding-left:7.85pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> </table>
        <div style="margin-top:14.01pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;"> <span style="letter-spacing:0.2pt;">(1)</span> <br/> </div>
        <div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">  <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (b)&#160;are the amounts of total compensation reported for the principal executive officer (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">PEO</span><span style="letter-spacing:0.2pt;">&#8221;), Dr.&#160;Hayward (our Chairman, Chief Executive Officer and President), for each corresponding year in the &#8220;Total&#8221; column of the Summary Compensation Table. Refer to &#8220;Executive Compensation&#8201;&#8212;&#8201;Executive Compensation Tables&#8201;&#8212;&#8201;Summary Compensation Table.&#8221; </span> </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;"> <span style="letter-spacing:0.2pt;">(2)</span> <br/> </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">

          <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (c)&#160;represent the amount of &#8220;compensation actually paid&#8221; to Dr.&#160;Hayward, as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr.&#160;Hayward during the applicable year. In accordance with the requirements of Item&#160;402(v) of Regulation&#160;S-K, the following adjustments were made to Dr.&#160;Hayward&#8217;s total compensation for each year to determine the compensation actually paid which is reported above: </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div><table style="width:436pt;height:74.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:183.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:-0.16pt;">Year </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Reported <br/> Summary <br/> Compensation <br/> Table Total for <br/> PEO </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Reported <br/> Value of Equity <br/> Awards</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(a)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Equity <br/> Award <br/> Adjustments</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(b)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Compensation <br/> Actually Paid to <br/> PEO </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.25pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2024 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">387,623</td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-1">&#160;&#160;&#160;&#8212;</span></td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-2">&#160;&#160;&#160;&#8212;</span></td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">387,623</td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.5pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2023 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">468,000</td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-4">&#8212;</span></td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-5">&#8212;</span></td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">468,000</td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> </table>
        <div style="margin-left:20pt; margin-top:12.3pt; width:436pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-left:20pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(a)</span>
          <br/>
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">

          <span style="letter-spacing:0.2pt;">The grant date fair value of equity awards represents the total of the amounts reported in the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns in the Summary Compensation Table for the applicable year. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(b)</span>
          <br/>
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">

          <span style="letter-spacing:0.2pt;">There was no equity award adjustment for each of the applicable&#160;years shown above, as all equity awards granted were fully vested on the date of grant. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"> <span style="letter-spacing:0.2pt;">(3)</span> <br/> </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">

          <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (d)&#160;represent the average of the amounts reported for the Company&#8217;s named executive officers as a group (excluding Dr.&#160;Hayward, who has served as our Chairman, Chief Executive Officer and President) in the &#8220;Total&#8221; column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers (excluding Dr.&#160;Hayward) included for purposes of calculating the average amounts in each applicable year are as follows: (i)&#160;for 2024 and 2023, Beth M. Jantzen, Clay Shorrock and Judith Murrah. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"> <span style="letter-spacing:0.2pt;">(4)</span> <br/> </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">

          <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (e)&#160;represent the average amount of &#8220;compensation actually paid&#8221; to the named executive officers as a group (excluding Dr.&#160;Hayward), as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the named executive officers as a group (excluding Dr.&#160;Hayward) during the applicable year. In accordance with the requirements of Item&#160;402(v) of Regulation&#160;S-K, the following adjustments were made to average total compensation for the named executive officers as a group (excluding Dr.&#160;Hayward) for each year to determine the compensation actually paid, using the same methodology described above in Note 3: </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:436pt;height:83.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:170.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:-0.16pt;">Year </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average <br/> Reported <br/> Summary <br/> Compensation <br/> Table Total for <br/> Non-PEO NEOs </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average <br/> Reported <br/> Value of Equity <br/> Awards </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average Equity <br/> Award <br/> Adjustments</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(a)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average <br/> Compensation <br/> Actually Paid to <br/> Non-PEO NEOs </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.25pt 0pt 1.5pt 0pt; width:170.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2024 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">297,352</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-6">&#8212;</span></td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-3">&#160;&#160;&#160;&#8212;</span></td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">297,352</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2023 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">514,917</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">206,583</td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-7">&#8212;</span></td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">308,333</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> </table>
        <div style="margin-left:20pt; margin-top:12.3pt; width:436pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-left:20pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(a)</span>
          <br/>
        </div>
        <div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">

          <span style="letter-spacing:0.2pt;">There was no equity award adjustment for each of the applicable&#160;years shown above, as all equity awards granted were fully vested on the date of grant. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(5)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">

          <span style="letter-spacing:0.2pt;">Cumulative total shareholder return (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">TSR</span><span style="letter-spacing:0.2pt;">&#8221;) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company&#8217;s share price at the end and the beginning of the measurement period by the Company&#8217;s share price at the beginning of the measurement period. No dividends were paid on stock awards or Options in either of fiscal 2024 or 2023. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(6)</span>
          <br/>
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">

          <span style="letter-spacing:0.2pt;">The dollar amounts reported represent the amount of net income reflected in the Company&#8217;s audited financial statements for the applicable year. </span>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"> <span style="letter-spacing:0.2pt;">(7)</span> <br/> </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">

          <span style="letter-spacing:0.2pt;">The dollar amounts reported represent the amount of consolidated revenues reflected in the Company&#8217;s audited financial statements for the applicable year. </span>
        </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CoSelectedMeasureName', window );">Company Selected Measure Name</a></td>
<td class="text">Revenues<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote</a></td>
<td class="text"><div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;"> <span style="letter-spacing:0.2pt;">(1)</span> <br/> </div><div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">  <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (b)&#160;are the amounts of total compensation reported for the principal executive officer (&#8220;</span><span style="font-style:italic;letter-spacing:0.2pt;">PEO</span><span style="letter-spacing:0.2pt;">&#8221;), Dr.&#160;Hayward (our Chairman, Chief Executive Officer and President), for each corresponding year in the &#8220;Total&#8221; column of the Summary Compensation Table. Refer to &#8220;Executive Compensation&#8201;&#8212;&#8201;Executive Compensation Tables&#8201;&#8212;&#8201;Summary Compensation Table.&#8221; </span> </div><div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"> <span style="letter-spacing:0.2pt;">(3)</span> <br/> </div><div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">

          <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (d)&#160;represent the average of the amounts reported for the Company&#8217;s named executive officers as a group (excluding Dr.&#160;Hayward, who has served as our Chairman, Chief Executive Officer and President) in the &#8220;Total&#8221; column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers (excluding Dr.&#160;Hayward) included for purposes of calculating the average amounts in each applicable year are as follows: (i)&#160;for 2024 and 2023, Beth M. Jantzen, Clay Shorrock and Judith Murrah. </span>
        </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">$ 387,623<span></span>
</td>
<td class="nump">$ 468,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="nump">$ 387,623<span></span>
</td>
<td class="nump">468,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToPeoCompFnTextBlock', window );">Adjustment To PEO Compensation, Footnote</a></td>
<td class="text"><div style=" float:left; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;"> <span style="letter-spacing:0.2pt;">(2)</span> <br/> </div><div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;">

          <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (c)&#160;represent the amount of &#8220;compensation actually paid&#8221; to Dr.&#160;Hayward, as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr.&#160;Hayward during the applicable year. In accordance with the requirements of Item&#160;402(v) of Regulation&#160;S-K, the following adjustments were made to Dr.&#160;Hayward&#8217;s total compensation for each year to determine the compensation actually paid which is reported above: </span>
        </div><div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div><table style="width:436pt;height:74.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:183.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:-0.16pt;">Year </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Reported <br/> Summary <br/> Compensation <br/> Table Total for <br/> PEO </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Reported <br/> Value of Equity <br/> Awards</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(a)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Equity <br/> Award <br/> Adjustments</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(b)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Compensation <br/> Actually Paid to <br/> PEO </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.25pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2024 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">387,623</td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-1">&#160;&#160;&#160;&#8212;</span></td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-2">&#160;&#160;&#160;&#8212;</span></td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">387,623</td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.5pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2023 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">468,000</td> <td style="padding:0pt;padding-left:6.005pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-4">&#8212;</span></td> <td style="padding:0pt;padding-left:13.565pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-5">&#8212;</span></td> <td style="padding:0pt;padding-left:11.535pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">468,000</td> <td style="padding:0pt;padding-left:8.27pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> </table><div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div><div style=" float:left; margin-left:20pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(a)</span>
          <br/>
        </div><div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">

          <span style="letter-spacing:0.2pt;">The grant date fair value of equity awards represents the total of the amounts reported in the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns in the Summary Compensation Table for the applicable year. </span>
        </div><div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div><div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(b)</span>
          <br/>
        </div><div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">

          <span style="letter-spacing:0.2pt;">There was no equity award adjustment for each of the applicable&#160;years shown above, as all equity awards granted were fully vested on the date of grant. </span>
        </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="nump">$ 297,352<span></span>
</td>
<td class="nump">514,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="nump">$ 297,352<span></span>
</td>
<td class="nump">308,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToNonPeoNeoCompFnTextBlock', window );">Adjustment to Non-PEO NEO Compensation Footnote</a></td>
<td class="text"><div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"> <span style="letter-spacing:0.2pt;">(4)</span> <br/> </div><div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">

          <span style="letter-spacing:0.2pt;">The dollar amounts reported in column (e)&#160;represent the average amount of &#8220;compensation actually paid&#8221; to the named executive officers as a group (excluding Dr.&#160;Hayward), as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the named executive officers as a group (excluding Dr.&#160;Hayward) during the applicable year. In accordance with the requirements of Item&#160;402(v) of Regulation&#160;S-K, the following adjustments were made to average total compensation for the named executive officers as a group (excluding Dr.&#160;Hayward) for each year to determine the compensation actually paid, using the same methodology described above in Note 3: </span>
        </div><div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div><table style="width:436pt;height:83.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"> <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:170.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:-0.16pt;">Year </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average <br/> Reported <br/> Summary <br/> Compensation <br/> Table Total for <br/> Non-PEO NEOs </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average <br/> Reported <br/> Value of Equity <br/> Awards </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average Equity <br/> Award <br/> Adjustments</span><span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;">(a)</span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td> <td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"> <div style="text-align:center;"> <span style="letter-spacing:-0.16pt;">Average <br/> Compensation <br/> Actually Paid to <br/> Non-PEO NEOs </span> </div> </td> <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.25pt 0pt 1.5pt 0pt; width:170.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2024 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">297,352</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-6">&#8212;</span></td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-3">&#160;&#160;&#160;&#8212;</span></td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">297,352</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"> <td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.85pt;text-align:left;"> <div style="white-space:nowrap;"> <span style="letter-spacing:0.2pt;">2023 </span> </div> </td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">514,917</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">206,583</td> <td style="padding:0pt;padding-left:7.21pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"><span style="-sec-ix-hidden: hidden-fact-7">&#8212;</span></td> <td style="padding:0pt;padding-left:12.765pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt; width:6pt;">&#8203;</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td> <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">308,333</td> <td style="padding:0pt;padding-left:9.77pt;width:0pt;">&#8203;</td> <td style="padding:0pt; width:0pt;">&#8203;</td> </tr> </table><div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div><div style=" float:left; margin-left:20pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <span style="letter-spacing:0.2pt;">(a)</span>
          <br/>
        </div><div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">

          <span style="letter-spacing:0.2pt;">There was no equity award adjustment for each of the applicable&#160;years shown above, as all equity awards granted were fully vested on the date of grant. </span>
        </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock', window );">Compensation Actually Paid vs. Total Shareholder Return</a></td>
<td class="text"><div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;">
          <img alt="[MISSING IMAGE: bc_tsr-bw.jpg]" src="bc_tsr-bw.jpg" style="height: 315px; width: 556px;"/>
        </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsNetIncomeTextBlock', window );">Compensation Actually Paid vs. Net Income</a></td>
<td class="text"><div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img alt="[MISSING IMAGE: bc_netloss-bw.jpg]" src="bc_netloss-bw.jpg" style="height: 315px; width: 556px;"/>
        </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock', window );">Compensation Actually Paid vs. Company Selected Measure</a></td>
<td class="text"><div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img alt="[MISSING IMAGE: bc_revenues-bw.jpg]" src="bc_revenues-bw.jpg" style="height: 315px; width: 556px;"/>
        </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="nump">$ 107.08<span></span>
</td>
<td class="nump">107.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (7,088,000)<span></span>
</td>
<td class="num">$ (10,023,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CoSelectedMeasureAmt', window );">Company Selected Measure Amount</a></td>
<td class="nump">3,431,000<span></span>
</td>
<td class="nump">13,367,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="text">Dr.&#160;Hayward<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=1', window );">Measure:: 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonGaapMeasureDescriptionTextBlock', window );">Non-GAAP Measure Description</a></td>
<td class="text"><div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"> <span style="letter-spacing:0.2pt;">(7)</span> <br/> </div><div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">

          <span style="letter-spacing:0.2pt;">The dollar amounts reported represent the amount of consolidated revenues reflected in the Company&#8217;s audited financial statements for the applicable year. </span>
        </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(206,583)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO | Equity Awards Adjustments, Excluding Value Reported in Compensation Table</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToNonPeoNeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToNonPeoNeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToPeoCompFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToPeoCompFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CoSelectedMeasureAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CoSelectedMeasureAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CoSelectedMeasureName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CoSelectedMeasureName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsNetIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsNetIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonGaapMeasureDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonGaapMeasureDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_PeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgDiscLineItems', window );"><strong>Award Timing Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiDiscTextBlock', window );">Award Timing MNPI Disclosure</a></td>
<td class="text"><div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-weight:normal;font-size:10pt;"> <span style="letter-spacing:0.2pt;">The Company did not grant equity awards to any executive officer or Board member during fiscal year 2024 due to the small number of shares available under the Current Plan. The Compensation Committee and the Board have a historical practice of not granting equity awards to executive officers during closed quarterly trading windows as determined under the Company&#8217;s Insider Trading Policy. Annual grants of equity awards, which historically have included stock options, are typically made to the Corporation&#8217;s executive officers, including named executive officers, during the open-trading-window period of the fiscal quarter in which they are awarded. Consequently, the Company has not granted, and does not expect to grant, any equity awards to any named executive officers during the period commencing four business days prior to and ending one business day following the filing with the SEC of any Company report on Forms 10-K, 10-Q or 8-K that discloses material non-public information about the Company. The Compensation Committee and the Board do not take material non-public information into account when determining the timing of equity awards, and the Company has not timed the disclosure of material non-public information in order to affect the value of executive compensation. </span> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMethodTextBlock', window );">Award Timing Method</a></td>
<td class="text"><div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-weight:normal;font-size:10pt;"> <span style="letter-spacing:0.2pt;">The Company did not grant equity awards to any executive officer or Board member during fiscal year 2024 due to the small number of shares available under the Current Plan. The Compensation Committee and the Board have a historical practice of not granting equity awards to executive officers during closed quarterly trading windows as determined under the Company&#8217;s Insider Trading Policy. Annual grants of equity awards, which historically have included stock options, are typically made to the Corporation&#8217;s executive officers, including named executive officers, during the open-trading-window period of the fiscal quarter in which they are awarded. Consequently, the Company has not granted, and does not expect to grant, any equity awards to any named executive officers during the period commencing four business days prior to and ending one business day following the filing with the SEC of any Company report on Forms 10-K, 10-Q or 8-K that discloses material non-public information about the Company. The Compensation Committee and the Board do not take material non-public information into account when determining the timing of equity awards, and the Company has not timed the disclosure of material non-public information in order to affect the value of executive compensation. </span> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgPredtrmndFlag', window );">Award Timing Predetermined</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock', window );">Award Timing, How MNPI Considered</a></td>
<td class="text"><div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-weight:normal;font-size:10pt;"> <span style="letter-spacing:0.2pt;">The Company did not grant equity awards to any executive officer or Board member during fiscal year 2024 due to the small number of shares available under the Current Plan. The Compensation Committee and the Board have a historical practice of not granting equity awards to executive officers during closed quarterly trading windows as determined under the Company&#8217;s Insider Trading Policy. Annual grants of equity awards, which historically have included stock options, are typically made to the Corporation&#8217;s executive officers, including named executive officers, during the open-trading-window period of the fiscal quarter in which they are awarded. Consequently, the Company has not granted, and does not expect to grant, any equity awards to any named executive officers during the period commencing four business days prior to and ending one business day following the filing with the SEC of any Company report on Forms 10-K, 10-Q or 8-K that discloses material non-public information about the Company. The Compensation Committee and the Board do not take material non-public information into account when determining the timing of equity awards, and the Company has not timed the disclosure of material non-public information in order to affect the value of executive compensation. </span> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MnpiDiscTimedForCompValFlag', window );">MNPI Disclosure Timed for Compensation Value</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgDiscLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgDiscLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgHowMnpiCnsdrdTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMethodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMethodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiDiscTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiDiscTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgPredtrmndFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgPredtrmndFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MnpiDiscTimedForCompValFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MnpiDiscTimedForCompValFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !2(A%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !2(A%J_US1P\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( !2(A%KI%HJ9>P(  /L&   8
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&ULM95=;]L@%(;_"O*D756UXS@?ZA)+
M2=IJU=8J2O9Q,>V"VB<V*@8/2-/\^QVPXV:2B[:+Y2(&?-Z7YP ^S Y2/>D2
MP)"7B@L]#TICZJLPU%D)%=67L@:!;W925=1@5Q6AKA70W(DJ'L91- XKRD20
MSMS86J4SN3><"5@KHO=51=5Q"5P>YL$@. UL6%$:.Q"FLYH6L 7SM5XK[(6=
M2\XJ$)I)013LYL%B<+6<VG@7\(W!09^UB<WD4<HGV[G+YT%D@8!#9JP#Q<<S
MK(!S:X08OUK/H)O2"L_;)_=;ESOF\D@UK"3_SG)3SH-I0'+8T3TW&WGX"&T^
M(^N72:[=/SDTL<,D(-E>&UFU8B2HF&B>]*5=AS-!/'Y#$+>"V'$W$SG*:VIH
M.E/R0)2-1C?;<*DZ-<(Q83=E:Q2^9:@SZ4H^@YJ%!JWL0)BULF4CB]^0#6)R
M+X4I-;D1.>1_&H3(T('$)Y!E['7<0GU)AM$%B:,X\?@-N\2&SF_XAM^US/9X
M> RY$\W1M6?@QV>,(G<&*OVS+^G&,NFWM-_'E:YI!O, /P -ZAF"]/V[P3CZ
MX %..N#$Y_X*_.580Q^<7[[>W)!!LO" C#J0D==I@12Y([GEM.@C\>MWE&OP
M<(P[CK%W!V^$8>;X3_LW_@_[-^EP)]ZT6]P-%$P;17'Y'FC5NY%^GT5=<P8Y
MN7Y8D&W&0&2@+W 5,@_CM&.<_@WC"C=748ZF.;R03W#LH_0[1?B;)$DRBONP
MPK."5($J7-G5))-[89K:U(UVE7W1%+37\.9:N*>J8$(3#CN41I<3/'RJ*;5-
MQ\C:E;=':;!8NF:)MQ,H&X#O=U*:4\=.T-UWZ6]02P,$%     @ %(B$6I.R
MIWKE"@  &D@  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6SM7&V3VC@2
M_IY?H6*WMI@J G[A;5ZKR$RRF[U+,C5D]^H^"EN +[;%6C9DKN['7TM^Q[+P
M$'.7W>++#-BM5C^2NOM1R_AF1X,O;$U(B+YZKL]N.^LPW%P-!LQ:$P^S/MT0
M'^XL:>#A$+X&JP';! 3;HI'G#@Q-&P\\[/B=NQMQ[3&XNZ%1Z#H^>0P0BSP/
M!\]OB$MWMQV]DUYX<E;KD%\8W-UL\(K,2?C;YC& ;X-,B^UXQ&<.]5% EK>=
MF7YU;PYY R'QNT-VK/ 9<2@+2K_P+^_MVX[&+2(NL4*N L._+;DGKLLU@1U_
M)$H[69^\8?%SJOV=  ]@%IB1>^K^P['#]6UGVD$V6>+(#9_H[A>2 !IQ?19U
MF?B+=HFLUD%6Q$+J)8W! L_QX__X:S(031H820-CKX$^K&E@)@U, 32V3,!Z
MP"&^NPGH#@5<&K3Q#V)L1&M X_A\&N=A '<=:!?>/>)GM&7HD01B2?@600\.
MLUS*HH"@U^BW^0/J_GAQ,PBA,]YD8"6*W\2*C1K%NH$^4#]<,_36MXE=5C
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MP<\['-BH2Z, W:^QPV-E#SXY9(G>9IH^)9JP;Z-'"'R.3?P05/#>";;68%P
MES?4MQU_A9YYH !8W+"D;Q$FDKY3N!P:2*1ALA0218#N0QQ:0K<A3=7D)A6E
MQ4CKU_R?;EPGW^2BL6(F;:$P)+4\FU/CXE7#.87(!I=YMO##PLQR] FHTLP"
M9XRPZSZC#7;LM%L8@,)L]1!F8CE$25?8@O&W19+;.>$:O0^)AX::T=U>\&Z>
MR"IR8^WSUW_KRQ:C39%/0\YY.7>-S12&%*PMF0DS[$/GBV<$2X";NF<CLJ.
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MBFC[51'MOBOB%+S3S'FGJ:[>'>D.Q[PM0HK^VQ7%P >%MZQX)%B)E\_PPRM
M$+_%)+L:O^#FC7YU+]X#LW=]IE_-Q.M>!KF:^*TY'W"P<GR&7+($E5I_ JPQ
MB%]$$W\)Z4:\RV5!PY!ZXN.:8)L$7 #N+RD-TR^\@^QU0'?_!5!+ P04
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MIUV4C"R4"9"&*8DT' N\GJXV<Y\?$KXRZ,W9''DG!Z7N?;"E!4Z](.!06<]
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M<O7UZELV>^?]?=9^QT<R;O+Q] ;O_@%02P,$%     @ %(B$6@%EQ>[
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M4$L! A0#%     @ %(B$6FBS2.6J!   &Q<  !@              ("!\14
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !2(A%H\N%?>
M$ (  -T$   8              " @=$:  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    "  4B(1:\N][JP8#   M$   #0
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:+GAM;%!+!08     #  , ! #   U)0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>11</ContextCount>
  <ElementCount>29</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>5</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>1</UnitCount>
  <MyReports>
    <Report instance="tm252562-4_pre14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tm252562-4_pre14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tm252562-4_pre14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tm252562-4_pre14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>apdn-20240930.xsd</File>
    <File>apdn-20240930_def.xml</File>
    <File>apdn-20240930_lab.xml</File>
    <File doctype="PRE 14A" isUsgaap="true" original="tm252562-4_pre14a.htm">tm252562-4_pre14a.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bc_netloss-bw.jpg</File>
    <File>bc_revenues-bw.jpg</File>
    <File>bc_tsr-bw.jpg</File>
    <File>ic_chairper-bw.jpg</File>
    <File>ic_member-bw.jpg</File>
    <File>lg_applieddna-4c.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="45">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>22
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm252562-4_pre14a.htm": {
   "nsprefix": "apdn",
   "nsuri": "http://adnas.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "apdn-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "apdn-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "apdn-20240930_lab.xml"
     ]
    },
    "inline": {
     "local": [
      "tm252562-4_pre14a.htm"
     ]
    }
   },
   "keyStandard": 29,
   "keyCustom": 0,
   "axisStandard": 3,
   "axisCustom": 0,
   "memberStandard": 5,
   "memberCustom": 0,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/ecd/2024": 7,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 11,
   "entityCount": 1,
   "segmentCount": 5,
   "elementCount": 266,
   "unitCount": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ecd/2024": 45,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm252562-4_pre14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm252562-4_pre14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm252562-4_pre14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:PvpTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm252562-4_pre14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm252562-4_pre14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:AwardTmgMnpiDiscTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm252562-4_pre14a.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm252562-4_pre14a.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm252562-4_pre14a.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r96",
      "r112",
      "r147"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r77",
      "r89"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r116"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89",
      "r140"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r82",
      "r93",
      "r109",
      "r144"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r148"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r76",
      "r100"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r89"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148",
      "r152",
      "r160"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r164"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r183"
     ]
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r97",
      "r113",
      "r139",
      "r148"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r95",
      "r111",
      "r146"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r98",
      "r114",
      "r149"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r106",
      "r141"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r91",
      "r107",
      "r142"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r81",
      "r92",
      "r108",
      "r143"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r88",
      "r99",
      "r115",
      "r150"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r110",
      "r145"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>23
<FILENAME>0001104659-25-032262-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-032262-xbrl.zip
M4$L#!!0    ( !2(A%HJ=P2VR@4  *@<   1    87!D;BTR,#(T,#DS,"YX
M<V3=65MSVC@4?N^OT/II=SJ.#82D,"$=QX1+2 (!S(9V.AUA"U!BRT:2(>37
MKR0PER;0P*0[M&^V="[?=W3.T<&<?7X*?#!&E.&0%+34D:D!1-S0PV10T)R6
M;K7L:E7[? [ A[._=!V4$4$4<N2!WA3881"U7 S:%!+6#VD _N;!/T '0\ZC
MO&%,)I,C5\@P%U/$PIBZB,D%H.O"8&+2ID@:S(,2Q<"**#"/0=K,'Z?SJ31P
MVK9X26=G*A_.GEB>N4,40(!\%"#"2\)M$?5A[/."-HJAC_L8>1K@D X0OX4!
M8A%T44&;8X(>@0J$(<P>F[F,8"QB0%C>Q^1Q(2:A/_6H?Q32@9 T,X;<[D&&
M$O&G%_*3C)).Y7(Y0^TFHC'3^31";"&M+,?,2#:DAYQNIO1,:F&>O69;R*6,
M^YOKEHK!0E:8\_BZ];ETUIAM)J(P\L@;8N%Q^GHHQ(8A(4N-M&YF5A$+&;PE
M@)@P#HF+-'7VX , \C0A(2&'7*3?^6QQOAQ%F/3#\_F26)0!S2>'T$1]H$*<
MEV *&L-!Y,NC46M#BOH%35+5$V+??=@[$C@3$4A=&OIH^_D9$0TC1#D6)[1R
M_,K "^UULG+;$#Z1?[V$K!GG[T7'0_W_G8[PB0F61[6-DQ1M"Q9 /CC-ZBO9
MIJQ9GJ=L0;^(12'+!L0T@+T9T^_T^ZL"BR19.ES".A=43=,4#:B(F>N'+*9(
MO#3@%(P9:" J>Y1,P?7]I2.P]'1F_&@<O'0=,^35R;EZCD2+$_T()O&9&YB+
M;%5=#^R/BMO=NM!W8W^3U^1DC+6C65::L59JJB:-%T69E*I(RI!R0%[TU"VU
M#F;=^CITE;DM*O)-3_1TN:2GTJ*]'#TQ3R;9'BB62;X;BD1O'Q3*'$/NT2 <
M&\CU5&M]'0#;)"X?5*DG7G=RZB&\B]-$7#ZL.U6W\]=_;SHGW[[>NU'\U"79
MG/=\.AYTI\0IQI/R*<V=UM(/3GO*_-.Q^VSZ5]S@]JD]_E*I7SVTG,NK7M=O
M/9MW03ME/;O#FO4PR%JCSA4..]5LB3N5T#R]\":C&JQ%T<U5RR?=R;T-*UYW
M$F>L:NDX>PR?@W2CU&S<U9VV6:Q,RN9D6N[9=QD'=ZN7P]+(?ZSG!NG3D1FF
M![G ,2L?,S68^C0DHQ,K[%D=''?,LMU$HY,:+#Z6XKAQ?SQBE\6R?X.N;Q]M
M)_,E& \NF^C1J0VB:N/DI#8<Q];%U46UVZP\/YT$^$L4'C>LFT]V*Q,XD]Q#
M?!LUIKGK>G#QL>(T[R/GME1ZKOB=-*N'A6_ ;C7EO+)KQN9FG9&@@1R(WI:U
M/J5K6KH:)43.IDX6.;MC[;QZQV_*I9]IJG>V F7G"M)9W-N[BH3N6E+OZE\6
MQ8[^UPIJ7_\OQK<W=K!$0:9!=NET[G,^,RNG!>UR%&,^M2:0>LSR'F+&Y>;J
MHQBN5X5*$/O(:X<W"/&5V]0.R>P"93<HZ"$JAF\UQ8ALR'MA #&I<A3(BT<#
ML,<XA:X85CF-Y?0AA\:\F$IPZ+5G6C%5%#5 L"\F*#F7S&1%+!G'/):[91K&
M44&;J6-A?F5T^&6\=@ZE/81D@*I$.* =Z,?(8O5^!PD69% 4U5KOVS&E0G*F
M*7>05XRIV)YO=!&D!QW5=Z6XWB'>*<0-$04JG?S)0=Z)Y%H?>J<HSSS.%/^T
MX+Z%VW)*VS^@TMPE\>K]>LSE'"R_PEC$<\AX!4"90B)>JF1QY(?==G\%T]T3
MN(C'V$/$8W5:YT-$+R$EPB=K0"Q^**TJW89<24RP^GWK(U=A6, _Z&"_.\V=
MK[R##L_^U\P\81?AJ?=_R-'?I=OM0>1M.:"L"?4PB!!A"GQ;XA:S5GN(K"CR
ML2O?#S-">Z#?U/%O$=\\:AX&\[= 7/G8\1-^C=DGLP.EMHYN(ZNYV,%ULHVX
MMC6QETKJ"FTA.L;R=PWCATIN \X=CNTW(+D[O]^ON>X/7'UZ-!9_]*G+YS]0
M2P,$%     @ %(B$6IF*@"?Y @  < <  !4   !A<&1N+3(P,C0P.3,P7V1E
M9BYX;6R]5&MOVC 4_;Y?X65?-DUI0L*C0; J#>] H80P:%55)C'@$CO!20CP
MZQ>'AUJMU=9)W4=?GWO.N??:MW*U)1[8(!9BGU:%W(4L $0=W\5T415L2]0M
MH]T6KGX \*GR611!$U'$8(1<,-L!PR>!Y6 P8I"&<Y\1\#4BWX (EE$4E"4I
M29(+)\6$#F8H]&/FH) '@"BFA"=*@R%.6 8-AH$>,"#G@2*7\THYIP![9*0'
MI7!(^53Q,%W-8(A ZIN&5>&9TG;&O N?+21%EE7I!!0.R/*6!U[@$S5#YS1-
MD[+;,S3$KP%3VIPTZ74M9XD(%#$-(T@=+A#B<I@%N[X#HZR3?_0%WD3PDWB"
MB3PDYA11S5UL0_=L,<6XT5GF.4%!.EP*O%\ 5)COH2&:@ZS$<K0+4%4(,0D\
M[CR++1F:5P48N#154_*RILI<ZPN//+)'W74Q+PIZ-4P0Y2\E% "GM8?MLP7H
M4I@-5^(WTJM)4C;US!5DSM\:>Z-1ISIYAPJ97_>D)+IH#F,O$L!1YKG1,P>F
MD92F2$>,]'MZZO?P1.]_]L;%A_N)$\3;*2UH[KZT64QWU*[%2;/$M)*I/-FC
M7>B5-LY>]CJ1%!DE8W/7ZG>>++O>F4T]:R_?DE%.WSM+4W]:%/3UN(/]<;O0
MB.R6+Y>NW61M0C,(>AW+H]-D8L"6.TUB56\W\H4\W!-ET!@.;OOV2*ZUDJ:<
M[)HSXU:U\;1=7S;6WJJO+9326O:5A49LN?5=-6'N<DG71=V?Z6,<C^6F,43K
MH@EKJT8<#R;Y=5BO-;T>ZMZL#%N](YM%?8A6MKD(VH-BT5QN8OVZ<]V>#EO[
M;9'@N\#/#_3>I6&IQ$ZTI_@F&.RT[K!9M\W^O%^$UX:_)R0_]7:KZ@,PK"'_
MM/]AVCZ!F/[SL _9A[?Y46:7*05SXAD2S\+O\_L:P4=_IZPQ(D%DAM@[N_LB
M-?/Y42ZAY[W/&T\X.TI_.J;9HNJFVD<''/:NO?:B&K2-$'61>Q2IG#<^W\>_
M %!+ P04    "  4B(1:+YO@2\<(  #D60  %0   &%P9&XM,C R-# Y,S!?
M;&%B+GAM;.U<6U?B2!!^WU_1R[[HV4$"J R.NH=!4;S!"*C,G#E[0M) -#<[
M"8B_?ON2Q 2YY0+)N/,T$BI5U=5?UU?=U<SA/R^*#$80&9*F'F7R.UP&0%70
M1$D='&4ZK6RE5:W7,_\< _#'X9_9+#B#*D2\"470FX"JIN@M00)MQ*M&7T,*
MV#*5;9 %0]/4#W*Y\7B\(V 90Y 0-#0+"= @#T VBQ4Z*JL($H4'H(8D4-$1
MX'9!@3O8+1SD"Z#3KN(/A3WVRA^'LJ0^]7@# NRW:AQE/)9>>DC>T= @5^"X
M8LX1S##)@Q?RP"<_+E+I?+E<SM%O75%#FB6(U>9S#]=7+6$(%3XKJ8;)JP(Q
M8$@'!GUXI0F\22.YU"\P5X)\RCIB6?(HFR]DB_F=%T/,L+@!<"CS/2A?82E
M?3] F@P7F"5?Y^Q!4GESHF-Y^&)"581O>HEF3?#)R&10&G)>I(:/,KPNJO^>
M/EN2.:F,>20:%?'1,DP%JJ;WSYJ&O$(U7I*AV-:N(32;$!',D!A6-5642.",
M:ZCTH&MKB&"?F<)Q*.QRY2)'HO#7>HWG:#"<:)#A^N+A0#D3)/)$RR8C^*_<
MDRF>L36RE*&:[;0RQQZ] "L&3#-@J@'3#=H:(-J!1SUXTP]^, L_#]FHCKV!
MJB _=G@D.*/&?RZ)E"V1$S1L43>SOJ#UD:9L"'6FMHG)(2B+$V*B)EC$)YJ
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M]@QW'\7G ?ZO@3AAO[#^'* ER#<>9GECJ7!1@E'N_U[MEZZMJJ)^)9H:EOW
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MX'*5^LG(9/JI5;U8+("00V*[OBWX2 2:8-)R=>:%9<Y L9SQ.\M0;)0/%M^
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M:*JAS5H]\ENS_++@HEKAR,;<H&=NN?;X?AZP3=CX$C%9UXSU*U3ITRK%->&
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MI IE3@-U=Y]C)4_TQC'Z;)<[]I/Q#)>I_/+?/.%%HDH1[5(\9Z<@@_("Q?)
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M4(@1>!+1K?;JESX8Q5-(MUY &@N-MQ&/UCM.HWQ:S]@#)%K#2<.Y)_ F9ZM
MH'?I P]P4Z.N>-VYD%7W-^ZXA7JDMI;;!'_HB.B[L(Y<T^20,['NT@W^M#(S
M2U7XFL;:>O2T[C=UB92I-+XGG!)/VQY ,;";EBJ,@0T4UUR8"W+HX^+@8TS'
M<%],2A1\P55DU9*E0^@&S=6G __.G/W#]?[R+[C>%+M0*,S%" E#$C [0.#.
M,_H;7@%M9/?A$:NH@-';?FRCG(LU\R?RX05N(V^0E*BM&_.N#>RV7BQ5(C=F
MM"!\9X!9;GUO!M%N.X<Z":SR*I]^ +[0B#L5?<GM07"=5746-6#+#70L8D@>
M.-/Y(NSX!^#JM06VNIHUQ_:GR\#5-7I11N=RB&[]XN(R-4TR[D0AG#5GGMUZ
MYNX-S:0M:?ZU67<<>$"U-*&X^_4<\9:UC^ZC.19\I?.0]33N</VCM;,I?2&(
MG:3$AC/@\CJ-?:W,K[Y%<M$DNFO[6PX?#38&JC:BX3P/5&K#+V;FOOD!X+6[
M%K6;CUT[[$OH@.:4:ID/7KH2<?XM ,!Q(^ C22$O:7D)3=E\YB>I%"H#KM^1
M_];S _#LMQR.P/]C^>[7L+,>YXAK;%Y!\./N)6I'IQN>M9"DZ#2O(7W&UVJ3
M;>:K6.R5:_JF8L=.)!+V^A;D].60)L9J;.6#X!M4J48^5@KZZC8K2GT2KVOB
ME0F0B(+Q@9H-?C31)-<4U)W<+P;[=*O"PX4_-_<'P$45[\$Q35Q&SNN7$10R
M5P9Q!HT'&JE+0(8"$+AVU^A>@PYC[79(XZ2C=CV/DK?0E[$Y_AN<MZ\4B>?7
M7?5SY04J215?1HED,)B];B%:K3U:SJME-O.\M]D:V6 4CD5,ZCZ+<^IU,8"\
MYY^:TQED8?2.E%&D[])O]<"[A56#)4VY8)O%HLER<S=C7SZ/VS;#B;9CD2_E
MS[FXXF,D&Z]^)^-KTK_X9!:9LBWC@.K>NK"Q2 *2AD96_OV^U^Q9WW/IK4</
M4!K!STCN!S'SNS;926X))TX/+2+K4G]]X.*BJZJG)-,0YGC0'K*IXR(1YW-&
MTK\/!U:5AOB=-2CLU,"RGN-:V/ZF"T]9&$=89669:]7>\BP;Z[&P*OU0*.O
MSI2007F3HT4D"^[7#VF*?$JZ(LV1DA6(13F6'*36H['H\@=R(@YJ]_X5B7*:
M@EF2_-;]-*+Y%4S^V+IG/J#7YVQ:Z2[VM:ET*A@5WNQR7REA+0F6%;0WW/O]
MLE;M22KUPO&3HX];!MG9FE;I=P>Y^U ?"CA$2[IW=W!@5%<3MNT!VOW2#\ ]
M?_?RJ2DK<'IUVR6+'JLEYSR3=QQ=-3?-QU1;!^<YFI'#M6O+ZK%;-QN?YCIF
M<^G^ (CS760+N<6O4G@$/Q4Z[H#9S-2Y:]IOL \'N"]D"UP]+9)OU7S?]I8N
M<=#]!^#;\;V:AB;9@G'""V7KV]KD]Y45=IEG&@=F3B\H/BW\T.#GO<VE%JH(
M3L*PS7,:7<<8MMY*&Y,Y] \C;VI@\3-C9>6PH&O)]&C%P^GA\J]*_-13$?^-
ML2  ]4WXIW'=5SDLU7IEVBC@_;X]%TMV=7!7;)R@&(!7O&Y>:]I'%A1@1MJ?
MEV9UN#_<+U?28U2SNC-: ;9,[4T(E -4:3AQR++VPN%=CSABH;!"5;9<N>\[
M#"4K95^^&YLR,!4FS-2*>@B2_<:O&55T<5KLPM(+)8V>T6Q*#0OR3]ZV<FM@
MB 1AJ[M2(C@<TQ-=X#7/IY5UI;"Q(X\DN\ 1ET5015]ED*&]D 9L;6:HQ>);
MVIYOU!_$$!Z0<:X<1!_?>\]>7;U.-1P]7L/Z<AI8>UX:@/\;F[\M YJ58]^7
MV6]V63_),LIO%S+6P)8*1/&*VE)2(+E.)LV8,%'G/6^A)&['X:^ZZ+I:CH5&
M(WD)S^BC 50M+0%"^-R/P63\G?WI=?%)@8S^FT_^.)Y3EQ%%G-*W,(J(K^7U
M$!HQ?[2G$^_TOM?;339?=-@3O9?H?$TP!*2/?96>D$'HG6>VGPK)/9T[_5+P
MI>7I_$N7"[&[DYX?_<"9!AC<XHY:>4/5T;G(W3Q!6AJ.8[\7Z;8GOS'194GP
M;O'=1!M\B=J9;W:3^V8]HH^S@*+1["J7HL\UD]\W;6YMELFXWF%D3[R ?K(!
M&3THE6 7( Y;$X?S03$"L-%<@>XS/P!P=]8 6]++:1$9MR(?C5H)9Y1ZG.3M
MH5PV(A;CH.;[5_F\_G?E4QE,>UN^BT[=NFCN9.0*V>C3;^P=;P)#J"+Z93DR
M&R5Q71@P3=# ]27)\C9+^C>[BF0_.-LMD^,GU+M%4M[VYT^SU@PO'6B42>=;
MA5^YS&E172=3K2/M"9\<K%C$Y)TY32Q0"Q=,"WV1.B.[*]F2K$\?6H\0WBTK
MZQ&ZD/SD<R7H!R#W.B01>7[G_8E^0%(O3-;QHV;$%Q-(0ZV_ 5.ATJIC4A@?
M:L>3T5WV>\L/P/H6+428'#(T;GJT8=JNJV&M=+&U3K)KY>W+ZKHW4;9S#_6%
M4_7Y-Q=.80-69;PJG"7W)M6^'T3>-2-]GW:C+T&GDT@L?BZ&O*GV5:1<%6'0
MFFKKO<2_?*3D_*>!@S=;,BM_I(T\#4J4&/F9'?'_S:P'2)QB:%*O:CCP3Y8D
M-LJ$8Y>D'XXGL[X$2/KT[9.O9QOJ2.U'C^G:1BJY#/<F['1?^JEEE?[M[?"
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M/";EF-JK'6D(LD1K!?+.W;JI3^IY198.B51?\()/I#SSHN'7)N)6;^? JJ.
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MU7_?,(>827K",_ J0]CB-1->8E$![F%0RY7-![*,GQ6L_M1-W>_1@M^:5OX
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MJ04='NZ$BD1G?JB%6T7_ /R=E*C68P*.3VMVE7 E-H&JE#\KR&)RJ*&UHK3
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ML0._GHASKW%"B$)X8?2:45*8/8=Z3XIKF9GU>].O[E_P+VYIF]2!TP0%_0"
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M_5((2G"T'S^9#\*YP Y2&1E3,1%Q^F_P[I]R)FL.Q1<-VC+-H8E"%@+R4B[
M\81'8K>L)RW42B*_IV6MQ)^1\&L]?A*-D^\TW'YVX9+M<-?+^^3)"OXJHQJC
MQ;5>W54JC;&T*V*%1O?.^0V<3'$\<BE[B9B(DP?K/K4/3M1(\^)5!@5VTYAQ
ME+F/_J_VKBNJ"69;QX8@H(* $M ?(:%)4#I(DVH* 1(ZH8CT0 (!:0)60"(]
M-.D""4@)8!)"5T$Z!)2F$)I4Z2H(\ENX_WDY+]?_WKO..NL^G?TT:\_#WFMF
MS9YO?WO6'BN%,%>W=FR#C/X\E& /&R)<32W4Y3)V[SIJ=VCU4> ;?+!HJMZ-
M_J4LZT<-E+"/J.6CC L"N?,QT&,U?WLF?]^2KV2_C)X[I4VQM+3M+<Z/.]D7
M!-.#PI3GC:'H'T,$T24FRT%1/^%"3%W0U'DK+>I+\:(7O-^_Q[C'+]:FFL%O
M&Y@PHH3+X#;J,/L&[N/S1X,5_ONC#\"APKV< T!:]0' =GD;ZH ,)#S]1\/)
M$/<#0$'>+XKNP!D35,@CG<0#0)#=6S9U( Z%7O"2Q8*R(J9:$C/Y-UT+0U5S
M#$)'DV)"SQQK1RY[RY?>Q,]%PJJ>[%MNJD>10&E9(,+0*KWCZ&24ZZ:TH)UK
M<XA$C8TKU[[V&8)S%:WB*8.]56MWK+:PHQ/Q1#YHD4:7<(+&?C%ZQ9>V61?I
M,3Y]67BBUIGC$(Q<TXB+,C/XTV;@*8NN2 "YI8/AI@A)A]##55*209(36.38
M*BV@\\/'_8]RBO-K89TCGD!NP[<?P0&+]O%$C1["H2J%OZ(6I*EY7DG2&UZ2
MXM2!8?8S*HS?NK+X>Y!U4>JT$8JB ]*!\\>U>&)S4['K+3R<C?#!M5C9IEN7
M?ZARYZXAP,$90GWRZAF?'O9XB_>4;A[+'\MJ%ID,2I!1HZV!"^=>!'_1\CB'
M&ZFEUKD&2F5TC]EKO%1G%,333M!F8(;4Q9H**7(F]$=/=3=N<#537MG"$FT=
M*KRJ D2TN1T>;N8VVJ#6Z1+>*;8ZJL:X=&9\0?RIF'Z1&3M2Z:EOV7([C*?[
MF)[XMM=F7M.QOI40?[]WDLIC<ESID%.*;06(_D"H7J$&C)327G-#19J9\Q:C
M6A<N%:A3P26DG=LO9>=N3GSD*7_!41^=#O'6U<I R"/5/SU0/9,7R=P,N3 =
MO(2L@&PL3AMGRF4MCZ<A@BC\O,PW>1Q>8'Z3YC>6YP+WD$BGGBG2'O>N_*:,
M8/+Z)6<#2/N2[QM;55(4/VG>PZW8^J7F\6Z'0X)?0N1WZH+GQIY6C;J?B'C"
M>/.A,[$\$"O2.48$CB#L<X>H/B/&N?O-N08>:9@X@E\X$.0$IY0GV9VPGW^-
MT-J'AOD)\:_%.J5E%&C%-J^?Y9=;*/>H#LE;ZF,+K05@9V4"[29ITLDSWI>*
M&IGG@LAR22P55>RM'(CS0H;Z83F(GXNM?G&270.^\J2)"LR[7$C8<@52:)A(
M^G-D3 1NM03TCZ^.4;0]YF,Q53>5@VEB:R(T?&T;ZN%'^MSE:%2<A@SY!1DH
M! N3\9E;&'V=>M17?M+1E]TR*!A,V_PPNO&E/G&4R*#<(F'*.DLP/OV*>IY;
M#UY063W,]Q/?$S8ZQ-_V];RY:'\MV60'+-G'ZK<L9)1QC.>3][N>Q<6>Z+'6
MK/T3,M^8,QE@ZS112\-7'<'1WXZ,J 5XI:1A"9(%"N!GC"^?KURW"1[2L@^:
M0NI@+RDDNCU<')H061;<XN.L$F:&\.(BF>\F5]5084&*&,T"2QA$%3=9CTC*
MG,))*]<PE!^T)=W/5^>5N!.;U]I\.>3(NG-O29R1+MVGT-! %H?P+IDDC(-6
M!? D5C]8 \9W-BGV\2.FM].OKW5I56,YL3^?;*?TF&R;"<0X*^+:EFA>/BDM
MLA*?L^\9^=S"'PO1&OB@L:9)02+@65$^J@/+Q:Y PD_GK&[.SR^KE]I3PU03
MYS;V=UB!%&#C)>[R&.:X%&\#@G!L 'M9^TY8-N>^^HUC4V[1B"TK_C'#])>,
MN49R:7)"H ,JQ;.U73 N#%E3O<7MTUU9&3#M?(T!=Z&MF4AW#^CF41?!ZI<;
M#Q^QVE9E3F4OMK_[N*YV?IB.J2C2=^^53XX7,.:%HH#]*50\&.30'-U^S"*G
M*:!MG#W*:Y([TBALCL)(OF5:N+'1K&B9R_R<;ZICJ+*=2$G.B?-6OU:G,3&T
M\^N/H6S<%7;,I#*#%FS(U-@.T'?4KWU*@TEV]ZGK@&Y4_GPKE;?92>1",7P2
M5V%>G>2LY@_N&A*7;STT+C 0#^X;9[-O=3W/=!'G32_F,<S R41KH8FT9)J!
M%ZIR<,!) *:C+G[4-ZFVGHE[P0[[V2'_.:>AC,J(4Y#;CICOK_^@*YJMSTLN
M1'XVMK0WVWI WZL^J1(/H3NJ%-T18+5R:&58?;)FEP7)2G35NSRTC%-T"/]9
MR(!,+\NKLOJ>\\\-_@D37'NP6@3M:GSPIDIJ&;3=SN=6%IZ]C9_9Z@SAR5ZN
M$*VQ<K20\2R\^+@#\E=F;R] *1OP9<'';$=?U1^FJ.CZ^_&R^%LJB,KI9X(7
M1(A\'\!5R6;=04-MYX.XW\Z.OD[DK"<<4O/=0KCA9/<SK(:WUI'[R3-WJ#'Q
M@X50C RAG=K9(TF#1?QQ,@Q@PV+4)4T;/:S5C&2'+)JW+HM#=L6W#4MGM+3\
M+ET0O9#@[/_*6K-NBTG6V2PK$KV^];XF?PX39"I^0E!<ZY'E.) + 7J:X6UV
M4OTH9FN^\4X<KG4*THZPV!/@'%MOLT@T<E"!8.'6>,IQ"@*NXE9SHF!Z6*Z.
MZ0)/C"J9.Y]'& )"B>Y@-,8X+7($.^L$:"UX(0@,9TZ>D+L@['?_L\2OO!<<
MYY2U!PJF0BV"N7M!-B6]C>]\L3^\_ ;]\A/SS_6=%)ZE>18:<HZ3J"/Y7T+\
M-INL-K,ZRE8BR?,;-W:@;UG;TDYW1:PC7UEVB)6$= @W&5*P]^L:D3Z>RZK$
M4W#5&4*+4:L]3'I0/OD"'D-(_.J3"4663#B*;N;#OYTP0/@548?,1 -CO$?[
M$@$Z>W==-!D7*B>MA:(;&Q6="BP\8DXH5*;!,)\R^MQ2/5$KXO!!446[.>#5
M<_?^!DC\30TM83JJJ\C*&LR6DI5>>$^_L!GAR=\?,U>?GN)E]QDFDLV%->,W
M-4L5GQT!:3-VHS>G0SPW7P2-I\+BH)<G!.I][A?"(Y>1H\^2&7Q\S-MQLK.&
M-Q);3T2(J*]D8F2R4@0\8'<TB4%TY7P>(E1)GD.<_!O7JICDJB8#Y'LF'IRJ
M(D:$&_,ZG)K- E3\?,W6MKHS.I@+.36I31^UV7#8;S78.^7[U>J[C8Z_^3^G
M!6RM<!/E-J+!+<4X/)E$5RD+$]?ZI?#DU*T=JQU/;7/8[?7%)A<('F(J8];R
M0 O8P&^81I&1/VHH5A7HBEO&5GD[N&.I+:2%\?Z<QUK0,)A]VO@OJ5R2'5_
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M+:1R]W/J#YT#P)?K!X#OO@> 78#!#[<#P*F7/_["";_8NC_OG3X ".N^WCH
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MCS4NZ^4)P\QTAVSM,2 0T3A5C=?K[3)AQ.&>]A;;^ZLF<&FN!4MTN0#,<_&
MH7.<N%_=)GG8[1D"H_*6ZUW7?:!?%BAY:W6EU^Z[???V[>E<Z'7+24Z;'8)%
MIG^+2ZQT/9S0.'.;[NPN7M)8'C3Y'B)NE'TI>:A1"<^7S>6PEK!*<+,G32@6
M7VYY(HW7[,Z8FA[U\QN#,HM;DL11C6WVRQ?@P+$H^D#S=+IJA",XQ7_6(4!.
MY'BH:NK*KM%4K4\IL$W.ZNKK>GA:=(;Z!T.W<W*5U6(HE$:8_Y[*"249PIY"
MJI(U9VQL@R5%^*]LO^3FB<<M.^U]QC(;V%*4:?8PR2?E9D8L6;6'/Q>48ZH1
M72A5!K7FB44M5=QIIT>++P:E%FYT%K7<8+5'J?5K G7;4. ZH3F3O@&X]0,5
MJ>E#NKA-FQ!NCR]E2V.=&&1/[(\V3X/UEE08>8+ DNTZHU_C3CKM_*]'@=]^
M>_$,'XK#/WHL-,/P4-UD\]OFCY=IK0(Q+"J(O2)WX1%&A6_VZ]DCWQGF36>"
M,?CS+X_?&2R]+YSE6.CH:!T@M#/NC\;*4;_ P)PCB"$[I1^'A@U_8UG4K]GY
MPZ/&Q.V]2TUUA-<94PL9;#SF$SGGZ)XB"7?"'BDK@1(CQ6>H\QT>*_UUO"GA
MJ_7,YYF?5V3^#V/9/8\# )?VP'IDGW/C:B'KSA!U*(6S!*YF9[#R[:07J%06
M]MDT0NL:]>U[D6IO_*4XR$MTSJK/LDC&NB$,"XH=&AI7K75?O^CE3TK]9B?Q
M*715JS^Z!5A7-OWQV4VK<G$8E5Y\$PV#)G[O":,H;_?H"S ^B@>J2_PP%Z3O
MXI>8E$FF60=>^]="@1U8A1AVR23T:U4-#*S9*MG"6P8??OWJFBH%_;X@= ,O
MCM,F/;Y^B35E5$&6Q^!)M[[,PTV^'+F68U.O.A^.2C-T9S^<9*+G.PAS!OC:
MB_RYXFK\\"'*12<\XOZ\6%SILQ!6HYKIO L9][/#\Z1*I+)!Y*FKPZ@T2GWI
M>1\T%]X';>[]391'\"'>]WN,FM([=VACK/PPK%H9\5R3RQ1.&,N VR?@^?A(
M9D#+B"PM?[$S"*^9.XOK6%?W\SJDMG+D8][V#[SZ3@Z*UO[%X@OBAQR#]'>J
MOLZ/&(=)(;V>-"6N7KQ@F8E%FC!NAREKT3UM]HW'[TW5?359V\@),K-]$!#1
MW8O5Q*+$$CP3@>FOHEK+0Q[5;%99.;O4*0MTG9"[U-UG=_&R8<+%!DAE_"!P
M A-Q2ECY6=^DP(U)$5G7\,;IO;U(5A?'HD*N;[%M7N!;I_@>13)5<@UF+P2#
M$PW#S/A?<>V&!\_5ALO/X-^JDC=V>O%&1Q3-4W%*3T N=?E#Z8'8;\9WN5\=
M<9T)4MK:=>\P"O>VBG]?[IV15@1'_N54TE&Q=Y Y/\B'.DE4SU.D0,D9(#(B
M<TD)4NKV.K(./3$TR ]GW!B1'IA$3C6HG=>>HLI*%^,6X&$EYS-&2L&(M)Z_
M=E;1&.H-PBJAF^<_+-VK*BR<-*>6F%:SHV&F"S+::GXMVF6G2P;\N]F2Y@_L
M;<W:P-7P(+?F 7,AD9./-\NGPSN<%CE&"5&2VMQ?AM5,6!Z4QIY"'P1R1?LJ
MEX-9(N?Q:_\Z)/CM-;^XCC\7.3&]*1GBZO?<(O!&A>W96/>N^6PG;R;K$2^Y
M#&KA$0^*KT]9OE?</C5XI#F'VG#<LW#?7]9W@OF\4=7!XQ*RPR":!3:E<%#J
M?88?R)LMG"P1^Q_]:!47T##MNFT2/'U;?/]]E3H)G>T_Y#WR4'$V5$DNF6<6
M ) HXI%<TKP9NU$2WHTP[06E7"UA*RF31^.S^+)F[T'_Y17XI_RVT2$ 8&CT
MJO[_!W+]L[Z6=+RN4<+QS'7CUNW;C&5A'8=[*;LY'W]=.S[A5[P/^,/[1=("
M(++D3]WD0_]1_T?][U3?/P TKOYPC+S\8^9'9T$K^?C!^'\!4$L#!!0    (
M !2(A%JM+PS$+I(   .X   2    8F-?<F5V96YU97,M8G<N:G!G['IW0)/;
MLF^0(EVITDL(G5!"1XI ""0TZ54Z2$)OTL1*"STA= 2%T'LOB@)!>A$(2)<F
M4@0!11#;<^]S]GGGGK?/O>^^=^_]ZTS:]\WZS<R:F35KK63EY]S/5<!E! P.
M Y!<  #<?CT /]\#&* AKE[A !( &0  @/UBK9$!/(.#_56DI'R#))W=_%S<
M)5W]?*3"G/VE9"2EI0"J&F'^SJY>[L%\+NXWD;YJP ]/7P#YD&YJ0"MY0VE#
M?VUW3Z1>1*"[6821N6N$EZNR&U!#G4\U3"7,Q]_'/=B9+\S'VS=()4P-^+MR
ME5_7O[&E@'R_0X*]U(":OS7P61M>Y]/V"W3G4Y2$@%VEI:7Y%)4EW=S=99T5
M%:5E)?@@TA"(E+22E(P26$9!15Y:15::[Z\$_&4PT,U#Q10*^ZNY7W=JP+_Z
M%1H:*ADJ*^D7>%-*1EE964H:(@6!@'\AP$'AOL'.86#?(($_-$#=@UP#D?[!
M2#]?OM_NG5W\0H+5@, _O/#Q-S3\F^(_#9B/C]0?Z*!@4W>/?Q\=9![N[RYE
MZA[D%Q+HZOX++O!WIOY]T3^ ;JY_P_F'!'K_[J>;JY2[M[N/NV]PT"^LS._8
M7SU7,0Y$_LJALS?4SS7DMU8X5 T8$H)T4Y&'0J25E"%RRK):,*B6C(RRC)RF
MDKRR-%161EY:25OI#P5_+_B+(^GV2U9)05%35EE'6EH9HBDC Y-6EE&2TX+)
M0Y2DY16@4)CF'[)PWZ!@9U]7]S]DD7^3A<+^75D5[4!WYV"_0',_/^\_1@O<
MVSLD*#CP-S8?1$%2GD_$T-D5Z1OL%^0I^ELR_]I=]T#D+7<W6*"?#]_OV5!!
M_DDG%"#.OYZ*2F!Y5W=EL)R<L@Q864Y1%JPD"X%(*RA 9&7=I8%_E7?[DP#\
M7\E+_>J4FZM*,#+8V_VO@TW3._BO5][(WY*IXNWL>_.76K";NX=SB'<P4/UZ
MX"^75*7^ OF%E?K?8E)_ITSJ'X;N'ZQ?]?#;Y=]J\=?-WZK9W?=7"0?^JM6?
M^P"]ZYY^OT7.SY]/5E(:H*0%-R3[;7X  "YQD=@"2#D%=;E^S2$7?CU^;Q/\
MO>WRMS5>]&#;4)B4G(O<1>O0O9\' /K?LP-PZ_[53O)S$1 -("/]C7Z]DU&0
M_7I=)"<C([](24%QD8*"DIJ2ZA=14E/3_D:_WNGH:&D9?B/FOQ$)&3DYY47*
M2]34EYCIZ>F9_]/TLQO 0$GRGM25E(0!<(&!A)2!Y&<?H.37%'CA BD)">!O
M1$9.<9'D BDE%0G)W[-_(Y(+EP$ "@ I*<5%*AHJ"O(+%TE^\4C)R!D8*?B9
M+LI@S9C-631-,)/ J73G!DA@D;:KO%# ?2V!)D)P#.L52M-&V6E<B((BVQ.7
M()"<1<]&LZ#E@XRUWH?%?;!;>@R_&R3].WL,))K\,A=^+@!H27]UDX&4 : !
M^)K9V$AZR!:^1>4KD40LENV;8#K58?R:V]14-GPG@+2CZJK*[;)W@ /4^'BA
MZ)?NJW]I\*??JGZ_<UR8_R_ OP#_ OQ7 ,Q/V#J.#Q+I7W00F'ZD"BF'A\NP
ML!+?6.J>E7W(3L@'_(_1A<1W&C8_O,V-2\\;-5YJW.XS7_V?,\[LJ'P^\=&E
M*$IQ!O-#].L6L.P? "_#TKV<=9_4[J,*E#XS9 M*?V$T1YK4B/:AH>Z#=_C]
MG>IZUS,LL7ZV5GL\QP'E(HT8"P4F4:2/+_HM/O/A&)I5R3E6'4*F/YM[O&!,
M@Y+W*(RR,*MQC(^I$-4O7?E$S&*T&1P<Q#V*BYTB">*%>O7CY?:>:>$^ZMF:
M;PA?@,"1<$QN@, \VIL\S,O0IGP3E6VO-DF#4B/&TKL_JMH6-J$7Y2%#:J[#
MFGX"PIZ)'JUKW@@I4WI24E7PHG26_L;@@Q@-H=K;ED-EB]Y-$FE(6;D"LC &
M'W6#:S<C%,U@LRJH%R8PV(XLY\O^@+&G(=1R2DFW7!]@PWBC6^.EKIFM[-8H
ME]II9WT.6&7*L],> =H.=AB*2)B'14:33J6:3**LA[.TG<8>TE6))SB[%6NE
M(AD3,X3N[ "2%6V1B"WWP4=^[+&/-68$<Y> <GH$A0_T9I:<_GQ,R ]B\F2@
MN2E#5+ @>]GM7C04(6E>&)W4L"G-,KNPIVMB;'CC)5$O:"960F6-$8O8E#]C
M2/TZ!WBIY"5X>A)W>6IC+QQG(]N.R"QY(F)JKW$M:30^J7[S"FSTLN?WH+H3
M<[H;"L,I1C=X\=SW><Z5!<7>U*(FPN_G&AS!G5(<=1R#S7WVQ,]M(S[9+AAY
M"'J51K>)SC#:R8:BHJ2"=0S3A525QD=QNS;QO<P?)R2&1+0]!4QQ'K>CH=;9
MU">[/NK+$'FF5I/%X@!0Z[N:7FTQ 54:4DNVG!PGG6'2WC@;I,_U,L['+:EJ
ML_JRR7(O^@65UK)?5;/$JG-)DRP0K'82B@OR.*TGLVPZ][8#W!!>U:P>:)V1
MA!$D V!'V&9'+T3F@Z"]CD>ILRNC?DJ):"B]J2;/#'N87N)E'IQ*D^%NM%*7
MAD??]W'.S<8Z0[):;=-+Y R\28,78U8ZIC@"39UO+/7'R+@AA+@<-ZC$-N5!
M#7*8,]IN/?Q,KI\I>&O;1V!.4EG0N%1ER..! P@6%G9(0O)#P--Z5O?ZC\?1
MZ,V:A3Q%?3&K%';S%P]T4T;I-"F,8#"H6QAF7X"/XV$21[H=\0UR=_F*R )&
M$-V8GV#XI/=NQ>-'<@5N.86/,YQT8H'KLFR='37:A($3=Y53HXX;0"W*>I,F
MP=*,'&&TCQQ8R0?\N-JIQ?*Q),6=F9 9GL>[5U<ZD9I5ZE^%O#L"-[*6Z%-.
M.(SC%3(N2TS$!^8J-^1@?7"4PZ"\,>SA ., K28[Z].9W5<1-DQCW!O^N[D/
M23)8'1K O7,H4."5(A3$>$E"AORZ3-%9L;JH<=-KHVL= :#&&$8!L=CA^KX\
MM9+\Q+2)-R17XSCZ=U?<Q[$S-:W)%F5+",?P!\/$3*XS^I*KT@/.!;US17/V
M]XL5FAO1QG:2"Q&G_D\@'9?J<$-T(&+8E>A#<#3?3#/X2 #-0&-6=UT<,3DL
M+U;:RDD9ON&9-)7%'1#&OA$GS'^,8:!.VM"#SE[GR+EH993J:5"C]L:-$!GG
MX#F]XY<KI2,&_PD0QNF$7^VKN3#ZXWWH]5Z#7LOWTUT2T<_\NV<=[O.HR].0
MGR2WN.M$9LX&YB7:3@H:(0*@AA@P%%>@OE,>'\UB*K^2@O;.%54,X&BU*2%G
M-\ITL3T<3E?7,EFW9BC@NVKME<QOX9E@QUF.J6%UTV$?,$7 J](R5N&%]W!N
M%\;[ISJ?X/2:L/'52KML/KX\9&4W5,OAD:5.8E9U<JZAW+U/!]%M$YU*_3LN
M1ANQVAH/$ ,>]@$#3C0=3<ZO=6Z%1,>N$YR55]*.T:VO"CEPQ4 ^YN;</3T4
M'/$0'L3AUH>IJGH2IN168(:PN%^>V(LD4?=XC*_-+)=]SY8,9IB1]U%MU"R5
MO9EAE%-U 80Y,R"SY78M.;F:*J_IQ1,YRGK3%GDGURR%O;'@8A;O)3YZJ9:"
MS&D:9-57ST.'L":%D:IOSF5<LFY&8@1>>C9 _O);V1:=B$3*=P:>*Z&Q)^2\
M_#P4'FL%IMV?>5:NL\C;:TXJI@\W5AY+Y.S*"LTA#DU'6W,$%-A?G =0BH2\
M9N9#B@_;WBK1-L,**8Q-\=JV85R4H#4'5)"1^J-/,0_4:V87K*[/%#V/<]0I
M*O!K?=XYC%U/II(5\",U]1?H2\WJ62>I%[;6+(_NF&U<2*3#8;J$M*86:'K0
M.:MV4!;FW ^ZN\JZ%-@MN2$\S)V;IH< .LXUK::#.G !; RZRNJRB50?<Y+!
M6_EIBT;5:1XCY(F)?8= A#XRYUZ,;HU<*3[M/4(\;+H$8I/O7K+^#!_F 52E
M'5D&WY.ZYF1O]J*CIJ:Z>/K2291AN4<;!<T<0YXA9BMD&5^#EJ#2C>VU!*Y^
M7K,L>U317'3%_]GI3&K7#90'-(/SO;AS#@/K-+R,.[\]-BGVU&QG'S+,^Z+1
MI:O-8*CF>!#7)&E?L5!,(-RG%*L)NU_JO!.NDLG2K+C!:._+&;O#Z:NOC[)E
M5WT*U\U:/5X501-^ (E[8N5D[^?0Q+KZLI)979LM[ZEB@1XQ676#2[A>VJ+:
MK<K]+#?S$5]7"97V"7"&!^C9"GO:G1T7+3+.W"K%K?[[X(I+KZ^VYR^B!,PD
MLU;K^B(!)D_[N@!]*P=!)IJB-HWL3'V>@JZQ%(TOR=OZGS@5;R1E6:\]JHZO
M$VUY%^\94L)A3 [W2YNZPTC+PZ4=_OD@+#!SV99Q_RD\&-L"RK1A:K#FF?KZ
M6'8[-$2!R6.V-WOZXQX.9Y02X[(AU"AKY'+H>N]AEF]E=HM+\GPR<,4,=4=5
MP,3/<DKF);20P>G.-1[;%/-XE8@%;XN#M[ X_BVN[E3QY.82T*%:W/TT.HM2
MK_:RR.+5W<YE[Y:Y(6=3SNIT:I5L6VP)Z_LE8%\#8<V=A?U.PCHXZB NL4IJ
M)=7L018/ZI%_GENA#ZSPVNS=:&MV8>290K3%#&O;E&W.R<NBMF0%4TIB*:<#
MO3LXUBW#R4-G@Y_L"N?=T_BI%\A&^>7^%_/V)0DCRF75KJE"&@<;Z,!5D?JN
MV0@K@\[I*[.3J\^//'RRK'9R P@*IGV##8<%/13LI=XJIVPM8AOZRO(I%EH1
M"OO3@2IHN-\TC *YN,$/>W7Y'W9#)K??[6F,): __9-](BG5^D_ %Z_R%S"I
M83Y[MB3$'?'=+@%2X\Y]0X7\+(JK4H9.*W=0ZZ+X3%/X.1D*]M)'RK^'^^R%
M/FM<S$FP?&QI46\>Q55Z'HK&D>RF0GZ.I.\"I]HL&>;;8S87AN7F.U=\HF%6
M.7-&,&?*$*7;+*)7]9ZOTD:@=7A3<Y]T"$'?=Y:/:\O.)^KI4YD(#^PP?"&-
MGY\-9$/;0<R+02^=XVY$(>:@"Y=1)H4=]REK0KHI/\@2//5#A' O@/K5&VNP
MP^G4#"')Y *^UYVEIT;:,V-:<:4S%2%#+^&;[JVC&P3!\BE?U:.WWLD(#<D5
M4V;7"+HAP7[.XPC<IYVA<N3I'E5_/KP]RPY^-9'"LV]P(GWYZ(%:,$]N<<LZ
MQ=.VIMBEH;3WR=EYQ\*</I+X,0^<./.6I:G$G&O<&_+(;>OWI@'Z\?(6R4SR
M%;[,>&WOQE:C]O$0=[BWA"%JDRS,WS2EX*O>./'*]>R&EF=YHK>D$#Y2HCIY
MM 4Y/%1O5=5>3>[W++2;YZ8Z$E_S+3YD?)E9W%K",0;&VO<H%0B%!;+R%[NO
M+ X\+BD,D?I10$JO9^-ZO^I6.@0>6:D6#6SFP1%QU*]8B:>'8,?6&?$,A6$[
MEH/.E7.3@GU/JS5&/6SC*0R#W>[]OGEH:YF#LUZT:G[K7#*68!"?K<PVFHIT
M@D87+LF0^\36YE0HJ>GHLGC8IOS05@D@%A(0<S:",]7/8-%E&@,DPK8O(X2>
M3RX8/<]Z45E1.2/$#2Q 7?556?& >REVD;OINQ4)_ 3T=1MFF577AA1D$QD^
MV0;OM6 #YR8,MGW]G)X^L-?"#F$S'@2YOWU[>BV(U'#Z30#!?+@M*<?=CI6T
MH;@3VAI:JZL55'&Q 0%G>#N0SA7N3T_[T')BLO/.5&Y#ET+>(_VGH1VH)_63
M>1*Y#0%N^CVMZ6C>DEC5Y]OB3!41R*/&2N@CU0@/Z' %%8;KD?-*/2XW*;,X
MQ:/ '..SN)T&%,HGYMXTV@7[1A30M&(]%O4,(F'.M4'&S5!K* (M!"T]ZH%O
M+L;=,]FSHE[4];<RM646**_/[KBDY3:EE\'#E<6XZ&D;CX;BL9GXC1:E,S*>
M#/E324^]\T!%6@RPTQQTQ>XJ&UF9Y9Y;E-/'"&BQ[+CN<.%%/KI40L3>0C*3
ML54% W9% .%.O*G?<3V.V9#5+0>SNF(ZYUSYLJ7NRPO""[3[%U*2U.<Q_J?7
M4<EL[NF&J$$F;T\:#)VA/O4;:?MHZRSA)<W ;('7OVJUZ23T)V"(OO*#OF>-
M?6<$O.*U&8;!I.C9]019=GB3C]CREEJ[\_8Z*2$9)?)1#AR=G-%0YYI?;-F7
M*8:('_TAQLRF,/C0'%DBY,@=<KO\>7[83$/14,!5LQ<0M\'49:!6X@>:'DQ
M0-G*VO,B:*"L?]$[58VTA:F6;UCI'E?"/(.[YPVE3[("KD^+'C<>,^8A16RB
MIDP-DC0-^[ULFK\I=6:0('RUT2B%DXOWGS!R:WNIWF8K@14^EZ3*B+BH=V<
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MU"U2@R8D^\^P;[\^L7,ON3RUH5 *Q K7JL0/@45_E1!NOWNT0=9H@M+$V96
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MANY-*H-=\C\!)R)CCK?)Z^G+M3@ERN&"JNV@>@GC P#C97W3(9"^)3L.:EW
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MU3P%4\?'7B"WL356*JN(SXVY_3IVUV\NC$8/N\T+-3RX722W)?0P;$P/*,_
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M;4K1FKDMJ5#\(>CO$+1=\X_>_<'W8ROL@)Q\]$__'?,#,$]R58N/')/X90\
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M&_\ M&L/E\Q? YQZTM3X%>PQCDW_HCAY#N%<*&'B-R6+C]N*6'HH8:]>K5)
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M^<W6#.+J, T#=WD7D'R]3:*ZR1XB@;+-X 'J0W?TY&#?(J9DYG!)/PUF)CN
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MT5Z8.]H.E EX^1<& /Z,:.=X^C SWJ'2E.+>G?'J[8DM@/O.B:]*6MMM^O^
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M4=D"SEX%ZW']ZD/._+K^E ?^4]Z%'ZO7X@=:!L.DY%SD:*U#WY_N UC^9!T
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M@5- ]!"H/7]/S*E)LYI[01HGG3&:$SXU83 F[2W%FZ+^A?'<EZ1F-YV(S+F
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M]E\AS_*TO^W0](<=#5=9-PD"6;EBB- =;#B]@3'3I_TGC"HYMH^%2VER&"^
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MI_QGSL'J!02%+3R+I>S<NWWV@Q2)JB*)PSU"U(ENG= /<,2#DBEMT5Y5LU.
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M)8>&HRMAY*AZTRJ[AHR1P09428S+5,*U\7XY++O;XE3ZM58GO5JBE-=5,\*
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M  #J GM ;-<"4=.*EG#IK,7XY_R&.<"Z_#%N/.,6N^,=4MINY.D7ZU^-;-
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M.V:T(^HX^2H0A*]KT/#9"> L?XBIN+739@2R_H;!M-%DXP:1#S5$1!%;79Y
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MOB+HR ;P 0!>ZHU06M=61SFO:^;D^$^1_/TBV(P@BE:I(]CWI]CW/DVQ6G?
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MZ6E4%/V/IU.GT'NL35=[ 1FKW01-U$(VZI7JKR"ZO'>@GT<]B547P"'@\]:
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M!ZAAKP6RIX![KK5;ZRA >O6%9&B%=4VF)=)BS[XHJKG)X'61'A)RR..H*91
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M@[#08H<[ '195H=7L][JXNV+6Q.!KOI=7T[^YH@QQM;OO@?+19TOXD(_-4_
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M]>0X_N D<?!1?1&Z5Q/US8T[BB<?]@_W:[N-6?SQ%;VOMO(6_[3'FSE7LCH
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ME):=_!Z?D;!Q'H@QG&^(D06A'-6>GC#Q3##FEQ%/D1S,'*#<LU!>NT$2>7,
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MS>00SU"-Q.Q^)&'J*:&8DLOR>EF!G):ELSF"MS7;1D^=6I_."[ :B(KC;0!
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MGKUB<H<C(+Q PQ$(B0+231!ZHV=WXU1QUTZ.XB@OIH;S"_%S;W@7C]/2\,4
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MM*CBA3?.G*MR45$FS_TN54%GK'FDA;HEAV$Z 59,V:B%FFSJWHRD,\)=IZ7
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M+.^Z^P6\,,W8],<NWI DUGTO%+DU[5TW<0P])O=%H=!S(HVFVI[/W=OE@D/
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MBGDU**FD_@[V@Y6 T!8EKUWN_H<;PI!58*K+]D4!DYFZ</MJ36SM+=@Q)_C
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MF70S:(D;PQE8A>PJ6.#.CQ,*@!Z@I1-G^"R=D8JL'&&=T6-XR MF'/K;P4/
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MP8K3,:FWHVL,AL$ #AER= )'2^2B%EJ$(_FH,H[P@1%%&QB\&R=IO]<0&&T
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MI$V#*-96_!@Q;P:ZIB0?A4\E:ZH C"HE:* @R)9\N&%P0FXTT0E1OIH\DB#
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M-&9[SZWD5,#@/)]R4J?YF2B]+P:^%0=TPN&]/E(#N5E'/]9EX%'HLM#-((-
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M-FCL&+W#]Y>GWLTH0M;C'"<0GT"S%WI/:='P?B.TY1UB'*%%2EF/CXZS3-7
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M!NOC<^LGFE1J0%5'9[_?7'P2;Z$YJ1%Q%%S3; 2Y[Z8LJF:U;UJ&WZ?"X?Q
MWVOVK5XH)R/Q9-5 ]0["_0-KM5UAW.4V=:ML6S!)YONY:.<EK"3BN1HES 43
MH=S/-XJ*BTRVJC%!47:L5H$E6\X.&<F@=**LE$A6G=7J.HSR$81I.+I)MXU\
M5E7&M\\"_T(D,T2Y\ZM)5MD?\#)2OAO)]>\J9UJB)6W.LKE'%.L0Z5@?8C]Q
M%BY= ^NPO@F34\"_9E2Q[PV#Y+,QN9&S%AP2STZR2%- 4"P9.&DYID7'I:##
M),VUX<G55/I"?A*(=@+/ @/AQKP\Y[?GE=?GQKQ,P/ L5,'4$@(T*6Z),J$N
M(JE28\3_Q<WFIKEQA3)$4.'H.B""XOW,B: B7VFLN!-)9X\C&!]Y9D2O-RX$
MO)$T3AR.F*[-=;BQ-HEU4YIMSJ\V6OKS%5>9CAU\&IUA(%#_+)!81XQ ;H(9
MWA,A2(8G^ B4$5BC8[980%IY,:)LM9G:<55T;19)#MM?TO3S_GDRSY[4Z?KC
MZ:@S87>R1'A2/PF\$4@P"7Z6L3]XIT2$I36,80MG:8(^(S(M)10/W$<00O;$
M'(\DP'CN<5**PKP$)+PUNU*-04H@F$::8Y,8CJ+FW_@V\F(5]1V,P@FA5L_*
M6P0O$)Q !T*D]%2*!'/%UHA;XPZ_I9HG:-/+;7IYR<STNVUZN4TOM^GE'R:]
M+*=?G6$L[&KY$C.OX>!<?FZ:R *F&LA9"#Z'*N?+3!6$G)/#,JR<V? SN==U
M1O<+\C57@E3NGMGVC-BU$\NDJ!/EK2K@0Y0F,.B34#'&-],A8*P#)#@8^Q4?
ML%*;,G2QI4K.-L>82NEA(]"S$NFQ,*.4ZBZ_>,<E]EPGUIMF1'_I%=-BG3Z"
MN\8Y@G/.3EXD:,/@A'V*02V\:IE?7+;B)"%=X&XP_D?!G# F]C -QJ$5Z1<I
M"[^$V8@I:2),F*K$YTHP(4):8%!?H^75XWP"7Z"_9 4&TYE)N#66[:ST&D68
MBT_*8>YX'NK>J3 T*E3!9S-BB7)O;QO ]NN;W]?!LHOG_49Y?\Y*"2A8ER)C
M-OI+-(45C9\LE/#]/88QYN7%@T6F8'H0C:L+HE6&+(+T$*I_@XZ^+E@4?MDX
MC+%74+C"&^F%*ZP@W8.SZH.$3\-QQ(.;H9X<JUOLORREX;8#89*;>A(TAHD&
M% +5L#(*1$*&NA6?B<FGLW1,G]5[>W+$M%-33GKLX>7;D"9\PP;2Y"_<U93F
M# B*5MZ,!HA R5%:1[TWPX J1OA0&A%%TUKJ@=),IE)L),"Z6DE9>7SC]#&I
M'Z&<@+>K#D_:O8Q=B.*LR/!?.BG:[W8'UJ'#M^+1\W4$@%Z'C]]("M3RE.LK
M%<2FW^UWZP_2+8JPO&O#CR@79;DG&VQ<+B1=7I_U&FRA/X,L0P;/UVWEN!!#
M/A'7@2O[",T3D!_=3%: 7$_J/'[B@^-)W>Y4 <HDKVBU^YPZ$F4FN52-<9),
MBX8.4B[5@(BMH5K93@-"Y"ZQI)%((W+":*IU;PV<U\)6E-6^#6^4WZ%901!:
M \YPQE]Z*R-<[=+M[>RW[^1 CL2!1/2$.OMOP@S62?H>:6'PG=__8H1D:WK2
M??ZBG;Y,8^(:V4][KY_F[1%^XDY1\FJLXR4LUR%7>+[A<UIU6@HX0\#(4/P#
M'I.,R(TT$(["*R7/06,T;>U,SNV,MI.,R8X*8;<+[J F-/OT<'7R-GP20O6Q
M1.ZNB(EP6(%#*I_GJ[0O6F_L'!@H#6O8NY(>H8I18;;\9\'TJ(P%RG/60GO1
M&QX1[1K$\9<V'8'E(_NJ<1#!0)',"C330QK#QO)8;R-<1@A ^>:]/_X\_?1&
MM:4TF"R/N5<I\7.'D^\@BIK-9'Q"]7KK8;),U.;S44-TZB%'DHAM\C0;73I+
M Y-MK[92Q[L!LTV9XBLMON_:C3QI)*#>-$3X3Y1/T36V@&T!LL*D-)Z_''1Z
MQXA30Q()N8W1)ZH]DNH9M+""8%1RTPCUCG]2L:.\P,0Y?^\0CQFB!>!:@C39
M<;ODE,.W./J/ 5[RNHV/VXG5DF]A!TNK>IHV9I 9/_DOW4ZWVVO .-MMKJ3<
MJ1GW10E94U@L)<?#("9YS"<([D!^,40OTYEO&EZ6D'R6"6W#7RS2R:"QSD(U
M)58ZQ-H$&%[8Q_BJC% U4U'O'"&SJT-"&TSI K"4>+/5?"8A,VBL[+\93S8)
MZ6B2#'R<2@4!_MHJO&EDGZ%)&,5!GG,K94:H8*M,5JRY8#\HX:""8TVY@1FJ
M# $U[?@NAI/0^X#[TCNK\,>\/*3',_8V;Q*FLLB+*;PS^I=T>*V0$&4IGS=$
M151#O./:"@'9RW4$[E+#3P$V@GK>1P^H3Q7>"P^ER=,,$PM<:U!WVJ(N@2F
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MWG1%$4"&;R4W'"EDPOD]H@:X(T&L2>#"/.Q%;_BCT5Q?7RKV'B<A6<>8_>/
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MY&!OZ%@--<;;>J<1(^ CU9$@%V#'*T$7?@V(+AU:S766=!*7_7R$6U@FJB%
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M3_=<(/('_D#5EESC-X1]RDS%R+3:Q+\U*23ZOBR4#BI*+04CV(@/H>HV2@\
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M"PK7B-)@!C3<F\RR37H"5SH ?ST@\Q_XI=>"O'S%V%QJO0M+0K##!UEA6.T
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ML;0@'5!G#JP#QM3(X3_.K__NW?YZ?7[N_?W\]/I&'+ V![#S(;S7D ,X:7,
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MU.<D?81?WNLX=93G!;["9&-5S?EH D=UF* %>$<[R)YF;0_2TW%QBIQ7!T9
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M M"7#F;^WQESNUD,Y:_1H+^2/XBIWI&D1VQ<G1E/,Q<MP6$7#8;Z\#2>YMP
M@F&KP7=3'J'V)H:8J;NT /LTRU.^02PLXA+PZ7?0Y.3J&$]('/="'_.H-_?4
M#WA%U*KD7:B=BBF3-6'FCZ 2_=*I6_:$)((*Y2QPI@A_P/'$'XL[[6C;2&2L
MQD2/M/'68@#AC.:\"R6_.#H4=0&AD:OVSJ^;[*,3A)&(UR2#PD3 9@&G)4-
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M=M@$D^4-_>M?$W_*WSA@J82H-+V1ZZLN>BM /?&*(D"H@Q= Q1^B@PEMG]N
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M9V=(7M:\OGK#0R1Z:5^?D]\.[\,?L"1\Y,YO;[F<.UZJ+B9PDS]%]I+6 E\
M%4I-L(P3B*ID:3;>^#/,7?_#GW+26W1M75?1A3W1[JB^5L*++6I][?@N#FB2
M1\L"CH(-Z\;*I("-Z4N*]WP6%PC73!E-G43C*H+PW+7G0!9^ "K)]_6UU/(
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M#AQUY/JD]6??GAQ ]:75LA0Q TU*+&UFB-Z<FXJ=Q, 4+,'CW@A@+D)/V#L
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M;ES S19PFW"7U%8_#B3A\:2$P;^]=6 %U'R1"*_Y+-)(N--2)(ST[MIAQ,9
MRO#@K4 $?KF<:N7NQ7EU.$D(]2PKY:A$:@AA:9J!^'+M60@FG/K7$I6!Z&Z'
M"L-) ;WE ?Z3<AZ^-+XO5-&Z'SKC/,A:U=;LAS*J/])_[S1^E7>1R"AX&T3J
MK*QH:5W?Q;*MR!=V-O1+;7-Y0(LLITGK:2K7E\C+0[*=AV1!!.<Y6PE)EM@I
M:Y9H 3>WA!9T-2-&)5GX(PN.7@A^K=;+P>]UA#K-<Z-W#==D)7\^-?PY3W5
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M/G'X+;M(^,&5X >(&[SPO@>V207/$#B!=<H0UF07M[? @/!Y@:7?;2^V@[G
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M.9A&=$O1N- =F4H.JB]MYL;3&7*Q)OL8![A,8J39(7R,8B_0Q(,$OCT"/3=
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M8T_2@*05\CO:N!.NO-4=+3]&^N72=)A\@(X4!;@H-FFF=L5919R3O*O"T2D
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MPNO73@;:%_N="4>T; Q><8R*;A\53],;K7>O&\MN=<:-DZ]+[/=?_?(A: K
M_&;/L2M?H3[Q"-LNGD]L)R /]_G$X;<LH3(FR4SVX^78U].+8%\(.&Z/)K"C
M #Z>^:([(_5#!;0@3"782(>6!U+HDHW!5#N+3',!:F'1Q.YHHM>>7";=DOXT
M<4;KG>R\+/\J?U0L');^8L%&U,Y+VOCI=[Q<T(Q<@ <&+29)[:JX:^(BO4VN
M$-T7_$N_A#GAMCFW/QO_^\8' L'CK<GC*WZJ<_;!(LY>9"H:,^HUVW5C]>VM
MLOIE@%>L?3F"*AEZ-0R?BI_KNE$%9U^SE>**/'XD>3Q\!RP'&TJDG!Y9BN04
MU2T+U5T&KI+GBPUL;HR_C.5+L>-I,*8VAM1,=L4NC*+U:^XPHOTJG.G656U#
MQ;ZTS6=V#5S#$VTE@<U2L\62+>OM=.W9#(0/-?]!%MQDGXHG$-T>J6,E=N,@
MV;AR;\EL*TE[_.]8]/0(V0,/>-)[.;_'I/ERB1!.1 @)#?AQTEN:WK:@\Z1H
MJ>QH5&(/_7N>=.[(J<B+F/7C[F]GQ?O;SM[?K8N%X@DK.%9&BE281.UF2_\/
MKZC.172>T3]M]ON)]58PGBI>D#=X5;L'?96*+K;;;>$J2+4X=X58?[F=M1(
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MOASS90,)>MI @O;)R6S?QP_H!'DP@PBT0[.5AA+(AL?Y/L^M?(.U=J_7/$6
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M<VFW[6UIM]5GJ(U^"R@?"PKJ-[JG@\;@M%5U ?PX"B.X1729$M7V&[+R,?L
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MY^I#O#S;7PXE45[U0IA ?%]A\']PI';<SBQ0,/73YS:--\@9*OJ>MQ]TD+
MGF!9 [C+?TBC]!QN'UAU$=R[]^[]N,G@V^-^#^RWSP#G?_ [&R3\Y3_8R:G5
MZ364ZJZOK $*5^_"U71=IL("O\4>[A76%SYX:]#M5%AYZW"9A6[X4YRBL;%9
M)B&%[]..MGNKK'P?CS?*2M:5N0;EAEEMQ&$Y0(PT?,G^]N?KJ+.ULH^ZM]1Y
MM+Q=9X:'DIJ?K4VEY0?[WAFSC[ Q]!OB;W_WN<O. MA;0>K!UE F]:TS=CWA
MXS'WP':U00NPX >1X[H\F,-%BX,H\5U:_W][7];<-I*E^SZ_ K=B;H0TEY:I
MS>NT(V19+JO*EM227-4U$_T $B %&P1H+*+I7W_/EAL6BJ1DF7+QH;LLDD!N
M)S//\IWO=+O/]EU_);LKN]WM>=V5.YW]N[C(NL\Z3[J[2U]D,/C[O[6@T=M?
M4=CS%8[U0O=^1)QW$;&:_][9WN_L[3]=WSNK<N_<63[83W+OO G[UKVSNVU=
M/ N4<5#W#CUB8JC\!@=N]?Y0Q1(MHXOBD7S"\"-$Y,9;9A$Z&R>JIXZ.OH\S
M4TRWO(.\WE*E<V!1(4 L2HIOGA_GZ3R]2)'"YLJ/!_JMP@S2U@B]QK2C@I5Y
MRXE8-S]!R'(\'6\7J+0N<NXF3!9H&D5T[7L;?!-OTO+"=8V=2# N>_&E]#$4
M^SJ&90<YV8&A"!IL9Q<CE:%W"::I]QHTCH/K,"GAMV=;IUL<N-S!\[#A\M_!
MB.9<E[^4/&@[IF^^MD7 [A^NQ0W?_O8V.V15+W#NX1JKM;[#O\\=?F=)MS_)
M'=YN.]Y4+<&ZN=^=+&LRGL!=<W'ECZ),+K; 5Q_4+YIW)WC-'&319^\H2N 6
M@]-A%V[=,/L61U._ \=_YH=QNP_S;DR_W5N9?CB*'W&#0+-W<']@YU?Y]H#^
M_8B[8V^W\W3_KN\.V%H=.')_UKMC#>E90WI^>;7_9 WI64-Z%H?TP/NB %[P
M[O3L@W6^K+$^RV)]5-&=)]WE9V'AX\*6L1[<4?-/S",U,^]./UX<O3M]_^;X
MY%<4DK/STW_]Y7TXN#PZ/SYX?]&4F=8@V6W):@O<DS3X* E@X )^LB;ZV7>0
MB4NIEG"%JF"0CE'GX5(*K-@A1VR!VA:\BDP <D A=6P81#XJ(:PO(D]SEG[&
M7 /0&W+8B?E@"LI[C'GJ:(L3OS+K_7!R(0GUURD,#MX$9T9>]Z1-4M131Y@T
MX%!/HR+#>B=\X8^,<M_3S9&CS$/M- ZEH1ST,\X+D)^S2<&<M/;[434$E0Z>
M0GW2RCY@A3/&H0S"+./G8=1BOEPA#![?@3JL&#*@%J-#C*T55)HB5 QAA3.?
M66UA1K&&!<Z',T:FO<T+&. UO(]G3*\!:Z^'].>4=/A)&,?XWSR%^5#+L '/
M,,-NDB+/;YAO8K*'=%.21>@=BC"XNBAJ]*/0-U0&N"KPK)[L]IF&^1F!RA^-
MXY8EQ/B>+%Z94,480KRPPQ!LCK+/) J&&1A,SQ :#=@*(:#*8  2$P:513S%
M>9VF)3^K'P/5/<()QZ>G2'+.DU6?JTT<)OT,_EOFFA9YBG]/L.P(S#@8I/:R
M6](,0Z?7R_ Z[N_H81QJE)2@I\-_8^HK*M_8PT&$/!'8G0FQBV?6;[+P&GK,
M;X=7Y##16][Q ,2@($[E B[X#OTR2;TX38;DI<ZOR#3PL41D-,;<#K!KG#ZA
MR+&A-B8!Q]_+M.$*A_ L/E9=8TD"&)1%B4Y9K*HRT&/AYVEFE!STTW%DRK34
M]B9V CN+\DZ;#:YR?&8J]K_('&\^F@,CT)6N0&MH!=%\6IBQ&U:=>Y\I<PE'
M038W,K;+8\2D#;\ HR_V,ZI%4Z+7.[/,,VMSJ0FA/F;A$!WG.  3)* &D>L>
M6?6WO#]%NF!R1F-TM%@;K6T9>+&0%]S9:,0S/LDB./D3[&"*J5-X%(-%O^7]
M!;U"^GN9HI*6A3KC[#[,9 GC<'R%:P%2]F1W^]'.7O?1LV?=+KX4^;Y#82G7
MC4DCT+$7BUQ_U<ON^YL.=K93/PL+.'Q:-2,/;=\8-^>;DP/OHD^G-VQN3!6;
M\1#8].]"/X;[33WBO<E@16<\ O8V2,[K+$T_FR1W!-<][\Z>SGGTM>[: /[I
M#."G:P.XT0!^%\;7(=9%[J#+M\DX);OS^=_9^CV]?/WQX5F_=U1^>J7LYOT?
M:S??PY1JB_OT\MW1N??ZX\7QR='% S*P[U'L_M0H9RS%A,H9JI-@9!1D9:L*
M+*P9@]:.M@":1BDJI12.\57N;U(BV",,N?0AJ;Q4G%/LW[# IT!!\7OI=8CV
MA%6?137(9:- '^V3E1D.T#2OOYYI"*3XBU,G"E2?.$7#F[77OI\%K.E>8^E$
MBU\@"\UH>F0Y?XU856XH_!B!!HJ:YJ<R&)(NC%$A]$A(OV\(4SPDA>GA'WFK
MIVK=XYSN/ULK:>LHQ?)ZVL79P<G#T]-6Y>AIBE(\K"#%!8C3[QBD ,7I[/ST
M[/3BX/V%=W#RQCLY_7!\<G!Y?'KR@#2IA07C&'U8B$ @#<?V=)%NDN:@A+ R
MA([1*" WVX */??C,D>%2#21JOMLP#YMA"T]06Y=5&=&2EL:.#XU5F^4FTNW
M.RI!!6GP4PL-3(.722EG.GP1QJ#D)<@?E,614M!N6DX2I3:!^<V'D613R?[;
M(5C6DZ8WMDD#^F/1C8Q^[3OHS]NPEUD=VEZX0Z"9BBIY35Y/5:MP]I)1],:/
M8Z4;$U$R/QPQFD>J?.[:53Y%P<4'!H4 H!O)E_$+>B/]&]Z(S,TZI.)VK:/$
MSY*:GA.?L"?;AR]\4*,)>H2.?5OK5N[E7@A[CI$_620^])$?Q02OJ@1T%#^4
M-$_*-X',DY!=ZAAC4I1E4D==CR0+AV7LLT^8R(*]\S(.!12]YS]Z)I_B<T=?
M^S" (=@&?<1*#4'55S$[LQG=9=+=(D6_+Z/+Q]!<FFFCP1K*F?Y]?D6!"[/]
M[!C?VO]\G_[G'WQ%O)UQ,UC['0/8Q/W%UT7$A-C!G5P/)@0V\3DR0\$E7&%?
MF<7XPI 8 E.J<.QK)CH.W=&Y( %C?==([%)R+>:X4<28IPB__@V]6@7VZ+B2
M]^*\K*^>&5?/NW0"UPZL$"PO!LGFD :4-PH?MO:=+0S,K8WZ;4K9B(]\O_6"
M,C]PZE3SO?7!7WX5Z+KB/;&,!.%SY/+!>=%<A%+(8'NG"R<2=!3OK313<JUN
M4IGA_>H,LUP4MF#,;(9_)]?T\UJ3C%VI+"+O]FWUXT$:@VJF[B_\!*.JA(R8
M()7E9]K990^6$%^5EG#$CDPBE*4<A*H-WI4R;^C8DW,*SR X=)R!.(=!E*!!
M[:N#0V U=')18'LJ-=VA<QW\4/@R.^J71F>2QN7LXR/)UVXSBG9'X< +PKR?
M16,;W2V_$$1^EI:P^VS-1,;XDOY@#89>WT/0AYI&>4G;8WAS6"@!/L)3Y8Q\
MR6%J]"YV#,:"1*,*%<?C%&/K;N8 _8(CYB_I.?&LDFYALM4T@,1<#-23A:#/
M]WX)'A$D!G?G13@NK,0,/O7@&' 5M^WG[9H;"0VG2Y:YB&HIZF]L.W))9X-Y
MH[1 =9OI2P[4M8_21*0A4]7W(.Q,0Z?<6YPO;)(=,)"2(6(P"))1:TGUH@8H
M(S*!F8<U;;0AGVI&OS:;%!5JZ@B]+T]AOT>%]D[W%,1+23A*YT:^J:38:DJK
MU ([P5\1Y$ME?9#?W=GJ<."%R''\I(NF#,R%GWETR#N'9X-E,L["ZR@M9UHE
M=$*1YG*K.[9>UF:A&W]#)9/""467K+T*0<3'/J%HZDL9E!H3Z Q8J6,MQS"A
M'EG>R52W;]K*/&O 6>7]=$&*C"AS3@YK;?WK.VCVZMD=G'$EV6^8=3?->2-5
M6H+MR5;NR(=;0;LO:!4V5_O<:[U2]2$AFCCNJ/9;%2FPTWZ)\W6']RSUJ*DC
MZ@)FV]CJ1R\MU1OHE+"3J<AG(%T29!SF<+,"P7>5G$\Z]4N=4\J8T0>FVS.^
M"09A0#3;=L8W#/BEW1]]F"@#1>"(TB$G]%<#^J'-H\9%K%0I>OL1:VA;0[AU
MJ9\A7M-5783@CAACD&@GVGZ8KB0$X-:9$/N4>IZ%<NOAUD4%NIB$HM[:EPUH
M=/H,-^NDF-%4KR.US^P/K_Q =Y^.GD3^7=,M1.U@CTN(ER91#D1#S&DD[!PT
MFO@10AF+=!C2E4!WF@VRDSBIZ:$_S$*!!**TD'JK>\S&+X,LXYC^Z(44S?4)
M&THH2W4):0ZZT2CB?,TM[X"QF"K)#C>!B^Q6L%A] A("T8 !%S1=;QVY7:=^
MS9Z>E0O'+AY4?;X.JJZ#JLL'50_.3]^N@ZK+'B#UH.K>[BUFX4=$50].3CX>
MO/?.C\Y.SR^]TQ/O[>GY!]"T'_U.H57&J1V?X*<487TX =:[F!Q]X:/6*T"O
M<\J-1T/C+8R5ITIIE0-00^$G5+R47>P5'\1N5[%#L.*+.L9 LT-H#3'77IF&
M+[V\?Q4&E*16T8('4<Q*9Q4HABENE-;6T3H*Z:KX)>K98 1FPY#]!%-'&TQ=
M0U1T&3*5*/T%E3$:!!B(+V8$:#JM<9C.K'!+QSLH*(D,3C?O-:B!WF]P)7P+
M$TH4H> =>R"O_2AF%H<!TA\A10*/*66391+V\@C-?&3OE05%[@5,+]-80K89
MXZE,I/A0[2C@T9M?#\[-R\PBHBSD) P=_/]_T@(^P[_@W4OYO[443B:3+3](
M_'P+M-$Y7 KZP:W[VZP.'<NLW;IS5S3VKZ?>:69)Z.L4_7!$V*RJ&MU9_YF#
MYHX'\#A_#,*,6LK!EO?.GTZ@_W?6XQTJ-NETV>U@RYL\J^* )T.U7LM?&ZW%
MVZ[.!?^B1T@5=2GBK\@@#SREJGFM7$A+C_@[+-%-RU./'"\7XCJ\ DM7\;T>
M7F'@X>AKV"_)BWTZ&$1@E2[B2[Q%R/^.%:_FHYVG[6"<14(+CZQT&.Y2@WRH
M$.5544Q_ LOV27=MV:XMVUM8MF<':\-VV?.C 2U<W02K;M>.QQ@R_2KE3>]=
M$S9JXX\8/>.CC]ZP-7_Z=H;&<GAT?GG\]OCPX/)H]@\//AR=O('_77J7I][E
MNZ.YW^D=GQR>GI^=GI,#8<9CLYL_.WM_#",BT_+P^.CD\.BB@Z^^1ROGWF-Z
M[?:TMX%&CT );A6W5O$(.&87T#$MLDJO;][@I=G03^#8YX!.^#5B9X%!6/PJ
M)6RM9KWW_D29<1>%!&??A+$_(:KC-Z='%]Z[H_.CUW^)9/T%\G=PN1"T]?LM
MW?P@O./SB\L7?"#9_[_ K&-5A[X"KQS_H;TS88:T*7V9.I /,[G,<CEB;]3=
M"<V,%I>2(NUG,E)!Z,$L1+)EZ3[^,] ($Q/\1UJ08>:/KU0@+>1H91:F@V4
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M%AT62M,$!M\B&RCGH+.4A"]$_$6ULPNAJ.[]0'Z+0#<*ONBTI]DSTS<G8:[
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MYVC&F/16D?)D?@]&F2;SV44;_<VEQ[<"BLB\^)LU'NFGPB,=/%KL,EP#DM:
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MF*UUD+ 7D*T;S(F,TC)'6U'M8IDUQ. &RH/0Z"(J=+JEXVAP+6$C#RG-$T\
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MAB'QZKHKR1IODLX$KA1. 01=B/A!K_U.$S'!<0(;,0HL-\GM).!80ES7&I-
M& +U=EX2%8F@^BU22 3C<](7APBP3,($)*<?6E8775$5,T:R%ND-4A##>I3C
MJW9$!L&D159R-98,K:ZL]8(T6C^*!4IK;G?6Z:+AG;=<%]:[U%TWQ/@?$6]X
M]"P?7VR^VSQB N\@<Y00A/A-6^/61$^D($RU[P]=B)LR]G^ENQV7#U,+[N8.
M4ZLHIX0"-FL6&[.0U#A#" 2O*8+56.51L.;XRT]E@!$\K(#0=XED+@JYE-^$
M,?)=6B!H4%ZD)K@5P+2-)["Y$U#_8G;,H>$#OV#G [;\T->_*<O_A$JKW_+D
M0JY 4Z-=[] * K *;*^2 .D@:YD7YB669Y7D*@A 9Z%ZDLC;Z+3 N/8B5^OH
MQ\H"IHJ. ZN&//I#$[7T^,CA510.O+=P+R8D5Z?T\XR@7-9I=,;P1T-U;L$*
M%:3;ZG'-F;A)9YSJN]]8#DB&6'>8U'+"J#-)",=@%"M.DL+NKGJ5+WC**HF_
MN:H;N^].+W-"TMMEL=4^%FTR*.,IK]H+'*!Q,JI2?UR#X3KRR18:)M$W-"#I
M $*37!Z86@5\K**PM/H6IB]/30LOR:>#ASV^O, J#^DX8I\1,BK%LU^E'PCT
M ZIV,!X"43;2QX3JXTM%'<H_[L 2@)!M[&]:=8IX9FV\S4@02IR;I^M<Z'H?
M84 _6<?VU['].6+[V]W[">ZO@_CK(/[?*8BO3H3]6\S"PON_IM/-/3%:VSOX
M<'3R!OYWZ5V>>I?OCEHGQ_,.SL[>'Q^]\=Z<''@7A\=')X='%QWO^.1P:\9#
M.]V=KG?TSX_'EW_A3Z&AXS^.O+/W!R=-VF/#WFA9T97&6I+K&TT%N)MIMA!5
MVL=3YCCI;\F<,'^1R<KDG$W+(X8?*#\8VNZH>*'1HV*6QM57!^FZ(1YX6+.L
M.0QD7-P9^9#2S*2--_?:[IJE56+O;JB_\X-78UNK1LZOO>HA278F-N?)O8%\
M]5'-4&JTDZI\[!0K$(8XR?S%9<Y"3%!7?*RL7]?>XT:FW7A U9?;"%A0WM:;
M_7QVEQ>PYA9:[U7@-X?%D6A]A;N3?+"SN0.#3Z5 :_S<+!W,;67A D< .I+8
M^S4:E:,Z?MPF'A2<O,LTV>PM!6'8[72[3SO[()WULT(3(QCW^5V/Q!\.T252
M-&#B&\94[;XSQ.:$]-P9)-N/%F6(XQ.2JB-8:*PE%HA'(:>??!,"OC*1UQBH
M2X%8_Q)M2,GVJ+=9R_'+M'/0AU^,=)56V*MY$14Z@F[3Q0TY2:,ECDY8KSPR
MH7=5([ @GCO-.6W1UK6*EZD=,3#4(U.OJ8:+>D>1%G"L,+U-P,GW$=C=*DM.
M17(Q%DBS59\42J?1SA K2TU!TC:U6T\2G!VT6V+C[?L^;F$8-U4@/TF31T<*
M0J#N*Q6GQ]P_9$)'+NK SSP*2YCIXD06[S]W]KL@5-UEDN7TL?3]#;3_@IV[
M_?SYR_G_L\03#^ST/M(I].I&94W(D +/S-QG43 1#@4>443<M7C \OF4M>F@
M <M\[+3,QUTH\:V:^?TIV=X@3OWB!4Z$G@)[5FKCKHF-:TEU*QN.7RQ3B5].
MKJ(BI"ZCU3S)_/'BHO5Z^F(AH[ RY#E&4!]V;4S.9.UU:UOD_SQZU(O]_N>8
M>$'9EG_T:'$3F#;_ BO:C^$D?8'5&T!EM5P>7M7G07Z*;L5/T56M[G1W7\Z[
M@?:J&XBC&FK9MY_4)J?E39Z%B_?X.?NU_+7IO+==72O^18] JVI!\5=L$R@+
MX:77.L2E1UP=[QV<H"=P<+[P?O/1\W6PY;WSIP0X6O:8NY<^7R*PY(5W>.6C
M*QVTT#-0;)"<GI$G''LYTJ$:B;W<V@?>73N]?T*G]_;=.[WK+N\@RL>Q/WWA
MX0G]RZO_CKZ^N I].#]>>=Y_T%]1 /*K_H)?G92C,(OZI)+ -)RC'[??_<6+
M@G_\PC]^-/#[Q2/X*('-"TV$T8LW@L>]G(ZAE;/S(V][[^"_'SMOA#9T(V\Q
MY16-"J>5G7HKVZJ5L!^\. @^7::HV1^,BE^HJ@L]5^;!+][7/'J11/$_?L&X
M.PSTL=O0JYO:WJVWO7-?;3^MM[U[7VWOU=O>NZ^V]^MM[]]7VT_J;3^YK[:?
MU]M^>O=MMVUDLVN/R(P_##$#/3X&*^;K[^&4^Q9]O7[T]/FS)[^\0I7BZ=[>
MWOY.;3_/WY+V]+Z-_:'3PM-?7@W\. \;#XO']@'%S>D\DOS5?\,Q_/E%WK\*
M1SZTZ7VEOSGRY(^#Y-%.%]2"Y[O=K:\T<_1U 2?4/W[)B5+WE\<\?]8[52-Y
M6F98,N#K*$YR6*JB&+]X_'@RF6Q][67Q5IH-'^]TN[N/%4<^K 1^$;V0.5 /
M\EAA,G  'A[1_#/VH+RBC_2'I$E@]#SS:%2ATW >]K>&Z?7CP^/?W56I/JR;
M>EQIRVJ?ZPI7VH>A9 7B(U_!S.T^VNX^ZFZKEYCO/'F]-99 /;3WJ/O\T6[7
MM,S?V+W1+>/Z.G,V>PJW']X4[BPSA;O?;PIW?L04FJD)AW@"6(.7KP+HR%?$
ML$7%!R+)](((?HF(JNIY^#7*?WF%'QU]*:8'DRS(CY.+<C3*IOAU7B27O?AM
MFAV,XU[\5\9OXZ[5&GFU6!^T5G\(JS%,LZGIRUF8WM"2F8K'E;GXZ;;I[D\H
M8_!=?O2U'P__\./S<58$=:&[40#6PO8=A&WO)Q2VO_N!MFJ7YO[]RQAZ5[W_
M_?/#'T_^_;__ZH_+KW\E^\^#;T^OAW]-DX]ORLFO3[/G3W_?^?3Q<IK'3Z_[
MW[KQ;\7CXO#IX?7_O#O][=/%QZ/?>G_%%]^Z_QQ=;A]\ZU_]?O!IN'_PY8_?
MHO2/X_VWQ<=W:??IZV#RY7?_]_'XPV\7<?+7Y%^'_KO@KTFY>W#\=F]_S_\V
MVCE[>W[VS]./E]TW[R:_=B?37WN'_]S]&/UU?'3U]DO\^?3Y<.?IEVZZ,WP^
M^MA]]_]V?_>WGUTE7YX<I+V#/Z+RC^ZOA^?AER>_^V\^ORW+LW_M?<F/WOP*
MQ^7[D\^''W?_9W0]/#H//W_\?3@^/GORY/>KZ_+@]6^OC_\Z?_?MZY-1]#_C
M=._LX,.SPXO=T<?)\T_ER?AL^OPLB8<G2?;_OO6FD_/XMS)^\_'#X>0?__8.
M+\X?/7JUOA+^OMOUR?I*^!Y7PDF:@)B=W"AI?Q/%X^E/*&6K=*2MQ<T1MV<_
MH;BM#[55NSJ?_X12MC[45E;<ML4IOHH"AU&"H'F!/S#2D)?5?A:>KGR_%:0C
M/TI>P9RW?&,W_;C>MI:^G^F*PWB6*PH8V'IE=U_0G*^B/-W;V7[ZXN/%&_4R
M]15W4WV*[U2Q' G=\)\JV/T?_R&Q<?E_))-_!9]=%:/XU?\'4$L! A0#%
M  @ %(B$6BIW!+;*!0  J!P  !$              ( !     &%P9&XM,C R
M-# Y,S N>'-D4$L! A0#%     @ %(B$6IF*@"?Y @  < <  !4
M     ( !^04  &%P9&XM,C R-# Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( !2(
MA%HOF^!+QP@  .19   5              "  24)  !A<&1N+3(P,C0P.3,P
M7VQA8BYX;6Q02P$"% ,4    "  4B(1:6)K%+I"<  #>P@  $0
M    @ $?$@  8F-?;F5T;&]S<RUB=RYJ<&=02P$"% ,4    "  4B(1:K2\,
MQ"Z2   #N   $@              @ '>K@  8F-?<F5V96YU97,M8G<N:G!G
M4$L! A0#%     @ %(B$6K-U&7@\E@  J[H   T              ( !/$$!
M &)C7W1S<BUB=RYJ<&=02P$"% ,4    "  4B(1:79 [_08$  #-!0  $@
M            @ &CUP$ :6-?8VAA:7)P97(M8G<N:G!G4$L! A0#%     @
M%(B$6BEQ>K7M P  N 4  !               ( !V=L! &EC7VUE;6)E<BUB
M=RYJ<&=02P$"% ,4    "  4B(1:H-(8'ZDG  !&*@  %
M@ 'TWP$ ;&=?87!P;&EE9&1N82TT8RYJ<&=02P$"% ,4    "  4B(1:>,QN
M>_"> 0!_K0X %0              @ '/!P( =&TR-3(U-C(M-%]P<F4Q-&$N
9:'1M4$L%!@     *  H @@(  /*F P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>tm252562-4_pre14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="apdn-20240930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsInSummryCompstnTblForAplblYrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">ecd:EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000744452</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-7946">Applied DNA Sciences, Inc</dei:EntityRegistrantName>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c0" id="ixv-7947">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgMnpiDiscTextBlock contextRef="c0" id="ixv-5937">&lt;div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-weight:normal;font-size:10pt;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;The Company did not grant equity awards to any executive officer or Board member during fiscal year 2024 due to the small number of shares available under the Current Plan. The Compensation Committee and the Board have a historical practice of not granting equity awards to executive officers during closed quarterly trading windows as determined under the Company&#x2019;s Insider Trading Policy. Annual grants of equity awards, which historically have included stock options, are typically made to the Corporation&#x2019;s executive officers, including named executive officers, during the open-trading-window period of the fiscal quarter in which they are awarded. Consequently, the Company has not granted, and does not expect to grant, any equity awards to any named executive officers during the period commencing four business days prior to and ending one business day following the filing with the SEC of any Company report on Forms 10-K, 10-Q or 8-K that discloses material non-public information about the Company. The Compensation Committee and the Board do not take material non-public information into account when determining the timing of equity awards, and the Company has not timed the disclosure of material non-public information in order to affect the value of executive compensation. &lt;/span&gt; &lt;/div&gt;</ecd:AwardTmgMnpiDiscTextBlock>
    <ecd:AwardTmgMethodTextBlock contextRef="c0" id="ixv-5938">&lt;div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-weight:normal;font-size:10pt;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;The Company did not grant equity awards to any executive officer or Board member during fiscal year 2024 due to the small number of shares available under the Current Plan. The Compensation Committee and the Board have a historical practice of not granting equity awards to executive officers during closed quarterly trading windows as determined under the Company&#x2019;s Insider Trading Policy. Annual grants of equity awards, which historically have included stock options, are typically made to the Corporation&#x2019;s executive officers, including named executive officers, during the open-trading-window period of the fiscal quarter in which they are awarded. Consequently, the Company has not granted, and does not expect to grant, any equity awards to any named executive officers during the period commencing four business days prior to and ending one business day following the filing with the SEC of any Company report on Forms 10-K, 10-Q or 8-K that discloses material non-public information about the Company. The Compensation Committee and the Board do not take material non-public information into account when determining the timing of equity awards, and the Company has not timed the disclosure of material non-public information in order to affect the value of executive compensation. &lt;/span&gt; &lt;/div&gt;</ecd:AwardTmgMethodTextBlock>
    <ecd:AwardTmgHowMnpiCnsdrdTextBlock contextRef="c0" id="ixv-5939">&lt;div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;font-weight:normal;font-size:10pt;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;The Company did not grant equity awards to any executive officer or Board member during fiscal year 2024 due to the small number of shares available under the Current Plan. The Compensation Committee and the Board have a historical practice of not granting equity awards to executive officers during closed quarterly trading windows as determined under the Company&#x2019;s Insider Trading Policy. Annual grants of equity awards, which historically have included stock options, are typically made to the Corporation&#x2019;s executive officers, including named executive officers, during the open-trading-window period of the fiscal quarter in which they are awarded. Consequently, the Company has not granted, and does not expect to grant, any equity awards to any named executive officers during the period commencing four business days prior to and ending one business day following the filing with the SEC of any Company report on Forms 10-K, 10-Q or 8-K that discloses material non-public information about the Company. The Compensation Committee and the Board do not take material non-public information into account when determining the timing of equity awards, and the Company has not timed the disclosure of material non-public information in order to affect the value of executive compensation. &lt;/span&gt; &lt;/div&gt;</ecd:AwardTmgHowMnpiCnsdrdTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="c0" id="ixv-7948">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <ecd:AwardTmgPredtrmndFlag contextRef="c0" id="ixv-7949">true</ecd:AwardTmgPredtrmndFlag>
    <ecd:MnpiDiscTimedForCompValFlag contextRef="c0" id="ixv-7950">false</ecd:MnpiDiscTimedForCompValFlag>
    <ecd:PvpTableTextBlock contextRef="c0" id="ixv-5947">&lt;table style="width:456pt;height:95.56pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;tr style="line-height:9pt;height:31.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:60pt;text-align:left;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Summary &lt;br/&gt; Compensation &lt;br/&gt; Table Total &lt;br/&gt; for PEO&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(1)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Compensation &lt;br/&gt; Actually Paid &lt;br/&gt; to PEO&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(2)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Average &lt;br/&gt; Summary &lt;br/&gt; Compensation &lt;br/&gt; Table Total &lt;br/&gt; for Non-PEO &lt;br/&gt; NEOs&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(3)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Average &lt;br/&gt; Compensation &lt;br/&gt; Actually Paid &lt;br/&gt; to Non-PEO &lt;br/&gt; NEOs&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(4)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Value of Initial &lt;br/&gt; Fixed $100 &lt;br/&gt; Investment Based On&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(6)&lt;/span&gt;&lt;span style="letter-spacing:-0.16pt;"&gt;: &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Net (Loss) &lt;br/&gt; (thousands)&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(6)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" rowspan="2" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Revenues &lt;br/&gt; (thousands)&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(7)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td rowspan="2" style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt; width:60pt;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Year&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;text-align:center;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Total Shareholder &lt;br/&gt; Return&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(5)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;td style="padding:3.25pt 0pt 2.5pt 0pt; width:60pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;(a) &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"&gt; &lt;div style="white-space:nowrap; text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;(b) &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"&gt; &lt;div style="white-space:nowrap; text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;(c) &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"&gt; &lt;div style="white-space:nowrap; text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;(d) &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"&gt; &lt;div style="white-space:nowrap; text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;(e) &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"&gt; &lt;div style="white-space:nowrap; text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;(f) &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"&gt; &lt;div style="white-space:nowrap; text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;(g) &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="padding:3.25pt 0pt 2.5pt 0pt;"&gt; &lt;div style="white-space:nowrap; text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;(h) &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:8.96999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;"&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; width:60pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.18pt;"&gt;2024 &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"&gt;387,623&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"&gt;387,623&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"&gt;297,352&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"&gt;297,352&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:25.02pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;"&gt;107.08&lt;/td&gt; &lt;td style="padding:0pt;padding-left:25.02pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.355pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"&gt;(7,088&lt;span style="position:absolute;"&gt;)&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.355pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.85pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;"&gt;3,431&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.85pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:8.96999999999997pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;"&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; width:60pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.18pt;"&gt;2023 &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"&gt;468,000&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"&gt;468,000&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"&gt;514,917&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;"&gt;308,333&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.695pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:25.02pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;"&gt;107.08&lt;/td&gt; &lt;td style="padding:0pt;padding-left:25.02pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.355pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"&gt;(10,023&lt;span style="position:absolute;"&gt;)&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.355pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:2.64pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.85pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.52pt 0pt 1.79pt 0pt; min-width:20.25pt; text-align:right; white-space:nowrap;"&gt;13,367&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.85pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
        &lt;div style="margin-top:14.01pt; width:456pt;"&gt;
          &lt;div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; "&gt;&#x200b;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;(1)&lt;/span&gt; &lt;br/&gt; &lt;/div&gt;
        &lt;div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;"&gt;  &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported in column (b)&#160;are the amounts of total compensation reported for the principal executive officer (&#x201c;&lt;/span&gt;&lt;span style="font-style:italic;letter-spacing:0.2pt;"&gt;PEO&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#x201d;), Dr.&#160;Hayward (our Chairman, Chief Executive Officer and President), for each corresponding year in the &#x201c;Total&#x201d; column of the Summary Compensation Table. Refer to &#x201c;Executive Compensation&#x2009;&#x2014;&#x2009;Executive Compensation Tables&#x2009;&#x2014;&#x2009;Summary Compensation Table.&#x201d; &lt;/span&gt; &lt;/div&gt;
        &lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;
        &lt;div style=" float:left; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;(2)&lt;/span&gt; &lt;br/&gt; &lt;/div&gt;
        &lt;div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported in column (c)&#160;represent the amount of &#x201c;compensation actually paid&#x201d; to Dr.&#160;Hayward, as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr.&#160;Hayward during the applicable year. In accordance with the requirements of Item&#160;402(v) of Regulation&#160;S-K, the following adjustments were made to Dr.&#160;Hayward&#x2019;s total compensation for each year to determine the compensation actually paid which is reported above: &lt;/span&gt;
        &lt;/div&gt;
        &lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;&lt;table style="width:436pt;height:74.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:183.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Year &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Reported &lt;br/&gt; Summary &lt;br/&gt; Compensation &lt;br/&gt; Table Total for &lt;br/&gt; PEO &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Reported &lt;br/&gt; Value of Equity &lt;br/&gt; Awards&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(a)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Equity &lt;br/&gt; Award &lt;br/&gt; Adjustments&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(b)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Compensation &lt;br/&gt; Actually Paid to &lt;br/&gt; PEO &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;2024 &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.005pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;387,623&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.005pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:13.565pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-1"&gt;&#160;&#160;&#160;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:13.565pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:11.535pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-2"&gt;&#160;&#160;&#160;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:11.535pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:8.27pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;387,623&lt;/td&gt; &lt;td style="padding:0pt;padding-left:8.27pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;2023 &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.005pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;468,000&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.005pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:13.565pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-4"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:13.565pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:11.535pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-5"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:11.535pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:8.27pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;468,000&lt;/td&gt; &lt;td style="padding:0pt;padding-left:8.27pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
        &lt;div style="margin-left:20pt; margin-top:12.3pt; width:436pt;"&gt;
          &lt;div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; "&gt;&#x200b;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style=" float:left; margin-left:20pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt;
          &lt;span style="letter-spacing:0.2pt;"&gt;(a)&lt;/span&gt;
          &lt;br/&gt;
        &lt;/div&gt;
        &lt;div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The grant date fair value of equity awards represents the total of the amounts reported in the &#x201c;Stock Awards&#x201d; and &#x201c;Option Awards&#x201d; columns in the Summary Compensation Table for the applicable year. &lt;/span&gt;
        &lt;/div&gt;
        &lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;
        &lt;div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt;
          &lt;span style="letter-spacing:0.2pt;"&gt;(b)&lt;/span&gt;
          &lt;br/&gt;
        &lt;/div&gt;
        &lt;div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;There was no equity award adjustment for each of the applicable&#160;years shown above, as all equity awards granted were fully vested on the date of grant. &lt;/span&gt;
        &lt;/div&gt;
        &lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;
        &lt;div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;(3)&lt;/span&gt; &lt;br/&gt; &lt;/div&gt;
        &lt;div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported in column (d)&#160;represent the average of the amounts reported for the Company&#x2019;s named executive officers as a group (excluding Dr.&#160;Hayward, who has served as our Chairman, Chief Executive Officer and President) in the &#x201c;Total&#x201d; column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers (excluding Dr.&#160;Hayward) included for purposes of calculating the average amounts in each applicable year are as follows: (i)&#160;for 2024 and 2023, Beth M. Jantzen, Clay Shorrock and Judith Murrah. &lt;/span&gt;
        &lt;/div&gt;
        &lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;
        &lt;div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;(4)&lt;/span&gt; &lt;br/&gt; &lt;/div&gt;
        &lt;div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported in column (e)&#160;represent the average amount of &#x201c;compensation actually paid&#x201d; to the named executive officers as a group (excluding Dr.&#160;Hayward), as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the named executive officers as a group (excluding Dr.&#160;Hayward) during the applicable year. In accordance with the requirements of Item&#160;402(v) of Regulation&#160;S-K, the following adjustments were made to average total compensation for the named executive officers as a group (excluding Dr.&#160;Hayward) for each year to determine the compensation actually paid, using the same methodology described above in Note 3: &lt;/span&gt;
        &lt;/div&gt;
        &lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;
        &lt;table style="width:436pt;height:83.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:170.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Year &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Average &lt;br/&gt; Reported &lt;br/&gt; Summary &lt;br/&gt; Compensation &lt;br/&gt; Table Total for &lt;br/&gt; Non-PEO NEOs &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Average &lt;br/&gt; Reported &lt;br/&gt; Value of Equity &lt;br/&gt; Awards &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Average Equity &lt;br/&gt; Award &lt;br/&gt; Adjustments&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(a)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Average &lt;br/&gt; Compensation &lt;br/&gt; Actually Paid to &lt;br/&gt; Non-PEO NEOs &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; width:170.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;2024 &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;297,352&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.21pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-6"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.21pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:12.765pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-3"&gt;&#160;&#160;&#160;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:12.765pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;297,352&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;2023 &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;514,917&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.21pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;206,583&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.21pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:12.765pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-7"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:12.765pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;308,333&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
        &lt;div style="margin-left:20pt; margin-top:12.3pt; width:436pt;"&gt;
          &lt;div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; "&gt;&#x200b;&lt;/div&gt;
        &lt;/div&gt;
        &lt;div style=" float:left; margin-left:20pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt;
          &lt;span style="letter-spacing:0.2pt;"&gt;(a)&lt;/span&gt;
          &lt;br/&gt;
        &lt;/div&gt;
        &lt;div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;There was no equity award adjustment for each of the applicable&#160;years shown above, as all equity awards granted were fully vested on the date of grant. &lt;/span&gt;
        &lt;/div&gt;
        &lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;
        &lt;div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt;
          &lt;span style="letter-spacing:0.2pt;"&gt;(5)&lt;/span&gt;
          &lt;br/&gt;
        &lt;/div&gt;
        &lt;div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;Cumulative total shareholder return (&#x201c;&lt;/span&gt;&lt;span style="font-style:italic;letter-spacing:0.2pt;"&gt;TSR&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#x201d;) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between the Company&#x2019;s share price at the end and the beginning of the measurement period by the Company&#x2019;s share price at the beginning of the measurement period. No dividends were paid on stock awards or Options in either of fiscal 2024 or 2023. &lt;/span&gt;
        &lt;/div&gt;
        &lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;
        &lt;div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt;
          &lt;span style="letter-spacing:0.2pt;"&gt;(6)&lt;/span&gt;
          &lt;br/&gt;
        &lt;/div&gt;
        &lt;div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported represent the amount of net income reflected in the Company&#x2019;s audited financial statements for the applicable year. &lt;/span&gt;
        &lt;/div&gt;
        &lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;
        &lt;div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;(7)&lt;/span&gt; &lt;br/&gt; &lt;/div&gt;
        &lt;div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported represent the amount of consolidated revenues reflected in the Company&#x2019;s audited financial statements for the applicable year. &lt;/span&gt;
        &lt;/div&gt;</ecd:PvpTableTextBlock>
    <ecd:CoSelectedMeasureName contextRef="c0" id="ixv-7951">Revenues</ecd:CoSelectedMeasureName>
    <ecd:PeoTotalCompAmt contextRef="c0" decimals="0" id="ixv-7952" unitRef="usd">387623</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c0" decimals="0" id="ixv-7953" unitRef="usd">387623</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c0" decimals="0" id="ixv-7954" unitRef="usd">297352</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c0" decimals="0" id="ixv-7955" unitRef="usd">297352</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c0" decimals="2" id="ixv-7956" unitRef="usd">107.08</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-7957" unitRef="usd">-7088000</us-gaap:NetIncomeLoss>
    <ecd:CoSelectedMeasureAmt contextRef="c0" decimals="-3" id="ixv-7958" unitRef="usd">3431000</ecd:CoSelectedMeasureAmt>
    <ecd:PeoTotalCompAmt contextRef="c1" decimals="0" id="ixv-7959" unitRef="usd">468000</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c1" decimals="0" id="ixv-7960" unitRef="usd">468000</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c1" decimals="0" id="ixv-7961" unitRef="usd">514917</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c1" decimals="0" id="ixv-7962" unitRef="usd">308333</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt contextRef="c1" decimals="2" id="ixv-7963" unitRef="usd">107.08</ecd:TotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss contextRef="c1" decimals="-3" id="ixv-7964" unitRef="usd">-10023000</us-gaap:NetIncomeLoss>
    <ecd:CoSelectedMeasureAmt contextRef="c1" decimals="-3" id="ixv-7965" unitRef="usd">13367000</ecd:CoSelectedMeasureAmt>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="c0" id="ixv-6163">&lt;div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;(1)&lt;/span&gt; &lt;br/&gt; &lt;/div&gt;&lt;div style=" margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;"&gt;  &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported in column (b)&#160;are the amounts of total compensation reported for the principal executive officer (&#x201c;&lt;/span&gt;&lt;span style="font-style:italic;letter-spacing:0.2pt;"&gt;PEO&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;&#x201d;), Dr.&#160;Hayward (our Chairman, Chief Executive Officer and President), for each corresponding year in the &#x201c;Total&#x201d; column of the Summary Compensation Table. Refer to &#x201c;Executive Compensation&#x2009;&#x2014;&#x2009;Executive Compensation Tables&#x2009;&#x2014;&#x2009;Summary Compensation Table.&#x201d; &lt;/span&gt; &lt;/div&gt;&lt;div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;(3)&lt;/span&gt; &lt;br/&gt; &lt;/div&gt;&lt;div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported in column (d)&#160;represent the average of the amounts reported for the Company&#x2019;s named executive officers as a group (excluding Dr.&#160;Hayward, who has served as our Chairman, Chief Executive Officer and President) in the &#x201c;Total&#x201d; column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers (excluding Dr.&#160;Hayward) included for purposes of calculating the average amounts in each applicable year are as follows: (i)&#160;for 2024 and 2023, Beth M. Jantzen, Clay Shorrock and Judith Murrah. &lt;/span&gt;
        &lt;/div&gt;</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName contextRef="c0" id="ixv-7966">Dr.&#160;Hayward</ecd:PeoName>
    <ecd:AdjToPeoCompFnTextBlock contextRef="c0" id="ixv-6173">&lt;div style=" float:left; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:normal;font-size:10pt;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;(2)&lt;/span&gt; &lt;br/&gt; &lt;/div&gt;&lt;div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;font-weight:normal;font-size:10pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported in column (c)&#160;represent the amount of &#x201c;compensation actually paid&#x201d; to Dr.&#160;Hayward, as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr.&#160;Hayward during the applicable year. In accordance with the requirements of Item&#160;402(v) of Regulation&#160;S-K, the following adjustments were made to Dr.&#160;Hayward&#x2019;s total compensation for each year to determine the compensation actually paid which is reported above: &lt;/span&gt;
        &lt;/div&gt;&lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;&lt;table style="width:436pt;height:74.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:183.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Year &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Reported &lt;br/&gt; Summary &lt;br/&gt; Compensation &lt;br/&gt; Table Total for &lt;br/&gt; PEO &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Reported &lt;br/&gt; Value of Equity &lt;br/&gt; Awards&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(a)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Equity &lt;br/&gt; Award &lt;br/&gt; Adjustments&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(b)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Compensation &lt;br/&gt; Actually Paid to &lt;br/&gt; PEO &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;2024 &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.005pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;387,623&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.005pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:13.565pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-1"&gt;&#160;&#160;&#160;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:13.565pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:11.535pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-2"&gt;&#160;&#160;&#160;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:11.535pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:8.27pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;387,623&lt;/td&gt; &lt;td style="padding:0pt;padding-left:8.27pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; width:183.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;2023 &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.005pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;468,000&lt;/td&gt; &lt;td style="padding:0pt;padding-left:6.005pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:13.565pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-4"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:13.565pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:11.535pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-5"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:11.535pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:8.27pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;468,000&lt;/td&gt; &lt;td style="padding:0pt;padding-left:8.27pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; "&gt;&#x200b;&lt;/div&gt;&lt;div style=" float:left; margin-left:20pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt;
          &lt;span style="letter-spacing:0.2pt;"&gt;(a)&lt;/span&gt;
          &lt;br/&gt;
        &lt;/div&gt;&lt;div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The grant date fair value of equity awards represents the total of the amounts reported in the &#x201c;Stock Awards&#x201d; and &#x201c;Option Awards&#x201d; columns in the Summary Compensation Table for the applicable year. &lt;/span&gt;
        &lt;/div&gt;&lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;&lt;div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt;
          &lt;span style="letter-spacing:0.2pt;"&gt;(b)&lt;/span&gt;
          &lt;br/&gt;
        &lt;/div&gt;&lt;div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;There was no equity award adjustment for each of the applicable&#160;years shown above, as all equity awards granted were fully vested on the date of grant. &lt;/span&gt;
        &lt;/div&gt;</ecd:AdjToPeoCompFnTextBlock>
    <ecd:PeoTotalCompAmt contextRef="c0" decimals="0" id="ixv-7967" unitRef="usd">387623</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c0" decimals="0" id="ixv-7968" unitRef="usd">387623</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt contextRef="c1" decimals="0" id="ixv-7969" unitRef="usd">468000</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt contextRef="c1" decimals="0" id="ixv-7970" unitRef="usd">468000</ecd:PeoActuallyPaidCompAmt>
    <ecd:AdjToNonPeoNeoCompFnTextBlock contextRef="c0" id="ixv-6330">&lt;div style=" float:left; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;(4)&lt;/span&gt; &lt;br/&gt; &lt;/div&gt;&lt;div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported in column (e)&#160;represent the average amount of &#x201c;compensation actually paid&#x201d; to the named executive officers as a group (excluding Dr.&#160;Hayward), as computed in accordance with Item&#160;402(v) of Regulation&#160;S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the named executive officers as a group (excluding Dr.&#160;Hayward) during the applicable year. In accordance with the requirements of Item&#160;402(v) of Regulation&#160;S-K, the following adjustments were made to average total compensation for the named executive officers as a group (excluding Dr.&#160;Hayward) for each year to determine the compensation actually paid, using the same methodology described above in Note 3: &lt;/span&gt;
        &lt;/div&gt;&lt;div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"&gt;&#x200b;&lt;/div&gt;&lt;table style="width:436pt;height:83.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;"&gt; &lt;td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:170.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Year &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Average &lt;br/&gt; Reported &lt;br/&gt; Summary &lt;br/&gt; Compensation &lt;br/&gt; Table Total for &lt;br/&gt; Non-PEO NEOs &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Average &lt;br/&gt; Reported &lt;br/&gt; Value of Equity &lt;br/&gt; Awards &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Average Equity &lt;br/&gt; Award &lt;br/&gt; Adjustments&lt;/span&gt;&lt;span style=" position:relative; bottom:3.25pt;line-height:5pt;font-size:5pt;letter-spacing:-0.12pt;"&gt;(a)&lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td colspan="4" style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;"&gt; &lt;div style="text-align:center;"&gt; &lt;span style="letter-spacing:-0.16pt;"&gt;Average &lt;br/&gt; Compensation &lt;br/&gt; Actually Paid to &lt;br/&gt; Non-PEO NEOs &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; width:170.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;2024 &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;297,352&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.21pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-6"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.21pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:12.765pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-3"&gt;&#160;&#160;&#160;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:12.765pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;297,352&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;"&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; width:170.85pt;text-align:left;"&gt; &lt;div style="white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;2023 &lt;/span&gt; &lt;/div&gt; &lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;514,917&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.21pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;206,583&lt;/td&gt; &lt;td style="padding:0pt;padding-left:7.21pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:12.765pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-7"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:12.765pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:6pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; "&gt;$&lt;/td&gt; &lt;td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;"&gt;308,333&lt;/td&gt; &lt;td style="padding:0pt;padding-left:9.77pt;width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;td style="padding:0pt; width:0pt;"&gt;&#x200b;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; "&gt;&#x200b;&lt;/div&gt;&lt;div style=" float:left; margin-left:20pt; margin-top:7.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt;
          &lt;span style="letter-spacing:0.2pt;"&gt;(a)&lt;/span&gt;
          &lt;br/&gt;
        &lt;/div&gt;&lt;div style=" margin-top:7.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;There was no equity award adjustment for each of the applicable&#160;years shown above, as all equity awards granted were fully vested on the date of grant. &lt;/span&gt;
        &lt;/div&gt;</ecd:AdjToNonPeoNeoCompFnTextBlock>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c0" decimals="0" id="ixv-7971" unitRef="usd">297352</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c0" decimals="0" id="ixv-7972" unitRef="usd">297352</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt contextRef="c1" decimals="0" id="ixv-7973" unitRef="usd">514917</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt contextRef="c8" decimals="0" id="ixv-7974" unitRef="usd">-206583</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt contextRef="c1" decimals="0" id="ixv-7975" unitRef="usd">308333</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonGaapMeasureDescriptionTextBlock contextRef="c10" id="ixv-6466">&lt;div style=" float:left; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"&gt; &lt;span style="letter-spacing:0.2pt;"&gt;(7)&lt;/span&gt; &lt;br/&gt; &lt;/div&gt;&lt;div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;"&gt;

          &lt;span style="letter-spacing:0.2pt;"&gt;The dollar amounts reported represent the amount of consolidated revenues reflected in the Company&#x2019;s audited financial statements for the applicable year. &lt;/span&gt;
        &lt;/div&gt;</ecd:NonGaapMeasureDescriptionTextBlock>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="c0" id="ixv-6504">&lt;div style="position:relative;margin-top:11.2pt; text-align:center; width:456pt;"&gt;
          &lt;img alt="[MISSING IMAGE: bc_tsr-bw.jpg]" src="bc_tsr-bw.jpg" style="height: 315px; width: 556px;"/&gt;
        &lt;/div&gt;</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <ecd:CompActuallyPaidVsNetIncomeTextBlock contextRef="c0" id="ixv-6530">&lt;div style="position:relative;margin-top:8pt; text-align:center; width:456pt;"&gt;
          &lt;img alt="[MISSING IMAGE: bc_netloss-bw.jpg]" src="bc_netloss-bw.jpg" style="height: 315px; width: 556px;"/&gt;
        &lt;/div&gt;</ecd:CompActuallyPaidVsNetIncomeTextBlock>
    <ecd:CompActuallyPaidVsCoSelectedMeasureTextBlock contextRef="c0" id="ixv-6538">&lt;div style="position:relative;margin-top:10pt; text-align:center; width:456pt;"&gt;
          &lt;img alt="[MISSING IMAGE: bc_revenues-bw.jpg]" src="bc_revenues-bw.jpg" style="height: 315px; width: 556px;"/&gt;
        &lt;/div&gt;</ecd:CompActuallyPaidVsCoSelectedMeasureTextBlock>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">PRE 14A</dei:DocumentType>
    <ecd:AdjToCompAmt
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c7"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c6"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <ecd:AdjToCompAmt
      contextRef="c9"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-7986">0000744452</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-7987">false</dei:AmendmentFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
